Document:

Employment
Agreement

 

This
Employment Agreement (“Agreement”), dated as of December 22, 2016 (the “Effective Date”),
is entered into between Motus GI Holdings, Inc. having a place of business at 150 Union Square New Hope, PA 18938 (“Employer”
or the “Company”), and James J. Martin, an individual residing at 18401 SW 85 Court, Cutler Bay, Florida
33157 (“Executive”). Employer and Executive shall collectively be referred to as the “Parties.”

 

WHEREAS,
the Parties desire to memorialize the terms and conditions of the Executive’s employment with Employer under this Agreement
as of the Effective Date; and

 

WHEREAS,
Executive is willing to accept his employments and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements set forth herein, Employer and Executive hereby agree as follows:

 

ARTICLE
I

POSITION
DUTIES AND RESPONSIBILITIES

 

1.01
Position, Duties and Authority. During his employment with the Company, Executive shall serve as Employer’s Chief
Financial Officer and shall have such responsibilities, duties and authority as may, from time to time, be assigned by the Company’s
Chief Executive Officer or her/his designee consistent with that position. During his employment, Executive shall devote all of
Executive’s business time, attention, skill and efforts exclusively to the business and affairs of Employer and the promotion
of its interests; provided, however, that Executive shall be entitled to consult for Non Invasive Monitoring Systems, Inc. up
to 8 hours per calendar quarter so long as such services do not impact the services to be provided to the Employer hereunder.
Notwithstanding the foregoing, Executive may engage in charitable, educational, religious, civic and similar types of activities
to the extent that such activities do not inhibit or prohibit the performance of Executive’s duties hereunder or inhibit
or conflict with the business of Employer. Executive’s principal base of operation for the performance of his duties shall
be the State of Florida; provided, however, that Executive shall perform such duties and responsibilities at such other places
as shall from time to time be reasonably necessary to fulfil his obligations under this Agreement in the Employer’s discretion.

 

ARTICLE
II

COMPENSATION
AND EXPENSES

 

2.01
Compensation. For all services rendered by Executive in any capacity during his employment, including, without limitation,
services as an officer, director or member of any committee of Employer, or any subsidiary, affiliate or division thereof, Executive
shall be compensated as follows (subject, in each case, to the provisions of Article III below):

 

(A)
Salary. During his employment, Employer shall pay to Executive a salary of $210,000 if annualized (the “Base Salary”).
Executive’s Base Salary shall be subject to periodic review and adjustment.

 

    	 

    	 

    

 

(B)
Benefits. During his employment, Executive shall be entitled to participate in all Employer’s Executive benefit plans
and programs as Employer generally maintains from time to time during his employment for the benefit of its executives, in each
case subject to the eligibility requirements and other terms and provisions of such plans or programs, including any such bonus
programs. Employer agrees that the Executive shall accrue no less than three weeks of paid time off for vacation, sick and personal
time per year. Employer may amend, modify or rescind any executive benefit plan or program and change Executive contribution amounts
to benefit costs without notice in its discretion.

 

(C) Equity. Subject to the terms of the Company’s 2016 Equity Incentive Plan (the “Plan”) and approval
of the Board of Directors of the Company (the “Board”) or the Compensation Committee of the Board (the “Compensation
Committee”), upon or immediately following the final closing of the private placement offering of the Company’s common
stock, the Executive will be granted options to purchase up to the number of shares equal to one percent (1.0%) of the Fully-Diluted
(as defined in the Plan) shares of the Company’s common stock, on the terms and conditions determined by the Board or the
Compensation Committee, with an exercise price of $5.00 per share (provided that the Board or the Compensation Committee determines
that such exercise price represents no less than fair market value per share on the date of grant in accordance with the Plan),
with a vesting schedule and other terms and conditions to be determined by the Compensation Committee. During the term of this
Agreement, subject to the terms and conditions established within the Plan or any successor equity compensation plan as may be
in place from time to time and separate award agreements, the Executive also shall be eligible to receive from time to time stock
options, stock unit awards, performance shares, performance units, incentive bonus awards, other cash-based awards and/or other
stock-based awards (as permitted by the Plan), in amounts, if any, to be approved by the Board or the Compensation Committee in
its discretion. The agreement governing the Options shall provide for accelerating vesting upon a change of control, which terms
shall be agreed to by the Employer and the Executive..

 

2.02
Expenses. Executive shall receive reimbursement from Employer for all reasonable out-of-pocket expenses incurred by Executive
during his employment in connection with the performance of Executive’s duties and obligations under this Agreement, according
to Employer’s annual budget, expense account and/or reimbursement policies in place from time to time and provided that
Executive shall submit reasonable documentation with respect to each such expense.

 

ARTICLE
III

TERMINATION

 

3.01
Employment At-Will. The Parties’ employment relationship shall be at-will. Each will endeavor to provide the other
with a minimum of at least two weeks advance written notice of its/his intent to terminate, to the extent practicable.

 

    	-2-

    	 

    

 

ARTICLE
IV

CONFIDENTIALITY,
NON-COMPETITION, NON-SOLICITATION

AND
OTHER COVENANTS

 

4.01
Confidentiality. Executive shall be provided with access to Confidential Information relating to Employer, its business,
potential business or that of its clients and customers. “Confidential Information” includes all trade secrets,
know-how, show-how, theories, technical, operating, financial, and other business information, whether or not reduced to writing
or other medium and whether or not marked or labeled confidential, proprietary or the like, specifically including, but not limited
to, information regarding source codes, software programs, computer systems, concepts, creations, costs, plans, materials, enhancements,
research, specifications, works of authorship, techniques, documentation, models and systems, sales and pricing techniques, designs,
inventions, discoveries, products, improvements, modifications, methodology, processes, concepts, records, files, memoranda, reports,
plans, proposals, price lists, product development and project procedures. Confidential Information does not include general
skills, experience or information that is generally available to the public, other than information which has become generally
available as a result of Executive’s direct or indirect act or omission.

 

With
respect to Confidential Information of Employer and its clients and customers:

 

(A)
Executive will use Confidential Information only in the performance of Executive’s duties for Employer. Executive will not
use Confidential Information at any time (during or after Executive’s employment with Employer) for Executive’s personal
benefit, for the benefit of any other individual or entity, or in any manner adverse to the interests of Employer and its clients
and customers except to the extent permitted by applicable law, including to enable Executive to exercise any protected legal
right he may have;

 

(B)
Executive will not disclose Confidential Information at any time (during or after Executive’s employment with Employer)
except to authorized Employer personnel, unless Employer consents in advance in writing or unless the Confidential Information
indisputably becomes of public knowledge or enters the public domain (other than through Executive’s direct or indirect
act or omission) or as authorized by a court or regulatory agency.

 

(C)
Executive will safeguard the Confidential Information by all reasonable steps and abide by all policies and procedures of Employer
in effect from time to time regarding storage, copying, destroying, and handling of documents; and

 

(D)
Executive will return or destroy all materials, models, software, prototypes and the like containing and/or relating to Confidential
Information, together with all other property of Employer and its clients and customers, to Employer when Executive’s employment
relationship with Employer terminates or otherwise on demand and, at that time Executive will certify to Employer, in writing
and under oath, that Executive has complied with this Agreement. Executive shall not retain any copies or reproductions of correspondence,
memoranda, reports, notebooks, drawings, photographs, databases, diskettes, or other documents or electronically stored information
of any kind relating in any way to the business, potential business or affairs of Employer and its clients and customers.

 

    	-3-

    	 

    

 

(E)
Executive acknowledges receipt of the following notice under the Defend Trade Secrets Act: An individual will not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret if he/she (i) makes such disclosure
in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney and such disclosure
is made solely for the purpose of reporting or investigating a suspected violation of law; or (ii) such disclosure was made in
a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal.

 

4.02
Obligations to Other Persons. Executive does not have any non-disclosure or other obligations to any other individual or
entity (including without limitation, any previous employer) concerning proprietary or confidential information that Executive
learned of during any previous employment or associations. Executive shall not disclose to Employer or induce Employer to use
any secret or confidential information or material belonging to others, including, without limitation, Executive’s former
employers, if any. Executive does not have any non-competition agreements, non-solicitation agreements or other restrictive covenants
with any previous employer or other individual or entity.

 

4.03
Covenants Against Competition and Solicitation.

 

(A)
Executive acknowledges and understands that, Executive’s position with Employer affords Executive extensive access to Confidential
Information of the Company. Executive therefore agrees that during the course of Executive’s employment with Employer and
for twelve (12) months after termination of Executive’s employment with Employer (for any reason or no reason) (collectively,
“Restricted Period”), Executive shall not: (i) anywhere within the United States of America or any other country
in which the Company then conducts or proposes to conduct business, either directly or indirectly, as an owner, stockholder, member,
partner, joint venturer, officer, director, consultant, independent contractor, agent or executive, engage in any business or
other commercial activity which is engaged in or is seeking to engage in a “Competitive Business.” As used in this
Agreement, “Competitive Business” shall mean any individual or enterprise engaged in (x) cleansing of body
cavities, tubular structures or other orafices or devices added on or attached to endoscopes or (y) any other business competitive
with the business of the Company on the date of termination.

 

(B)
Executive further agrees that, during the Restricted Period, Executive shall not, directly or indirectly, either on Executive’s
own behalf or on behalf of any other individual or commercial enterprise: (i) contact, communicate, solicit or transact any business
with or assist any third party in contacting, communicating, soliciting or transacting any business with (A) any of the customers
or clients of the Company, (B) any prospective customers or clients of the Company, or (C) any individual or entity who or which
was within the most recent twelve (12) month period a customer or client of Company, for the purpose of inducing such customer
or client or potential customer or client to be connected to or benefit from any competitive business or to terminate its or their
business relationship with the Company; (ii) solicit, induce or assist any third party in soliciting or inducing any individual
or entity who is then (or was at any time within the preceding twelve (12) an employee, consultant, independent contractor or
agent of Company) to leave the employment of the Company or cease performing services for the Company; (iii) hire or engage or
assist any third party in hiring or engaging, any individual or entity that is or was (at any time within the preceding twelve
(12) months) an employee, consultant, independent contractor or agent of the Company, or (iv) solicit, induce or assist any third
party in soliciting or inducing any other person or entity (including, without limitation, any third-party service provider or
distributor) to terminate its relationship with the Company or otherwise interfere with such relationship. A “prospective
customer or client” is any individual or entity with respect to whom or which Employer was engaged in a solicitation at
any time during the twelve (12) months preceding his termination of Executive’s employment with Employer and in which solicitation
Executive was in any way involved, or about whom or which Executive had access to Confidential Information.

 

    	-4-

    	 

    

 

4.04
Non-Disparagement. Executive will not at any time (during or after Executive’s employment with Employer) disparage
the reputation of Employer, its clients and customers and its or their respective officers, directors, agents or employees. Employer
will not at any time, (during or after Executive’s employment with Employer) disparage the reputation of Executive. In the
event that Employer is asked to verify Executive’s employment with Employer, Employer will confirm only the dates of employment
and position unless expressly authorized to provide additional information by Executive.

 

4.05
Cooperation With Investigations/Litigation. Executive agrees, upon Employer’s request, to reasonably cooperate both
during and after Executive’s employment with Employer in any Employer investigation, litigation, arbitration, or regulatory
proceeding regarding events that occurred during Executive’s tenure with Employer. Executive will make himself reasonably
available to consult with Employer’s counsel, to provide information, and to appear to give testimony. Employer will reimburse
Executive for reasonable out-of-pocket expenses Executive incurs in extending such cooperation, so long as Executive provides
advance written notice of Executive’s request for reimbursement and provides satisfactory documentation of the expenses.

 

4.06
Reasonable Restrictions/Damages Inadequate Remedy. The Parties to this agreement acknowledge that the restrictions contained
in this Article are reasonable and necessary to protect the legitimate business interests of Employer and that any breach by Executive
of any provision contained in this Article may result in immediate irreparable injury to Employer for which a remedy at law would
be inadequate. Accordingly, the Parties shall be entitled to temporary or permanent injunctive or other equitable relief (without
being obligated to post a bond or other collateral) in the event of any breach or threatened breach of the provisions of this
Article, in addition to any other remedy that may be available whether at law or in equity.

 

4.07
Separate Covenants. In the event that any court of competent jurisdiction shall determine that any one or more of the provisions
contained in this Article shall be unenforceable in any respect, then such provision
shall be deemed limited and restricted to the extent that the court shall deem the provision to be enforceable. It is the intention
of the parties to this Agreement that the covenants and restrictions in this Article be given the broadest interpretation permitted
by law. The invalidity or unenforceability of any provision of this Article shall not affect the validity or enforceability of
any other provision hereof. If, in any judicial or arbitration proceedings, a court of competent jurisdiction or arbitration panel
should refuse to enforce all of the separate covenants and restrictions in this Article, then such unenforceable covenants and
restrictions shall be eliminated from the provisions of this Agreement for the purpose of such proceeding to the extent necessary
to permit the remaining separate covenants and restrictions to be enforced in such proceeding.

 

    	-5-

    	 

    

 

ARTICLE
V

 

OWNERSHIP
OF PROPRIETARY RIGHTS

 

5.01
Proprietary Rights. For the purposes of this Agreement, “Proprietary Rights” shall mean all right, title
and interest (including any copyrights, patent rights, trademarks, servicemarks and trade names) in and to, or associated with,
or arising from, any and all notes, data, reference materials, sketches, drawings, memoranda, documentation, and any and all work
product conceived, created, reduced to any medium of expression and/or produced as part of the activities of Executive for the
Company, including all written, graphical, pictorial, visual, audio, and audiovisual elements relating thereto, software code
or records in any way incorporating or reflecting any Confidential Information and any original works of authorship, derivative
works, inventions, developments, concepts, know-how, improvements, trade secrets or ideas, whether or not fixed in a tangible
medium of expression, that are conceived or developed in whole or in part by the Executive alone or in conjunction with others,
whether or not conceived or developed during regular working hours by, or in association with, the Company that are made through
the use of any Confidential Information or any of the Company’s equipment, facilities, supplies, or trade secrets, or that
relate to the Company’s business or the Company’s actual or demonstrably anticipated research and development, or
that result from any work performed by the Executive for the Company.

 

5.02
Ownership of Proprietary Rights. The Executive covenants and agrees with the Company that all Proprietary Rights shall
belong exclusively to the Company, and the Executive agrees to assign and hereby assigns to the Company, all rights, title and
interest throughout the world in and to all Proprietary Rights. The Executive agrees to promptly make full written disclosure
to the Company, and will hold in trust for the sole right and benefit of the Company, all Proprietary Rights. The Executive agrees
that, upon request of the Company and without any separate remuneration or compensation, the Executive shall take such action
and execute and deliver such documents and instruments as may be necessary or proper to vest in the Company all right, title and
interest in and to all such Proprietary Rights. Without limiting the foregoing, the Executive further agrees that for any original
works of authorship created by the Executive, the Company shall be deemed the author thereof under the United States Copyright
Act; provided, however, that in the event and to the extent such works do not to constitute “works made for
hire” as a matter of law, the Executive agrees to irrevocably assign and transfer, and hereby irrevocably assigns and transfers
to the Company, all right, title and interest in and to such works, including but not limited to copyrights.

 

5.03
Maintenance of Records. The Executive covenants and agrees to take commercially reasonable measures to keep and maintain
adequate and current written records of all inventions and works of authorship made by the Executive (solely or jointly with others)
during the term of the Executive’s relationship with the Company. The records may be in the form of notes, sketches, drawings,
flow charts, electronic data or recordings, laboratory notebooks, and any other format. The records will be available to and remain
the sole property of the Company at all times. The Executive agrees not to remove such records from the Company’s place
of business except as expressly permitted by the Company policy, which may, from time to time, be revised at the sole election
of the Company. The Executive agrees to return all such records (including any copies thereof) to the Company at the time of termination
of services with the Company.

 

    	-6-

    	 

    

 

5.04
Recordation of Rights. The Executive covenants and agrees to assist the Company, or its designee, at the Company’s
expense, in every proper way to secure the Company’s, or its designee’s, rights in the inventions and any copyrights,
patents, trademarks, servicemarks, moral rights, or other intellectual property rights relating thereto in any and all countries,
including the disclosure to the Company or its designee of all pertinent information and data with respect thereto, the execution
of all applications, specifications, oaths, assignments, recordations, and all other instruments that the Company or its designee
shall deem necessary in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive such rights,
and in order to assign and convey to the Company or its designee and any successors, assigns and nominees the sole and exclusive
rights, title and interest in and to such inventions, and any copyrights, patents or other intellectual property rights relating
thereto. The Executive further agrees that the obligation to execute or cause to be executed, when it is in the Executive’s
power to do so, any such instrument or papers shall continue after the termination of this Agreement until the expiration of the
last such intellectual property right to expire in any country of the world. If the Company or its designee is unable because
of the Executive’s mental or physical incapacity or unavailability or for any other reason to secure the Executive’s
signature to apply for or to pursue any application for any United States or foreign patents, copyrights, or other registrations
covering inventions or works of authorship assigned or to be assigned to the Company or its designee as above, then the Executive
hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Executive’s agent
and attorney-in-fact, to act for and on the Executive’s behalf and stead to execute and file any such applications and to
do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of letters
patent, copyright or other registrations thereon with the same legal force and effect as if originally executed by the Executive.
The Executive hereby waives and irrevocably quitclaims to the Company or its designee any and all claims, of any nature whatsoever,
that the Executive now or hereafter has for infringement of any and all proprietary rights assigned to the Company or such designee.

 

ARTICLE
VI

MISCELLANEOUS

 

6.01
Benefit of Agreement and Assignment. This Agreement shall inure to the benefit of Employer and its successors and assigns
(including, without limitation, the purchaser of all or substantially all of its assets) and shall be binding upon Employer and
its successors and assigns. This Agreement shall also inure to the benefit of and be binding upon Executive and Executive’s
heirs, administrators, executors and assigns. Executive may not assign or delegate Executive’s duties under this Agreement,
without the prior written consent of Employer.

 

6.02
Notices. All notices, requests, demands and other communications required or permitted hereunder shall be given in writing
and shall be deemed to have been duly given (A) on the date delivered if personally delivered, (B) upon receipt by the receiving
party of any notice sent by registered or certified mail (first-class mail, postage pre-paid, return receipt requested) or (C)
on the date targeted for delivery if delivered by nationally recognized overnight courier or similar courier service, in each
case addressed to the Employer or Executive, as the case may be, at the respective addresses indicated in the caption of this
Agreement or such other address as either party may in the future specify in writing to the other.

 

    	-7-

    	 

    

 

6.03
Section 409A Compliance. All payments under this Agreement are intended to comply with or be exempt from the requirements
of Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). As used in this Agreement,
the “Code” means the Internal Revenue Code of 1986, as amended. To the extent that any provision in this Agreement
is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so that no payments due under
this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code. For purposes
of Section 409A, each payment made under this Agreement shall be treated as a separate payment. In no event may Executive, directly
or indirectly, designate the calendar year of payment. In no event whatsoever shall Employer be liable for any additional tax,
interest or penalty that may be imposed on Executive under Section 409A or damages for failing to comply with Section 409A.

 

6.04
Entire Agreement. This Agreement contains the entire agreement of the parties hereto with respect to his employments and
conditions of Executive’s employment during his employment and activities following termination of this Agreement and supersedes
any and all prior agreements and understandings whether written or oral, between the parties with respect to the subject matter
of this Agreement. This Agreement may not be changed or modified except by an instrument in writing, signed by Employer and Executive.

 

6.05
No Waiver. The waiver by other party of a breach of any provision of this Agreement shall not operate or be construed as
a continuing waiver or as a consent to or waiver of any subsequent breach hereof.

 

6.06
Headings. The Article and Section headings in this Agreement are for the convenience of reference only and do not constitute
a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

 

6.07
Governing Law; Jurisdiction. Any and all actions or controversies arising out of this Agreement or Executive’s employment,
including, without limitation, tort claims, shall be construed and enforced in accordance with the internal laws of the State
of New York, without regard to the choice of law principles thereof. Any and all actions arising out of this Agreement or Executive’s
employment by Employer or termination therefrom shall be brought and heard in the state and federal courts of the State of New
York located in New York County and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts.
Employer and Executive hereby agree to waive their respective rights to a trial by jury.

 

6.08
Executive Withholdings and Deductions. All payments to Executive hereunder shall be subject to such withholding and other
Executive deductions as may be required by law.

 

6.09
Counterparts. This Agreement may be executed in one more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.

 

6.10
Agreement to Take Actions. Each party to this Agreement shall execute and deliver such documents, certificates, agreements
and other instruments, and shall take all other actions, as may be reasonably necessary or desirable in order to perform his/her
or its obligations under this Agreement.

 

6.11
Survival. The Parties acknowledge and agree that the terms and conditions of Articles IV, Article V and Article VI shall
survive the termination of this Agreement and Executive’s employment hereunder.

 

[signature
page is next]

 

    	-8-

    	 

    

 

IN
WITNESS WHEREOF, Employer and Executive have duly executed this Agreement as of the date first written above.

 

	 	MOTUS
    GI HOLDINGS, INC.:
	 	 	 
	 	BY:	/s/
    Mark Pomeranz
	 	Name:	Mark
    Pomeranz
	 	Title:	Chief
    Exective Officer
	 	 	 
	 	EXECUTIVE:
	 	 	 
	 	/s/ James J. Martin
	 	James J. Martin

 

    	-9-SUBSCRIPTION
AGREEMENT

 

FOR

 

MOTUS
GI MEDICAL TECHNOLOGIES LTD.

 

Dated:
_________________, 2016

 

Motus
GI Medical Technologies Ltd.

c/o
Aegis Capital Corp.

810
Seventh Avenue – 18th Floor

New
York, NY 10019

 

Ladies
and Gentlemen:

 

1.
Subscription. The undersigned (the “Purchaser”) will purchase a 10% Convertible Promissory Note
(the “Note”, substantially in the form attached hereto as Exhibit B), together with a warrant
(the “Warrant”, substantially in the form attached hereto as Exhibit C) exerciseable for that
number of shares of Series A Convertible Preferred Stock, nominal value NIS 0.01 per share (the “Preferred Shares”)
of Motus GI Medical Technologies Ltd. (the “Company”), equal to 33% of the principal amount (the “Principal
Amount”) being subscribed for as set forth on the signature page to this subscription agreement (the “Subscription
Agreement”).

 

2.
Payment. The Purchaser will immediately make a wire transfer payment to the order of JPMorgan Chase, for credit
to Bank Leumi Le Israel, for the account of, “Motus GI Medical Technologies Ltd.,” in the Principal
Amount being subscribed for. Together with the wire transfer of the full Principal Amount, the Purchaser is delivering a completed
and executed Signature Page to this Subscription Agreement along with a completed and executed Investor Questionnaire, which is
attached hereto as Exhibit A. By executing this Subscription Agreement (this “Subscription Agreement”),
you will also be deemed to have executed the Joinder to Convertible Notes Agreement (the “Joinder”), in the
form of Exhibit D to this Subscription Agreement, and the Convertible Notes Agreement, dated June 9, 2015, as amended (the “CNA”),
as an Additional Purchaser (as defined in the CNA) in a Deferred Closing (as defined in the CNA), in the form of Exhibit E to
this Subscription Agreement (this Subscription Agreement, together with the Joinder, the CNA, the form of Note and the form of
Warrant are collectively referred to herein as the “Transaction Documents”), and will be bound by the respective
terms of this Subscription Agreement and the CNA.

 

3.
Deposit of Funds. All payments made as provided in Section 2 hereof will be deposited by the Purchaser as soon as
practicable with the Company. If the Company or Aegis Capital Corp. (“Aegis” or the “Placement
Agent”) rejects a subscription, either in whole or in part (at the sole discretion of the Company or Aegis), the
rejected subscription funds or the rejected portion thereof will be returned promptly to such Purchaser without interest, penalty,
expense or deduction.

 

4.
Acceptance of Subscription. The Purchaser understands and agrees that the Company or Aegis, each in its sole discretion,
reserves the right to accept this or any other subscription for the Note and the Warrants, in whole or in part, notwithstanding
prior receipt by the Purchaser of notice of acceptance of this or any other subscription. The Company will have no obligation
hereunder until the Company executes an executed copy of the Subscription Agreement. If the Purchaser’s subscription is
rejected in whole (at the sole discretion of the Company or Aegis), all funds received from the Purchaser will be returned without
interest, penalty, expense or deduction, and this Subscription Agreement will thereafter be of no further force or effect. If
Purchaser’s subscription is rejected in part (at the sole discretion of the Company or Aegis) and the Company accepts the
portion not so rejected, the funds for the rejected portion of such subscription will be returned without interest, penalty, expense
or deduction, and this Subscription Agreement will continue in full force and effect to the extent such subscription was accepted.

 

    	 	- 1 -	 

    	 

    

 

5.
Representations and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants, and agrees as
follows:

 

(a)
None of the Note, the Warrants, or the Preferred Shares (collectively referred to hereafter as the “Securities”)
are registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities
laws. The Purchaser understands that the offering and sale of the Securities is intended to be exempt from registration under
the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D promulgated thereunder, based, in
part, upon the representations, warranties and agreements of the Purchaser contained in this Subscription Agreement and the CNA;

 

(b)
The Purchaser and the Purchaser’s attorney, accountant, purchaser representative and/or tax advisor, if any (collectively,
“Advisors”), have received and have carefully reviewed this Subscription Agreement, and each of the
Transaction Documents and all other documents requested by the Purchaser or its Advisors, if any, and understand the information
contained therein, prior to the execution of this Subscription Agreement;

 

(c)
Neither the Securities and Exchange Commission (the “Commission”) nor any state securities commission
has approved or disapproved of the Securities or passed upon or endorsed the merits of this offering or confirmed the accuracy
or determined the adequacy of the Transaction Documents. The Transaction Documents have not been reviewed by any Federal, state
or other regulatory authority. Any representation to the contrary may be a criminal offense;

 

(d)
All documents, records, and books pertaining to the investment in the Securities including, but not limited to, all information
regarding the Company and the Securities, have been made available for inspection and reviewed by the Purchaser and its Advisors,
if any;

 

(e)
The Purchaser and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from the Company’s
officers and any other persons authorized by the Company to answer such questions, concerning, among other related matters, the
Securities, the Transaction Documents and the business, financial condition, results of operations and prospects of the Company
and all such questions have been answered by the Company to the full satisfaction of the Purchaser and its Advisors, if any;

 

(f)
In evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or other information
(oral or written) other than as stated in the Transaction Documents;

 

(g)
The Purchaser is unaware of, is in no way relying on, and did not become aware of the offering of the Securities through or as
a result of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement
or other communication published in any newspaper, magazine or similar media or broadcast over television, radio or over the Internet,
in connection with the offering and sale of the Securities and is not subscribing for the Securities and did not become aware
of the offering through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of
a subscription by, a person not previously known to the Purchaser in connection with investments in securities generally;

 

    	 	- 2 -	 

    	 

    

 

(h)
The Purchaser has taken no action which would give rise to any claim by any person for brokerage commissions, finders’ fees
or the like relating to this Subscription Agreement or the transactions contemplated hereby (other than fees to be paid by the
Company to Aegis);

 

(i)
The Purchaser, either alone or together with its Advisors, if any, has such knowledge and experience in financial, tax, and business
matters, and, in particular, investments in securities, so as to enable it to utilize the information made available to it in
connection with this offering to evaluate the merits and risks of an investment in the Securities and the Company and to make
an informed investment decision with respect thereto;

 

(j)
The Purchaser is not relying on the Company, Aegis or any of their respective employees or agents with respect to the legal, tax,
economic and related considerations of an investment in any of the Securities and the Purchaser has relied on the advice of, or
has consulted with, only its own Advisors;

 

(k)
The Purchaser is acquiring the Securities solely for such Purchaser’s own account for investment and not with a view to
resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any
person to sell or transfer all or any part of any of the Securities and the Purchaser has no plans to enter into any such agreement
or arrangement;

 

(l)
The Purchaser understands and agrees that purchase of the Securities is a high risk investment and the Purchaser is able to afford
an investment in a speculative venture having the risks and objectives of the Company. The Purchaser must bear the substantial
economic risks of the investment in the Securities indefinitely because none of the Securities may be sold, hypothecated or otherwise
disposed of unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from
such registration is available. Legends will be placed on the certificates representing the Note, the Warrants and the Preferred
Shares issuable upon exercise of the Warrants to the effect that such securities have not been registered under the Securities
Act or applicable state securities laws and appropriate notations thereof will be made in the Company’s books;

 

(m)
The Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies
and has no need for liquidity from its investment in the Securities for an indefinite period of time;

 

(n)
The Purchaser is aware that an investment in the Securities involves a number of very significant risks and has carefully read
and considered the matters set forth in the Transaction Documents and understands any risk may materially adversely affect the
Company’s operations and future prospects;

 

(o)
At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises
any Warrants, it will be an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by
the Securities and Exchange Commission under the Securities Act and has truthfully and accurately completed the Investor Questionnaire
attached as Exhibit A to this Subscription Agreement and will submit to the Company such further assurances of such status
as may be reasonably requested by the Company;

 

    	 	- 3 -	 

    	 

    

 

(p)
The Purchaser: (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority
to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions
hereof and thereof; (ii) if a corporation, partnership, or limited liability company, or association, joint stock company, trust,
unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring
the Securities, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or
its charter or other organizational documents, such entity has full power and authority to execute and deliver this Subscription
Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase
and hold the Securities, the execution and delivery of this Subscription Agreement has been duly authorized by all necessary action,
this Subscription Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation
of such entity; or (iii) if executing this Subscription Agreement in a representative or fiduciary capacity, represents that it
has full power and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing
individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom
the Purchaser is executing this Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or
limited liability company or partnership, or other entity has full right and power to perform pursuant to this Subscription Agreement
and make an investment in the Company, and represents that this Subscription Agreement constitutes a legal, valid and binding
obligation of such entity. The execution and delivery of this Subscription Agreement will not violate or be in conflict with any
order, judgment, injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound;

 

(q)
The Purchaser and its Advisors, if any, have had the opportunity to obtain any additional information, to the extent the Company
had such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Transaction Documents including, but not limited to, the terms and conditions of the Securities
as set forth therein and all other related documents, received or reviewed in connection with the purchase of the Securities and
have had the opportunity to have representatives of the Company provide them with such additional information regarding the terms
and conditions of this particular investment and the financial condition, results of operations, business and prospects of the
Company deemed relevant by the Purchaser or its Advisors, if any, and all such requested information, to the extent the Company
had such information in its possession or could acquire it without unreasonable effort or expense, has been provided by the Company
in writing to the full satisfaction of the Purchaser and its Advisors, if any;

 

(r)
The Purchaser represents to the Company that any information which the undersigned has heretofore furnished or is furnishing herewith
to the Company is complete and accurate and may be relied upon by the Company in determining the availability of an exemption
from registration under Federal and state securities laws in connection with the offering of securities as described in the Transaction
Documents;

 

(s)
The Purchaser has significant prior investment experience, including investment in non-listed and unregistered securities. The
Purchaser has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should
occur. The Purchaser’s overall commitment to investments which are not readily marketable is not excessive in view of the
Purchaser’s net worth and financial circumstances and the purchase of the Securities will not cause such commitment to become
excessive. This investment is a suitable one for the Purchaser;

 

(t)
The Purchaser is satisfied that it has received adequate information with respect to all matters which it or its Advisors, if
any, consider material to its decision to make this investment;

 

(u)
The Purchaser acknowledges that any and all estimates or forward-looking statements or projections included in the Transaction
Documents were prepared by the Company in good faith, but that the attainment of any such projections, estimates or forward-looking
statements cannot be guaranteed, will not be updated by the Company and should not be relied upon;

 

    	 	- 4 -	 

    	 

    

 

(v)
No oral or written representations have been made, or oral or written information furnished, to the Purchaser or its Advisors,
if any, in connection with the offering of the Securities which are in any way inconsistent with the information contained in
the Transaction Documents;

 

(w)
Within five (5) days after receipt of a request from the Company, the Purchaser will provide such information and deliver such
documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company is subject;

 

(x)
THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF CERTAIN STATES AND ARE
BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES
ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID
ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED
UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE TRANSACTION DOCUMENTS. ANY REPRESENTATION TO THE
CONTRARY IS UNLAWFUL;

 

(y)
In making an investment decision, investors must rely on their own examination of Company and the terms of this offering, including
the merits and risks involved. Investors should be aware that they will be required to bear the financial risks of this investment
for an indefinite period of time;

 

(z)
(For ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary
has been informed of and understands the Company’s investment objectives, policies and strategies, and that the decision
to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA
that require diversification of plan assets and impose other fiduciary responsibilities. The Purchaser or Plan fiduciary (a) is
responsible for the decision to invest in the Company; (b) is independent of the Company and any of its affiliates; (c) is qualified
to make such investment decision; and (d) in making such decision, the Purchaser or Plan fiduciary has not relied on any advice
or recommendation of the Company or any of its affiliates; and

 

(aa)
The Purchaser has read in its entirety the Transaction Documents and all exhibits thereto, including, but not limited to, all
information relating to the Company, and the Securities, and understands fully to its full satisfaction all information included
in the Transaction Documents.

 

(bb)
The Purchaser represents that (i) the Purchaser was contacted regarding the sale of the Securities by the Company or the Placement
Agent (or another person whom the Purchaser believed to be an authorized agent or representative thereof) with whom the Purchaser
had a prior substantial pre-existing relationship and (ii) it did not learn of the offering of the Securities by means of any
form of general solicitation or general advertising, and in connection therewith, the Purchaser did not (A) receive or review
any advertisement, article, notice or other communication published in a newspaper or magazine or similar media or broadcast over
television or radio, whether closed circuit, or generally available; or (B) attend any seminar meeting or industry investor conference
whose attendees were invited by any general solicitation or general advertising;

 

    	 	- 5 -	 

    	 

    

 

(cc)
The Purchaser consents to the placement of a legend on any certificate or other document evidencing the Securities and, when issued,
the Preferred Shares, that such securities have not been registered under the Securities Act or any state securities or “blue
sky” laws and setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement.
The Purchaser is aware that the Company will make a notation in its appropriate records with respect to the restrictions on the
transferability of such Securities. The legend to be placed on each certificate shall be in form substantially similar to the
following:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”)
OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED
ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS
NOT REQUIRED.”

 

(dd)
The Purchaser acknowledges that if he or she is a Registered Representative of a Financial Industry Regulatory Authority (“FINRA”)
member firm, he or she must give such firm the notice required by the FINRA’s Rules of Fair Practice, receipt of which must
be acknowledged by such firm prior to an investment in the Securities.

 

(ee)
The Purchaser agrees not to issue any public statement with respect to this offering, the Purchaser’s investment or proposed
investment in the Company or the terms of any agreement or covenant between them and the Company without the Company’s prior
written consent, except such disclosures as may be required under applicable law.

 

(ff)
The Purchaser understands, acknowledges and agrees with the Company that this subscription may be rejected, in whole or in part,
by the Company, in the sole and absolute discretion of the Company, at any time notwithstanding prior receipt by the Purchaser
of notice of acceptance of the Purchaser’s subscription.

 

(gg)
The Purchaser acknowledges that the information contained in the Transaction Documents or otherwise made available to the Purchaser
is confidential and non-public and agrees that all such information shall be kept in confidence by the Purchaser and neither used
by the Purchaser for the Purchaser’s personal benefit (other than in connection with this subscription) nor disclosed to
any third party for any reason, notwithstanding that a Purchaser’s subscription may not be accepted by the Company; provided,
however, that (a) the Purchaser may disclose such information to its affiliates and advisors who may have a need for such information
in connection with providing advice to the Purchaser with respect to its investment in the Company so long as such affiliates
and advisors have an obligation of confidentiality, and (b) this obligation shall not apply to any such information that (i) is
part of the public knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the public knowledge
or literature and readily accessible by publication (except as a result of a breach of this provision) or (iii) is received from
third parties without an obligation of confidentiality (except third parties who disclose such information in violation of any
confidentiality agreements or obligations, including, without limitation, any subscription or other similar agreement entered
into with the Company).

 

    	 	- 6 -	 

    	 

    

 

6.
Representations and Warranties of the Company. The Company hereby acknowledges, represents, warrants, and agrees as follows:

 

(a)
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Israel and has full corporate power and authority to conduct its business as currently
conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction
in which the property owned or leased by it or the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or in good standing would not have, individually or in the aggregate,
a material adverse effect on the business, operations, conditions (financial or otherwise), assets, results of operations or prospects
of that entity individually or of the Company and its subsidiaries as a whole.

 

(b)
Authorization; Enforceability. The Company has all corporate right, power and authority to enter into this Subscription
Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors
and stockholders necessary for the authorization, execution, delivery and performance of this Subscription Agreement by the Company,
the authorization, sale, issuance and delivery of the Securities contemplated herein and the performance of the Company’s
obligations hereunder has been taken. This Subscription Agreement has been duly executed and delivered by the Company and constitutes
a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to
laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance,
injunctive relief or other equitable remedies, and to limitations of public policy. The issuance and sale of the Securities contemplated
hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person.

 

(c)
No Conflict; Governmental and Other Consents.

 

(i)
The execution and delivery by the Company of this Subscription Agreement and the consummation of the transactions contemplated
hereby will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of
any court or governmental authority to or by which the Company or any subsidiary is bound, or of any provision of the Articles
of Association of the Company or any subsidiary, and will not conflict with, or result in a breach or violation of, any of the
terms or provisions of, or constitute (with due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage,
security agreement, trust indenture or other agreement or instrument to which the Company or any subsidiary is a party or by which
it is bound or to which any of its properties or assets is subject, nor result in the creation or imposition of any lien upon
any of the properties or assets of the Company or any subsidiary.

 

(ii)
No consent, approval, authorization or other order of any governmental authority or other third-party is required to be obtained
by the Company or any subsidiary in connection with the authorization, execution and delivery of this Subscription Agreement or
with the authorization, issue and sale of the Securities, except such filings as may be required to be made with the Commission
and with any state or foreign blue sky or securities regulatory authority.

 

(d)
Litigation. There is no pending or, to the actual knowledge of any officer or director of the Company, after due investigation,
threatened legal or governmental proceedings to which the Company is a party which could materially adversely affect the business,
property, financial condition or operations of the Company or the Company’s ability to perform its obligations under this
Subscription Agreement.

 

    	 	- 7 -	 

    	 

    

 

7.
Indemnification. The Purchaser agrees to indemnify and hold harmless the Company, Aegis and each of their respective officers,
directors, managers, employees, agents, attorneys, control persons and affiliates from and against all losses, liabilities, claims,
damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing
or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false acknowledgment,
representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser of any covenant
or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription Agreement.

 

8.
Binding Effect. This Subscription Agreement will survive the death or disability of the Purchaser and will be binding upon
and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives, and permitted
assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder will be joint and several and the
agreements, representations, warranties and acknowledgments herein will be deemed to be made by and be binding upon each such
person and such person’s heirs, executors, administrators, successors, legal representatives and permitted assigns.

 

9.
Modification. This Subscription Agreement will not be modified or waived except by an instrument in writing signed by the
party against whom any such modification or waiver is sought.

 

10.
Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party notified, (b) when sent by confirmed email or facsimile if sent
during normal business hours of the recipient, or if not confirmed, then on the next business day, (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. The Company and the Purchaser
hereby consent to the delivery of communications and notices to such parties at their respective address, email or facsimile number
set forth on the signature page hereto, or to such other address as such party shall have furnished in writing in accordance with
the provisions of this Section 10.

 

11.
Assignability. This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or
assignable by the Purchaser and the transfer or assignment of any of the Securities will be made only in accordance with all applicable
laws.

 

12.
Applicable Law. This Subscription Agreement will be governed by and construed under the laws of the State of New York as
applied to agreements among New York residents entered into and to be performed entirely within New York. The parties hereto (1)
agree that any legal suit, action or proceeding arising out of or relating to this Subscription Agreement will be instituted exclusively
in New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York,
(2) waive any objection which the parties may have now or hereafter to the venue of any such suit, action or proceeding, and (3)
irrevocably consent to the jurisdiction of the New York State Supreme Court, County of New York, and the United States District
Court for the Southern District of New York in any such suit, action or proceeding. Each of the parties hereto further agrees
to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New
York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and
agrees that service of process upon it mailed by certified mail to its address will be deemed in every respect effective service
of process upon it, in any such suit, action or proceeding. THE PARTIES HERETO AGREE TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY
TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SUBSCRIPTION AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED
HEREBY.

 

    	 	- 8 -	 

    	 

    

 

13.
Blue Sky Qualification. The purchase of Securities pursuant to this Subscription Agreement is expressly conditioned upon
the exemption from qualification of the offer and sale of the Securities from applicable federal and state securities laws.

 

14.
Use of Pronouns. All pronouns and any variations thereof used herein will be deemed to refer to the masculine, feminine,
neuter, singular or plural as the identity of the person or persons referred to may require.

 

15.
Confidentiality. The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or
about the Company not otherwise properly in the public domain, was received in confidence. The Purchaser agrees not to divulge,
communicate or disclose, except as may be required by law or for the performance of this Subscription Agreement, or use to the
detriment of the Company or for the benefit of any other person or persons, or misuse in any way, any confidential information
of the Company, including any trade or business secrets of the Company and any business materials that are treated by the Company
as confidential or proprietary, including, without limitation, confidential information obtained by or given to the Company about
or belonging to third parties.

 

16.
Miscellaneous.

 

(a)
This Subscription Agreement, together with the other Transaction Documents, constitute the entire agreement between the Purchaser
and the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings,
if any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent
for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or
provisions.

 

(b)
Each of the Purchaser’s and the Company’s representations and warranties made in this Subscription Agreement will
survive the execution and delivery hereof and delivery of the Securities.

 

(c)
Each of the parties hereto will pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or
others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether
or not the transactions contemplated hereby are consummated.

 

(d)
This Subscription Agreement may be executed in one or more counterparts each of which will be deemed an original, but all of which
will together constitute one and the same instrument.

 

(e)
Each provision of this Subscription Agreement will be considered separable and, if for any reason any provision or provisions
hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality will not impair the operation
of or affect the remaining portions of this Subscription Agreement.

 

(f)
Paragraph titles are for descriptive purposes only and will not control or alter the meaning of this Subscription Agreement as
set forth in the text.

 

17.
Signature Page. It is hereby agreed by the parties hereto that the execution by the Purchaser of this Subscription Agreement,
in the place set forth hereinbelow, will be deemed and constitute the agreement by the Purchaser to be bound by all of the terms
and conditions hereof as well as by the Joinder, the CNA and each of the other Transaction Documents, and will be deemed and constitute
the execution by the Purchaser of all such Transaction Documents without requiring the Purchaser’s separate signature on
any of such Transaction Documents.

 

[Remainder
of page intentionally left blank.]

 

    	 	- 9 -	 

    	 

    

 

ANTI-MONEY
LAUNDERING REQUIREMENTS

 

	The
                                         USA PATRIOT Act
	 	What
    is money laundering?	 	How
    big is the problem and why is it important?
	

        The
        USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad. The Act imposes new
        anti-money laundering requirements on brokerage firms and financial institutions. Since April 24, 2002 all brokerage firms
        have been required to have new, comprehensive anti-money laundering programs. To help you understand these efforts, we
        want to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.
	 	

        Money
        laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources
        or activities. Money laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug
        trafficking, robbery, fraud, racketeering, and terrorism.
	 	

        The
        use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets.
        According to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at
        $1 trillion a year.

 

	What
    are we required to do to eliminate money laundering?
	 
	

        Under
        new rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer,
        set up employee training, conduct independent audits, and establish policies and procedures to detect and report suspicious
        transaction and ensure compliance with the new laws.
	 	

        As
        part of our required program, we may ask you to provide various identification documents or other information. Until you
        provide the information or documents we need, we may not be able to effect any transactions for you.

 

    	 	- 10 -	 

    	 

    

 

MOTUS
GI MEDICAL TECHNOLOGIES LTD.

SIGNATURE
PAGE TO

SUBSCRIPTION
AGREEMENT 

 

Purchaser
hereby elects to purchase a 10% Convertible Promissory Note for a total principal amount of $_________________, together with
a Warrant exerciseable for that number of shares of Series A Convertible Preferred Stock of Motus GI Medical Technologies Ltd.
equal to 33% of the principal amount of the Note (NOTE: to be completed by the Purchaser).

 

Date
(NOTE: To be completed by the Purchaser): __________________, 2016

 

 

If
the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

 

	 	 	 
	Print
    Name(s)	 	Social
    Security Number(s)
	 	 	 
	Print
    Name(s)	 	Social
    Security Number(s)
	 	 	 
	Signature(s)
    of Purchaser(s)	 	Signature
	 	 	 
	Address:	 	 
	 	 	Date
	 	 	 
	 	 	 

 

 

If
the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 
	 	 	Federal
    Taxpayer
	Name
    of Partnership,	 	Identification
    Number 
	Corporation,
    Limited 	 	 
	Liability
    Company or Trust	 	 
	 	 	 	 
	By:	 	 	 
	Name:	 	 	State
    of Organization
	Title:	 	 	 
	 	 	 	 
	Address:	 	 
	 	 	Date
	 	 	 
	 	 	 

 

AGREED
AND ACCEPTED:

 

MOTUS
GI MEDICAL TECHNOLOGIES LTD.

 

	By:	 	 	 
	Name:	 	 	Date
	Title:	 	 	 

 

    	 	 	 

    	 

    

 

Exhibit
A

 

FORM
OF INVESTOR QUESTIONNAIRE

 

MOTUS
GI MEDICAL TECHNOLOGIES LTD.

 

For
Individual Investors Only

 

(All
individual investors must INITIAL where appropriate. Where there are joint investors both parties must INITIAL):

 

	Initial
    _______ 	I
    have an individual net worth, or joint net worth with my spouse, as of the date hereof in excess of $1 million. For purposes
    of calculating net worth under this category, (i) the undersigned’s primary residence shall not be included as an asset,
    (ii) indebtedness that is secured by the undersigned’s primary residence, up to the estimated fair market value of the
    primary residence at the time of the sale of securities, shall not be included as a liability, (iii) to the extent that the
    indebtedness that is secured by the primary residence is in excess of the fair market value of the primary residence, the
    excess amount shall be included as a liability, and (iv) if the amount of outstanding indebtedness that is secured by the
    primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement, other than
    as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability.
	 	 
	Initial
    _______	I
    have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect
    my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 
	Initial
    _______	I
    am a director or executive officer of Motus GI Medical Technologies Ltd.

 

For
Non-Individual Investors

 

(all
Non-Individual Investors must INITIAL where appropriate):

 

	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by
    persons who meet at least one of the criteria for Individual Investors set forth above. 
	 	 
	Initial
    _______	The
    investor certifies that it is a partnership, corporation, limited liability company or any organization described in Section
    501(c)(3) of the Internal Revenue Code, Massachusetts or similar business trust that has total assets of at least $5 million
    and was not formed for the purpose of investing the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is an employee benefit plan within the meaning of the Employee Retirement Income Security Act of
    1974, whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and
    loan association, insurance company or registered investment adviser.

 

    	 	 	 

    	 

    

 

	Initial
    _______	The
    investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Subscription
    Agreement.
	 	 
	Initial
    _______	The
    undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons
    who meet either of the criteria for Individual Investors.
	 	 
	Initial
    _______	The
    investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its
    individual or fiduciary capacity.
	 	 
	Initial
    _______	The
    undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 
	Initial
    _______	The
    investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets
    exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 
	Initial
    _______	The
    investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing
    in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters
    that he is capable of evaluating the merits and risks of the prospective investment.
	 	 
	Initial
    _______	The
    investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or
    instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 
	Initial
    _______	The
    investor certifies that it is an insurance company as defined in §2(13) of the Securities Act, or a registered investment
    company.
	 	 
	Initial
    _______	An
    investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section
    2(a)(48) of that Act.
	 	 
	Initial
    _______	A
    Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small
    Business Investment Act of 1958.
	 	 
	Initial
    _______	A
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

    	 	 	 

    	 

    

 

MOTUS
GI MEDICAL TECHNOLOGIES LTD.

Investor
Profile (Must be completed by Investor)

Section
A - Personal Investor Information

 

For
All Purchasers

Certificate
Title: ______________________________________________________________________________

Individual(s)
executing this subscription: __________________________________________________________

Social
Security Number(s) for all signatories / Entity Federal I.D. Number: _______________________________

Date(s)
of Birth: ______________

Marital
Status: ______________

Years
Investment Experience: ______________

Aegis
Capital Account Executive or Outside Broker/Dealer: ______________

Check
if you are a FINRA member or affiliate of a FINRA member firm: ____

Check
Investment Objective(s) (See definitions on following page): ____Preservation of Capital ____Income

____Capital
Appreciation ____Trading Profits ____Speculation

____Other
(please specify)

The
source of funds for this investment is my personal or my entity’s assets _____Yes _____No

 

For
Purchasers as Individual or as Joint Tenants, Tenants in Common, and Community Property 

Annual
Income(s): ___________________

Liquid
Net Worth(s): _________________

Net
Worth(s) (excluding value of primary residence): ________________

Select
Tax Bracket(s): ____ 15% or below ____ 25% - 27.5% ____ Over 27.5%

 

For
All Purchasers, by the Primary Contact

Home
Street Address: ______________________________________________________________________

Home
City, State & Zip Code: _______________________________________________________________

Home
Phone: ___________________ Home Fax: _________________Home Email: ____________________

Employer:
___________________________________

Type
of Business: _____________________________

Employer
Street Address: ___________________________________________________________________

Employer
City, State & Zip Code: ____________________________________________________________

Bus.
Phone: _____________________Bus. Fax: ___________________Bus. Email: ____________________

 

For
All Purchasers

If
you are a United States citizen, please list the number and jurisdiction of issuance of any other government-issued
document evidencing residence and bearing a photograph or similar safeguard (such as a driver’s license or passport), and
provide a photocopy of each of the documents you have listed.

If
you are NOT a United States citizen, for each jurisdiction of which you are a citizen or in which
you work or reside, please list (i) your passport number and country of issuance or (ii) alien identification card number AND
(iii) number and country of issuance of any other government-issued document evidencing nationality or residence and bearing
a photograph or similar safeguard, and provide a photocopy of each of these documents you have listed. These photocopies must
be certified by a lawyer as to authenticity.

 

Government-Issued
Identification Document Number(s) and Jurisdiction(s):___________________________

Please
provide a legible photocopy of your Identification Document(s) along with your subscription

 

Section
B – Securities Delivery Instructions

____
Please deliver securities to the Employer Address listed in Section A.

____
Please deliver securities to the Home Address listed in Section A.

____
Please deliver securities to the following address: _____________________________________________

 

Section
C –Wire Transfer Instructions

____
I will wire funds from my outside account according to the “Subscription Instructions” Page.

____
I will wire funds from my Aegis Capital Account.

____The
funds for this investment are rolled over, tax deferred from __________ within the allowed 60 day window.

 

		 	
	Investor
    Signature	 	Date
	 	 	 
	Investor
    Signature	 	Date

 

    	 	 	 

    	 

    

 

Investment
Objectives: The typical investment listed with each objective are only some examples of the kinds of investments that have
historically been consistent with the listed objectives. However, neither Motus GI Medical Technologies Ltd. nor Aegis Capital
Corp. can assure that any investment will achieve your intended objective. You must make your own investment decisions and determine
for yourself if the investments you select are appropriate and consistent with your investment objectives.

 

Neither
Motus GI Medical Technologies Ltd. nor Aegis Capital Corp. assumes responsibility to you for determining if the investments you
selected are suitable for you.

 

Preservation
of Capital: An investment objective of Preservation of Capital indicates you seek to maintain the principal value of
your investments and are interested in investments that have historically demonstrated a very low degree of risk of loss of principal
value. Some examples of typical investments might include money market funds and high quality, short-term fixed income products.

 

Income:
An investment objective of Income indicates you seek to generate income from investments and are interested in investments
that have historically demonstrated a low degree of risk of loss of principal value. Some examples of typical investments might
include high quality, short and medium-term fixed income products, short-term bond funds and covered call options.

 

Capital
Appreciation: An investment objective of Capital Appreciation indicates you seek to grow the principal value of your
investments over time and are willing to invest in securities that have historically demonstrated a moderate to above average
degree of risk of loss of principal value to pursue this objective. Some examples of typical investments might include common
stocks, lower quality, medium-term fixed income products, equity mutual funds and index funds.

 

Trading
Profits: An investment objective of Trading Profits indicates you seek to take advantage of short-term trading opportunities,
which may involve establishing and liquidating positions quickly. Some examples of typical investments might include short-term
purchases and sales of volatile or low priced common stocks, put or call options, spreads, straddles and/or combinations on equities
or indexes. This is a high-risk strategy.

 

Speculation:
An investment objective of Speculation indicates you seek a significant increase in the principal value of your investments
and are willing to accept a corresponding greater degree of risk by investing in securities that have historically demonstrated
a high degree of risk of loss of principal value to pursue this objective. Some examples of typical investments might include
lower quality, long-term fixed income products, initial public offerings, volatile or low priced common stocks, the purchase or
sale of put or call options, spreads, straddles and/or combinations on equities or indexes, and the use of short-term or day trading
strategies.

 

Other:
Please specify.

 

    	 	 	 

    	 

    

 

Exhibit
B

 

Form
of 10% Convertible Promissory Note

 

    	 	 	 

    	 

    

 

Exhibit
C

 

Form
of Warrant

 

    	 	 	 

    	 

    

 

Exhibit
D

 

Joinder
to Convertible Notes Agreement 

 

    	 	 	 

    	 

    

 

Exhibit
E

 

Convertible
Notes Agreement, As Amended

 

    	 	 	 

    	 

    

 

Exhibit
B

 

Form
of 10% Convertible Promissory Note

 

    	 

    	 		 

    

 

Date:
______________

Purchaser:
________________________

Principal
Amount: US$________________

 

CONVERTIBLE

 

PROMISSORY
NOTE

 

For
value received, Motus GI Medical Technologies Ltd., an Israeli company (“Company”) promises to pay to
the Purchaser named above (“Holder”), the principal sum stated above (the “Principal Amount”)
in accordance with the terms set forth herein, as follows:

 

	1.	Note
    Part of a Series. This Note is being sold by the Company as part of a series of notes issued pursuant to that certain
    Convertible Notes Agreement dated as of June 9, 2015, by and among the Company and purchasers of such Notes, as amended (the
    “CNA”). The term “Notes” shall mean herein all Notes issued under the CNA.
	 	 
	2.	Interest.
    Interest shall accrue on the unpaid Principal Amount of this Note from the date of this Note until the actual repayment of
    all amounts due hereunder, at an annual rate of 10% (ten percent), compounded annually. Interest shall be computed on the
    basis of a year of 360 days for the actual number of days occurring in the period for which such interest is payable. Upon
    conversion of the Principal Amount in accordance with the terms hereof, all interest accrued thereon shall be converted together
    with the Principal Amount or repaid to the Holder in cash, after deduction of all applicable taxes with respect thereto, as
    shall be determined by the Company, at its sole discretion. The actual amount to be converted in accordance with the Company’s
    election, as specified in the preceding sentence, shall be hereinafter referred to as the “Conversion Amount.”
	 	 
	3.	Automatic
    Conversion upon QFR. To the extent not previously converted or repaid according to the terms specified herein, the
    Conversion Amount shall be automatically converted, immediately prior and subject to the closing of a QFR (as defined below),
    on the same terms and conditions applicable to the QFR, such that the Holder shall receive the same type of securities issued,
    and any other rights granted to the investors in such QFR (the “QFR Securities”), under the same terms
    as if the Holder had participated in the QFR as an investor (including any warrants or any other securities granted to the
    investors therein), but at a conversion price per share equal to the QFR Conversion Price (as defined below).
	 	 
	 	It
    being agreed and acknowledged that (a) the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of QFR Securities issued to the Holder shall be set to be the QFR Conversion Price, and any
    rights that are attached to the QFR Securities issued to the Holder which are determined, derived, calculated, triggered,
    or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend preferences,
    anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual QFR Conversion
    Price; and (b) in the event that the QFR Securities also comprise of warrants to purchase, or other securities convertible
    into, shares of the Company (any such preceding convertible security a “Convertible Security”), then (i)
    upon such conversion, the Holder shall be entitled to receive such number of warrants and/or Convertible Securities of the
    same class or type that are issued to the investors in the framework of the QFR, in a number which shall be determined using
    the same warrant and/or Convertible Securities coverage ratio offered to the investors in such QFR, such that the ratio between
    the shares and the warrants and/or Convertible Securities issued to the Holder shall be equal to the ratio between the shares
    and the warrants and/or Convertible Securities issued to each investor in such QFR; and (ii) the discount rate reflected in
    the QFR Conversion Price shall not apply in respect of the exercise price or conversion price (as applicable) of such warrants
    and/or Convertible Securities.

 

    	 

    	- 2 -

    

 

For
example, if the terms of the QFR are as follows:

 

	 	●	The
    QFR unit price is US$10.
	 	 	 
	 	●	Each
    unit is comprised of two (2) Ordinary Shares and one (1) warrant to purchase one (1) Ordinary Share.
	 	 	 
	 	●	The
    discount rate reflected in the QFR Conversion Price of the Holder is 10%. 
	 	 	 
	 	●	The
    exercise price of the warrants issued in the QFR is US$12.
	 	 	 
	 	●	The
    Conversion Amount of the Holder is US$1,800.

 

then,
in the framework of such QFR, the Holder shall be issued, upon conversion of the Conversion Amount, 200 Ordinary Shares ((US$1,800))/((1-10%)*US$10))
and 100 warrants to purchase 100 Ordinary Shares (100/2), at an exercise price per share of US$12, while an investor, who is not
a holder of Notes, and invests in the QFR the same amount (i.e., US$1,800), shall be issued only 180 Ordinary Shares and 90 warrants
to purchase 90 Ordinary Shares, at an exercise price per share of US$12.

 

The
term “QFR” means the first financing round consummated by the Company after the date of the Note, through an
equity investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance of
shares upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate investment
amount of not less than US$3,000,000 (Three US Dollars), excluding the outstanding principal amount of the Notes and all accrued
and unpaid interest thereon.

 

The
term “QFR Conversion Price” means a conversion price reflecting the lower of (i) a 10% discount on the price
paid by the investor(s) for the shares issued in the QFR; or (ii) US$1.15 per share. Notwithstanding the foregoing, in the event
that the QFR in an initial public offering with gross proceeds to the Company of not less than US$25,000,000 (Twenty Five Million
US Dollars) (including the outstanding principal amount of the Notes and all accrued and unpaid interest thereon) (the “QIPO”),
the QFR Conversion Price shall mean a conversion price reflecting a 50% discount on the price paid for the shares issued in the
QIPO and if the price in such QIPO is fixed per each unit offered in the QIPO, the discount shall be applicable to such unit price.

 

If
this Note is converted in accordance with this Section ‎3, written notice shall be delivered to the Holder of this Note, notifying
the Holder of the conversion, specifying the Conversion Amount, the date of such conversion, and the securities issued upon conversion.
For the avoidance of doubt, in such event this Note shall be null and void even if not surrendered to the Company.

 

    	 

    	- 3 -

    

 

	4	Automatic
    Conversion upon M&A Event. 

 

	 	4.1.	In
    the event that, prior to the conversion of the Conversion Amount or its repayment according to the terms specified herein,
    an M&A Event (as defined below) shall occur, then immediately prior and subject to the closing of such M&A Event,
    the Conversion Amount shall be automatically converted into Series A Preferred Shares, par value NIS 0.01 per share, of the
    Company (the “Preferred A Shares”), at a conversion price equal to the price per share paid by the Company’s
    investors in consideration for the Preferred A Shares (i.e., US$1) (the “M&A Conversion Price”). 
	 	 	 
	 	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the M&A Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    M&A Conversion Price.
	 	 	 
	 	 	The
    term “M&A Event” means (i) a merger or consolidation of the Company in which the Company’s shareholders
    immediately prior to such transaction do not own, directly or indirectly, more than 50% of the share capital of the surviving
    entity; (ii) the acquisition of more than 50% of the Company’s outstanding share capital by a single unaffiliated person,
    entity or group ,or by persons or entities acting in concert; (iii) the sale or transfer of all or substantially all of the
    assets of the Company; or (iv) a reverse triangular merger in which the Company is the surviving entity but the shares of
    the Company’s share capital outstanding immediately prior to the merger are converted by virtue of the merger into other
    property, whether in the form of securities, cash or otherwise.
	 	 	 
	 	4.2.	Irrespective
    of any other provision of this Note, in the event that prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company becomes a subsidiary of a newly-formed entity formed under the laws of one of the
    states of the United States (“Newco”) either by way of a reverse triangular merger or by way of share swap
    or by way of any other similar transaction or series of related transactions, the result of which will be the capital stock
    of the Company being wholly owned by Newco (or any other entity into which or with which Newco merges), and simultaneously
    with or in connection with such transaction(s) or shortly thereafter, Newco (or any other entity into which or with which
    Newco merges), consummates an equity financing of at least US$ 10,000,000 (the “New Financing”), the Conversion
    Amount will be automatically exchanged for a number of securities (including any “units” or basket of securities
    that consist of stock together with warrants and/or securities or rights convertible or exchangeable for stock) sold in the
    New Financing calculated on the basis of an exchange price of 90% of the sale price of the units issued in such New Financing.
    

 

    	 

    	- 4 -

    

 

	5.	Voluntary
    Conversion upon NQFR. In the event that, prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company shall consummate a financial round through an equity investment, either in one
    transaction or in series of transactions (including an initial public offering but excluding the issuance of any convertible
    notes or the issuance of shares upon conversion of such notes), which is not a QFR (a “NQFR”), then the
    holders of Notes reflecting 70% (Seventy percent) of the aggregate outstanding principal amount of the Notes (the “Majority
    Holders”), shall be entitled, no later than fourteen (14) days prior to the closing of such NQFR, to notify the
    Company in writing of their choice to convert the entire Conversion Amount of the Notes (the “Aggregate Conversion
    Amount”). In such event the entire Aggregate Conversion Amount shall be converted immediately prior and subject
    to the closing of the NQFR, on the same terms and conditions specified in Section ‎3 above (“Automatic Conversion
    upon a QFR”), mutatis mutandis. The election of the Majority Holders to convert the entire Aggregate Conversion
    Amount shall be binding on all of the holders of the Notes and each such holder shall be deemed to have elected to convert
    its respective portion of the Aggregate Conversion Amount in accordance with the terms and conditions specified herein.
	 	 
	6.	Maturity
    Date. If not converted or repaid according to the terms set forth herein until thirty (30) months from the date of
    this Note (i.e., ___________) (the “Maturity Date”), then at the Maturity Date the Conversion Amount shall
    be automatically converted into Preferred A Shares, at a conversion price per share equal to the price per share paid by the
    Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “Maturity Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the applicable Articles of
    Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Maturity Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Maturity Conversion Price.
	 	 
	7.	Event
    of Default. In the event that, prior to the conversion of the Conversion Amount or its repayment according to the
    terms hereunder an Event of Default occurs, then the Conversion Amount shall be, at the election of the Holder, at its sole
    discretion, either: (i) become immediately due and payable to the Holder in cash; or (ii) converted into Preferred A Shares,
    at a conversion price per share equal to the price per share paid by the Company’s investors in consideration for the
    Preferred A Shares (i.e., US$1) (the “Default Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Default Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Default Conversion Price.

 

    	 

    	- 5 -

    

 

	 	The
    term “Event of Default” means (a) dissolution, termination of existence, suspension or discontinuance of
    business or ceasing to operate as going concern for a period of more than thirty (30) days; (b) the appointment of a receiver,
    trustee, custodian or similar official, for the Company or any material portion of the property or assets of the Company and
    the continuation of such appointment without dismissal for a period of thirty (30) days or more; (c) the conveyance of any
    material portion of the assets of the Company to a trustee, mortgage or liquidating agent or an assignment for the benefit
    of creditors by the Company which is not dismissed within a period of thirty (30) days; (d) the commencement of any proceeding,
    whether federal or state, relating to bankruptcy, insolvency, dissolution, reorganization, composition, renegotiations of
    outstanding indebtedness, arrangement or otherwise to the relief or debtors or the readjustment of indebtedness, by or against
    the Company, which is not stayed, vacated or released within sixty (60) days of commencement; (e) any material breach by the
    Company of any covenant or obligation in the Note, CAN or any documents and agreements ancillary thereto (the “Transaction
    Documents”) which is not cured, if curable, within thirty (30) days following receipt by the Company of a written
    notice of such breach; (f) any material misrepresentation has occurred in the Transaction Documents, which is not cured, if
    curable, within thirty (30) days following receipt by the Company of a written notice of such breach; (g) the Company shall
    fail to make any required payment of interest, principal or otherwise under the Notes, which is not cured within thirty (30)
    days following receipt by the Company of a written notice of such failure. The Company undertakes to notify the Holder immediately
    following occurrence of any of the events detailed in clauses (a) to (g) above.
	 	 
	8	Conversion;
    Fractional Interests. Each conversion shall be deemed to have been effected as to this Note (or the specified portion
    thereof) on the date on which the requirements set forth above in this Note required to be satisfied by the Holder, or the
    circumstances that are required to exist, have been satisfied as to this Note (or portion thereof), and the person whose name
    any certificate or certificates for shares shall be issuable upon such conversion shall be deemed to have become on said date
    the holder of record of the shares represented thereby. No fractional shares or scrip representing fractional shares shall
    be issued upon conversion of this Note and the number of shares issued shall be rounded to the nearest whole number.
	 	 
	9	Payments;
    Taxes

 

	 	9.1.	Payments.
    All payments of interest and of principal shall be in U.S. Dollar (“US$”) or in the New Israeli Shekels
    (“NIS”) equivalent. If any payment is paid in a NIS equivalent, it shall be paid in accordance with the
    representative rate of exchange of the U.S. Dollar against the NIS last published by the Bank of Israel immediately prior
    to the certain payment date.
	 	 	 
	 	9.2.	Taxes
    on Payments. To the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be
    made by the Company pursuant to this Note. The Company shall be entitled to deduct and withhold any withholding taxes which
    the Company determines it is legally required to deduct or withhold from any payment to be made by the Company pursuant to
    this Note.

 

	10.	Not
    a Shareholder. Prior to the conversion of this Note or any portion thereof according to the provisions specified herein,
    the Holder, in its capacity as an Holder, shall not be entitled to any rights of a shareholder of the Company, including,
    without limitation, the right to vote or to receive dividends or other distributions, with respect to the Note and the shares
    issuable upon conversion of the Note.

 

    	 

    	- 6 -

    

 

	11.	Miscellaneous

 

	 	11.1.	Governing
    Law. This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall
    be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute arising
    under or in relation to this Agreement shall be resolved exclusively in the competent court in New York New York, and each
    of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	11.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Note may be assigned or transferred without the prior consent
    in writing of each party to this Note.
	 	 	 
	 	11.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Holder upon any breach or default by the other under this Note shall impair any such right or remedy, nor shall it be construed
    to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter occurring.
	 	 	 
	 	11.4.	Entire
    Agreement. This Note, when read together with the CNA, contains the entire understanding of the parties with respect
    to its subject matter and all prior negotiations, discussions, commitments, and understandings heretofore had between them
    with respect hereto are merged therein. In the case of any discrepancy between the provisions of this Note and the provisions
    of any other agreement previously entered into by the Company or the Holder, the provisions of this Note and the CNA shall
    prevail.
	 	 	 
	 	11.5.	Amendment.
    Any term of this Note – as well as of all other Notes - may be amended (either generally or in a particular instance
    and either retroactively or prospectively) only with the written consent of the Company and the Majority Holders. 
	 	 	 
	 	11.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Note.
	 	 	 
	 	11.7.	Notices.
    All notices and other communications made pursuant to this Note shall be in writing and shall be conclusively deemed to have
    been duly given if delivered in accordance with the notice provisions of the CNA. 
	 	 	 
	 	11.8.	Severability.
    If any provision of this Note is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Note and the remainder of this Note shall be interpreted as if such provision were
    so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Note shall be
    interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
    intention of the excluded provision as determined by such court of competent jurisdiction.

 

	 	Motus
    GI Medical Technologies Ltd.
	 	By:	                  
	 	Name:	
	 	Title:	

 

    	 

    	 

    

 

Exhibit
C

 

Form
of Warrant

 

    	 

    	 		 

    

 

NEITHER
THIS WARRANT CERTIFICATE NOR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER SECURITIES ACT, AND THIS WARRANT CERTIFICATE AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT CERTIFICATE MAY NOT BE SOLD, OFFERED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH APPLICABLE SECURITIES LAWS AND THE RESTRICTIONS, TERMS AND CONDITIONS SET FORTH HEREIN.

 

Motus
GI Medical Technologies Ltd.

 

Preferred
A SHARES warrant Certificate 

 

To
purchase

[_____]
Preferred A Shares (subject to adjustment) of

Motus
GI Medical Technologies Ltd. (the “Company”)

at
a per share price and subject to the terms detailed below

VOID
AFTER 17:00 p.m. Israel Standard Time

on
the last day of the Warrant Period (as defined below)

 

THIS
IS TO CERTIFY THAT, [_____________] (the “Holder”), is entitled to purchase from the Company, an aggregate
of up to [___________] (as may be adjusted hereunder) Preferred A Shares of the Company, nominal value NIS 0.01 per share (the
“Warrant Shares”), at an aggregate purchase price of US$ [__________], reflecting an exercise price per share
of US$ 1.00 (the “Exercise Price”), during the Warrant Period.

 

This
Warrant Certificate (this “Warrant”) is issued to the Holder in connection with that certain Convertible Notes
Agreement dated June 9, 2015 by and among the Company and the Purchasers listed on Exhibit A thereto, as amended (the “Convertible
Notes Agreement”).

 

	1.	EXERCISE
    OF WARRANT

 

	 	1.1.	Warrant
    Period. This Warrant may be exercised, subject to the terms and conditions hereof, in whole or in part, at one time or
    from time to time during the period commencing on __________[NTD: the date of the Closing/Deferred Closing] (the “Initial
    Date”) until the earlier of: (i) seven (7) years thereafter (i.e., __________); and (ii) the closing of an Exit
    Event (as defined in Section‎ 5 below); provided that such Exit Event is consummated within 180 days from the Exit Event
    Notice (each of (i) or (ii), the “Expiry Date”). The period between the Initial Date and the Expiry Date
    shall be referred to hereinafter as the “Warrant Period.”

 

    	 	 	 

    	 	2	 

    

 

	 	1.2.	Exercise
    for Cash. This Warrant may be exercised by presentation and surrender thereof to the Company at its principal office or
    at such other office or agency as it may designate from time to time, accompanied by:

 

	 	 	(a)	A
    duly executed notice of exercise, in the form attached hereto as Schedule ‎1.1 (the “Exercise Notice”);
    and
	 	 	 	 
	 	 	(b)	Payment
    to the Company, for the account of the Company, of the Exercise Price for the number of Warrant Shares purchased payable in
    immediately available funds by wire transfer to the Company’s bank account. The Exercise Price will be paid in United
    States Dollars or the equivalent sum in NIS according to the Bank of Israel exchange rate as published upon the date immediately
    prior to the exercise date.

 

	 	1.3.	Exercise
    on Net Issuance Basis. In lieu of payment to the Company as set forth in Section ‎1.1 above, the Holder may elect
    to exercise this Warrant into the number of Warrant Shares calculated pursuant to the formula below, by presentation and surrender
    thereof to the Company at its principal office or at such other office or agency it may designate from time to time, accompanied
    by a duly executed notice of exercise, in the form attached hereto as Schedule 1.3 (the “Net Issuance
    Notice”):

 

	 	 	 	      Y*(A
    - B)
	 	 	X
          =	--------------------
	 	 	 	          A

 

	 	 	Where:
    
	 	 	 	 
	 	 	X
    =	the
    number of Warrant Shares to be issued to the Holder;
	 	 	 	 
	 	 	Y
    =	the
    number of Warrant Shares in respect of which the net issuance election is being made;
	 	 	 	 
	 	 	A
    =	the
    Fair Market Value (as defined below) of one Warrant Share; and
	 	 	 	 
	 	 	B
    =	the
    Exercise Price of one Warrant Share.

 

    	 	 	 

    	 	3	 

    

 

For
purposes of this Section ‎1.3, the “Fair Market Value” of one Warrant Share as of a particular date (the
“Determination Date”) shall be:

 

	 	 	(a)	If
    the net issuance right is exercised in connection with and contingent upon an initial public offering of the Company’s
    shares (an “IPO”), then the initial “price to public” (i.e., before deduction of discounts,
    commissions or expenses) specified in the final prospectus or registration statement with respect to such offering.
	 	 	 	 
	 	 	(b)	If
    the net issuance right is exercised in connection with and contingent upon an Exit Event that is not an IPO, the price per
    Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) in such Exit Event. 
	 	 	 	 
	 	 	(c)	If
    the net issuance right is not exercised in connection with and contingent upon an Exit Event, then as follows:

 

	 	 	 	(i)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are traded on a securities exchange, the Fair Market Value shall be deemed to
    be the average of the closing prices of such shares on such exchange over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date;
	 	 	 	 	 
	 	 	 	(ii)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are quoted for trading on an over-the-counter system, the Fair Market Value shall
    be deemed to be the average of the closing bid prices of such shares over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date; and
	 	 	 	 	 
	 	 	 	(iii)	If
    there is no public market for the Preferred A Shares (or any securities to which the Preferred A Shares have been converted
    to in accordance with the Company’s organizational documents and applicable law), the Fair Market Value of the shares
    shall be determined in good faith by the Board of Directors of the Company.

 

    	 	 	 

    	 	4	 

    

 

	 	1.4.	Issuance
    of Warrant Shares. Upon presentation and surrender of this Warrant, accompanied by (a) the duly executed Exercise Notice
    and the payment of the applicable Exercise Price for the Warrant Shares being purchased pursuant to Section ‎1.1 above;
    or (b) the duly executed Net Issuance Notice pursuant to Section ‎1.3 above, as the case may be, the Company shall promptly
    (i) issue to the Holder the Warrant Shares to which the Holder is entitled; and (ii) deliver to the Holder the share certificate
    evidencing such Warrant Shares. 
	 	 	 
	 	 	Upon
    receipt by the Company of this Warrant and the applicable duly executed notice of exercise (and the Exercise Price for the
    Warrant Shares being purchased, if applicable), together with any other documents and/or approvals that may be required by
    law, the Holder shall be deemed to be the holder of record of the Warrant Shares issuable upon such exercise, notwithstanding
    that the share transfer books of the Company shall then be closed or that certificates representing such shares shall not
    then be actually delivered to the Holder. 
	 	 	 
	 	1.5.	Fractional
    Shares. No fractions of shares shall be issued in connection with the exercise of this Warrant, and the number of shares
    issued shall be rounded to the nearest whole number.
	 	 	 
	 	1.6.	Partial
    Exercise. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant for cancellation,
    execute and deliver a new Warrant evidencing the rights of the Holder to purchase the balance of the Warrant Shares purchasable
    hereunder.
	 	 	 
	 	1.7.	Additional
    Documents. The Holder will sign and deliver any and all documents or approvals required by law, to facilitate the issuance
    of the Warrant Shares upon exercise of this Warrant. 
	 	 	 
	 	1.8.	Loss
    or Destruction of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
    or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonable reimbursement of expenses and
    satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute
    and deliver a new Warrant of like tenor and date.

 

    	 	 	 

    	 	5	 

    

 

	2.	TAXES

 

	 	2.1.	The
    Holder acknowledges that the grant of the Warrant, the issuance of the Warrant Shares and the execution and/or performance
    of this Warrant may have tax consequences to the Holder and that the Company is not able to ensure or represent to the Holder
    the nature and extent of such tax consequences. 
	 	 	 
	 	2.2.	The
    Company shall pay all of the applicable taxes and other charges payable by the Company in connection with the issuance of
    the Warrant Shares and the preparation and delivery of share certificates in the name of the Holder (such as transfer taxes
    in respect of the issuance or delivery of Warrant Shares upon exercise of this Warrant), if any, but shall not pay any taxes
    payable by the Holder by virtue of the holding, issuance, exercise, sale of this Warrant or the Warrant Shares by the Holder.

 

	3.	RESERVATION
    OF SHARES; preservation of rights of holder

 

	 	3.1.	Reservation
    of Shares. The Company hereby agrees that, at all times prior to the expiration or exercise of this Warrant, it will maintain
    and reserve, free from pre-emptive or similar rights, such number of authorized but unissued shares so that this Warrant may
    be exercised without additional authorization of shares.
	 	 	 
	 	3.2.	Preservation
    of Rights. The Company will not, by amendment of its organizational documents or through reorganization, recapitalization,
    consolidation, merger, dissolution, transfer of assets, issue or sale of securities or any other voluntary act, avoid or seek
    to avoid the observance or performance of any of the covenants, stipulations, conditions or terms to be observed or performed
    hereunder, but will at all times in good faith assist in the carrying out of all the provisions hereof and in taking of all
    such actions and making all such adjustments as may be necessary or appropriate in order to fulfill the provisions hereof.

 

	4.	ADJUSTMENT

 

	 	4.1.	The
    number of Warrant Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment
    from time to time or upon exercise, as follows:

 

    	 	 	 

    	 	6	 

    

 

	 	 	(a)	Bonus
    Shares. In the event that during the Warrant Period the Company shall distribute a non-cash dividend or shares pursuant
    to a reclassification of its share capital, to all of the holders of shares of the Company (i.e., bonus shares), then this
    Warrant shall represent the right to acquire, in addition to the number of Warrant Shares indicated in the caption of this
    Warrant, the amount of such bonus shares that are distributed to persons holding the class of share capital for which the
    Warrant is exercisable and/or to receive the stock dividends which are distributed to persons holding the class of share capital
    for which the Warrant is exercisable, without payment of any additional consideration therefor, to which the Holder would
    have been entitled had this Warrant been exercised prior to the distribution of the stock dividends or the bonus shares. 
	 	 	 	 
	 	 	(b)	Consolidation
    and Division. In the event that during the Warrant Period the Company consolidates its share capital into shares of greater
    par value, or subdivides them into shares of lesser par value, then the number of Warrant Shares to be allotted on exercise
    of this Warrant after such consolidation or subdivision shall be reduced or increased accordingly, as the case may be, and
    in each case the Exercise Price shall be adjusted appropriately such that the aggregate consideration hereunder to the Company
    shall not change.
	 	 	 	 
	 	 	(c)	Capital
    Reorganization. In the event that during the Warrant Period a reorganization of the share capital of the Company is effected
    (other than subdivision, combination or reclassification provided for elsewhere in this Section 4) and the Preferred A Shares
    are exchanged for other securities of the Company, then, as part of such reorganization, provision shall be made so that the
    Holder shall be entitled to purchase upon exercise of this Warrant such kind and number of shares or other securities of the
    Company to which the Holder would have been entitled had this Warrant been exercised without taking into effect such reorganization.
    

 

    	 	 	 

    	 	7	 

    

 

	 	 	(d)	Irrespective
    of any other provision of this Warrant, in the event that during the Warrant Period the Company becomes a subsidiary of a
    newly-formed entity formed under the laws of one of the states of the United States (“Newco”) either by
    way of a reverse triangular merger or by way of share swap or by way of any other similar transaction or series of related
    transactions, the result of which will be the capital stock of the Company being wholly owned by Newco (or any other entity
    into which or with which Newco merges), and simultaneously with or in connection with such transaction(s) or shortly thereafter,
    Newco (or any other entity into which or with which Newco merges) consummates an equity financing of at least US$ 10,000,000(the
    “New Financing” and the “Qualified Transaction”, respectively), this Warrant shall be
    automatically exchanged for five-year Newco (or any other entity into which or with which Newco merges) warrants exercisable
    for Newco (or any other entity into which or with which Newco merges) Common Stock at an exercise price per share of 100%
    of the original issue price of the securities (including any “units” or basket of securities that consist of stock
    together with warrants and/or securities or rights convertible or exchangeable for stock) issued in the New Financing (the
    “Original Issue Price”). The number of Common Stock underlying such new warrant shall be equal to one-third
    (1/3) of the principal amount of that certain Note dated [________] issued by the Company to the Holder, divided by the Original
    Issue Price. For greater certainty, the Qualified Transaction described in this sub-section (d) shall not be deemed an Exit
    Event. 

 

	 	4.2.	Whenever
    an adjustment is effected hereunder, the Company shall promptly compute such adjustment and deliver to the Holder a certificate
    setting forth the number of Warrant Shares (or any other securities) for which this Warrant is exercisable and the Exercise
    Price as a result of such adjustment, a brief statement of the facts requiring such adjustment and the computation thereof
    and when such adjustment has or will become effective.
	 	 	 
	 	4.3.	Except
    as otherwise provided herein, Sections 4.1(a) to 4.1(d) hereof are intended to operate independently of one another. If an
    event occurs that requires the application of more than one subsection, all applicable subsections shall be given independent
    effect, but there shall be no duplicate adjustments if two separate subsections provide the same protection.
	 	 	 
	 	4.4.	Notices
    of Certain Transactions. In case:

 

	 	 	(a)	the
    Company shall take a record of the holders of its Preferred A Shares (or other stock or securities at the time deliverable
    upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution,
    or

 

    	 	 	 

    	 	8	 

    

 

	 	 	(b)	of
    the voluntary or involuntary dissolution, liquidation or winding-up of the Company
	 	 	 	 
	 	 	 	then,
    and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be,
    (i) the date on which a record is to be taken for the purpose of such dividend or distribution, and stating the amount and
    character of such dividend or distribution, or (ii) the effective date on which such voluntary dissolution, liquidation or
    winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Shares (or such other
    shares or securities at the time deliverable upon such voluntary dissolution, liquidation or winding-up) are to be determined.
    Such notice shall be mailed at least seven (7) days prior to the record date or effective date for the event specified in
    such notice. 

 

	5.	EXERCISE
    OF THE WARRANT UPON AN EXIT EVENT

 

Notwithstanding
anything to the contrary in this Warrant, if at any time during the Warrant Period, the Company consummates an Exit Event, or
at the discretion of the Board of Directors of the Company, in the event that the Company believes that an Exit Event is likely
to be consummated during such period, the Company shall provide written notice of such Exit Event (or, if applicable, an anticipated
Exit Event) to the Holder (the “Exit Event Notice”). Within fourteen (14) days after Holder’s receipt
of the Exit Event Notice, Holder must notify the Company if it intends to exercise this Warrant pursuant to Section ‎1.2 or
‎1.3 of this Warrant, in which case such exercise shall be effective contingent upon and immediately prior to the consummation
of the Exit Event. Thereafter, so long as the Company consummates such Exit Event within one hundred and eighty (180) days after
Holder’s receipt of the Exit Event Notice (to the extent the Exit Event shall not have occurred prior to the Exit Event
Notice), Holder shall have no further rights hereunder and this Warrant shall be automatically terminated if not so exercised.
If the Company fails to consummate such Exit Event within such time, then this Warrant shall remain in effect subject to the provisions
contained herein

 

    	 	 	 

    	 	9	 

    

 

For
the purposes hereof, an “Exit Event” shall mean the closing of (i) an initial public offering; (ii) a merger
of the Company with or into another corporation, (iii) an acquisition of all or substantially all of the shares of the Company,
(iv) the sale or license of all or substantially all of the assets of the Company, any with respect to (ii)-(iv), other than a
merger or transaction in which the persons that beneficially owned, directly or indirectly, a majority of the share capital of
the Company immediately prior to such merger or transaction, beneficially own, directly or indirectly, a majority of the total
shares of capital stock of the surviving or transferee entity. For greater certainty, the Qualified Transaction described in Section
4.1(d) shall not be deemed an Exit Event and the provisions of this Section 5 shall not apply solely in connection with such Qualified
Transaction.

 

	6.	RIGHTS
    OF THE HOLDER

 

	 	6.1.	This
    Warrant shall not entitle the Holder, by virtue hereof, to any voting rights or other rights as a shareholder of the Company,
    except for the rights expressly set forth herein.
	 	 	 
	 	6.2.	The
    Holder acknowledges that the Warrant Shares shall be subject to such rights, privileges, restrictions and limitations as set
    forth in this Warrant and the organizational documents of the Company (or any other agreement with respect thereto), as may
    be amended from time to time, and that, as a result, inter alia, of such limitations, it may be difficult or impossible
    for the Holder to realize his investment and/or to sell or otherwise transfer the Warrant Shares. The Holder further acknowledges
    that the Company’s shares are not publicly traded.

 

	7.	TERMINATION

 

Notwithstanding
anything to the contrary, this Warrant and all the rights conferred hereby shall terminate and expire at the aforementioned time
on the Expiry Date.

 

	8.	MISCELLANEOUS

 

	 	8.1.	Entire
    Agreement; Amendment. This Warrant sets forth the entire understanding of the parties with respect to the subject matter
    hereof and supersedes all existing agreements among them concerning such subject matter. All article and section headings
    herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provision
    of this Warrant. Subject to Section ‎8.8 below, no modification or amendment of this Warrant will be valid unless executed
    in writing by the Company and the Holder. 

 

    	 	 	 

    	 	10	 

    

 

	 	8.2.	Waiver.
    No failure or delay on the part of any of the parties in exercising any right, power or privilege hereunder and/or under any
    applicable law or the exercise of such right or power in a manner inconsistent with the provisions of this Warrant or applicable
    law shall operate as a waiver thereof. Any waiver must be evidenced in writing signed by the party against whom the waiver
    is sought to be enforced.
	 	 	 
	 	8.3.	Successors
    and Assigns; Assignment. Except as otherwise expressly limited herein, this Warrant shall inure to the benefit of, be
    binding upon, and be enforceable by the Holder and its respective successors, and administrators and is otherwise non-transferable
    without the prior consent of the Company. The Holder represents and warrants to the Company that this Warrant and the Warrant
    Shares, if and when purchased by the Holder, are for the Holder’s own account and for investment purposes only and not
    with a view for resale or transfer and that all the rights pertaining to the Warrant or the Warrant Shares, by law or equity,
    shall be purchased and possessed by the Holder for the Holder exclusively. 
	 	 	 
	 	8.4.	Governing
    Law. This Warrant shall be exclusively governed and construed in accordance with the laws of the State of New York, without
    regard to conflicts of laws provisions thereof.
	 	 	 
	 	8.5.	Notices.
    All notices and other communications made pursuant to this Warrant shall be in writing and shall be conclusively deemed to
    have been duly given if delivered in accordance with the notice provisions of the Convertible Notes Agreement. 
	 	 	 
	 	8.6.	Severability.
    If any provision of this Warrant is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Warrant and the remainder of this Warrant shall be interpreted as if such provision
    were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Warrant
    shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the
    meaning and intention of the excluded provision as determined by such court of competent jurisdiction.

 

    	 	 	 

    	 	11	 

    

 

	 	8.7.	Counterparts.
    This Warrant may be executed in any number of counterparts, each of which shall be an original, but all of which together
    shall constitute one instrument. Facsimile or electronic signatures of a party shall be binding as evidence of such party’s
    agreement hereto and acceptance hereof.
	 	 	 
	 	8.8.	Amendments.
    To the extent that any amendment(s) to the Convertible Notes Agreement or the transactions contemplated thereby result in
    a required amendment to the terms of this Warrant, this Warrant shall be deemed amended to the extent that the amendment(s)
    to the Convertible Notes Agreement are completed in accordance with the terms thereof.

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.

 

	Dated:	 	 	Motus
    GI Medical Technologies Ltd. 
	 	 	 	 	            
	 	 	 	Signature:	 
	 	 	 	Name:	 
	 	 	 	Title:	 

 

    	 	 	 

    	 	12	 

    

 

Schedule
1.2

 

Exercise
Notice

 

Date:
____________

 

To:
Motus GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to purchase _________ Warrant Shares (as such term is defined in the Warrant) pursuant to Section ‎1.1 of the
Warrant, and herewith makes payment of _____________, representing the full Exercise Price for such shares as provided for in
such Warrant.

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	 	 	 

    	 	13	 

    

 

Schedule
1.3

 

Net
Issuance Notice

 

Date:
____________

 

	To:	Motus
    GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to exercise the Warrant for the purchase of Warrant Shares (as such term is defined in the Warrant), pursuant to
the provisions of Section 1.3 of the Warrant.

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	 	 	 

    	 		 

    

 

Exhibit
D

 

Joinder
to Convertible Notes Agreement

 

    	 	 	 

    	 

    
 

JOINDER
TO

CONVERTIBLE
NOTES AGREEMENT

 

This
Joinder to Convertible Notes Agreement (this “Joinder”) is made as of _______, 2016 (the “Effective
Date”), by and between Motus GI Medical Technologies Ltd., a company organized under the laws of the State of Israel,
with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”), and ______________, the following persons
or entities, with offices at ______________________ (the “Additional Purchaser”).

 

	WHEREAS,
    	on
    June 9, 2015, a Convertible Notes Agreement was entered into by and among the Company and the Purchasers identified on Exhibit
    A thereto, which was amended on December 29, 2015, on February 15, 201 on July 25, 2016, and on October __, 2016 attached
    hereto as Exhibit A (together, the “CNA”). Capitalized terms used, but not defined herein,
    shall have the meaning ascribed to such terms in the CNA, of which this Joinder constitutes an integral part; and
	 	 
	WHEREAS,
    	pursuant
    to the CNA, the Company may consummate one or more Deferred Closing(s) during a period of one hundred and twenty (120) days
    following the Fifth Closing, in an aggregate amount that, together with the aggregate Loan Amount, shall not exceed US$12,000,000;
    and 
	 	 
	WHEREAS,	the
    Additional Purchaser desires to join the CNA and consummate a Deferred Closing, subject to the terms and conditions more fully
    set forth in this Joinder.

 

NOW
THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations,
warranties, and covenants herein contained, and intending to be legally bound hereby, the parties hereby agree as follows:

 

	1.	Transaction

 

	 	1.1.	At
    the Deferred Closing (as defined below), subject to the terms and conditions hereof, the Additional Purchaser shall transfer
    to the Company the amount of US$[_________] (the “Additional Loan Amount”) and the Company will issue,
    sell, transfer, assign and deliver to the Additional Purchaser a convertible note in the form attached hereto as Exhibit
    B (the “Deferred Closing Note”). In addition, at the Deferred Closing and subject thereto, the
    Company will issue to the Additional Purchaser a warrant to purchase [________] Preferred A Shares, all subject to the terms
    and the conditions of the warrant certificate attached hereto as Exhibit C (the “Deferred Closing Warrant”).

 

    	 	 	 

    	 	 	 

    

 

	2.	By
    execution of this Joinder and upon payment of the Additional Loan Amount at the Deferred Closing, subject to the fulfillment
    of the conditions specified in Sections ‎4 and ‎5 hereof, the Additional Purchaser shall automatically become a party,
    as of the Deferred Closing, to the CNA and for all purposes under the CNA, the Additional Purchaser shall be deemed to be
    a “Purchaser” and the Additional Loan Amount shall be deemed to be part of the “Loan Amount”. 

 

	3.	Deferred
    Closing 

 

	 	3.1.	Time
    and Place of the Deferred Closing. The sale of the Deferred Closing Notes and the issuance of the Deferred Closing
    Warrants, shall take place at a deferred closing (the “Deferred Closing”) at the offices of Company’s
    counsel, Fischer Behar Chen Well Orion & Co., at Ha-Migdal, 3 Dani’el Frisch St., Tel Aviv, on _________, 2016,
    or at such other time and place as the Company and the Additional Purchaser shall mutually agree in writing (the “Deferred
    Closing Date”).
	 	 	 
	 	3.2.	Deliveries
    and Transactions at the Deferred Closing. At the Deferred Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	(a)	Delivery
    of Deferred Closing Note. The Company shall deliver to the Additional Purchaser a validly executed Note, in the form of
    Exhibit B, reflecting the Deferred Closing Note purchased by the Additional Purchaser hereunder.
	 	 	 
	 	(b)	Delivery
    of Deferred Closing Warrant. The Company shall deliver to the Additional Purchaser a validly executed Warrant, in the
    form of Exhibit C, reflecting the Deferred Closing Warrant of the Additional Purchaser.
	 	 	 
	 	(c)	Payment.
    The Additional Purchaser shall pay to the Company the Additional Loan Amount, in accordance with Section 1.2 of the CNA.

 

	4.	Conditions
    to the Deferred Closing by the Additional Purchaser. The Additional Purchaser obligation to consummate the transactions
    contemplated hereby at the Deferred Closing is subject to the satisfaction and fulfillment, prior to or at the Deferred Closing,
    of each of the following conditions precedent (any or all of which may be waived, in whole or in part, by the Additional Purchaser,
    which waiver shall be at the sole discretion of the Additional Purchaser):

 

	 	4.1.	Accurate
    Representations and Warranties. The representations and warranties of the Company in Section 3 of the CNA (as qualified
    by the Disclosure Schedule and amended in the Third Amendment and Joinder to CNA), shall be true and correct when made and
    shall be true and correct in all material respects as of the Fifth Closing Date.
	 	 	 
	 	4.2.	Compliance
    with Covenants. The Company shall have performed and complied with all of its covenants, agreements and undertakings set
    forth herein.

 

    	 	 	 

    	 	 	 

    

 

	 	4.3.	Actions
    Taken; Delivery of Documents. All the actions to be taken by the Company as set forth in Section ‎3.2 above, shall
    have been completed to the satisfaction of the Additional Purchaser. 
	 	 	 
	 	4.4.	Proceedings
    and Documents. All corporate and other proceedings in connection with the transactions contemplated by the Joinder shall
    be satisfactory in substance and form to the Additional Purchaser, and the Additional Purchaser shall have received all such
    counterpart copies of such documents as the Additional Purchasers may reasonably request.

 

	5.	Conditions
    to Closing by the Company. The Company’s obligation to consummate the transactions contemplated hereby at the
    Deferred Closing is subject to the satisfaction and fulfillment, prior to or at the Deferred Closing, of each of the following
    conditions precedent (any or all of which may be waived, in whole or in part, by the Company, which waiver shall be at the
    sole discretion of the Company):

 

	 	5.1.	Accurate
    Representations and Warranties. The representations and warranties of the Additional Purchaser in this Joinder shall have
    be true and correct when made and shall be true and correct in all material respects as of the Deferred Closing Date.
	 	 	 
	 	5.2.	Compliance
    with Covenants. The Additional Purchaser shall have performed and complied with all of his covenants, agreements, and
    undertakings as set forth in this Joinder.
	 	 	 
	 	5.3.	Consents.
    The Company shall have secured all permits, consents and authorizations that shall be necessary or required lawfully to consummate
    the transactions contemplated by this Joinder, including without limitation, third party consents and approvals and corporate
    approvals including without limitation, in connection with the issuance of any securities upon conversion of the Deferred
    Closing Notes and the issuance of any securities upon exercise of the Deferred Closing Warrant. 

 

	6.	Representations
    and Warranties of the Company.

 

The
Company hereby represents and warrants to the Additional Purchaser that all representations and warranties set forth in Section
3 of the CNA (as qualified by the Disclosure Schedule and as amended in the Third Amendment and Joinder to CNA) shall have been
true when made and shall have been true and correct in all material respects as of the Fifth Closing Date.

 

	7.	Representations
    and Warranties of the Additional Purchaser

 

The
Additional Purchaser hereby represents and warrants to the Company and acknowledges that the Company is entering into the Joinder
in reliance thereon, that all the representations and warranties set forth in Section 4 of the CNA are true and correct in respect
of such Additional Purchaser as of the date hereof and shall be true and correct in all material respects as of the Deferred Closing,
provided that any reference in Section 4 of the CNA to: (i) the CNA shall also include the Joinder; and (ii) the Closing shall
refer for purposes herein to the Deferred Closing.

 

	8.	General

 

The
Joinder together with the CNA constitutes the full and entire understanding and agreement between the parties hereto with regard
to the subject matter hereof and thereof. The provisions of Section 9 of the CNA are incorporated herein by reference with any
reference therein to the Agreement applying herein to this Joinder.

 

[Signature
Page to Follow]

 

    	 	 	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Joinder to Convertible Notes Agreement as of the date herein above
set forth.

 

THE
COMPANY:

 

	Motus
    GI Medical Technologies Ltd. 	 
	 	 	 
	By:	                                         	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

THE
ADDITIONAL PURCHASER:

 

	By:	                                         	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

    	 	 	 

    	 	 	 

    

 

EXHIBIT
E

 

Convertible
Notes Agreement, As Amended

 

    	 	 	 

    	 

    
 

CONVERTIBLE
NOTES Agreement

 

This
Convertible Notes Agreement (this “Agreement”) is made and entered into as of the 9 day of June, 2015, by and
among Motus GI Medical Technologies Ltd., a company organized under the laws of the State of Israel, with offices at Keren
Hayesod 22 Tirat Carmel, Israel (the “Company”), and the persons and entities identified in Exhibit A
attached hereto (each, a ’Purchaser’ and together, the “Purchaser” and each Purchaser
and the Company separately, a “Party” and together, the “Parties”).

 

	WHEREAS,
    	the
    Company requires additional funds to continue to operate its business; and
	 	 
	WHEREAS,
    	in
    considering the terms and conditions of this proposed fundraising the Board of Directors of the Company (the “Board”)
    consulted the Company’s management and identified and considered many factors, including the Company’s current
    cash position, the cash requirements for the Company’s future operations and projected cash flows from the Company’s
    business and the lack of other immediately available funding alternatives, and after careful consideration the Board has concluded
    that it is in the best interests of the Company and its shareholders to raise funds by means of a convertible loan as proposed;
    and 
	 	 
	WHEREAS,	the
    Company is interested to sell to the Purchasers, and the Purchasers are willing to purchase from the Company, convertible
    promissory notes, all under and pursuant to the terms and conditions set forth herein.

 

NOW
THEREFORE, in consideration of the representations, warranties, and covenants herein contained, and intending to be legally
bound hereby, the parties agree as follows:

 

	1.	Transaction

 

	 	1.1.	Loan
Amount; Sale and Purchase of Notes and Issuance of Warrants. Subject to the terms and conditions of this Agreement, each
of the Purchasers will lend to the Company the amount set forth opposite such Purchaser’s name in Exhibit A
attached hereto (such Purchaser’s portion, the “Loan Amount”), to be transferred to the Company in four installments
as follows:
	 	 	 
	 	 	At
    the First Closing (as defined below) and subject thereto, each Purchaser shall transfer to the Company the amount set forth
    next to such Purchaser’s name in the column titled ‘First Installment’ in the table set forth in Exhibit
    A and the Company will issue, sell, transfer, assign and deliver to each of the Purchasers a convertible note in the form
    attached hereto as Exhibit B1 (the “First Notes”), to be allocated among the Purchasers in
    accordance with the column titled ‘First Installment’ in the table set forth in Exhibit A (the “First
    Installment”). In addition, at the First Closing and subject thereto, the Company will issue to each Purchaser a
    warrant to purchase such number of Preferred A Shares, par value NIS 0.01 per share, of the Company (the “Preferred
    A Shares”) as set forth next to such Purchaser’s name in the column titled ‘First Warrant’ in
    the table set forth in Exhibit A, all subject to the terms and the conditions of the warrant certificate attached hereto
    as Exhibit B2 (the “First Warrants”).

 

    	 

    	- 2 -

    

 

	 	 	At
    the Second Closing (as defined below) and subject thereto, each Purchaser shall transfer to the Company the amount set forth
    next to such Purchaser’s name in the column titled “Second Installment” in the table set forth in Exhibit
    A and the Company will issue, sell, transfer, assign and deliver to each of the Purchasers a convertible note in the form
    attached hereto as Exhibit C1 (the “Second Notes”), to be allocated among the Purchasers
    in accordance with the column titled “Second Installment” in the table set forth in Exhibit A (the “Second
    Installment”). In addition, at the Second Closing and subject thereto, the Company will issue to each Purchaser
    a warrant to purchase such number of Preferred A Shares as set forth next to such Purchaser’s name in the column titled
    “Second Warrant” in the table set forth in Exhibit A, all subject to the terms and the conditions of the
    warrant certificate attached hereto as Exhibit C2 (the “Second Warrants”).
	 	 	 
	 	 	At
    the Third Closing (as defined below) and subject thereto, each Purchaser shall transfer to the Company the amount set forth
    next to such Purchaser’s name in the column titled “Third Installment” in the table set forth in Exhibit
    A and the Company will issue, sell, transfer, assign and deliver to each of the Purchasers a convertible note in the form
    attached hereto as Exhibit D1 (the “Third Notes”), to be allocated among the Purchasers in
    accordance with the column titled “Third Installment” in the table set forth in Exhibit A (the “Third
    Installment”). In addition, at the Third Closing and subject thereto, the Company will issue to each Purchaser a
    warrant to purchase such number of Preferred A Shares as set forth next to such Purchaser’s name in the column titled
    ‘Third Warrant’ in the table set forth in Exhibit A, all subject to the terms and the conditions of the
    warrant certificate attached hereto as Exhibit D2 (the “Third Warrants”).
	 	 	 
	 	 	At
    the Fourth Closing (as defined below) and subject thereto, each Purchaser shall transfer to the Company the amount set forth
    next to such Purchaser’s name in the column titled “Fourth Installment” in the table set forth in Exhibit A
    and the Company will issue, sell, transfer, assign and deliver to each of the Purchasers a convertible note in the form attached
    hereto as Exhibit E1 (the “Fourth Notes”), to be allocated among the Purchasers in accordance
    with the column titled “Fourth Installment” in the table set forth in Exhibit A (the “Fourth Installment”).
    In addition, at the Fourth Closing and subject thereto, the Company will issue to each Purchaser a warrant to purchase such
    number of Preferred A Shares as set forth next to such Purchaser’s name in the column titled “Fourth Warrant” in
    the table set forth in Exhibit A, all subject to the terms and the conditions of the warrant certificate attached hereto
    as Exhibit E2 (the “Fourth Warrants”).
	 	 	 
	 	 	The First Notes, the Second Notes, the Third Notes and the Fourth Notes shall be referred to herein collectively
as the “Notes”. The First Warrants, the Second Warrants, the Third Warrants and the Fourth Warrants shall be referred
to herein collectively as the “Warrants”.

 

	 	1.2.	Payment.
    The Loan Amount will be paid in U.S. Dollars (“US$”) or in the New Israeli Shekels (“NIS”)
    equivalent. If the Loan Amount is paid in a NIS equivalent, it shall be paid in accordance with the representative rate of
    exchange of the US$ against the NIS last published by the Bank of Israel immediately prior to the applicable Closing Date

 

    	 

    	- 3 -

    

 

	2.	Closings

 

	 	2.1.	Time
    and Place of the First Closing. The sale of the First Notes and the issuance of the First Warrants shall take place
    at a first closing (the “First Closing”) at the offices of Company’s counsel, Fischer Behar Chen Well
    Orion & Co., at Ha-Migdal, 3 Dani’el Frisch St., Tel Aviv, Israel, on June 9, 2015, or at such later time and place as
    the Company and the Purchasers shall mutually agree in writing (the “First Closing Date”).
	 	 	 
	 	2.2.	Deliveries
    and Transactions at the First Closing. At the First Closing, the following transactions shall occur simultaneously (no transaction shall be deemed
to have been completed or any document delivered until all such transactions have been completed and all required documents delivered):

 

	 	 	2.2.1.	Board
    Resolutions. Copies of duly executed resolutions of the Board, in the form attached hereto as Exhibit ‎2.2.1
    shall be delivered to the Purchasers, approving, inter alia, the execution, delivery and performance by the Company
    of this Agreement and all other documents and agreements ancillary to such agreements (collectively, the “Transaction
    Documents”), to which the Company is a party, and the transactions contemplated hereby and thereby, including the
    issuance of the Issued Securities (as defined below). 
	 	 	 	 
	 	 	2.2.2.	Shareholders
    Resolutions. Copies of duly executed resolutions of the Company’s shareholders, in the form attached hereto as Exhibit
    ‎2.2.2(a), shall be delivered to the Purchasers, approving, inter alia: (i) the execution, delivery and performance
    by the Company of the Agreement and the transactions contemplated hereby, including the issuance of the Issued Securities;
    and (ii) the replacement of the Company’s current Articles of Association with the Third Amended and Restated Articles
    of Association, substantially in the form attached hereto as Exhibit ‎2.2.2(c) (the “Amended Articles”).
	 	 	 	 
	 	 	2.2.3.	Delivery
    of First Notes. The Company shall deliver to each Purchaser a validly executed Note, in the form of Exhibit B1,
    reflecting the First Notes purchased by each Purchaser hereunder.
	 	 	 	 
	 	 	2.2.4.	Delivery
    of First Warrants. The Company shall deliver to each Purchaser a validly executed Warrant, in the form of Exhibit B2,
    reflecting the First Warrants of each Purchaser.
	 	 	 	 
	 	 	2.2.5.	Payment.
    The Purchasers shall pay to the Company the First Installment, in accordance with Section ‎1.2 above. 

 

	 	2.3.	Time
    and Place of the Second Closing. The sale of the Second Notes and the issuance of the Second Warrants shall take place
    at a second closing (the “Second Closing”) at the offices of Company’s counsel, Fischer Behar Chen
    Well Orion & Co., at Ha-Migdal, 3 Dani’el Frisch St., Tel Aviv, Israel, within ninety (90) days after the First Closing,
    or at such other time and place as the Company and the Purchasers shall mutually agree in writing (the “Second Closing
    Date”). 

 

    	 

    	- 4 -

    

 

	 	2.4.	Deliveries
    and Transactions at the Second Closing. At the Second Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.4.1.	Delivery
    of Second Notes. The Company shall deliver to each Purchaser a validly executed Note, in the forms of Exhibit C1,
    reflecting the Second Notes purchased by each Purchaser hereunder.
	 	 	 	 
	 	 	2.4.2.	Delivery
    of Second Warrants. The Company shall deliver to each Purchaser a validly executed Warrant, in the form of Exhibit
    C2, reflecting the Second Warrants of each Purchaser.
	 	 	 	 
	 	 	2.4.3.	Payment.
    The Purchasers shall pay to the Company the Second Installment, in accordance with Section ‎1.2 above.

 

	 	2.5.	Time
    and Place of the Third Closing. The sale of the Third Notes and the issuance of the Third Warrants shall take place
    at a third closing (the “Third Closing”) at the offices of Company’s counsel, Fischer Behar Chen Well
    Orion & Co., at Ha-Migdal, 3 Dani’el Frisch St., Tel Aviv, Israel, within one hundred and eighty (180) days after the
    First Closing, or at such other time and place as the Company and the Purchasers shall mutually agree in writing (the “Third
    Closing Date”). 
	 	 	 
	 	2.6.	Deliveries
    and Transactions at the Third Closing. At the Third Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.6.1.	Delivery
    of Third Notes. The Company shall deliver to each Purchaser a validly executed Note, in the forms of Exhibit D1,
    reflecting the Third Notes purchased by each Purchaser hereunder.
	 	 	 	 
	 	 	2.6.2.	Delivery
    of Third Warrants. The Company shall deliver to each Purchaser a validly executed Warrant, in the form of Exhibit D2,
    reflecting the Third Warrants of each Purchaser.
	 	 	 	 
	 	 	2.6.3.	Payment.
    The Purchasers shall pay to the Company the Third Installment, in accordance with Section ‎1.2 above.

 

	 	2.7.	Time
    and Place of the Fourth Closing.The sale of the Fourth Notes and the Fourth Warrants shall take place at a fourth
    closing (the “Fourth Closing”) at the offices of Company’s counsel, Fischer Behar Chen Well Orion &
    Co., at Ha-Migdal, 3 Dani’el Frisch St., Tel Aviv, Israel, at such time and place as the Company and the Purchasers shall
    mutually agree in writing, but in any event not later than fourteen (14) days after the Board determines that the Company’s
    cash position requires the infusion of additional funds to continue to operate its business (the “Fourth Closing Date”).
    

 

    	 

    	- 5 -

    

 

	 	2.8.	Deliveries
    and Transactions at the Fourth Closing. At the Fourth Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.8.1.	Delivery
    of Fourth Notes. The Company shall deliver to each Purchaser a validly executed Note, in the forms of Exhibit E1,
    reflecting the Fourth Notes purchased by each Purchaser hereunder.
	 	 	 	 
	 	 	2.8.2.	Delivery
    of Fourth Warrants. The Company shall deliver to each Purchaser a validly executed Warrant, in the form of Exhibit
    E2, reflecting the Fourth Warrants of each Purchaser.
	 	 	 	 
	 	 	2.8.3.	Payment.
    The Purchasers shall pay to the Company the Fourth Installment, in accordance with Section ‎1.2 above.

 

	3.	Representations
    and Warranties of the Company. The Company hereby represents and warrants to the Purchasers, that the following representations
    and warranties are true and correct as of the date hereof and shall be true and correct in all material respects as of the
    First Closing Date, all except as set forth in a Disclosure Schedule attached hereto as Exhibit ‎3 (the
    “Disclosure Schedule”):

 

	 	3.1.	Organization.
    The Company is duly organized and validly existing under the laws of the State of Israel, and has full corporate power and
    authority to own, lease and operate its properties and assets and to conduct its business as now being conducted and as proposed
    to be conducted.
	 	 	 
	 	3.2.	Authorization
    and Approvals. All corporate action on the part of the Company necessary for the authorization, execution, delivery, and
    performance of all of the Company’s obligations under this Agreement has been (or will be) taken prior to the First
    Closing. This Agreement, when executed and delivered by or on behalf of the Company, shall constitute the valid and legally
    binding obligations of the Company, legally enforceable against the Company in accordance with its terms. No consent, approval,
    order, license, permit, action by, or authorization of or designation, declaration, or filing with any governmental authority
    on the part of the Company is required that has not been, or will not have been, obtained by the Company prior to the First
    Closing, in connection with the valid execution, delivery and performance of this Agreement.
	 	 	 
	 	3.3.	No
    Conflicts. This Agreement does not contravene any provisions of the Company’s Articles of Association or any applicable
    law, and, to the knowledge of the Company, any judicial restriction binding on or affecting the Company.
	 	 	 
	 	3.4.	Capitalization.
    The authorized share capital of the Company immediately prior to the First Closing shall consist of NIS 255,000 divided into
    (i) 12,000,000 Ordinary Shares, par value NIS 0.01 each, of which 4,296,786 are issued and outstanding, and (ii) 13,500,000
    Series A Preferred Shares, par value NIS 0.01 each, all of which are issued and outstanding. An accurate capitalization table
    listing all of the Company’s shares, options, and warrants (or other rights or securities convertible into or exchangeable
    for shares in the Company (collectively, the “Equity Securities”) and their respective record holders and,
    to the knowledge of the Company, beneficial owners on a fully diluted basis is set forth in Exhibit ‎3.4
    attached hereto (the “Cap Table”).

 

    	 

    	- 6 -

    

 

	 	3.5.	The
    Issued Securities. The securities contemplated to be issued by the Company in accordance with this Agreement and any shares
    issuable upon conversion or exercise thereof, including without limitation, the Notes, the shares issuable upon conversion
    thereof, the Warrants and the shares issuable upon exercise thereof (collectively, the “Issued Securities”),
    when issued in accordance with this Agreement (and assuming payment in full therefor), will be duly and validly issued and
    authorized, fully paid and nonassessable and will have the rights, preferences, privileges, and restrictions set forth in
    the Company’s Articles of Association as shall be in effect from time to time
	 	 	 
	 	3.6.	Litigation.
    Except as set forth on Exhibit ‎3.6 attached hereto, no action, proceeding or governmental inquiry or investigation
    is pending or, to the knowledge of the Company, threatened against the Company or any of its officers, directors, or employees
    (in their capacity as such), or against any of the Company’s properties, or with regard to the Company’s business
    or assets, before any court, arbitration board or tribunal or administrative or other governmental agency, nor, to the knowledge
    of the Company, is there any basis for any of the foregoing nor is there any the Company intends to initiate.
	 	 	 
	 	3.7.	Material
    Liabilities. Except as set forth on Exhibit ‎3.7 attached hereto, the Company does not have any liability,
    debt or obligation, which exceeds US$200,000, whether accrued, absolute or contingent or otherwise, including to previous
    employees or consultants for any reason. The Company has not provided any loans or advances to any person or given a guarantee
    or created any charge, lien or other encumbrance on any of its assets and/or its un-issued share capital for any obligation
    of any person.

 

	4.	Representations
    and Warranties of the Purchasers. Each Purchaser, severally and not jointly, warrants and represents to the Company
    as follows: 

 

	 	4.1.	The
    Purchaser is duly organized, validly existing and in good standing under the laws of jurisdiction of its incorporation or
    organization. All corporate action on the part of the Purchaser necessary for the authorization, execution, delivery, and
    performance of all of the Purchaser obligations under the Agreement has been taken. This Agreement, when executed and delivered
    by or on behalf of the Purchaser, shall constitute the valid and legally binding obligations of the Purchaser, legally enforceable
    against the Purchaser in accordance with their terms.
	 	 	 
	 	4.2.	The
    execution and delivery of this Agreement and the consummation of the transactions contemplated herein will not result in the
    breach of any term of, or constitute a default under, any contract or agreement to which the Purchaser may be bound. No approval
    or consent from any person, entity or authority, is required by the Purchaser for the execution, delivery and performance
    by it of this Agreement that has not been, or will not have been, obtained by the Purchaser on or prior to the First Closing.
	 	 	 
	 	4.3.	The
    Purchaser has knowledge and experience in financial and business matters, is capable of evaluating the merits and risks of
    the transactions evidenced by this Agreement, and can bear the economic consequences of its investment for an indefinite period
    of time. Without derogating from the Purchaser’s right to rely on the representations and warranties of the Company
    set forth in Section ‎3 above, the Purchaser acknowledges that it and its advisers and representatives have had an opportunity
    to ask questions of, and receive answers from the Company and any other person acting on behalf of the Company concerning
    such investment.

 

    	 

    	- 7 -

    

 

	 	4.4.	The
    Purchaser understands that the Issued Securities, have not been, and may not be, registered under the Israeli securities law
    or any other securities regulations by reason of a specific exemption from the registration provisions of such securities
    regulations.
	 	 	 
	 	4.5.	The
    Purchaser represents and agrees that the Issued Securities, when issued to such Purchaser hereunder, are or will be purchased
    only for investment purposes, for its own account, and not as a nominee or agent, and not with the view to, or for resale
    in connection with, any distribution thereof.

 

	5.	Conditions
    to Closing by the Purchasers. The Purchasers obligation to consummate the transactions contemplated hereby at each
    Closing is subject to the satisfaction and fulfillment, prior to or at the applicable Closing, of each of the following conditions
    precedent (any or all of which may be waived, in whole or in part, by each of the Purchasers, which waiver shall be at the
    sole discretion of each Purchaser with respect to itself):

 

	 	5.1.	Accurate
    Representations and Warranties. The representations and warranties of the Company in Section ‎3 of this Agreement
    shall be true and correct when made and shall be true and correct in all material respects as of the First Closing Date.
	 	 	 
	 	5.2.	Compliance
    with Covenants. The Company shall have performed and complied with all of its covenants, agreements and undertakings set
    forth herein.
	 	 	 
	 	5.3.	Actions
    Taken; Delivery of Documents. All the actions to be taken by the Company’s shareholders or by the Company as set
    forth in Section ‎2.2, ‎2.4 or ‎2.6 above, as applicable, above shall have been completed to the satisfaction
    of the Purchasers. 
	 	 	 
	 	5.4.	Proceedings
    and Documents. All corporate and other proceedings in connection with the transactions contemplated by this Agreement
    shall be satisfactory in substance and form to the Purchasers, and the Purchasers shall have received all such counterpart
    copies of such documents as the Purchasers may reasonably request.

 

	6.	Conditions
    to Closing by the Company. The Company’s obligation to consummate the transactions contemplated hereby at each
    Closing is subject to the satisfaction and fulfillment, prior to or at the applicable Closing, of each of the following conditions
    precedent (any or all of which may be waived, in whole or in part, by the Company, which waiver shall be at the sole discretion
    of the Company):

 

	 	6.1.	Accurate
    Representations and Warranties. The representations and warranties of the Purchasers in this Agreement shall be true and
    correct when made and shall be true and correct in all material respects as of the applicable Closing Date.
	 	 	 
	 	6.2.	Compliance
    with Covenants. The Purchasers shall have performed and complied with all of their covenants, agreements, and undertakings
    as set forth in this Agreement.
	 	 	 
	 	6.3.	Consents.
    The Company shall have secured all permits, consents and authorizations that shall be necessary or required lawfully to consummate
    the transactions contemplated by the Transaction Documents, including without limitation, third party consents and approvals,
    corporate approvals and waivers from shareholders of the Company entitled to preemptive rights, participation rights, anti-dilution
    rights or any other similar rights in connection with the transactions contemplated by the Transaction Documents, including
    without limitation, in connection with the issuance of any securities upon conversion of the Notes and the issuance of any
    securities upon exercise of the Warrants. 

 

    	 

    	- 8 -

    

 

	7.	Covenants

 

	 	7.1.	Use
    of Proceeds. The Company will use the Loan Amounts and any part thereof to finance its activities in accordance with a
    budget approved and amended from time to time by the Board.
	 	 	 
	 	7.2.	OCS
    Undertaking. To the extent that at any time hereinafter a Purchaser shall hold such number of securities of the Company
    such that it shall be legally required to sign an undertaking to the OCS, then such Purchaser shall sign such undertaking
    as may be required by the OCS at such time.

 

	8.	Taxes;
    Withholding
	 	 
	 	To
    the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be made by the Company
    pursuant to this Agreement. The Company shall be entitled to deduct and withhold any withholding taxes which the Company determines
    it is legally required to deduct or withhold from any payment to be made by the Company pursuant to this Agreement. 

 

	9.	Miscellaneous

 

	 	9.1.	Governing
    Law. This Agreement shall be deemed to be a contract made under the laws of the State of New York, and for all purposes
    shall be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute
    arising under or in relation to this Agreement shall be resolved exclusively in the competent court in New York, New York
    and each of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	9.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Agreement may be assigned or transferred without the prior
    consent in writing of each party to this Agreement.
	 	 	 
	 	9.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Purchasers upon any breach or default by the other under this Agreement shall impair any such right or remedy, nor shall it
    be construed to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default
    thereafter occurring. 
	 	 	 
	 	9.4.	Entire
    Agreement. This Agreement (together with the schedules and exhibits attached hereto) contains the entire understanding
    of the parties with respect to its subject matter and all prior negotiations, discussions, commitments, and understandings
    heretofore had between them with respect hereto are merged therein. In the case of any discrepancy between the provisions
    of this Agreement and the provisions of any other agreement previously entered into by the Company and/or any of the Purchasers,
    the provisions of this Agreement shall prevail.

 

    	 

    	- 9 -

    

 

	 	9.5.	Amendment.
    Any term of this Agreement may be amended (either generally or in a particular instance and either retroactively or prospectively)
    only with the written consent of the Company and Purchasers who are holding 70% or more of the aggregate outstanding principal
    amount of the Notes. 
	 	 	 
	 	9.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Agreement.
	 	 	 
	 	9.7.	Counterparts.
    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together
    shall constitute one and the same instrument.
	 	 	 
	 	9.8.	Further
    Actions. At any time and from time to time, each party agrees, without further consideration, to take such actions and
    to execute and deliver such documents as may be reasonably necessary to effectuate the purposes of this Agreement.
	 	 	 
	 	9.9.	Notices.
    All notices and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed
    to have been duly given: (a) in the case of hand delivery to the address shown below, on the next Business Day (as defined
    below) after delivery; (b) in the case of delivery by an internationally recognized overnight courier to the address set forth
    below, freight prepaid, on the next Business Day after delivery; (c) in the case of a notice sent by facsimile transmission
    to the number, and addressed as, set forth below, on the next Business Day after delivery, if facsimile transmission is confirmed;
    (d) in the case of a notice sent by an email to the email address set forth below, on the next Business Day after delivery.
    The term “Business Day” means a day on which the banks are open for business in the country of receipt
    of any notice.

 

	Contact
    details:	 
	 	 
	The
    Company	Motus
    GI Medical Technologies Ltd.
	 	 	 
	 	Keren
    Hayesod 22
	 	 	 
	 	Tirat
    Carmel, Israel 3902638
	 	 	 
	 	Tel:	 	 
	 	Fax:	 	 
	 	e-mail:	 	 
	 	 	 
	 	with
    a copy to (which shall not constitute service of process):
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 
	 	Tel:
    	 	 
	 	Fax:	 	 
	 	email:
    	 	 
	 	 	 
	Purchasers	To
    the addresses set forth in Exhibit A.

 

    	 

    	- 10 -

    

 

	 	 	A
    party may change or supplement the contact details for service of any notice pursuant to this Agreement, or designate additional
    addresses or facsimile numbers for the purposes of this Section ‎9.9, by giving the other party written notice of the
    new contact details in the manner set forth above.
	 	 	 
	 	9.10.	Severability.
    If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law,
    then such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such
    provision were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this
    Agreement shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law,
    to the meaning and intention of the excluded provision as determined by such court of competent jurisdiction.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Convertible Notes Agreement on the date first above written.

 

	Motus
    GI Medical Technologies Ltd.	 
	 	 	 
	By:	 	 	 	 
	Title:	 	 	 	 

 

[Purchaser’s
Signature Pages to Follow]

 

    	 

    	- 11 -

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Convertible Notes Agreement on the date first above written.

 

 

	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
    MOTUS Co-Investment Partners, LLC
	 	 	 	 	 
	By:
    	 	 	 	 	By:
    	 	 	 
	Title:	 	 	 	 	Title:	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Ascent
    Biomedical Ventures II, L.P.(3)	 	Ascent
    Biomedical Ventures Synecor, L.P.
	 	 	 	 	 
	By:	 	 	 	 	By:	 	 	 
	Title:	 	 	 	 	Title:	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Jacobs
    Investments Company LLC	 	 
	 	 	 	 	 
	By:	 	 	 	 	 	 
	Title:	 	 	 	 	 	 

 

[Purchasers’
Signature Page to Convertible Notes Agreement]

 

    	 

    	- 12 -

    

 

Exhibit
A

 

Loan
Amount and Notes

 

	Name	 		Loan
                                         Amount	 	 	 	First
                                         Installment	 	 	 	Second
                                         Installment	 	 	 	Third
                                         Installment	 	 	 	Fourth
                                         Installment	 	 	 	Address	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Orchestra
    Medical Ventures II, L.P.	 	US$	1,239,996	 	 	US$	309,999	 	 	US$	309,999	 	 	US$	$
                                         309,999	 	 	US$	309,999	 	 	 	 	 
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	US$	977,511	 	 	US$	325,837	 	 	US$	325,837	 	 	US$	$
                                         325,837	 	 	US$	0	 	 	 	 	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	US$	1,665,108	 	 	US$	416,277
                                         	 	 	US$	$
                                         416,277	 	 	US$	$
                                         416,277	 	 	US$	$
                                         416,277	 	 	 	 	 
	Ascent
    Biomedical Ventures Synecor, L.P.	 	US$	831,304	 	 	US$	207,826	 	 	US$	$
                                         207,826	 	 	US$	207,826	 	 	US$	207,826	 	 	 	 	 
	Jacobs
    Investments Company LLC	 	US$	782,032	 	 	US$	195,508
                                         	 	 	US$	195,508	 	 	US$	$
                                         195,508	 	 	US$	195,508	 	 	 	 	 
	Total	 	US$	5,495,951	 	 	US$	1,455,447	 	 	US$	1,455,447	 	 	US$	1,455,447	 	 	US$	1,129,610	 	 	 	 	 

 

    	 

    	- 13 -

    

 

Warrants

 

	Name	 	First
    Warrants	 	Second
    Warrants	 	Third
    Warrants	 	Fourth
    Warrants	 	Total
    Warrants
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Orchestra
    Medical Ventures II, L.P.	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	409,200	 
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	107,526	 	 	 	107,526	 	 	 	107,526	 	 	 	0	 	 	 	322,578	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	137,371	 	 	 	137,371	 	 	 	137,371	 	 	 	137,371	 	 	 	549,484	 
	Ascent
    Biomedical Ventures Synecor, L.P.	 	 	68,583	 	 	 	68,583	 	 	 	68,583	 	 	 	68,583	 	 	 	274,332	 
	Jacobs
    Investments Company LLC	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	258,072	 
	Total	 	 	480,298	 	 	 	480,298	 	 	 	480,298	 	 	 	372,772	 	 	 	1,813,666	 

 

    	 

    	 

    

 

EXHIBIT
B1

________,
2015

 

Purchaser:
_________________

Principal
Amount: US$ _________

 

CONVERTIBLE

PROMISSORY
NOTE

 

For
value received, Motus GI Medical Technologies Ltd., an Israeli company (“Company”) promises to pay to
the Purchaser named above (“Holder”), the principal sum stated above (the “Principal Amount”)
in accordance with the terms set forth herein, as follows:

 

	1.	Note
    Part of a Series. This Note is being sold by the Company as part of a series of notes issued pursuant to that certain
    Convertible Notes Agreement dated as of _______, 2015, by and among the Company and purchasers of such Notes (the “CNA”).
    The term “Notes” shall mean herein all Notes issued under the CNA.
	 	 
	2.	Interest.
    Interest shall accrue on the unpaid Principal Amount of this Note from the date of this Note until the actual repayment
    of all amounts due hereunder, at an annual rate of 10% (ten percent), compounded annually. Interest shall be computed on the
    basis of a year of 360 days for the actual number of days occurring in the period for which such interest is payable. Upon
    conversion of the Principal Amount in accordance with the terms hereof, all interest accrued thereon shall be converted together
    with the Principal Amount or repaid to the Holder in cash, after deduction of all applicable taxes with respect thereto, as
    shall be determined by the Company, at its sole discretion. The actual amount to be converted in accordance with the Company’s
    election, as specified in the preceding sentence, shall be hereinafter referred to as the “Conversion Amount.”
	 	 
	3.	Automatic
    Conversion upon QFR. To the extent not previously converted or repaid according to the terms specified herein, the
    Conversion Amount shall be automatically converted, immediately prior and subject to the closing of a QFR (as defined below),
    on the same terms and conditions applicable to the QFR, such that the Holder shall receive the same type of securities issued,
    and any other rights granted to the investors in such QFR (the “QFR Securities”), under the same terms
    as if the Holder had participated in the QFR as an investor (including any warrants or any other securities granted to the
    investors therein), but at a conversion price per share equal to the QFR Conversion Price (as defined below).
	 	 
	 	It
    being agreed and acknowledged that (a) the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of QFR Securities issued to the Holder shall be set to be the QFR Conversion Price, and any
    rights that are attached to the QFR Securities issued to the Holder which are determined, derived, calculated, triggered,
    or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend preferences,
    anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual QFR Conversion
    Price; and (b) in the event that the QFR Securities also comprise of warrants to purchase, or other securities convertible
    into, shares of the Company (any such preceding convertible security a “Convertible Security”), then (i)
    upon such conversion, the Holder shall be entitled to receive such number of warrants and/or Convertible Securities of the
    same class or type that are issued to the investors in the framework of the QFR, in a number which shall be determined using
    the same warrant and/or Convertible Securities coverage ratio offered to the investors in such QFR, such that the ratio between
    the shares and the warrants and/or Convertible Securities issued to the Holder shall be equal to the ratio between the shares
    and the warrants and/or Convertible Securities issued to each investor in such QFR; and (ii) the discount rate reflected in
    the QFR Conversion Price shall not apply in respect of the exercise price or conversion price (as applicable) of such warrants
    and/or Convertible Securities.

 

    	 	 	 

     

    

 

For
example, if the terms of the QFR are as follows:

 

	 	●	The
    QFR unit price is US$10.
	 	 	 
	 	●	Each
    unit is comprised of two (2) Ordinary Shares and one (1) warrant to purchase one (1) Ordinary Share.
	 	 	 
	 	●	The
    discount rate reflected in the QFR Conversion Price of the Holder is 10%. 
	 	 	 
	 	●	The
    exercise price of the warrants issued in the QFR is US$12.
	 	 	 
	 	●	The
    Conversion Amount of the Holder is US$1,800.

 

then,
in the framework of such QFR, the Holder shall be issued, upon conversion of the Conversion Amount, 200 Ordinary Shares ((US$1,800))/((1-10%)*US$10))
and 100 warrants to purchase 100 Ordinary Shares (100/2), at an exercise price per share of US$12, while an investor, who is not
a holder of Notes, and invests in the QFR the same amount (i.e., US$1,800), shall be issued only 180 Ordinary Shares and 90 warrants
to purchase 90 Ordinary Shares, at an exercise price per share of US$12.

 

The
term “QFR” means the first financing round consummated by the Company after the date of the Note, through an
equity investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance of
shares upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate investment
amount of not less than US$10,000,000 (Ten Million US Dollars), including the outstanding principal amount of the Notes and all
accrued and unpaid interest thereon.

 

The
term “QFR Conversion Price” means a conversion price reflecting a 10% discount on the price paid by the investor(s)
for the shares issued in the QFR and if the price in such QFR is fixed per each unit offered in the QFR, the discount shall be
applicable to such unit price. Notwithstanding the foregoing, in the event that the QFR in an initial public offering with gross
proceeds to the Company of not less than US$25,000,000 (Twenty Five Million US Dollars) (including the outstanding principal amount
of the Notes and all accrued and unpaid interest thereon) (the “QIPO”), the QFR Conversion Price shall mean
a conversion price reflecting a 50% discount on the price paid for the shares issued in the QIPO and if the price in such QIPO
is fixed per each unit offered in the QIPO, the discount shall be applicable to such unit price.

 

    	 	 -2-	 

     

    

 

If
this Note is converted in accordance with this Section ‎4, written notice shall be delivered to the Holder of this Note, notifying
the Holder of the conversion, specifying the Conversion Amount, the date of such conversion, and the securities issued upon conversion.
For the avoidance of doubt, in such event this Note shall be null and void even if not surrendered to the Company.

 

	4.	Automatic
    Conversion upon M&A Event. In the event that, prior to the conversion of the Conversion Amount or its repayment
    according to the terms specified herein, an M&A Event (as defined below) shall occur, then immediately prior and subject
    to the closing of such M&A Event, the Conversion Amount shall be automatically converted into Series A Preferred Shares,
    par value NIS 0.01 per share, of the Company (the “Preferred A Shares”), at a conversion price equal to
    the price per share paid by the Company’s investors in consideration for the Preferred A Shares (i.e., ________) (the
    “M&A Conversion Price”). 
	 	 
		It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the M&A Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    M&A Conversion Price.
	 	 
	 	The
    term “M&A Event” means (i) a merger or consolidation of the Company in which the Company’s shareholders
    immediately prior to such transaction do not own, directly or indirectly, more than 50% of the share capital of the surviving
    entity; (ii) the acquisition of more than 50% of the Company’s outstanding share capital by a single unaffiliated person,
    entity or group ,or by persons or entities acting in concert; (iii) the sale or transfer of all or substantially all of the
    assets of the Company; or (iv) a reverse triangular merger in which the Company is the surviving entity but the shares of
    the Company’s share capital outstanding immediately prior to the merger are converted by virtue of the merger into other
    property, whether in the form of securities, cash or otherwise.
	 	 
	5.	Voluntary
    Conversion upon NQFR. In the event that, prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company shall consummate a financial round through an equity investment, either in one
    transaction or in series of transactions (including an initial public offering but excluding the issuance of any convertible
    notes or the issuance of shares upon conversion of such notes), which is not a QFR (a “NQFR”), then the
    holders of Notes reflecting [__]% (___ percent) of the aggregate outstanding principal amount of the Notes (the “Majority
    Holders”), shall be entitled, no later than fourteen (14) days prior to the closing of such NQFR, to notify the
    Company in writing of their choice to convert the entire Conversion Amount of the Notes (the “Aggregate Conversion
    Amount”). In such event the entire Aggregate Conversion Amount shall be converted immediately prior and subject
    to the closing of the NQFR, on the same terms and conditions specified in Section ‎3 above (“Automatic Conversion
    upon a QFR”), mutatis mutandis. The election of the Majority Holders to convert the entire Aggregate Conversion
    Amount shall be binding on all of the holders of the Notes and each such holder shall be deemed to have elected to convert
    its respective portion of the Aggregate Conversion Amount in accordance with the terms and conditions specified herein.

 

    	 	 -3-	 

     

    

 

	6.	Maturity
    Date. If not converted or repaid according to the terms set forth herein until thirty (30) months from the date of
    this Note (i.e., ________) (the “Maturity Date”), then at the Maturity Date the Conversion Amount shall
    be automatically converted into Preferred A Shares, at a conversion price per share equal to the price per share paid by the
    Company’s investors in consideration for the Preferred A Shares (i.e., ________) (the “Maturity Conversion
    Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Maturity Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Maturity Conversion Price.
	 	 
	7.	Event
    of Default. In the event that, prior to the conversion of the Conversion Amount or its repayment according to the
    terms hereunder an Event of Default occurs, then the Conversion Amount shall be, at the election of the Holder, at its sole
    discretion, either: (i) become immediately due and payable to the Holder in cash; or (ii) converted into Preferred A Shares,
    at a conversion price per share equal to the price per share paid by the Company’s investors in consideration for the
    Preferred A Shares (i.e., ________) (the “Default Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Default Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Default Conversion Price.
	 	 
	 	The
    term “Event of Default” means (a) dissolution, termination of existence, suspension or discontinuance of
    business or ceasing to operate as going concern for a period of more than thirty (30) days; (b) the appointment of a receiver,
    trustee, custodian or similar official, for the Company or any material portion of the property or assets of the Company and
    the continuation of such appointment without dismissal for a period of thirty (30) days or more; (c) the conveyance of any
    material portion of the assets of the Company to a trustee, mortgage or liquidating agent or an assignment for the benefit
    of creditors by the Company which is not dismissed within a period of thirty (30) days; (d) the commencement of any proceeding,
    whether federal or state, relating to bankruptcy, insolvency, dissolution, reorganization, composition, renegotiations of
    outstanding indebtedness, arrangement or otherwise to the relief or debtors or the readjustment of indebtedness, by or against
    the Company, which is not stayed, vacated or released within sixty (60) days of commencement; (e) any material breach by the
    Company of any covenant or obligation in the Note, CAN or any documents and agreements ancillary thereto (the “Transaction
    Documents”) which is not cured, if curable, within thirty (30) days following receipt by the Company of a written
    notice of such breach; (f) any material misrepresentation has occurred in the Transaction Documents, which is not cured, if
    curable, within thirty (30) days following receipt by the Company of a written notice of such breach; (g) the Company shall
    fail to make any required payment of interest, principal or otherwise under the Notes, which is not cured within thirty (30)
    days following receipt by the Company of a written notice of such failure. The Company undertakes to notify the Holder immediately
    following occurrence of any of the events detailed in clauses (a) to (g) above.

 

    	 	 -4-	 

     

    

 

	8.	Conversion;
    Fractional Interests. Each conversion shall be deemed to have been effected as to this Note (or the specified portion
    thereof) on the date on which the requirements set forth above in this Note required to be satisfied by the Holder, or the
    circumstances that are required to exist, have been satisfied as to this Note (or portion thereof), and the person whose name
    any certificate or certificates for shares shall be issuable upon such conversion shall be deemed to have become on said date
    the holder of record of the shares represented thereby. No fractional shares or scrip representing fractional shares shall
    be issued upon conversion of this Note and the number of shares issued shall be rounded to the nearest whole number.
	 	 
	9.	Payments;
    Taxes

 

	 	9.1.	Payments.
    All payments of interest and of principal shall be in U.S. Dollar (“US$”) or in the New Israeli Shekels
    (“NIS”) equivalent. If any payment is paid in a NIS equivalent, it shall be paid in accordance with the
    representative rate of exchange of the U.S.t Dollar against the NIS last published by the Bank of Israel immediately prior
    to the certain payment date.
	 	 	 
	 	9.2.	Taxes
    on Payments. To the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be
    made by the Company pursuant to this Note. The Company shall be entitled to deduct and withhold any withholding taxes which
    the Company determines it is legally required to deduct or withhold from any payment to be made by the Company pursuant to
    this Note.

 

	10.	Not
    a Shareholder. Prior to the conversion of this Note or any portion thereof according to the provisions specified herein,
    the Holder, in its capacity as an Holder, shall not be entitled to any rights of a shareholder of the Company, including,
    without limitation, the right to vote or to receive dividends or other distributions, with respect to the Note and the shares
    issuable upon conversion of the Note.
	 	 
	11.	Miscellaneous

 

	 	11.1.	Governing
    Law. This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall
    be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute arising
    under or in relation to this Agreement shall be resolved exclusively in the competent court in [_____], and each of the parties
    hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	11.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Note may be assigned or transferred without the prior consent
    in writing of each party to this Note.

 

    	 	 -5-	 

     

    

 

	 	11.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Holder upon any breach or default by the other under this Note shall impair any such right or remedy, nor shall it be construed
    to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter occurring.
	 	 	 
	 	11.4.	Entire
    Agreement. This Note, when read together with the CNA, contains the entire understanding of the parties with respect
    to its subject matter and all prior negotiations, discussions, commitments, and understandings heretofore had between them
    with respect hereto are merged therein. In the case of any discrepancy between the provisions of this Note and the provisions
    of any other agreement previously entered into by the Company or the Holder, the provisions of this Note and the CNA shall
    prevail.
	 	 	 
	 	11.5.	Amendment.
    Any term of this Note – as well as of all other Notes - may be amended (either generally or in a particular instance
    and either retroactively or prospectively) only with the written consent of the Company and the Majority Holders. 
	 	 	 
	 	11.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Note.
	 	 	 
	 	11.7.	Notices.
    All notices and other communications made pursuant to this Note shall be in writing and shall be conclusively deemed to have
    been duly given if delivered in accordance with the notice provisions of the CNA. 
	 	 	 
	 	11.8.	Severability.
    If any provision of this Note is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Note and the remainder of this Note shall be interpreted as if such provision were
    so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Note shall be
    interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
    intention of the excluded provision as determined by such court of competent jurisdiction.

 

	 	Motus
    GI Medical Technologies Ltd.
	 	By:	                  
	 	Name:	 
	 	Title:	 

 

    	 	 -6-	 

     

    

 

EXHIBIT
B2

 

NEITHER
THIS WARRANT CERTIFICATE NOR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER SECURITIES ACT, AND THIS WARRANT CERTIFICATE AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT CERTIFICATE MAY NOT BE SOLD, OFFERED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH APPLICABLE SECURITIES LAWS AND THE RESTRICTIONS, TERMS AND CONDITIONS SET FORTH HEREIN.

 

Motus
GI Medical Technologies Ltd.

 

Preferred
A SHARES warrant Certificate

 

To
purchase

[____]
Preferred A Shares (subject to adjustment) of

Motus
GI Medical Technologies Ltd. (the “Company”)

at
a per share price and subject to the terms detailed below

VOID
AFTER 17:00 p.m. Israel Standard Time

on
the last day of the Warrant Period (as defined below)

 

THIS
IS TO CERTIFY THAT, [_________] (the “Holder”), is entitled to purchase from the Company, an aggregate
of up to [______] (as may be adjusted hereunder) Preferred A Shares of the Company, nominal value NIS 0.01 per share (the “Warrant
Shares”), at an aggregate purchase price of US$ [______], reflecting an exercise price per share of US$ 1.00 (the “Exercise
Price”), during the Warrant Period.

 

This
Warrant Certificate (this “Warrant”) is issued to the Holder in connection with that certain Convertible Notes
Agreement dated _________ by and among the Company and the Purchasers listed on Exhibit A thereto (the “Convertible Notes
Agreement”).

 

1.
EXERCISE OF WARRANT

 

	 	1.1.	Warrant
    Period. This Warrant may be exercised, subject to the terms and conditions hereof, in whole or in part, at one time or
    from time to time during the period commencing on __________[the applicable Closing Date] (the “Initial Date”)
    until the earlier of: (i) seven (7) years thereafter (i.e., _________); and (ii) the closing of an Exit Event (as defined
    in Section ‎5 below); provided that such Exit Event is consummated within 180 days from the Exit Event Notice (each of
    (i) or (ii), the “Expiry Date”). The period between the Initial Date and the Expiry Date shall be referred
    to hereinafter as the “Warrant Period.”

 

    	 

    	 

    

 

	 	1.2.	Exercise
    for Cash. This Warrant may be exercised by presentation and surrender thereof to the Company at its principal office or
    at such other office or agency as it may designate from time to time, accompanied by: 

 

	 	(a)	A
    duly executed notice of exercise, in the form attached hereto as Schedule ‎1.1 (the “Exercise Notice”);
    and
	 	 	 
	 	(b)	Payment
    to the Company, for the account of the Company, of the Exercise Price for the number of Warrant Shares purchased payable in
    immediately available funds by wire transfer to the Company’s bank account. The Exercise Price will be paid in United
    States Dollars or the equivalent sum in NIS according to the Bank of Israel exchange rate as published upon the date immediately
    prior to the exercise date.

 

	 	1.3.	Exercise
    on Net Issuance Basis. In lieu of payment to the Company as set forth in Section ‎1.2 above, the Holder may elect
    to exercise this Warrant into the number of Warrant Shares calculated pursuant to the formula below, by presentation and surrender
    thereof to the Company at its principal office or at such other office or agency it may designate from time to time, accompanied
    by a duly executed notice of exercise, in the form attached hereto as Schedule 1.3 (the “Net Issuance
    Notice”):

 

	X	=	                         Y*(A
    - B)
	                               A

 

Where:

 

	 	X
    =	the
    number of Warrant Shares to be issued to the Holder;
	 	 	 
	 	Y
    =	the
    number of Warrant Shares in respect of which the net issuance election is being made;
	 	 	 
	 	A
    =	the
    Fair Market Value (as defined below) of one Warrant Share; and
	 	 	 
	 	B
    =	the
    Exercise Price of one Warrant Share.

 

    	-2- 

    	 		 

    

 

For
purposes of this Section ‎1.3, the “Fair Market Value” of one Warrant Share as of a particular date (the
“Determination Date”) shall be: 

 

	 	(a)	If
    the net issuance right is exercised in connection with and contingent upon an initial public offering of the Company’s
    shares (an “IPO”), then the initial “price to public” (i.e., before deduction of discounts,
    commissions or expenses) specified in the final prospectus or registration statement with respect to such offering.
	 	 	 
	 	(b)	If
    the net issuance right is exercised in connection with and contingent upon an Exit Event that is not an IPO, the price per
    Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) in such Exit Event. 
	 	 	 
	 	(c)	If
    the net issuance right is not exercised in connection with and contingent upon an Exit Event, then as follows:

 

	 	(i)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are traded on a securities exchange, the Fair Market Value shall be deemed to
    be the average of the closing prices of such shares on such exchange over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date;
	 	 	 
	 	(ii)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are quoted for trading on an over-the-counter system, the Fair Market Value shall
    be deemed to be the average of the closing bid prices of such shares over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date; and
	 	 	 
	 	(iii)	If
    there is no public market for the Preferred A Shares (or any securities to which the Preferred A Shares have been converted
    to in accordance with the Company’s organizational documents and applicable law), the Fair Market Value of the shares
    shall be determined in good faith by the Board of Directors of the Company.

 

    	-3- 

    	 		 

    

 

	 	1.4.	Issuance
    of Warrant Shares. Upon presentation and surrender of this Warrant, accompanied by (a) the duly executed Exercise Notice
    and the payment of the applicable Exercise Price for the Warrant Shares being purchased pursuant to Section ‎1.2 above;
    or (b) the duly executed Net Issuance Notice pursuant to Section ‎1.3 above, as the case may be, the Company shall promptly
    (i) issue to the Holder the Warrant Shares to which the Holder is entitled; and (ii) deliver to the Holder the share certificate
    evidencing such Warrant Shares. 
	 	 	 
	 	 	Upon
    receipt by the Company of this Warrant and the applicable duly executed notice of exercise (and the Exercise Price for the
    Warrant Shares being purchased, if applicable), together with any other documents and/or approvals that may be required by
    law, the Holder shall be deemed to be the holder of record of the Warrant Shares issuable upon such exercise, notwithstanding
    that the share transfer books of the Company shall then be closed or that certificates representing such shares shall not
    then be actually delivered to the Holder. 
	 	 	 
	 	1.5.	Fractional
    Shares. No fractions of shares shall be issued in connection with the exercise of this Warrant, and the number of shares
    issued shall be rounded to the nearest whole number.
	 	 	 
	 	1.6.	Partial
    Exercise. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant for cancellation,
    execute and deliver a new Warrant evidencing the rights of the Holder to purchase the balance of the Warrant Shares purchasable
    hereunder.
	 	 	 
	 	1.7.	Additional
    Documents. The Holder will sign and deliver any and all documents or approvals required by law, to facilitate the issuance
    of the Warrant Shares upon exercise of this Warrant. 
	 	 	 
	 	1.8.	Loss
    or Destruction of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
    or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonable reimbursement of expenses and
    satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute
    and deliver a new Warrant of like tenor and date.

 

    	-4- 

    	 		 

    

 

2.
TAXES

 

	 	2.1.	The
    Holder acknowledges that the grant of the Warrant, the issuance of the Warrant Shares and the execution and/or performance
    of this Warrant may have tax consequences to the Holder and that the Company is not able to ensure or represent to the Holder
    the nature and extent of such tax consequences. 
	 	 	 
	 	2.2.	The
    Company shall pay all of the applicable taxes and other charges payable by the Company in connection with the issuance of
    the Warrant Shares and the preparation and delivery of share certificates in the name of the Holder (such as transfer taxes
    in respect of the issuance or delivery of Warrant Shares upon exercise of this Warrant), if any, but shall not pay any taxes
    payable by the Holder by virtue of the holding, issuance, exercise, sale of this Warrant or the Warrant Shares by the Holder.

 

3.
RESERVATION OF SHARES; preservation of rights of holder

 

	 	3.1.	Reservation
    of Shares. The Company hereby agrees that, at all times prior to the expiration or exercise of this Warrant, it will maintain
    and reserve, free from pre-emptive or similar rights, such number of authorized but unissued shares so that this Warrant may
    be exercised without additional authorization of shares.
	 	 	 
	 	3.2.	Preservation
    of Rights. The Company will not, by amendment of its organizational documents or through reorganization, recapitalization,
    consolidation, merger, dissolution, transfer of assets, issue or sale of securities or any other voluntary act, avoid or seek
    to avoid the observance or performance of any of the covenants, stipulations, conditions or terms to be observed or performed
    hereunder, but will at all times in good faith assist in the carrying out of all the provisions hereof and in taking of all
    such actions and making all such adjustments as may be necessary or appropriate in order to fulfill the provisions hereof.

 

    	-5- 

    	 		 

    

 

4.
ADJUSTMENT

 

	 	4.1.	The
    number of Warrant Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment
    from time to time or upon exercise, as follows:

 

	 	(a)	Bonus
    Shares. In the event that during the Warrant Period the Company shall distribute a non-cash dividend or shares pursuant
    to a reclassification of its share capital, to all of the holders of shares of the Company (i.e., bonus shares), then this
    Warrant shall represent the right to acquire, in addition to the number of Warrant Shares indicated in the caption of this
    Warrant, the amount of such bonus shares that are distributed to persons holding the class of share capital for which the
    Warrant is exercisable and/or to receive the stock dividends which are distributed to persons holding the class of share capital
    for which the Warrant is exercisable, without payment of any additional consideration therefor, to which the Holder would
    have been entitled had this Warrant been exercised prior to the distribution of the stock dividends or the bonus shares. 
	 	 	 
	 	(b)	Consolidation
    and Division. In the event that during the Warrant Period the Company consolidates its share capital into shares of greater
    par value, or subdivides them into shares of lesser par value, then the number of Warrant Shares to be allotted on exercise
    of this Warrant after such consolidation or subdivision shall be reduced or increased accordingly, as the case may be, and
    in each case the Exercise Price shall be adjusted appropriately such that the aggregate consideration hereunder to the Company
    shall not change.
	 	 	 
	 	(c)	Capital
    Reorganization. In the event that during the Warrant Period a reorganization of the share capital of the Company is effected
    (other than subdivision, combination or reclassification provided for elsewhere in this Section 4) and the Preferred A Shares
    are exchanged for other securities of the Company, then, as part of such reorganization, provision shall be made so that the
    Holder shall be entitled to purchase upon exercise of this Warrant such kind and number of shares or other securities of the
    Company to which the Holder would have been entitled had this Warrant been exercised without taking into effect such reorganization.
    

 

    	-6- 

    	 		 

    

 

	 	4.2.	Whenever
    an adjustment is effected hereunder, the Company shall promptly compute such adjustment and deliver to the Holder a certificate
    setting forth the number of Warrant Shares (or any other securities) for which this Warrant is exercisable and the Exercise
    Price as a result of such adjustment, a brief statement of the facts requiring such adjustment and the computation thereof
    and when such adjustment has or will become effective.
	 	 	 
	 	4.3.	Except
    as otherwise provided herein, Sections 4.1(a) to 4.1(c) hereof are intended to operate independently of one another. If an
    event occurs that requires the application of more than one subsection, all applicable subsections shall be given independent
    effect, but there shall be no duplicate adjustments if two separate subsections provide the same protection.
	 	 	 
	 	4.4.	Notices
    of Certain Transactions. In case:

 

	 	(a)	the
    Company shall take a record of the holders of its Preferred A Shares (or other stock or securities at the time deliverable
    upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution,
    or
	 	 	 
	 	(b)	of
    the voluntary or involuntary dissolution, liquidation or winding-up of the Company
	 	 	 
	 	 	then,
    and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be,
    (i) the date on which a record is to be taken for the purpose of such dividend or distribution, and stating the amount and
    character of such dividend or distribution, or (ii) the effective date on which such voluntary dissolution, liquidation or
    winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Shares (or such other
    shares or securities at the time deliverable upon such voluntary dissolution, liquidation or winding-up) are to be determined.
    Such notice shall be mailed at least seven (7) days prior to the record date or effective date for the event specified in
    such notice. 

 

    	-7- 

    	 		 

    

 

5.
EXERCISE OF THE WARRANT UPON AN EXIT EVENT

 

Notwithstanding
anything to the contrary in this Warrant, if at any time during the Warrant Period, the Company consummates an Exit Event, or
at the discretion of the Board of Directors of the Company, in the event that the Company believes that an Exit Event is likely
to be consummated during such period, the Company shall provide written notice of such Exit Event (or, if applicable, an anticipated
Exit Event) to the Holder (the “Exit Event Notice”). Within fourteen (14) days after Holder’s receipt
of the Exit Event Notice, Holder must notify the Company if it intends to exercise this Warrant pursuant to Section ‎1.2 or
‎1.3 of this Warrant, in which case such exercise shall be effective contingent upon and immediately prior to the consummation
of the Exit Event. Thereafter, so long as the Company consummates such Exit Event within one hundred and eighty (180) days after
Holder’s receipt of the Exit Event Notice (to the extent the Exit Event shall not have occurred prior to the Exit Event
Notice), Holder shall have no further rights hereunder and this Warrant shall be automatically terminated if not so exercised.
If the Company fails to consummate such Exit Event within such time, then this Warrant shall remain in effect subject to the provisions
contained herein 

 

For
the purposes hereof, an “Exit Event” shall mean the closing of (i) an initial public offering; (ii) a merger
of the Company with or into another corporation, (iii) an acquisition of all or substantially all of the shares of the Company,
(iv) the sale or license of all or substantially all of the assets of the Company, any with respect to (ii)-(iv), other than a
merger or transaction in which the persons that beneficially owned, directly or indirectly, a majority of the share capital of
the Company immediately prior to such merger or transaction, beneficially own, directly or indirectly, a majority of the total
shares of capital stock of the surviving or transferee entity.

 

6.
RIGHTS OF THE HOLDER

 

	 	6.1.	This
    Warrant shall not entitle the Holder, by virtue hereof, to any voting rights or other rights as a shareholder of the Company,
    except for the rights expressly set forth herein.
	 	 	 
	 	6.2.	The
    Holder acknowledges that the Warrant Shares shall be subject to such rights, privileges, restrictions and limitations as set
    forth in this Warrant and the organizational documents of the Company (or any other agreement with respect thereto), as may
    be amended from time to time, and that, as a result, inter alia, of such limitations, it may be difficult or impossible
    for the Holder to realize his investment and/or to sell or otherwise transfer the Warrant Shares. The Holder further acknowledges
    that the Company’s shares are not publicly traded.

 

    	-8- 

    	 		 

    

 

7.
TERMINATION

 

Notwithstanding
anything to the contrary, this Warrant and all the rights conferred hereby shall terminate and expire at the aforementioned time
on the Expiry Date.

 

8.
MISCELLANEOUS

 

	 	8.1.	Entire
    Agreement; Amendment. This Warrant sets forth the entire understanding of the parties with respect to the subject matter
    hereof and supersedes all existing agreements among them concerning such subject matter. All article and section headings
    herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provision
    of this Warrant. Subject to Section ‎8.8 below, no modification or amendment of this Warrant will be valid unless executed
    in writing by the Company and the Holder. 
	 	 	 
	 	8.2.	Waiver.
    No failure or delay on the part of any of the parties in exercising any right, power or privilege hereunder and/or under
    any applicable law or the exercise of such right or power in a manner inconsistent with the provisions of this Warrant or
    applicable law shall operate as a waiver thereof. Any waiver must be evidenced in writing signed by the party against whom
    the waiver is sought to be enforced.
	 	 	 
	 	8.3.	Successors
    and Assigns; Assignment. Except as otherwise expressly limited herein, this Warrant shall inure to the benefit of, be
    binding upon, and be enforceable by the Holder and its respective successors, and administrators and is otherwise non-transferable
    without the prior consent of the Company. The Holder represents and warrants to the Company that this Warrant and the Warrant
    Shares, if and when purchased by the Holder, are for the Holder’s own account and for investment purposes only and not
    with a view for resale or transfer and that all the rights pertaining to the Warrant or the Warrant Shares, by law or equity,
    shall be purchased and possessed by the Holder for the Holder exclusively. 
	 	 	 
	 	8.4.	Governing
    Law. This Warrant shall be exclusively governed and construed in accordance with the laws of the State of New York, without
    regard to conflicts of laws provisions thereof.

 

    	-9- 

    	 		 

    

 

	 	8.5.	Notices.
    All notices and other communications made pursuant to this Warrant shall be in writing and shall be conclusively deemed
    to have been duly given if delivered in accordance with the notice provisions of the Convertible Notes Agreement. 
	 	 	 
	 	8.6.	Severability.
    If any provision of this Warrant is held by a court of competent jurisdiction to be unenforceable under applicable law,
    then such provision shall be excluded from this Warrant and the remainder of this Warrant shall be interpreted as if such
    provision were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this
    Warrant shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law,
    to the meaning and intention of the excluded provision as determined by such court of competent jurisdiction.
	 	 	 
	 	8.7.	Counterparts.
    This Warrant may be executed in any number of counterparts, each of which shall be an original, but all of which together
    shall constitute one instrument. Facsimile or electronic signatures of a party shall be binding as evidence of such party’s
    agreement hereto and acceptance hereof.
	 	 	 
	 	8.8.	Amendments.
    To the extent that any amendment(s) to the Convertible Notes Agreement or the transactions contemplated thereby result
    in a required amendment to the terms of this Warrant, this Warrant shall be deemed amended to the extent that the amendment(s)
    to the Convertible Notes Agreement are completed in accordance with the terms thereof.

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its

officer
thereunto duly authorized.

 

 

	Dated:	 	 	Motus
    GI Medical Technologies Ltd. 
	 	 	 	 	 
	 	 	 	Signature:	 
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	 
	 	 	 	Title:	 

 

    	-10- 

    	 		 

    

 

Schedule
1.2

 

Exercise
Notice

 

Date:
____________

 

To:
Motus GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to purchase _________ Warrant Shares (as such term is defined in the Warrant) pursuant to Section ‎1.2 of the
Warrant, and herewith makes payment of _____________, representing the full Exercise Price for such shares as provided for in
such Warrant. 

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	 

    	 

    

 

Schedule
1.3

 

Net
Issuance Notice

 

Date:
____________

 

To:
Motus GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to exercise the Warrant for the purchase of Warrant Shares (as such term is defined in the Warrant), pursuant to
the provisions of Section 1.3 of the Warrant.

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	 

    	 

    

 

THIRD
AMENDED AND RESTATED ARTICLES OF ASSOCIATION

 

OF

 

MOTUS
GI MEDICAL TECHNOLIGIES, LTD.

 

A
PRIVATE COMPANY LIMITED BY SHARES

 

UNDER
THE COMPANIES LAW, 5759-1999

 

*
* * *

 

	 	1.	Definitions;
    Interpretation.

 

	 	1.1	Definitions

 

In
these Articles of Association, the following terms shall have the meaning appearing opposite them, unless another interpretation
is expressly stated herein:

 

	 	“ABV”-	 	means
    Ascent Biomedical Ventures II L.P., Ascent Biomedical Ventures Synecor, L.P., and all of their respective limited and general
    partners, members and any Permitted Transferee and any Permitted Transferee thereof of any of the foregoing;
	 	 	 	 
	 	“ABV
    Director”- 	 	means
    the Director appointed by ABV except as otherwise provided for herein in Article 40; 
	 	 	 	 
	 	“Affiliates”
    - 	 	means,
    with respect to any Person, any other Person, directly or indirectly, through one or more intermediary Persons, controlling,
    controlled by or under common control with such Person;
	 	 	 	 
	 	“Annual
    General Meeting”-	 	means
    the annual general meeting of the Company’s shareholders (if convened);
	 	 	 	 
	 	“Articles”
    -	 	means
    these Articles of Association, as amended from time to time;
	 	 	 	 
	 	“ATI”
    -	 	means
    Accelerated Technologies, Inc.;
	 	 	 	 
	 	“Board”
    or - 	 	 
	 	 	 	 
	 	“Board
    of Directors” -	 	means
    the Board of Directors of the Company;

 

    	 	 	 

    	 	 	 

    

 

	 	“Chairman”-	 	means
    the Chairman of the Board of Directors as set forth in Article 50 herein;
	 	 	 	 
	 	“Company”
    -	 	means
    Motus GI Medical Technologies, Ltd.;
	 	 	 	 
	 	“Companies
    Law” -	 	means
    the Israeli Companies Law, 5759-1999, as the same shall be amended from time to time;
	 	 	 	 
	 	“Conversion
    Notice”	 	has
    the meaning set forth in Article 5(c).
	 	 	 	 
	 	“Conversion
    Price”	 	has
    the meaning set forth in Article 5(d).
	 	 	 	 
	 	“Deemed
    Issuance” 	 	Deemed
    Issuance shall mean the issuance of options to purchase or rights to subscribe to any Additional Shares, or securities by
    their terms convertible of exchangeable for Additional Shares, or options to purchase or rights to subscribe to such convertible
    or exchangeable securities, which may be exercised of converted into Additional Shares; 
	 	 	 	 
	 	“Director”
    - 	 	means
    a member of the Board of Directors;
	 	 	 	 
	 	“Excluded
    Securities”	 	has
    the meaning set forth in Article 5(d)(ii)(G);
	 	 	 	 
	 	“Extraordinary
    General Meeting(s)” -	 	has
    the meaning set forth in Article 25;
	 	 	 	 
	 	“Founder”
    - 	 	means
    Boris Shtul Identity number 307247049 and NGT to the extent pertaining to the Ordinary Shares held by NGT;
	 	 	 	 
	 	“General
    Meeting(s)” - 	 	means
    either an Annual General Meeting or an Extraordinary General Meeting;
	 	 	 	 
	 	“IPO”
    - 	 	means
    the closing of a bona fide initial underwritten offering of the Company’s securities to the public on a recognized exchange
    (e.g. NASDAQ, AIM), pursuant to a registration statement under the U.S. Securities Act of 1933, as amended, the Israeli Securities
    Law - 1968, or similar securities laws of another jurisdiction; 
	 	 	 	 
	 	“Jacobs”
    -	 	means
    Jacobs Investments LLC and any Permitted Transferee thereof;
	 	 	 	 
	 	“NGT”-	 	means
    N.G.T. New Generation Technologies Ltd. and any Permitted Transferee thereof;
	 	 	 	 
	 	“NGT
    Director(s)”- 	 	means
    the Director appointed by NGT;

 

    	 	2 	 

    	 	 	 

    

 

	 	 “Office
    Holder” - 	 	means
    every Director and every officer of the Company, including without limitation, each of the persons defined as “Nosei
    Misra” in the Companies Law; 
	 	 	 	 
	 	“Orchestra”
    -	 	means
    Orchestra Medical Ventures II, Orchestra Medical Ventures II Annex, Orchestra Medical Ventures GP, LLC, Orchestra Motus Co-Investment
    Partners LLC and all of their respective limited and general partners, members and any Permitted Transferee of any of the
    foregoing;
	 	 	 	 
	 	“Orchestra
    Director(s)”- 	 	means
    the Director(s) appointed by Orchestra except as otherwise provided for herein in Article 40;
	 	 	 	 
	 	“Ordinary
    Director”- 	 	means
    the Director appointed by the holders of the majority of the issued and outstanding Ordinary Shares;
	 	 	 	 
	 	“Ordinary
    Shares” -	 	means
    the Company’s Ordinary Shares, nominal value NIS 0.01 each; 
	 	 	 	 
	 	“Original
    Issue Price” -	 	means,
    with respect to a Preferred Share, the Price Per Share (subject to adjustment in the event of share splits, share dividends,
    reclassifications and other like events); 
	 	 	 	 
	 	“Permitted
    Transferee” - 	 	means,
    with respect to: (A) any shareholder: (i) any member of such shareholder’s immediate family (including, with respect
    to Boris Shtul, Ms. Alexandra Pevzner I.D 307285841); (ii) any Person Affiliated with such shareholder subject to the approval
    of the Board which approval shall not be unreasonably withheld; (iii) any fund, or any beneficiary of any trust or any account
    or arrangement managed by such shareholder or by the general partner or managing entity of such shareholder, or by an affiliate
    thereof; (iv) any shareholder, member or other equity holder of such shareholder; or (B) with respect to Orchestra or ABV:
    any member, general partner or any limited partner of Orchestra or ABV, respectively; or (C) with respect to NGT: (i) any
    affiliate entity of NGT that shall be established pursuant to restructuring and/or reorganization of NGT or any transfer/sale
    of NGT’s holdings to other entity controlled by NGT’s shareholders pursuant to an assets purchase agreement or
    a merger; or (ii) NGT’s, employees and consultants (each in this subsection (ii), an “NGT Transferee”),
    provided that a transfer(s) to such NGT’s Transferee shall be limited to the aggregate amount of 300,000 Ordinary Shares
    of the Company and that such NGT’s Transferee assumes NGT’s rights and obligations towards the Company and/or
    its shareholders and is subject to the provisions of these Articles, as applicable; 

 

    	 	3 	 

    	 	 	 

    

 

	 	“Person”
    - 	 	means
    an individual, corporation, partnership, joint venture, trust, and any other body corporate or unincorporated organization;
	 	 	 	 
	 	“Preferred
    Shareholder(s)” - 	 	means
    the holders of the Preferred Shares; 
	 	 	 	 
	 	“Preferred
    Share(s)” -	 	means
    the Company’s Series A Preferred Shares, nominal value NIS 0.01 each;
	 	 	 	 
	 	“Price
    Per Share” -	 	means,
    with respect to a Preferred Share, the price actually paid for such Preferred Share upon the issuance thereof;
	 	 	 	 
	 	“Qualified
    IPO”-	 	means
    the Company’s IPO at a price per share which is at least 5 (five) times the Original Issue Price (adjusted for share
    combinations or splits or other recapitalizations of the Company’s Shares), yielding gross proceeds to the Company of
    at least US$30,000,000 (Thirty Million US Dollars); 
	 	 	 	 
	 	“Register
    of Shareholders” - 	 	means
    the register of shareholders that must be maintained pursuant to Section 127 of the Companies Law;
	 	 	 	 
	 	“Series
    A Director(s)” - 	 	means
    any of the Orchestra Director(s), the ABV Director and or the NGT director;
	 	 	 	 
	 	“Series
    A Investors” -	 	means
    the purchasers of Series A Preferred Shares under the Series A Share Purchase Agreement;
	 	 	 	 
	 	“Series
    A SPA” – 	 	means
    the Series A Share Purchase Agreement dated September 15, 2011 entered into between the Company and each of the purchasers
    of Series A Preferred Shares thereunder; and
	 	 	 	 
	 	“Year”
    and “Month” -	 	a
    Gregorian month or year.

 

	 	1.2	Interpretation

 

(a)
Any capitalized term used but not otherwise defined in these Articles shall have the meaning ascribed to it in the Companies Law.

 

(b)
Words and expressions importing the singular shall include the plural and vice versa; words and expressions importing the masculine
gender shall include the feminine gender; and words and expressions importing persons shall include bodies corporate.

 

(c)
The captions used in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction
of any portion hereof.

 

(d)
Any use, reference or application of the terms “conversion”, “convert”, “convertible”
or “converting” of Preferred Shares as detailed in these Articles shall be deemed to include conversion by
way of reclassification to the extent reasonably applicable in the context.

 

    	 	4 	 

    	 	 	 

    

 

(e)
For the purposes of these Articles the phrase “on an as-converted basis” means that with respect to any given
right in question, and for any calculation of shareholding in the Company, Preferred Shares shall be calculated as, and shall
have the effect of, such number of Ordinary Shares into which such Preferred Shares are convertible at that time.

 

(f)
All shares held (beneficially or of record), at the time of applicable calculation, by shareholders who are Permitted Transferees
(including Affiliates) of each other, shall be aggregated together for the purpose of determining the availability to such holders
of any rights under these Articles, and such rights – to the extent they are determined to be available at such time - may
be exercised (up to the maximum extent so determined to be available in the aggregate to all such shareholders) by any, some or
all of such shareholders who are Permitted Transferees (including Affiliates) of each other.

 

(g)
In the event of a conflict between by English version of these Articles and the Hebrew version thereof, the English version shall
govern.

 

	 	2.	Private
    Company; Objects of the Company

 

2.1
The Company is a private company, and accordingly:

 

	 	 	(a)	The
    Company may not offer its securities to the public.
	 	 	 	 
	 	 	(b)	The
    right to transfer shares of the Company is restricted as provided in these Articles.

 

2.2
The number of shareholders of the Company at any time (other than employees or former employees of the Company who continue to
be shareholders of the Company) shall not exceed 50; provided, however, that if two or more individuals hold a share or shares
of the Company jointly, they shall be deemed to be one shareholder for purposes of this Article.

 

2.3
The objects of the Company shall be to engage in any lawful activity.

 

2.4
The Company may contribute reasonable amounts for any suitable purpose or categories of purposes even if such contributions do
not fall within business considerations of the Company. The Board of Directors may determine the amounts of the contributions,
the purpose or categories of purposes for which the contribution is to be made, and the identity of the recipient of any contribution.

 

3.
Limitation of Liability. The liability of the shareholders is limited to the payment of the nominal value of the shares
in the Company held thereby, and which remains unpaid, and only to that amount. If the Company’s share capital shall at
any time include shares without a nominal value, the liability of the holders of such shares shall be limited to the payment of
up to NIS 0.01 for each such share held thereby, and which remains unpaid, and only to that amount.

 

    	 	5 	 

    	 	 	 

    

 

SHARE
CAPITAL

 

4.
Share Capital 

 

4.1
The authorized share capital of the Company is five hundred seventy two thousand New Israeli Shekels (NIS 572,000) divided into
thirty four million (34,000,000) Ordinary Shares, of nominal value NIS 0.01 each, and twenty three million two hundred thousand
(23,200,000) Series A Preferred Shares, of nominal value NIS 0.01 each.

 

4.2
The Preferred Shareholders shall have the rights, preference, privileges and restrictions granted to and imposed on the Preferred
Shares as may be specifically indicated in these Articles and/or as the context may reasonably require. The Ordinary Shares shall
have the rights and restrictions granted to and imposed on the same as set forth in these Articles.

 

4.3
The holders of Ordinary Shares are each entitled to receive notices of, and to attend, General Meetings of the shareholders of
the Company, and for each share held, to one vote at such meetings for all purposes, and, subject to Article 54 hereof, to share
in such dividends as may be declared in accordance with these Articles out of funds legally available therefore, and, subject
to Articles 73 and 74 hereof, upon liquidation or dissolution, to share in the assets of the Company legally available for distribution
to the shareholders after payment of all debts and other liabilities of the Company.

 

5.
The Preferred Shares

 

The
Preferred Shares confer on the holders thereof all rights accruing to holders of Ordinary Shares in the Company, and in addition,
bear the following rights:

 

(a)
Subject to any provisions hereof conferring special rights as to voting, or restricting the right to vote, every holder of Preferred
Shares shall have one vote for each Ordinary Share into which the Preferred Shares held by him of record could be converted (as
provided in this Article), on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by
written ballot or by any other means. The Preferred Shareholder shall be entitled to vote, together with the holders of Ordinary
Shares. Except as provided otherwise in these Articles or as otherwise provided by law, the Preferred Shareholders shall vote
together with the holders of the Ordinary Shares as a single class (on an as-converted basis).

 

(b)
Each Preferred Share shall be initially convertible at the option of the holder thereof, at any time after the date of issuance
of such share, at the registered office of the Company (“Office”), into such number of fully
paid and non-assessable Ordinary Shares as is determined by dividing the applicable Original Issue Price by the applicable Conversion
Price and subject to adjustment under Article 5(d)) at the time in effect for such share. Furthermore, each Preferred Share shall
be converted into such number of fully paid and non-assessable Ordinary Shares as is determined by dividing the applicable Original
Issue Price by the applicable Conversion Price and subject to adjustment under Article 5(d)) at the time in effect for such share
immediately prior to the closing of a Qualified IPO.

 

    	 	6 	 

    	 	 	 

    

 

(c)
Before any holder of Preferred Shares shall be entitled (in the case of a conversion at such holder’s option) to convert
the same into Ordinary Shares, he/she/it shall surrender the certificate or certificates therefor, duly endorsed, at the Office,
and shall give written notice by mail, postage prepaid, to the Company at its principal corporate office, of the election to convert
the same and shall state therein the name or names of any nominee for such holder in which the certificate or certificates for
Ordinary Shares are to be issued. In the event that any Preferred Shareholder holding conversion rights pursuant to Article 5
elects to convert any of its Preferred Shares into Ordinary Shares such shareholder shall surrender the certificate or certificates
representing such shares, to the Office, and shall give written notice to the Company at its Office, accompanied with a detailed
written explanation as to how many Preferred Shares the Preferred Shareholder wishes to reclassify (“Conversion Notice”).
Within a reasonable time after the receipt of the Conversion Notice by the Company, the Company shall seek any shareholders’
resolutions necessary to effectuate any such conversion by reclassification (if any). If no shareholders resolutions are required
to give effect to such reclassification, such reclassification shall be deemed to have been effected immediately prior to the
close of business on the date on which the Company received the Conversion Notice, or such later date as may be detailed in the
Conversion Notice. However, if such reclassification requires an additional shareholders resolution(s), then in such event, such
reclassification shall be deemed to have been effected immediately upon the adoption of the said resolution(s) or such later date
as may be detailed in the Conversion Notice. The Company shall, as soon as practicable after the conversion by reclassification
and tender of the certificate for the shares converted by reclassification, against the receipt of the original share certificate,
issue and deliver a certificate or certificates for the number of Ordinary Shares to which such shareholder shall be entitled
as a result of the aforesaid and shall indicate the same in the Register of Shareholders. If the conversion is in connection with
a an IPO, then the conversion shall be deemed to have taken place automatically upon the reclassification of Preferred Shares
into Ordinary Shares regardless of whether the certificates representing such shares have been tendered to the Company, but from
and after such conversion any such certificates not tendered to the Company shall be deemed to evidence solely the Ordinary Shares
received upon such conversion and the right to receive a certificate for such Ordinary Shares. If the conversion is in connection
with a an IPO, the conversion may, at the option of any holder tendering Preferred Shares for conversion, be conditioned upon
the closing with the underwriter of the sale of securities pursuant to such offering, in which event the person(s) entitled to
receive the Ordinary Shares issuable upon such conversion of the Preferred Shares shall not be deemed to have converted such Preferred
Shares until immediately prior to the closing of such offer of securities. The Company shall, as soon as practicable after the
conversion and tender of the certificate for the Preferred Shares converted, issue and deliver at such office to such holder of
Preferred Shares or to the nominee or nominees of such holder of Preferred Shares, a certificate or certificates for the number
of Ordinary Shares to which such holder shall be entitled as aforesaid. In the event that at any time the Company receives a Conversion
Notice or in the event of a Qualified IPO or any other conversion by reclassification contemplated in Article 5, each shareholder
shall execute any document and/or resolution requested by the Company reasonably necessary in order to give effect to the reclassification
privileges as set forth in Article 5.

 

(d)
The initial conversion price for the Preferred Shares shall be the Original Issue Price (subject to any adjustments under this
Article 5(d)) (the “Conversion Price”). The Conversion Price shall be adjusted from time to time as
follows:

 

(i)
(A) Upon each issuance (or Deemed Issuance, as defined above) by the Company of any Additional Shares (as defined below) at a
price per share less than the applicable Conversion Price then in effect, except for an issuance described in Article 5(d)(iv)
below, such Conversion Price will be reduced, for no additional consideration, in accordance with a weighted average anti-dilution
formula, to a price (calculated to the nearest cent) determined by the following formula :

 

CP2
= CP1 * (A+B) / (A+C)

 

	 	CP2	=	New
    Series A Conversion Price following the issuance of Additional Shares
	 	 	 	 
	 	CP1	=	Series
    A Conversion Price in effect immediately prior to the new issuance of Additional Shares

 

    	 	7 	 

    	 	 	 

    

 

	 	A	=	Number
    of Ordinary Shares deemed to be outstanding immediately prior to new issue of Additional Shares on an as converted basis,
    treating for this purpose as outstanding all Ordinary Shares issuable upon conversion of all issued Preferred Shares and all
    Ordinary Shares issuable upon conversion or exercise of any other then currently outstanding convertible securities, warrants
    or options, but such number of Ordinary Shares shall not include any convertible securities converting into the then applicable
    Additional Shares.
	 	 	 	 
	 	B	=	Aggregate
    consideration received by the Company with respect to the new issue of Additional Shares divided by CP1. (i.e.
    Aggregate consideration / CP1)
	 	 	 	 
	 	C	=	Number
    of Additional Shares issued 

 

(B)
No adjustments to the Conversion Price shall be made in an amount less than one agura (NIS 0.01) per share. No adjustment to the
Conversion Price shall be made if it has the effect of increasing the Conversion Price beyond the applicable Conversion Price
immediately prior to such adjustment.

 

(C)
The consideration for the issuance of Additional Shares in the case of the issuance of Additional Shares for cash shall be deemed
to be the amount of cash received therefor. In the case of the issuance of the Additional Shares for consideration in whole or
in part other than cash, the consideration other than cash shall be deemed to be the fair value thereof as determined by the Board
of Directors in good-faith. In the case of a Deemed Issuance of Additional Shares, the consideration for the Additional Shares
shall be deemed to be the aggregate consideration received by the Company on the issuance of the securities themselves, taken
together with any additional consideration (if any) to be paid to the Company on the exercise or conversion of the securities.

 

(D)
In the case of the issuance of options to purchase or rights to subscribe for Ordinary Shares, or securities by their terms convertible
into or exchangeable for Ordinary Shares or options to purchase or rights to subscribe for such convertible or exchangeable securities,
the aggregate maximum number of Ordinary Shares deliverable upon exercise (assuming the satisfaction of any conditions to exercise,
including without limitation, the passage of time, but without taking into account potential anti-dilution adjustments) of such
options to purchase or rights to subscribe for Ordinary Shares, or upon the exchange or conversion of such security, shall be
deemed to be Additional Shares issued at the time of the issuance of such options, rights or securities, at a consideration equal
to the consideration (determined in the manner provided in Sub-article (d)(i)(C)), received by the Company upon the issuance of
such options, rights or securities plus any additional consideration payable to the Company pursuant to the term of such options,
rights or securities (without taking into account potential anti-dilution adjustments) for the Ordinary Shares covered thereby;
provided, however, that if any options as to which an adjustment to the Conversion Price has been made pursuant to this Article
4(d)(i)(D) expire without having been exercised, then the Conversion Price shall be readjusted as if such options had not been
issued (without any effect, however, on adjustments to the Conversion Price as a result of other events described in this Article).

 

(E)
For purpose of Sub-article (d)(i) hereof, the consideration for any Additional Shares shall be taken into account at the U.S.
Dollar equivalent thereof, on the day such Additional Shares are issued or deemed to be issued pursuant to Sub-article (d)(i)(D).

 

(ii)
“Additional Shares” shall mean any Ordinary Shares issued, or deemed to have been issued pursuant to
Subarticle (d)(i)(D), by the Company other than:

 

    	 	8 	 

    	 	 	 

    

 

(A)
Ordinary Shares or Preferred Shares issued or issuable upon a pro-rata share split, share dividend, or any subdivision
of Ordinary Shares pursuant to a transaction described in Subarticles (d)(iii) or (d)(iv) hereof.

 

(B)
Ordinary Shares (or options to purchase such Ordinary Shares) issued or issuable to employees, directors, consultants of the Company
or other persons (including without limitation, corporate entities) pursuant to any option plan approved by the Board of Directors
including an Orchestra Director and an ABV Director.

 

(C)
Securities issuable upon conversion of any of the Preferred Shares, or as a dividend or distribution on the Preferred Shares.

 

(D)
Securities issued upon the conversion of any debenture, warrant, option, or other convertible security (the issuance of which
did not cause an adjustment hereunder).

 

(E)
Any Ordinary Shares issuable to ATI pursuant to the Consulting Services Agreement between the Company and ATI dated September
15, 2011.

 

(F)
Preferred Shares issuable in the Second Milestone Closing, Third Milestone Closing or Final Milestone Closing of the Series A
SPA (as such terms are defined therein), including any shares issuable pursuant to any acceleration of any of the aforementioned
closings, or pursuant to Section 2.2.6 of the Series A SPA, or Ordinary Share issued to or reclassified into Ordinary Shares for
a Defaulting Purchaser under the Series A SPA.

 

(G)
Securities issued by the Company in connection with an IPO or a Qualified IPO.

 

(I)
Securities constituting not more than 5% of Ordinary Shares, calculated on a fully diluted as converted basis, to a strategic
investor (as determined as such by the Board including an Orchestra Director and an ABV Director).

 

sub-Articles
5 (d)(ii) (A)-(G) inclusive, collectively referred to as “Excluded Securities”.

 

(iii)
If the Company subdivides or combines its Ordinary Shares, the Conversion Price shall be proportionately reduced, in case of subdivision
of shares, as at the effective date of such subdivision, or if the Company fixes a record date for the purpose of so subdividing,
as at such record date, whichever is earlier, or shall be proportionately increased, in the case of combination of shares, as
at the effective date of such combination, or, if the Company fixes a record date for the purpose of so combining, as at such
record date, whichever is earlier.

 

(iv)
If the Company at any time pays a dividend, with respect to its Ordinary Shares only, payable in additional shares of Ordinary
Shares or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional
shares of Ordinary Shares, without any comparable payment or distribution to the holders of Preferred Shares (hereinafter referred
to as “Ordinary Shares Equivalents”), then the Conversion Price shall be adjusted as at the date the
Company fixes as a record date for the purpose of receiving such dividend (or if no such record date is fixed, as at the date
of such payment) to that price determined by multiplying the applicable Conversion Price in effect immediately prior to such record
date (or if no record date is fixed then immediately prior to such payment) by a fraction (a) the numerator of which shall be
the total number of Ordinary Shares outstanding and those issuable with respect to Ordinary Shares Equivalents prior to the payment
of such dividend, and (b) the denominator of which shall be the total number of shares of Ordinary Shares outstanding and those
issuable with respect to such Ordinary Shares Equivalents immediately after the payment of such dividend (plus, in the event that
the Company paid cash for fractional shares, the number of additional shares which would have been outstanding had the Company
issued fractional shares in connection with such dividend).

 

    	 	9 	 

    	 	 	 

    

 

(e)
In the event the Company declares a distribution payable in securities of other persons, evidences of indebtedness issued by the
Company or other persons, assets (excluding cash dividends) or options or rights not referred to in Subarticle (d)(iv) other than
as part of a Deemed Liquidation, then, in each such case, the holders of the Preferred Shares shall be entitled to receive a proportionate
share of any such distribution, in respect of their holdings on an as-converted basis as of the record date for such distribution.

 

(f)
If at any time or from time to time there shall be a recapitalization of the Ordinary Shares (other than a subdivision, combination
or merger or sale of assets transaction provided for elsewhere in this Article 5), provision shall be made so that the holders
of the Preferred Shares shall thereafter be entitled to receive upon conversion of the Preferred Shares the number of Ordinary
Shares or other securities or property of the Company or otherwise, to which a holder of Ordinary Shares deliverable upon conversion
of the Preferred Shares would have been entitled immediately prior to such recapitalization. In any such case, appropriate adjustments
shall be made in the application of the provisions of this Article 5 with respect to the rights of the holders of the Preferred
Shares after the recapitalization to the end that the provisions of this Article 5 (including adjustments of the Conversion Price
then in effect and the number of shares issuable upon conversion of the Preferred Shares) shall be applicable after that event
as nearly equivalent as may be practicable.

 

(g)
The Company will not, by amendment of these Articles or through any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder in this Article 5 by the Company, but will at all times in good faith
assist in the carrying out of all the provisions of this Article 5 and in taking of all such action as may be necessary or appropriate
in order to protect the conversion rights of the holders of the Preferred Shares against impairment.

 

(h)
No fractional shares shall be issued upon conversion of the Preferred Shares, and the number of shares of Ordinary Shares to be
issued shall be rounded to the nearest whole share.

 

(i)
Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Article 5, the Company, at its
expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to
each holder of Preferred Shares a certificate setting forth each adjustment or readjustment and showing in detail the facts upon
which such adjustment or readjustment is based. The Company shall furnish or cause to be furnished to such holder a like certificate
setting forth (A) such adjustment or readjustment, (B) the Conversion Price at the time in effect, and (C) the number of shares
of Ordinary Shares and the amount, if any, of other property which at the time would be received upon the conversion of a Preferred
Share.

 

(j)
[RESERVED] 

 

(k)
The Company shall at all times reserve and keep available out of its authorized but unissued Ordinary Shares, solely for the purpose
of effecting the conversion of the Preferred Shares, such number of its Ordinary Shares as shall from time to time be sufficient
to effect the conversion of all issued and outstanding Preferred Shares; and if at any time the number of authorized but unissued
Ordinary Shares shall not be sufficient to effect the conversion of all then outstanding Preferred Shares, in addition to such
other remedies as shall be available to the holders of such Preferred Shares, the Company will take such corporate action as may,
in the opinion of its counsel, be necessary to increase its authorized but unissued Ordinary Share capital to such number of shares
as shall be sufficient for such purposes.

 

    	 	10 	 

    	 	 	 

    

 

(l)
Notwithstanding any of the aforesaid, in the event that a Purchaser (as defined in the Series A SPA) is a Defaulting Purchaser
(as defined in the Series A SPA), any Preferred Shares which have already been issued to such Defaulting Purchaser hereunder,
shall be immediately and automatically converted and/or reclassified into an equal number of Ordinary Shares on a non-preferential
basis, and each of the shareholders irrevocably undertakes to pass any resolution required to give effect to such conversion and/or
reclassification and to take any such actions as may be required to effect such conversion and/or reclassification.

 

6.
Increase of Share Capital

 

(a)
Subject to and in accordance with Article 75, the Company may, from time to time, by resolution of its shareholders, whether or
not all the shares then authorized have been issued, and whether or not all the shares issued have been called up for payment,
increase its authorized share capital. Any such increase shall be in such amount and shall be divided into shares of such nominal
amounts, with such rights and preferences and subject to such restrictions, as such resolution shall provide.

 

(b)
Except to the extent otherwise provided in such resolution, any new shares included in the authorized share capital increased
as aforesaid shall be subject to all the provisions of these Articles which are applicable to shares included in the existing
share capital, without regard to class (and, if such new shares are of the same class as a class of shares included in the existing
share capital, to all of the provisions that are applicable to shares of such class included in the existing share capital).

 

7.
Special Rights; Modification of Rights

 

(a)
Subject to and in accordance with Article 75, and without prejudice to any special rights previously conferred upon the holders
of existing shares in the Company the Company may, from time to time, by resolution of the holders of a majority of its shares
provide for shares with such preferred or deferred rights or rights of redemption or other special rights or restrictions, whether
in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such resolution.

 

(b)
If at any time the share capital is divided into different classes of shares, the rights, preferences, privileges or powers of,
or the restrictions attached to any class, subject to Article 75 and unless otherwise provided by these Articles, may be modified
or abrogated by the Company by resolution of its shareholders, subject to the consent in writing, or vote at a separate meeting,
of the holders of at least 50% of the issued shares of such class.

 

(c)
The provisions of these Articles relating to General Meetings shall, mutatis mutandis, apply to any separate General Meeting
of the holders of the shares of a particular class; provided, however, that the requisite quorum at any such separate General
Meeting shall be one or more shareholders present in person or by proxy and holding at least 50% of the issued shares of such
class.

 

(d)
Unless otherwise provided for in these Articles, the enlargement of an authorized class of shares, or the issuance of additional
shares of such a class out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 7 to
modify or abrogate the rights, preferences, privileges or powers of, or the restrictions attached to previously issued shares
of such class or of any other class;

 

    	 	11 	 

    	 	 	 

    

 

(e)
Any right or limitation provided for the express benefit of a specifically named shareholder may not be amended or waived without
the prior written consent of such shareholder.

 

8.
Consolidation, Subdivision, Cancellation and Reduction of Share Capital

 

(a)
The Company may, from time to time, by a resolution by the holders of at least 50% of the voting power of the Company calculated
on as converted basis (subject, however, to the provisions of Article 7(b) and 75 of these Articles and to applicable law):

 

(i)
consolidate and divide all or any part of its issued or unissued authorized share capital into shares of a per share nominal value
that is greater than the per share nominal value of its existing shares;

 

(ii)
subdivide its shares (issued or unissued) or any of them into shares of lesser nominal value than is fixed by these Articles;

 

(iii)
cancel any shares that, at the date of the adoption of such resolution, have not been purchased or subscribed for; or

 

(iv)
reduce its share capital in any manner, and with and subject to any incident authorized, and consent required, by law.

 

(b)
With respect to any consolidation of issued shares into shares of a greater nominal value per share, and with respect to any other
action that may result in fractional shares, the Board of Directors may, subject to these Articles, settle any dispute that may
arise with regard thereto as it deems fit, and in connection with any such consolidation or other action that may result in fractional
shares may, subject to Article 75, without limitation:

 

(i)
determine, as to any holder of shares so consolidated, which issued shares shall be consolidated into a share of a greater nominal
value per share;

 

(ii)
allot, in contemplation of or subsequent to such consolidation or other action, shares or fractional shares sufficient to preclude
or remove fractional share holdings; or

 

(iii)
redeem, in the case of redeemable preference shares and subject to applicable law, such shares or fractional shares sufficient
to preclude or remove fractional share holdings.

 

SHARES

 

9.
Issuance of Share Certificates: Replacement Certificates 

 

(a)
Share certificates shall bear the signature (or facsimile thereof) of one Director or of any other person or persons authorized
by the Board of Directors.

 

(b)
Each shareholder shall be entitled to one numbered certificate for all the shares of any class registered in his name, and if
the Board of Directors so approves, to several certificates, each for one or more of such shares.

 

    	 	12 	 

    	 	 	 

    

 

(c)
A share certificate registered in the names of two or more persons shall be delivered to the person first named in the Register
of Shareholders in respect of such co-ownership.

 

(d)
A share certificate that has been defaced, lost or destroyed may be replaced, and the Company shall issue a new certificate to
replace such defaced, lost or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership
and such indemnity, as the Board of Directors in its discretion deems fit.

 

10.
Registered Holder

 

Except
as otherwise provided in these Articles, the Company shall be entitled to treat the registered holder of each share as the absolute
owner thereof, and accordingly shall not, except as ordered by a court of competent jurisdiction or as required by law, be obligated
to recognize any equitable or other claim to, or interest in, such share on the part of any other person.

 

11.
Allotment of Shares; Preemptive Rights. 

 

(a)
Subject to the provisions of Articles 11(b) and 75, the shares shall be under the control of the Board of Directors, who shall
have the power to allot, issue or otherwise dispose of shares to such persons, at such times, on such terms and conditions (including,
inter alia, terms relating to calls as set forth in Article 13 hereof), and either at par value, at a premium or,
subject to the provisions of the Companies Law, at a discount or with payment of commission, all as the Board of Directors deems
fit; and, the Board of Directors shall also have the power to give any person the option to acquire from the Company any shares,
either at nominal value, at a premium or, subject to the provisions of the Companies Law, at a discount or with payment of commission,
for such period and for such consideration as the Board of Directors deems fit.

 

(b)
Until an IPO or a Deemed Liquidation, each Shareholder holding not less than 2% of the Ordinary Shares of the Company (on an as-converted
basis) (the “Preemptive Purchaser(s)” and the “Minimum Holdings”, respectively)
shall have pre-emptive rights to purchase, pro-rata, all (or any part) of New Securities (as defined below) that the Company may,
from time to time, propose to sell and issue. Each Preemptive Purchaser’s pro rata share shall be the ratio of the number
of shares of the Ordinary Shares of the Company (on an as-converted basis) then held by such Preemptive Purchaser as of the date
of the Rights Notice (as defined in Article 11(b)(ii)), to the sum of the total number of Ordinary Shares (on an as-converted
basis) issued and outstanding as of such date.

 

(i)
“New Securities” shall mean any Ordinary Shares or preferred shares of any kind of the Company, whether
now or hereafter authorized, and rights, options, or warrants to purchase said Ordinary Shares or preferred shares, and securities
of any type whatsoever that are, or may become, convertible into or exchangeable for said Ordinary Shares or preferred shares;
provided, however, that “New Securities” shall not include (i) Excluded Securities; or (ii) securities issued in an
IPO or in connection with the acquisition of another corporation, business entity or line of business of another business entity
by the Company by merger, consolidation, purchase of all or substantially all of the assets, or other reorganization as a result
of which the Company owns not less than fifty percent (50%) of the voting power of such corporation; or (iii) Preferred Shares
reclassified into Ordinary Shares pursuant to Section 8 of the Series A SPA;

 

(ii)
If the Company proposes to issue New Securities, it shall give each Preemptive Purchaser written notice to its registered address
(the “Rights Notice”) of its intention, describing the New Securities, the price, the general terms
upon which the Company proposes to issue them, and the number of shares that each Preemptive Purchaser has the right to purchase
under this Article 11(b). Each Preemptive Purchaser shall have seven (7) days from delivery of the Rights Notice to agree to purchase
all or any part of its pro-rata share of such New Securities. Additionally, only the Preferred Shareholders shall have seven (7)
days from delivery of the Rights Notice to agree to purchase all or any part of the pro-rata share of any other Preemptive Purchaser
entitled to such rights to the extent that such Preemptive Purchaser does not elect to purchase its pro-rata share, in each case
for the price and upon the general terms specified in the Rights Notice, by giving written notice to the Company setting forth
the quantity of New Securities to be purchased. If a Preemptive Purchaser does not respond to a Rights Notice within the aforesaid
seven (7) day period, it shall be deemed to have waived its preemptive rights in full in connection with the issuance of the New
Securities that are covered by such Rights Notice. If a Preferred Shareholder elects to purchase its full pro-rata shares and
also elects to purchase additional shares such that the Preemptive Purchasers in the aggregate have elected to purchase more than
100% of the New Securities, such New Securities shall be issued to such Preferred Shareholder in accordance with its pro-rata
share amongst the shares then held by all Preferred Shareholders.

 

    	 	13 	 

    	 	 	 

    

 

(iii)
To the extent that the Preemptive Purchasers fail to exercise in full their preemptive rights within the period or periods specified
in Article 11(b)(ii), the Company shall have one hundred and twenty (120) days after delivery of the Rights Notice to sell the
unsold portion of the New Securities at a price and upon general terms no more favorable to the purchasers thereof than specified
in the Company’s notice. If the Company has not sold the New Securities within said one hundred and twenty (120) day period
the Company shall not thereafter issue or sell any New Securities without first offering such securities to the Preemptive Purchasers
in the manner provided above.

 

(iv)
Notwithstanding any of the aforesaid, in the event that the implementation of the provisions of this Article ‎11 may require,
in the opinion of the Board of Directors, the publication of a prospectus under the Israeli Securities Law, as a result of the
number of Shareholders who are entitled to receive a Rights Notice, then the pre-emptive right pursuant to this Article 11 shall
be in effect only in respect of such number of Shareholders which shall not require the preparation of a prospectus (in accordance
with the Israeli Securities Law), and the Preemptive Purchasers who are entitled to purchase the largest pro rata portion of the
New Securities (as determined pursuant to Article 11(b) above) among all those Shareholders that are entitled to the pre-emptive
right hereunder.

 

12.
Payment in Installments

 

If,
pursuant to the terms of allotment or issuance of any share, all or any portion of the price thereof shall be payable in installments,
every such installment shall be paid to the Company on the due date thereof by the then registered holder(s) of the share or the
person(s) then entitled thereto.

 

13.
Calls on Shares

 

(a)
The Board of Directors may, from time to time, as it in its discretion deems fit, make calls for payment upon shareholders in
respect of any sum that has not been paid up in respect of shares held by such shareholders and which is not, pursuant to the
terms of allotment or issuance of such shares or otherwise, payable at a fixed time. Each shareholder shall pay the amount of
every call so made upon him (and of each installment thereof if the same is payable in installments), to the Company at the time(s)
and place(s) designated by the Board of Directors, as any such time(s) may subsequently be extended or place(s) changed. Unless
otherwise stipulated in the resolution of the Board of Directors (and in the notice referred to below), each payment in response
to a call shall be deemed to constitute a pro rata payment on account of all the shares of the shareholder making payment in respect
of which such call was made.

 

(b)
Notice of any call for payment by a shareholder shall be given in writing to such shareholder not less than fourteen (14) days
prior to the time of payment fixed in such notice, and shall specify the time and place of payment, and the person to whom such
payment is to be made. Prior to the time for any such payment fixed in a notice of a call given to a shareholder, the Board of
Directors may in its absolute discretion, by notice in writing to such shareholder, revoke such call in whole or in part, extend
the time fixed for payment of such call or designate a different place of payment or person to whom payment is to be made. In
the event of a call payable in installments, only one notice thereof need be given.

 

    	 	14 	 

    	 	 	 

    

 

(c)
If pursuant to the terms of allotment or issuance of a share, or otherwise, an amount is made payable at a fixed time (whether
on account of such share or by way of premium), such amount shall be payable at such time as if it were payable by virtue of a
call made by the Board of Directors and for which notice was given in accordance with sub-articles (a) and (b) of this Article
13, and the provisions of these Articles with regard to calls (and the nonpayment thereof) shall be applicable to such amount
(and the non-payment thereof).

 

(d)
Joint holders of a share shall be jointly and severally liable to pay all calls for payment in respect of such share and all interest
payable thereon.

 

(e)
Any amount called for payment that is not paid when due shall bear interest from the date fixed for payment until actual payment,
at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel) and shall be payable
at such time(s) as the Board of Directors may prescribe.

 

(f)
Upon the allotment of shares, the Board of Directors may provide for differences among the allottees of such shares as to the
amounts and times for payment and of calls for payment in respect of such shares.

 

14.
Prepayment

 

With
the consent of the Board of Directors any shareholder may pay to the Company any amount not yet payable in respect of his shares,
and the Board of Directors may approve the payment by the Company of interest on any such amount until the same would be payable
if it had not been paid in advance, at such rate and time(s) as may be approved by the Board of Directors. The Board of Directors
may at any time cause the Company to repay all or any part of the money so advanced, without premium or penalty. Nothing in this
Article 14 shall derogate from the right of the Board of Directors to make any call for payment before or after receipt by the
Company of any such advance.

 

15.
Forfeiture and Surrender

 

(a)
If any shareholder fails to pay an amount payable by virtue of a call, or interest thereon as provided for in accordance with
these Articles, on or before the day fixed for payment of the same, the Board of Directors may at any time after the day fixed
for such payment, so long as such amount or any portion thereof remains unpaid, forfeit all or any of the shares in respect of
which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon,
including, without limitation, attorneys’ fees and costs of legal proceedings, shall be added to, and shall for all purposes
(including the accrual of interest thereon) constitute a part of the amount payable to the Company in respect of such call.

 

(b)
Upon the adoption of a resolution as to the forfeiture of a shareholder’s share, the Board of Directors shall cause notice
thereof to be given to such shareholder, which notice shall state that, in the event of the failure to pay the entire amount so
payable by a date specified in the notice (which date shall be not less than fourteen (14) days after the date such notice is
given and which may be extended by the Board of Directors), such shares shall ipso facto be forfeited; provided, however,
that prior to such date the Board of Directors may nullify such resolution of forfeiture, but no such nullification shall stop
the Board of Directors from adopting a further resolution of forfeiture in respect of the non-payment of the same amount.

 

    	 	15 	 

    	 	 	 

    

 

(c)
Without derogating from Articles 56 and 61 of these Articles, whenever shares are forfeited as herein provided, all dividends,
if any, theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time.

 

(d)
The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.

 

(e)
Any share forfeited or surrendered as provided herein shall become the property of the Company, and the same, subject to the provisions
of these Articles, may be sold, re-allotted or otherwise disposed of as the Board of Directors deems fit.

 

(f)
Any shareholder whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or
surrendered shares, but shall nonetheless be liable to pay and shall promptly pay, to the Company all calls, interest and expenses
owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of
forfeiture or surrender until actual payment at the rate prescribed in Article 13(e) above, and the Board of Directors, in its
discretion, may enforce the payment of such moneys or any part thereof. In the event of such forfeiture or surrender, the Company,
by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owed to the Company
by the shareholder in question (but not yet due) in respect of all shares owned by such shareholder, solely or jointly with another.

 

(g)
The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold, re-allotted or otherwise
disposed of, nullify the forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the
Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 15.

 

16.
Lien

 

(a)
Except to the extent that the same may be waived or subordinated in writing, the Company shall have a first and paramount lien
upon all the shares registered in the name of each shareholder (without regard to any equitable or other claim or interest in
such shares on the part of any other person), and upon the proceeds of the sale thereof, for his debts, liabilities and obligations
to the Company arising from any amount payable by such shareholder in respect of any unpaid or partly paid share, whether or not
such debt, liability or obligation has matured. Such lien shall extend to all dividends from time to time declared or paid in
respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be
a waiver on the part of the Company of any lien existing on such shares immediately prior to such transfer.

 

(b)
The Board of Directors may cause the Company to sell a share subject to such a lien when the debt, liability or obligation giving
rise to such lien has matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such
debt, liability or obligation has not been satisfied within fourteen (14) days after written notice of the intention to sell shall
have been served on such shareholder, his executors or administrators.

 

    	 	16 	 

    	 	 	 

    

 

(c)
The net proceeds of any such sale, after payment of the costs thereof, shall be applied in or toward satisfaction of the debts,
liabilities or obligations of such shareholder in respect of such share, and any residue shall be paid to the shareholder, his
executors, administrators or assigns.

 

17.
Sale After Forfeiture or Surrender or in Enforcement of Lien

 

Upon
any sale of a share after forfeiture or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute
an instrument of transfer of the share so sold and cause the purchaser’s name to be entered in the Register of Shareholders
in respect of such share. The purchaser shall be registered as the shareholder and shall not be bound to see to the regularity
of the sale proceedings or to the application of the proceeds of such sale, and after his name has been entered in the Register
of Shareholders in respect of such share, the validity of the sale shall not be impeached by any person, and the remedy of any
person aggrieved by the sale shall be in damages only and against the Company exclusively.

 

18.
Redeemable Shares.

 

The
Company may, subject to applicable law and Article 74, issue redeemable shares and redeem the same.

 

TRANSFER
OF SHARES

 

19.
Prohibited Transfers; Rights of First Refusal; and Permitted Transfers.

 

(a)
Prohibited Transfers

 

(i)
The Ordinary Shares of employees of the Company shall not be transferable for so long as they are employed by the Company.

 

(ii)
Until the earlier of an (a) an IPO (b) a Deemed Liquidation, (c) 36 months from the date of the Initial Closing (as defined in
the Series A SPA) and (d) the Third Milestone Closing Date (as such term is defined in the Series A SPA), the Ordinary Shares
held by NGT and/or Boris Shtul (only after he is no longer employed by the Company) shall be transferable (subject to the rights
of first refusal set out herein) only with the prior written consent of Orchestra and ABV, provided however, that Orchestra and/or
ABV shall only have the right to reject such transferee(s) on reasonable grounds. After the Third Milestone Closing Date such
shares shall be transferable subject to the rights of first refusal set out below.

 

(iii)
Legend. Each certificate representing shares of the Holders shall be endorsed with the following legend:

 

THE
SALE OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THE ARTICLES
OF ASSOCIATION OF THE COMPANY. COPIES OF SUCH ARTICLES MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.

 

		(b)	Rights
                                         of First Refusal.

 

Until
an IPO or a Deemed Liquidation Event (as defined in Article 74), except for: (i) transfers and/or dispositions to Permitted Transferees,
or (ii) disposition as of the result of a realization of a pledge of ordinary shares held by NGT in favor of the State of Israel
or the Office of the Chief Scientist (up to an aggregate amount of 1,350,000 ordinary shares), any transfer of shares by any shareholder
shall be subject to the following:

 

    	 	17 	 

    	 	 	 

    

 

(i)
Each holder of Ordinary Share and/or Preferred Shares proposing to transfer all or any of its shares, pursuant to the terms of
a bona fide offer received from any person or entity, except to a Permitted Transferee (the “Offeror”)
shall first request the Company, by written notice (which shall contain all the information necessary to enable the Company to
do so), to offer such shares (for purposes of this Article 19(b), the “Offered Shares”), on the terms
of the proposed transfer, to the Preferred Shareholders (the “Primary Offeree(s)” and “Primary
Right”, respectively). The Company shall comply with such request by sending the Primary Offerees a written notice
(the “Offer”), stating therein the identity of the Offeror and of the proposed transferee(s) and the
proposed terms of sale of the Offered Shares. Any Primary Offeree may accept such Offer in respect of all or any of the Offered
Shares by giving the Company notice to that effect within twenty-one (21) days after being served with the Offer. Any Primary
Offeree that fails to respond to an Offer within the aforesaid twenty-one (21) day period shall be deemed to have waived its rights
in connection with the sale of the Offered Shares pursuant to such Offer.

 

(ii)
If the acceptances with respect to the Primary Right, in the aggregate, are in respect of all of, or more than, the Offered Shares,
then the accepting Primary Offerees shall acquire the Offered Shares, on the terms aforementioned, in proportion to their respective
holdings, provided, that no Primary Offeree shall be entitled to acquire under the provisions of this Article 19(b) more than
the number of Offered Shares initially accepted by such Primary Offeree, and upon the allocation to it of the full number of shares
so accepted, it shall be disregarded in any subsequent computations and allocations hereunder. Any shares remaining after the
computation of such respective entitlements shall be re-allocated among the accepting Primary Offerees (other than those to be
disregarded as aforesaid), in the same manner, until one hundred percent (100%) of the Offered Shares have been allocated as aforesaid.

 

(iii)
In the event that none of the Primary Offerees have elected to exercise the Primary Right in accordance with Article 19(b) above,
or if the amount of the Offered Shares the Primary Offerees elect to purchase does not equal or exceed the total amount of the
Offered Shares, the Company shall give notice of the Offer terms in writing to the Ordinary Shareholders holding at least 1% of
the outstanding Ordinary Shares who do not hold Preferred Shares (the “Secondary Offeree(s)”). Each
Secondary Offeree shall have the right (the “Secondary Right”) to purchase from the Offeror at the same
price and on the same terms (x) that portion of the Offered Shares as the aggregate number of shares of Ordinary Shares held by
such Secondary Offeree bears to the total number of shares of Ordinary Shares held by all the Secondary Offerees (the “Secondary
Basic Amount(s)”) and (y) such additional portion of the remaining Offered Shares as any Secondary Offeree indicates
it will purchase, for a period of seven (7) business days after delivery of such notice (the “Secondary Right Period”).
Any shares remaining after the computation of such respective entitlements shall be re-allocated among the accepting Secondary
Offerees, in the same manner, until one hundred percent (100%) of the Offered Shares have been allocated as aforesaid.

 

(iv)
If the acceptances set forth above, in the aggregate, are in respect of less than the number of Offered Shares, then the accepting
Primary Offerees and Secondary Offerees shall not be entitled to acquire the Offered Shares, and the Offeror, at the expiration
of the aforementioned twenty-one (21) day period or seven (7) day period (as applicable), shall be entitled to transfer all (but
not less than all) of the Offered Shares to the proposed transferee(s) identified in the Offer, provided, however, that in no
event shall the Offeror transfer any of the Offered Shares to any transferee other than such proposed transferee(s) or transfer
the same on terms more favorable to the proposed transferee than those stated in the Offer, and, provided, further, that any of
the Offered Shares not transferred within ninety (90) days after the expiration of such twenty-one (21) day period shall again
be subject to the provisions of this Article 19(b).

 

    	 	18 	 

    	 	 	 

    

 

(v)
For the purposes of any Offer under this Article 19(b), the respective holdings of any number of accepting Primary Offerees and
Secondary Offerees shall mean the respective proportions of the aggregate number of Ordinary and/or Preferred Shares held by such
accepting Primary Offerees and Secondary Offerees as determined prior to such Offer.

 

(vi)
The provisions of Article 19 shall apply, mutatis mutandis, to the transfer of any other Company securities that are convertible
or exercisable, into Preferred Shares and/or Ordinary Shares of the Company.

 

(c)
Permitted Transfers.

 

Notwithstanding
Articles 19(a) and (b), any Shareholder of the Company may transfer (whether or not for consideration) shares to a Permitted Transferee
without being subject to the provision of Articles 19(a) and (b). No transfer under this Article 19 shall be made to any transferee,
unless such transferee agrees in writing to be bound by all agreements binding upon the transferor immediately prior to such transfer.
No subsequent transfer of any of such shares may be made except in conformity with the provisions of this Article 19. Should any
shareholder wish to transfer shares to more than 2 Permitted Transferees, in a single transfer or a series of transfers, in accordance
with these Articles, such Permitted Transferees shall enter into a proxy or similar arrangement reasonably acceptable to the Board,
which proxy shall apply to all such Permitted Transferees as a group.

 

20.
Approval and Registration of Transfers.

 

(a)
No transfer, other than transfers to Permitted Transferees, shall be effective until approved by the Board, which approval shall
not be unreasonably withheld. The Board may reasonably and in good faith, subject to these Articles and subject to any of the
Company’s written agreements with or undertakings in writing towards any shareholder of the Company, refuse to approve such
transfer of shares to: (i) a direct competitor of the Company; (ii) any third party, until such time as the Board is satisfied
in its reasonable discretion that all applicable provisions of these Articles have been complied with in full and in good faith
in connection with such proposed transfer. The determination of whether a proposed transferee is a direct competitor shall be
in the sole discretion of the Board, provided that such determination is done reasonably and in good faith. Prior to the registration
of a transfer of shares, the Board may require proof of compliance with the provisions of these Articles in respect of such transfer.
If the Board makes use of its powers in accordance with this Article and refuses to register a transfer of shares, it must provide
written notice of its refusal to the transferee within fourteen (14) days from the date the deed of transfer was furnished to
the Company.

 

(b)
No transfer of shares shall be registered unless there has been compliance with the procedure set forth in Article 19, and made
in writing in the form appearing below, or any other form satisfactory to the Board of Directors from time to time. Such form
of transfer shall be delivered to the offices of the Company, together with share certificate(s) and such other evidence of title
as the Board of Directors may reasonably require. Until the transferee has been registered in the Register of Shareholders in
respect of the shares so transferred, the Company may continue to regard the transferor as the owner thereof.

 

Deed
of Transfer of Shares

 

__________
(the “Transferor”) hereby transfers to ____________, of ________________ (the “Transferee”)
_______ share(s) having nominal value of NIS ________ each in Motus GI Medical Technologies, Ltd., to the Transferee, its executors,
administrators, and assigns, subject to the several conditions on which the Transferor held the same at the time of the execution
hereof; and the Transferee, does hereby agree to take said share(s) subject to the conditions aforesaid. As witness we have hereunto
set our hands the ____ day of _____ 20__.

 

    	 	19 	 

    	 	 	 

    

 

	[Name
    of Transferee]	 	[Name
    of Transferor]
	 	 	 	 	 
	By:	 	 	By:	 
	 	 	 	 	 
	Name:
    	        	 	Name:
    	        
	 	 	 	 	 
	Address:
    	 	 	Address:
    	 
	 	 	 	 	 
	[Name
    of Witness to Transferee]	 	[Name
    of Witness to Transferor]
	 	 	 	 	 
	By:	 	 	By:	 
	 	 	 	 	 
	Name:
    	 	 	Name:
    	 
	 	 	 	 	 
	Address:
    	 	 	Address:
    	 

 

(c)
The deed of share transfer shall be executed both by the transferor and transferee, and the transferor shall be deemed to remain
a holder of the share until the name of the transferee is entered into the Register of Shareholders in respect thereof.

 

(d)
The Board of Directors may, to the extent it deems necessary in its discretion, close the Register of Shareholders for registrations
of transfers of shares during any year for one period, not to exceed two weeks, determined by the Board of Directors, and no registrations
of transfers of shares shall be made by the Company during any such period during which the Register of Shareholders is so closed.

 

21.
Record Date for Notices of General Meetings. Despite any contrary provision of these Articles, the Board of Directors may
fix a date, not exceeding forty-five (45) days prior to the date of any General Meeting, as the date as of which shareholders
entitled to notice of and to vote at such meeting shall be determined, and only those persons who were holders of record of voting
shares on such date shall be entitled to notice of and to vote at such meeting.

 

    	 	20 	 

    	 	 	 

    

 

TRANSMISSION
OF SHARES

 

22.
Decedent’s Shares.

 

(a)
In case of a share registered in the names of two or more holders, the Company may recognize the survivor(s) as the sole owner(s)
thereof unless and until the provisions of Article 22(b) of these Articles have been effectively invoked.

 

(b)
Any person becoming entitled to a share in consequence of the death of any person, upon producing evidence of the grant of probate
or letters of administration or declaration of succession (or such other evidence as the Board of Directors may reasonably deem
sufficient), shall be registered as a shareholder in respect of such share and such transfer shall not be subject to articles
19(a) and 19(b) hereof, or may, subject to the articles as to transfer herein contained, transfer such share.

 

23.
Receivers and Liquidators.

 

(a)
Notwithstanding Articles 19(a) and (b) hereof, the Company may recognize any receiver, liquidator or similar official appointed
to wind up, dissolve or otherwise liquidate a corporate shareholder, and a trustee, manager, receiver, liquidator or similar official
appointed in bankruptcy or in connection with the reorganization of, or similar proceeding with respect to a shareholder or its
properties, as being entitled to the shares registered in the name of such shareholder.

 

(b)
Such receiver, liquidator or similar official appointed to wind up, dissolve or otherwise liquidate a corporate shareholder, and
such trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization
of, or similar proceeding with respect to a shareholder or its properties, upon producing such evidence as the Board of Directors
may deem sufficient as to his authority to act in such capacity or under this Article, shall with the consent of the Board of
Directors (which the Board of Directors may grant or refuse in its absolute discretion), be registered as a shareholder in respect
of such shares, or may, subject to the regulations as to transfer contained in these Articles, transfer such shares.

 

GENERAL
MEETINGS

 

24.
Annual General Meeting.

 

The
Company shall not be required to hold an Annual General Meeting unless required for the purposes of appointing an auditor or unless
one of the shareholders or Directors requests the Company to hold such a meeting, provided, however, that the Directors’
report and the Company’s financial statements for that year are sent to all shareholders no later than fifteen (15) months
after the holding of the last preceding General Meeting (or the mailing of the last preceding Directors’ report and financial
statements as per this Article).

 

25.
Extraordinary General Meeting.

 

All
General Meetings other than Annual General Meetings (if convened) shall be called “Extraordinary General Meetings”.
The Board of Directors may, whenever it deems fit, convene an Extraordinary General Meeting, at such time and place, within
the State of Israel, as may be determined by the Board of Directors, and shall be obligated to do so upon a request in writing
in accordance with Sections 63 or 64 of the Companies Law.

 

    	 	21 	 

    	 	 	 

    

 

26.
Notice of General Meetings; Omission to Give Notice.

 

(a)
Notice of a General Meeting shall be delivered at least seven (7) days prior to the date for convening of the meeting (but not
more than forty-five (45) days before such date) to each of the shareholders listed in the Register of Shareholders to its registered
address in the manner specified in these Articles. Each such notice shall specify the place and the date and hour of the meeting,
the agenda, reasonable detail of the matters to be discussed at the meeting, and arrangements for voting by proxy if the matters
on the agenda for the meeting include matters in respect of which shareholders may vote by proxy under any law or in accordance
with these Articles. If the agenda of the meeting includes a proposal to amend these Articles, the text of the proposed amendment
shall be specified.

 

(b)
A resolution may be proposed and adopted at a meeting even though the notice prescribed in this Article has not been given, subject
to the consent of all of the shareholders entitled to vote thereon.

 

(c)
The non-receipt of notice sent to a shareholder to his/her/its registered address, shall not invalidate the proceedings at such
meeting.

 

PROCEEDINGS
AT GENERAL MEETINGS

 

27.
Quorum.

 

(a)
No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles
for such General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business.

 

(b)
In the absence of contrary provisions in these Articles, two or more shareholders (not in default in payment of any sum referred
to in Article 33(a) of these Articles), present in person or by proxy within half an hour after the time set for the General Meeting
and holding in the aggregate at least 50% of the outstanding voting power of the Company calculated on an as-converted basis shall
constitute a quorum of General Meetings.

 

(c)
If within half an hour from the time appointed for the meeting a quorum is not present, the meeting, if convened upon request
under Sections 63 or 64 of the Companies Law, shall be dissolved, but in any other case it shall be adjourned to the same day
in the next week, at the same time and place, or to such day and at such time and place as the Chairman of the meeting may determine
with the consent of the holders of at least 50% of the voting power represented at the meeting in person or by proxy and voting
on the question of adjournment. No business shall be transacted at any adjourned meeting except business that might lawfully have
been transacted at the meeting as originally called. At such adjourned meeting (other than an adjourned separate meeting of a
particular class of shares as referred to in Article 7 of these Articles), any two shareholders (not in default as aforesaid)
present in person or by proxy holding in the aggregate at least 50% of the outstanding voting power of the Company calculated
above on an as-converted basis shall constitute a quorum.

 

    	 	22 	 

    	 	 	 

    

 

28.
Chairman.

 

The
Chairman of the Board of Directors shall preside at every General Meeting of the Company. If at any meeting the Chairman is not
present within 15 minutes after the time fixed for holding the meeting or is unwilling to take the chair, the shareholders present
shall choose someone of their number to be the chairman of such meeting. The office of Chairman shall not entitle the holder thereof
to a casting vote.

 

29.
Adoption of Resolutions at General Meetings.

 

(a)
Subject to the provisions of Article 75, a resolution shall be deemed adopted if approved by the holders of at least 67% of the
voting power represented at the meeting in person or by proxy and voting thereon.

 

(b)
Every question submitted to a General Meeting shall be decided by a count of votes.

 

(c)
A declaration by the Chairman of the meeting that a resolution has been carried unanimously, or carried by a particular majority,
or defeated, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without
proof of the number or proportion of the votes recorded in favor of or against such resolution.

 

(d)
Shareholders may participate in a general meeting by means of a conference telephone call or similar communications equipment
by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this
Article shall constitute presence in person at such meeting.

 

30.
Resolutions in Writing.

 

A
resolution in writing signed by all shareholders of the Company then entitled to attend and vote at General Meetings or to which
all such shareholders have given their written consent (by letter, telegram, telex, facsimile or otherwise) shall be deemed to
have been unanimously adopted by a General Meeting duly convened and held.

 

31.
Power to Adjourn.

 

The
Chairman of a General Meeting at which a quorum is present may, with the consent of the holders of a majority of the voting power
represented in person or by proxy and voting on the question of adjournment, and shall if so directed by the meeting, adjourn
the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting except business
that might lawfully have been transacted at the meeting as originally called.

 

    	 	23 	 

    	 	 	 

    

 

32.
Voting Power.

 

Subject
to the provisions of Articles 5 and 33(a) and subject to any provisions of these Articles conferring special rights as to voting,
or restricting the right to vote, every shareholder shall have one vote for each share held by him of record, on every resolution,
without regard to whether the vote thereon is conducted by a show of hands, by written ballot or by any other means.

 

33.
Voting Rights.

 

(a)
No shareholder shall be entitled to vote at any General Meeting (or be counted as part of the quorum) unless all calls then payable
by him in respect of his shares in the Company have been paid.

 

(b)
A company or other corporate body being a shareholder of the Company may duly authorize any person to be its representative at
any meeting of the Company or to authorize or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise
on behalf of such shareholder all the power that the latter could have exercised if it were a natural person. Upon the request
of the Chairman of the meeting, written evidence of such authorization (in form acceptable to the Chairman) shall be delivered
to him.

 

(c)
Any shareholder entitled to vote may vote either in person or by proxy (who need not be a shareholder of the Company), or if the
shareholder is a company or other corporate body by a representative authorized pursuant to Article 33(b).

 

(d)
If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person or by
proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purposes of this Article 33(d),
seniority shall be determined by the order of registration of the joint holders in the Register of Shareholders.

 

PROXIES

 

34.
Instrument of Appointment.

 

(a)
An instrument appointing a proxy shall be in writing and shall be substantially in the following form:

 

“I
[Name of Shareholder] of [Address of Shareholder] being a shareholder of Motus GI Medical Technologies, Ltd. hereby appoint [Name
of Proxy] of [Address of Proxy] as my proxy to vote for me and on my behalf at the General Meeting of the Company to be held on
the _____ day of _____________ and at any adjournment(s) thereof.

 

Signed
this ____ day of ______________, [signature of appointer].”

 

or
in any usual or common form or in such other form as may be approved by the Board of Directors. Such proxy shall be duly signed
by the appointor or such person’s duly authorized attorney or, if such appointor is a company or other corporate body, under
its common seal or stamp or the hand of its duly authorized agent(s) or attorney(s).

 

(b)
The instrument appointing a proxy (and the power of attorney or other authority, if any, under which such instrument has been
signed) shall either be delivered to the Company (at its principal place of business or at the offices of its registrar or transfer
agent, or at such place as the Board of Directors may specify) not less than 24 hours before the time fixed for the meeting at
which the person named in the instrument proposes to vote, or presented to the Chairman at such meeting.

 

    	 	24 	 

    	 	 	 

    

 

35.
Effect of Death of Appointor or Transfer of Share or Revocation of Appointment.

 

(a)
A vote cast in accordance with an instrument appointing a proxy shall be valid despite the prior death or bankruptcy of the appointing
shareholder (or of his attorney-in-fact, if any, who signed such instrument), or the transfer of the share in respect of which
the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairman of such meeting
prior to such vote being cast.

 

(b)
An instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairman, subsequent to receipt
by the Company of such instrument, of written notice signed by the person who signed such instrument or by the shareholder appointing
such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument
appointing a different proxy (and such other documents, if any, required under Article 34(b) for such new appointment), provided
such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery
of the instrument revoked thereby as referred to in Article 34(b) of these Articles, or (ii) if the appointing shareholder is
present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairman of such meeting
of written notice from such shareholder of the revocation of such appointment, or if and when such shareholder votes at such meeting.
A vote cast in accordance with an instrument appointing a proxy shall be valid despite the revocation or purported cancellation
of the appointment, or the presence in person or vote of the appointing shareholder at a meeting for which it was rendered, unless
such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 35(b) at or prior
to the time such vote was cast.

 

BOARD
OF DIRECTORS

 

36.
Powers of Board of Directors.

 

(a)
General.

 

The
management of the business of the Company shall be vested in the Board of Directors, which may exercise all such powers and do
all such acts and things as the Company is authorized to exercise and do, and are not required by law or these Articles to be
done by the Company by action of its shareholders at a General Meeting. The authority conferred on the Board of Directors by this
Article 36 shall be subject to the provisions of the Companies Law, these Articles and any regulation or resolution consistent
with these Articles adopted from time to time by the Company by action of its shareholders at a General Meeting; provided, however,
that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors
that would have been valid if such regulation or resolution had not been adopted.

 

(b)
Borrowing Power.

 

Subject
to Article 75, the Board of Directors may from time to time, at its discretion, cause the Company to borrow or guaranty the payment
of any sum or sums of money for the purposes of the Company, and may secure or provide for the repayment of such sum or sums in
such manner, at such times and upon such terms and conditions as it deems fit, and in particular by the issuance of bonds, perpetual
or redeemable debentures, debenture stock, or any mortgages, charges or other security interest on the whole or any part of the
property of the Company, both present and future, including its uncalled or called but unpaid capital for the time being.

 

    	 	25 	 

    	 	 	 

    

 

(c)
Reserves.

 

The
Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves
for any purpose(s) that the Board of Directors, in its absolute discretion, shall deem fit, and may invest any sum so set aside
in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any
such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets
of the Company, and may subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose,
all as the Board of Directors may from time to time think fit.

 

37.
Exercise of Powers of Board of Directors.

 

(a)
A meeting of the Board of Directors at which a quorum is present shall be competent to exercise all the authorities, powers and
discretion vested in or exercisable by the Board of Directors.

 

(b)
Subject to Article 75 below, a resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved
by a majority of the Directors lawfully entitled to vote thereon and present when such resolution is put to a vote and voted thereon.

 

(c)
A resolution may be adopted by the Board of Directors without convening a meeting as a resolution in writing signed (by letter,
telegram, telex, facsimile or otherwise) by all of the Directors then in office and lawfully entitled to vote thereon.

 

38.
Delegation of Powers.

 

(a)
Subject to Section 112 of the Companies Law, the Board of Directors may delegate any or all of its powers to committees, each
comprising of at least: (i) one Orchestra Director, (ii) one ABV Director and (iii) up until the Second Milestone Closing Date,
one NGT Director or Ordinary Director) in each case if appointed, and it may from time to time revoke such delegation or alter
the composition of any such committee. Any committee so formed (in these Articles referred to as a “Committee of the
Board of Directors”), shall, in the exercise of the powers so delegated, conform to any regulations imposed on it
by the Board of Directors. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis,
be governed by the provisions herein contained for regulating the meetings of the Board of Directors, so far as not superseded
by any regulations adopted by the Board of Directors under this Article. Unless otherwise expressly provided by the Board of Directors
in delegating powers to a Committee of the Board of Directors, such Committee shall not be empowered to further delegate such
powers.

 

(b)
Without derogating from the provisions of Article 52, the Board of Directors may, subject to the provisions of the Companies Law,
from time to time appoint a secretary to the Company, as well as officers, agents, employees and independent contractors, as the
Board of Directors may think appropriate, and may terminate the service of any such person. The Board of Directors may, subject
to the provisions of the Companies Law, determine the powers and duties, as well as the terms and conditions of employment, of
all such persons, and may require security in such cases and in such amounts as it thinks appropriate.

 

(c)
The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of
persons to be the attorney or attorneys of the Company at law or in fact for such purpose(s) and with such powers, authorities
and discretions, and for such period and subject to such conditions, as it thinks fit, and any such power of attorney or other
appointment may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board
of Directors may think fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions
vested in him.

 

    	 	26 	 

    	 	 	 

    

 

39.
Number of Directors.

 

The
Board of Directors shall consist of up to seven (7) Directors, to be appointed as follows:

 

(a)
the Ordinary Shareholders, (by a majority class vote) shall be entitled to appoint one (1) Director;

 

(b)
Orchestra shall be entitled to appoint two (2) Directors;

 

(c)
ABV shall be entitled to appoint one (1) Director;

 

(d)
NGT shall be entitled to appoint one (1) Director;

 

(e)
Mr. Mark Pomeranz shall be appointed by the Directors appointed in accordance with the provisions of sub-Sections 39(a)-(d), as
a Director of the Company, and shall serve as a Director of the Company for as long as he continues to serve as the Chief Executive
Officer of the Company; and

 

(f)
the members of the Board of Directors (by a majority vote), shall be entitled to elect (1) Director, who shall be an independent
industry expert.

 

40.
Defaulting Purchasers

 

(a)
In the event that Orchestra funds all of ABV’s obligations under the Series A SPA, or visa versa, then in such case, Orchestra
or ABV, as the case may be, shall have the right to appoint the ABV Director or the Orchestra Directors, as the case may be.

 

(b)
In the event that Orchestra funds only a portion of ABV’s obligations under the Series A SPA, or visa versa, and the remaining
deficiency is met by the other shareholders, then in such case, the Orchestra Directors or ABV Director, shall be appointed by
the holders of the majority of the Preferred Shares taken up from the Defaulting Purchaser.

 

(c)
In the event that any of (i) ABV; (ii) Orchestra; (iii) NGT shall have become a Defaulting Purchaser (as such term is defined
in the Series A SPA) in connection with any Milestone Closing (as defined is the Series A SPA), then such Defaulting Purchaser
shall ipso facto cease to have any right to nominate its Director(s), and, subject to Article 40(a) and 40(b) above, any Director(s)
theretofore appointed thereby shall automatically cease to serve as Directors. The aforesaid shall not affect any rights hereunder
to elect the Ordinary Director.

 

41.
Appointment and Removal of Directors.

 

(a)
Except as otherwise provided in these Articles, Directors shall not be elected but shall be appointed as provided for herein.

 

    	 	27 	 

    	 	 	 

    

 

(b)
The appointment or removal of a Director shall be effected by the delivery of a notice to the Company at its principal office,
signed by the holders of the shares entitled to effect such appointment or removal. Any appointment or removal shall become effective
on the date fixed in the notice or upon delivery of the notice to the Company, whichever is later.

 

42.
Qualification of Directors.

 

No
person shall be disqualified to serve as a Director by reason of his not holding shares in the Company or by reason of his having
served as a Director in the past.

 

43.
Continuing Directors in the Event of Vacancies.

 

Subject
to Article 39, in the event of one or more vacancies in the Board of Directors, the remaining Directors may continue to act in
every matter and, pending the filling of any vacancy pursuant to the provisions of Articles 39 and 41, may appoint Directors to
fill any such vacancy temporarily (such temporarily appointed Director being automatically deemed to be removed from the Board
upon the appointment of a Director to fill the previous vacancy in accordance with Articles 39 and 41); provided, however, that
if they number less than a majority of the number provided for pursuant to Article 39 of these Articles, they may act only in
an emergency or to fill the office of Director that has become vacant up to the minimum number or in order to call a General Meeting
of the Company for the purpose of electing Directors to fill any or all vacancies, so that at least a majority of the number of
Directors provided for pursuant to Article 39 are in office as a result of such meeting.

 

44.
Vacation of Office.

 

(a)
The office of a Director shall be vacated, ipso facto, upon his death, or if he be found lunatic or become of unsound mind,
or if he becomes bankrupt (or if the Director is a company, upon its winding-up).

 

(b)
The office of a Director shall be vacated by his written resignation. Such resignation shall become effective on the date fixed
therein or upon the delivery to the Company, whichever is later.

 

45.
Remuneration of Directors; Reimbursement of Expenses

 

A
Director may be paid remuneration by the Company for his services as a Director, to the extent such remuneration shall have been
approved by a General Meeting of the Company. The Company shall reimburse Directors for reasonable expenses incurred in connection
with their service on the Board of Directors.

 

46.
Conflict of Interests.

 

Subject
to the provisions of the Companies Law, no Director shall be disqualified by virtue of his office from holding any office or relationship
of profit with the Company or with any company in which the Company shall be a shareholder or have another interest, or from contracting
with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into by
or on behalf of the Company in which any Director shall in any way be interested, be avoided, nor, other than as required under
the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office or relationship
of profit or realized from such contract or arrangement by reason only of such Director’s holding that office or of the
fiduciary relations thereby established, but the nature of his interest, as well as any material fact or document, must be disclosed
by him at the meeting of the Board of Directors at which the contract or arrangement is first considered, if his interest then
exists, or in any other case no later than the first meeting of the Board of Directors after the acquisition of his interest.

 

    	 	28 	 

    	 	 	 

    

 

47.
Alternate Directors.

 

(a)
A Director may, by written notice to the Company, appoint an alternate for himself (in these Articles referred to as an “Alternate
Director”), remove such Alternate Director and appoint another Alternate Director in place of any Alternate Director
appointed by him whose office has been vacated for any reason whatsoever. Unless the appointing Director, by the instrument appointing
an Alternate Director or by written notice to the Company, limits such appointment to a specified period of time or restricts
it to a specified meeting or action of the Board of Directors, or otherwise restricts its scope, the appointment shall be for
an indefinite period, and for all purposes.

 

(b)
Any notice given to the Company pursuant to Article 47(a) shall become effective on the date fixed therein, or upon the delivery
thereof to the Company, whichever is later.

 

(c)
An Alternate Director shall have all the rights and obligations of the Director who appointed him, provided, however, that he
may not in turn appoint an alternate for himself, and provided further, that an Alternate Director shall have no standing at any
meeting of the Board of Directors or any committee thereof while the Director who appointed him is present.

 

(d)
Any person that meets the qualifications of a director under the Companies Law may act as an Alternate Director. One person may
act as an Alternate Director for more than one Director, and a person serving as a director of the Company may act as an Alternate
Director.

 

(e)
An Alternate Director shall have the duties and responsibility of a Director. The appointment of an Alternate Director shall not
negate the responsibility of the Director who appointed him.

 

(f)
The office of an Alternate Director shall be vacated under the circumstances, mutatis mutandis, set forth in Article 44,
and such office shall ipso facto be vacated if the Director who appointed such Alternate Director ceases to be a Director.

 

PROCEEDINGS
OF THE BOARD OF DIRECTORS

 

48.
Meetings.

 

(a)
The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Directors
deem fit, provided, however, that the Board of Directors shall meet at least quarterly, unless otherwise agreed by a vote of the
majority of the Directors.

 

(b)
Any one (1) Director may at any time, and the Chairman of the Board of Directors upon the request of any Director shall, convene
a meeting of the Board of Directors, but not less than five (5) days notice shall be given of any meeting so convened, provided,
that the Board of Directors may convene a meeting without such prior notice with the consent of all of the Directors. Notice of
any such meeting may be given in writing or by mail, telex, email, telegram or facsimile. Despite anything to the contrary in
these Articles, failure to deliver notice to a Director of any such meeting in the manner required hereby may be waived by such
Director, and a meeting shall be deemed to have been duly convened despite such defective notice if such failure or defect is
waived prior to action being taken at such meeting by all Directors entitled to participate in such meeting to whom notice was
not duly given.

 

    	 	29 	 

    	 	 	 

    

 

(c)
Directors may attend any meeting via telephone so long as all may hear and be heard.

 

49.
Quorum.

 

Until
otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted
by the presence in person or by telephone conference of a majority of the number of Directors appointed pursuant to Article 39
and lawfully entitled to vote on the subject matter of the relevant meeting, including at least one (1) Orchestra Director and
the ABV Director (in each case if appointed) and until the Second Milestone Closing Date, the NGT Director, provided, that, all
members of the Board of Directors received due notice of such meeting or telephone conference. No business shall be transacted
at a meeting of the Board of Directors unless the requisite quorum is present (in person or by telephone conference) when the
meeting proceeds to business. If within half an hour from the time appointed for the meeting a quorum is not present it shall
be adjourned to the next business day, at the same time and place, unless a majority of the Board of Directors decides otherwise.
No business shall be transacted at any adjourned meeting except business that might lawfully have been transacted at the meeting
as originally called. At such adjourned meeting the Directors (appointed pursuant to Article 39) present, and lawfully entitled
to vote on the subject matter of the relevant meeting shall constitute a quorum. A Director who waives his/her right to be present
at a meeting of the Board of Directors shall not be taken into account for the purpose of establishing the quorum requirements
provided in this Article 49.

 

50.
Chairman of the Board of Directors.

 

The
Board may from time to time (by a majority vote) elect a Chairman from the acting Directors, and decide the period of time he
shall hold such an office, and he shall preside at the meetings of the Board of Directors. The Chairman shall preside at every
meeting of the Board of Directors, but if there is no such Chairman, or if at any meeting he is not present within fifteen (15)
minutes of the time fixed for the meeting, or if he is unwilling to take the chairmanship, the Directors present shall choose
one of their number to be the chairman of such meeting. The Chairman shall not have a casting or deciding vote.

 

51.
Validity of Acts Despite Defects.

 

All
acts done bona fide at any meeting of the Board of Directors, or of a committee of the Board of Directors, or by any person(s)
acting as Director(s), shall, even if it is subsequently discovered that there was some defect in the appointment of the participants
in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid
as if there were no such defect or disqualification.

 

GENERAL
MANAGER

 

52.
General Manager.

 

The
Board of Directors may from time to time appoint one or more persons, whether or not Directors, as General Manager, and may confer
upon such person(s), and from time to time modify or revoke, such title(s) and such duties and authorities as the Board of Directors
may deem fit, subject to such limitations and restrictions as the Board of Directors may from time to time prescribe. Unless otherwise
determined by the Board of Directors, the General Manager shall have authority with respect to management of the Company in the
ordinary course of business.

 

    	 	30 	 

    	 	 	 

    

 

MINUTES

 

53.
Minutes.

 

(a)
Minutes of each General Meeting, of each meeting of the Board of Directors and of each meeting of a Committee of the Board of
Directors shall be recorded and duly entered in books provided for that purpose, and shall be held by the Company at its principal
office or such other place as shall be determined by the Board of Directors. Such minutes shall, in all events, set forth the
name of the persons present at the meeting and all resolutions adopted at the meeting.

 

(b)
Any such minutes, if purporting to be signed by the Chairman of the Board of Directors, shall constitute prima facie evidence
of the matters recorded therein.

 

DIVIDENDS

 

54.
Declaration of Dividends; Dividend Preference.

 

Subject
to Article 75, the holders of Preferred Shares shall be entitled to non-cumulative dividends (whether paid in cash or otherwise),
at a rate of eight percent (8%) per year, payable out of funds legally available therefore, prior and in preference to the payment
of dividends on any other class of shares of the Company (the “Dividend Preference”). Such dividends
shall be payable only when, as and if approved by the Board of Directors.

 

Following
the full payment of the Dividend Preference, the holders of Preferred Shares shall be entitled to participate, pro rata,
in any dividends paid on the Ordinary Shares, on an as-converted basis.

 

55.
Funds Available for Payment of Dividends.

 

No
dividend shall be paid otherwise than in accordance with the provisions of the Companies Law.

 

56.
Amount Payable by Way of Dividends.

 

Subject
to the rights of the holders of Preferred Shares as to dividends pursuant to Article 54 above, any dividend paid by the Company
shall be allocated among the shareholders entitled thereto in proportion to the sums paid up or credited as paid up on account
of the nominal value of their respective holdings of the shares in respect of which such dividend is being paid without taking
into account the premium paid up for the shares. The amount paid up on account of a share that has not yet been called for payment
or fallen due for payment and upon which the Company pays interest to the shareholder shall not be deemed, for the purposes of
this Article, to be a sum paid on account of the share.

 

57.
Interest.

 

No
dividend shall carry interest as against the Company.

 

    	 	31 	 

    	 	 	 

    

 

58.
Payment in Specie.

 

Upon
the resolution of the Board of Directors, the Company (i) may cause any moneys, investments or other assets forming part of the
undivided profits of the Company, standing to the credit of a reserve fund or to the credit of a reserve fund for the redemption
of capital, or in the control of the Company and available for dividends, or representing premiums received on the issuance of
shares and standing to the credit of the share premium account, to be capitalized and distributed among such of the shareholders
as would be entitled to receive the same if distributed by way of dividend and in the same proportion, on the basis that they
become entitled thereto as capital, or may cause any part of such capitalized fund to be applied on behalf of such shareholders
in paying up in full, either at par or at such premium as the resolution may provide, any unissued shares or debentures or debenture
stock of the Company that shall be distributed accordingly, in payment, in whole or in part, of the uncalled liability on any
issued shares or debentures or debenture stock; and (ii) may cause such distribution or payment to be accepted by such shareholders
in full satisfaction of their interest in the said capitalized sum.

 

59.
Implementation of Powers under Article 58.

 

For
the purpose of giving full effect to any resolution under Article 58, and without derogating from the provisions of Article 7
hereof, the Board of Directors may settle any difficulty that may arise in regard to the distribution as it deems expedient, and
in particular may issue fractional certificates, and may fix the value for distribution of any specific assets, and may determine
that cash payments shall be made to any shareholders upon the basis of the value so fixed, or that fractions of less value than
the nominal value of one share may be disregarded in order to adjust the rights of all parties, and may vest any such cash, shares,
debentures, debentures stock or specific assets in trustees upon such trusts for the persons entitled to the dividend or capitalized
fund as may seem expedient to the Board of Directors.

 

60.
Dividends on Unpaid Shares.

 

Without
derogating from Article 56, the Board of Directors may give an instruction that shall prevent the distribution of a dividend to
the holders of shares on which the full nominal amount has not been paid up.

 

61.
Retention of Dividends.

 

(a)
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share on which
the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities or obligations in respect of
which the lien exists.

 

(b)
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share in respect
of which any person is, under Articles 22 and 23, entitled to become a shareholder, or which any person is, under such Articles,
entitled to transfer, until such person shall become a shareholder in respect of such share or shall transfer the same.

 

62.
Unclaimed Dividends.

 

All
unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board of Directors
for the benefit of the Company until claimed. The payment by the Board of Directors of any unclaimed dividend or such other moneys
into a separate account shall not constitute the Company a trustee in respect thereof. The principal (and only the principal)
of an unclaimed dividend or such other moneys shall be, if claimed, paid to a person entitled thereto.

 

    	 	32 	 

    	 	 	 

    

 

63.
Mechanics of Payment.

 

Any
dividend or other moneys payable in cash in respect of a share may be paid by check or draft sent through the post to, or left
at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two
or more persons are registered as joint holders of such share or are entitled jointly thereto in consequence of the death or bankruptcy
of the holder or otherwise, to the joint holder whose name is registered first in the Register of Shareholders or his bank account
or the person whom the Company may then recognize as the owner thereof or entitled thereto under Article 22 or 23 hereof, as applicable,
or such person’s bank account), or to such person and at such other address as the person entitled thereto may by writing
direct. Every such check or draft shall be made payable to the order of the person to whom it is sent, or to such person as the
person entitled thereto as aforesaid may direct, and payment of the check or draft by the bank upon which it is drawn shall be
a good discharge to the Company.

 

64.
Receipt from a Joint Holder.

 

If
two or more persons are registered as joint holders of any share, or are entitled jointly thereto in consequence of the death
or bankruptcy of the holder or otherwise, any one of them may give effectual receipts for any dividend or other moneys payable
or property distributable in respect of such share.

 

ACCOUNTS;
AUDITS

 

65.
Books of Account.

 

The
Board of Directors shall cause accurate books of account to be kept in accordance with the provisions of the Companies Law and
of any other applicable law. Such books of account shall be kept at the principal office of the Company, or at such other place
or places as the Board of Directors may deem fit, and they shall always be open to inspection by all Directors. Such books of
account and other corporate documents and records shall also be open to inspection by the shareholders and by auditors appointed
by the members, provided that such shareholders and auditors shall enter into confidentiality undertakings reasonably satisfactory
to the Board of Directors.

 

66.
Audit.

 

At
least once in every fiscal year the accounts of the Company shall be audited and the correctness of the profit and loss account
and balance sheet certified by one or more duly qualified auditors.

 

67.
Auditors.

 

The
appointment, authorities, rights and duties of the auditor(s) of the Company shall be regulated by Companies Law; provided, however,
that the Board of Directors shall have the authority to fix the remuneration of the auditor(s).

 

    	 	33 	 

    	 	 	 

    

 

RIGHTS
OF SIGNATURE, STAMP AND SEAL

 

68.
Rights of Signature, Stamp and Seal.

 

(a)
The Board shall be entitled to authorize any person or persons (who need not be Directors) to act and sign on behalf of the Company,
and the acts and signature(s) of such person(s) on behalf of the Company shall bind the Company to the extent such person acted
and signed within the scope of his or their authority.

 

(b)
The Board may provide for a seal. If the Board so provides, it shall also provide for the safe custody thereof. Such seal shall
not be used except by the authority of the Board of Directors and in the presence of the person(s) authorized to sign on behalf
of the Company, who shall sign every instrument to which such seal is affixed.

 

NOTICES

 

69.
Notices.

 

(a)
For purposes of this Section, the term “Business Day” means a day on which the banks are open for business
in the country of receipt of any notice.

 

(b)
All notices and other communications made pursuant to these Articles shall be in writing and shall be conclusively deemed to have
been duly given:

 

(i)
in the case of hand delivery to the address of the respective Person, on the next Business Day after delivery;

 

(ii)
in the case of delivery by an internationally recognized overnight courier to the address of the respective Person, freight prepaid,
on the next Business Day after delivery;

 

(iii)
in the case of a notice sent by facsimile transmission to the fax number of the respective Person, on the next Business Day after
delivery, if facsimile transmission is confirmed;

 

(iv)
in the case of a notice sent by email to the email address of the respective Person (if any), on the date of written acknowledgment
of receipt of such e-mail by the recipient.

 

(c)
In the event that notices are given pursuant to one of the methods listed in sub-clauses (b)(i) to (iii) above, a copy of the
notice should also be sent by email (if one is provided).

 

(d)
A Person may change or supplement the contact details for service of any notice pursuant to these Articles, or designate additional
addresses, facsimile numbers and email addresses for the purposes of this Section, by giving the other Persons written notice
of the new contact details in the manner set forth above.

 

    	 	34 	 

    	 	 	 

    

 

EXEMPTION,
INDEMNITY AND INSURANCE

 

70.
Exemption From Liability

 

Subject
to the provisions of the Companies Law, the Company may exempt an Office Holder in advance from all or part of such Officer Holder’s
responsibility or liability for damages caused to the Company due to any breach of such Office Holder’s duty of care towards
the Company.

 

71.
Indemnification

 

(a)
Subject to the provisions of the Companies Law, the Company may indemnify any Office Holder to the fullest extent permitted by
the Companies Law, with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed
on or incurred by such Office Holder in such Office Holder’s capacity as an Office Holder of the Company:

 

(i)
A financial obligation imposed on an Office Holder in favor of another person by a court judgment, including a compromise judgment
or an arbitrator’s award approved by a court of law;

 

(ii)
Reasonable legal expenses, including attorney’s fees, expended by the Office Holder as a result of an investigation or proceeding
instituted against the Office Holder by a competent authority, provided that such investigation or proceeding concluded without
the filing of an indictment against him and either (A) concluded without the imposition of any financial liability in lieu of
criminal proceedings, or (B) concluded with the imposition of a financial liability in lieu of criminal proceedings but relates
to a criminal offense that does not require proof of criminal intent; and

 

(iii)
Reasonable legal expenses, including attorney’s fees, which the Office Holder incurred or with which the Office Holder was
charged by a court of law, in a proceeding brought against the Office Holder, by the Company or by another on behalf of the Company,
or in a criminal prosecution in which the Office Holder was acquitted, or in a criminal prosecution in which the Office Holder
was convicted of an offense that does not require proof of criminal intent.

 

(b)
Subject to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder as aforesaid (i) prospectively,
provided, that, in respect of Article 71(a)(i), the undertaking is limited to events which, in the opinion of the Board of Directors
are foreseeable in light of the Company’s actual operations when the undertaking to indemnify is given, and to an amount
or criteria set by the Board of Directors as reasonable under the circumstances, and further provided that such events and amount
or criteria are set forth in the undertaking to indemnify, and (ii) retroactively.

 

    	 	35 	 

    	 	 	 

    

 

72.
Insurance

 

(a)
Subject to the provisions of the Companies Law, the Company may enter into a contract to insure an Office Holder for all or part
of the liability that may be imposed on such Office Holder in connection with an act performed by such Office Holder in such Office
Holder’s capacity as an Office Holder of the Company, with respect to each of the following:

 

(i)
breach of his duty of care to the Company or to another person;

 

(ii)
breach of his duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to
assume that the action in question would not prejudice the interests of the Company; and

 

(iii)
a financial obligation imposed on him in favor of another person.

 

(b)
Articles 70, 71 and 72(a) shall not apply under any of the following circumstances:

 

(i)
a breach of an Office Holder’s fiduciary duty, in which the Office Holder did not act in good faith and with reasonable
grounds to assume that the action in question would not prejudice the interests of the Company;

 

(ii)
a grossly negligent or intentional violation of an Office Holder’s duty of care;

 

(iii)
an intentional action by an Office Holder in which such Office Holder intended to reap a personal gain illegally; and

 

(iv)
a fine or ransom levied on an Office Holder.

 

(c)
The Company may procure insurance for or indemnify any person who is not an Office Holder, including without limitation, any employee,
agent, consultant or contractor, provided, however, that any such insurance or indemnification is in accordance with the provisions
of these Articles and the Companies Law.

 

(d)
The Company may procure insurance for or indemnify any person who is not an Office Holder, including without limitation, any employee,
agent, consultant, the Observer or contractor (and in case of an Officer holders - to the extent that the insurance, release or
indemnity is not prohibited by law), provided, however, that any such insurance or indemnification is in accordance with the provisions
of these Articles and the Companies Law, and was duly approved by the Board of Directors.

 

WINDING
UP

 

73.
Winding Up.

 

In
the event of a liquidation, bankruptcy, winding-up, dissolution, or reorganization of the Company (other than a solvent reorganization),
the following shall apply:

 

(a)
First, each Preferred Share shall entitle its holder to a per share distribution in the amount of the applicable Original Issue
Price (adjusted for share combinations or subdivisions or other recapitalizations of the Company’s shares) multiplied by
1.5, less the amount of the Dividend Preference and other distributions actually paid, plus an amount equal to declared but unpaid
dividends, if any, on each Preferred Share prior to payments to the other shareholders of the Company (the “Preference”).
In the event that the assets of the Company available for distribution shall be insufficient to pay the Preference in full to
the Preferred Shareholders, all of such assets shall be distributed among the holders of the Preferred Shares in proportion to
the full Preference such holders would otherwise be entitled to receive, subject to applicable law.

 

    	 	36 	 

    	 	 	 

    

 

(b)
In the event of a Deemed Liquidation Event, and to the extent that the assets of the Company available for distribution and are
being distributed shall exceed the amount necessary to pay the Preference, any remaining assets, up to an aggregate amount of
US$350,000, shall be distributed to NGT or its assignee in preference to all holders of Ordinary Shares to cover the obligations
of NGT and/or the Company to the Office of the Chief Scientist in Israel (“NGT Payment”).

 

(c)
In the event that the assets of the Company that available for distribution shall exceed the amount necessary to pay the Preference
and the NGT Payment, the remaining assets shall be distributed among the holders of the Preferred Shares and the Ordinary Shares
in proportion to the respective percentage holdings of all of the Ordinary Shares (assuming conversion of the Preferred Shares).

 

74.
Deemed Liquidation Event

 

For
purposes of Article 73, in addition to any liquidation, dissolution, reorganization or winding up of the Company under applicable
law, the Company shall be deemed to be liquidated (a “Deemed Liquidation Event”): (a) in the event of
a consolidation, merger, acquisition, or reorganization of the Company with or into, or a sale of all or substantially all of
the Company’s assets, or substantially all of the Company’s issued and outstanding share capital, to, any other company,
or any other entity or person, other than a wholly-owned subsidiary of the Company, excluding a transaction in which shareholders
of the Company prior to the transaction will maintain voting control of the surviving or acquiring entity after the transaction
(provided, however, that shares of the surviving or acquiring entity held by shareholders of the Company acquired by means other
than the exchange or conversion of the shares of the Company shall not be used in determining if the shareholders of the Company
own more than fifty percent (50%) of the voting power of the surviving or acquiring entity (or its parent)), but shall be used
for determining the total outstanding voting power of the surviving or acquiring entity); (b) in the event that pursuant to a
transaction or series of transactions a person or entity acquires, fifty percent (50%) or more of the issued and outstanding shares
of the Company; or (c) in the event of any lease, transfer or exclusive license of all or substantially all of the assets of the
Company (other than to a wholly owned subsidiary of the Company). Upon any deemed liquidation event of the Company as described
in this Article 74, at the closing of the transaction at which the Company is deemed for purposes of this Article 74 to be liquidated,
the shareholders shall be paid in cash, securities or a combination thereof, an amount equal to the amount per share which would
be payable to the shareholders of the Company, respectively, pursuant to Article 73 as if all consideration being received by
the Company and its shareholders in connection with such transaction were being distributed in a liquidation of the Company.

 

MAJOR
DECISIONS

 

75.
Major Decisions.

 

(a)
Subject to Article 75(d) below, the Company shall not and shall ensure that no subsidiary of the Company shall, without first
obtaining: (A) the written consent of the holders of 67% of the Preferred Shares if the matter is brought before the Shareholders;
or (B) the affirmative vote of the majority of the ABV Director or the Orchestra Director(s) (if appointed) if the matter is brought
before the Board, either directly or by amendment, merger, consolidation or otherwise, do any of the following or cause any subsidiary
to carry out any of such actions:

 

    	 	37 	 

    	 	 	 

    

 

	 	 	(i)	Any
    amendment or replacement of the articles of association of the Company (“Amendment to Articles”);
	 	 	 	 
	 	 	(ii)	any
    amendment or change of the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of,
    the Preferred Shares;
	 	 	 	 
	 	 	(iii)	Any
    issuance of any class of shares having rights, preferences or privileges equal to or more favorable than the rights, preferences
    or privileges of the Preferred Shares;
	 	 	 	 
	 	 	(iv)	Any
    increase in the authorized share capital of the Company, or any increase in the number of issued Preferred Shares, except
    as contemplated by the Series A SPA;
	 	 	 	 
	 	 	(v)	Any
    purchase, redemption, subdivision, consolidation, re-designation or other variation of or in the share capital of the Company
    (including any action that reclassifies any outstanding shares) or the rights attaching to shares in the share capital of
    the Company;
	 	 	 	 
	 	 	(vi)	Any
    reduction in the amount standing to the Company’s capital redemption or share premium reserve;
	 	 	 	 
	 	 	(vii)	Any
    merger, consolidation, acquisition or similar transaction of the Company with one or more other companies in which the shareholders
    of the Company prior to such transaction, or series of transactions, would hold shares representing less than a majority of
    the voting power of the outstanding shares of the surviving corporation immediately after such transaction, or series of transactions;
	 	 	 	 
	 	 	(viii)	The
    sale of all or substantially all of the Company’s assets;
	 	 	 	 
	 	 	(ix)	Any
    transaction or series of transactions whereby the Company acquires another company, including the acquisition of shares representing
    a majority of the voting power of the outstanding shares of another company, or an acquisition of all or substantially all
    of another company’s assets;
	 	 	 	 
	 	 	(x)	Any
    resolution for the winding up or liquidation of the Company;
	 	 	 	 
	 	 	(xi)	Any
    declaration or payment of a dividend or resolution to declare a dividend;
	 	 	 	 
	 	 	(xii)	[Reserved]
	 	 	 	 
	 	 	(xiii)	Material
    change in the nature of the business of the Company or in the Company’s business plan or budget (“Change
    of Business Plan or Budget”);
	 	 	 	 
	 	 	(xiv)	Any
    increase or decrease in the authorized number of directors of the Company;
	 	 	 	 
	 	 	(xv)	Instruct
    or enter into any engagement, agreement or understanding whatsoever with any broker, advisor (including, without limitation,
    financial, accounting, auditing or legal advisors), investment bank or similar party (each a “Service Provider”),
    to provide any services in connection with the listing of any of the Company’s shares or the merger or consolidation
    of the Company with or into, or the sale of all or substantially all of the assets or shares of the Company to, any person
    or entity;

 

    	 	38 	 

    	 	 	 

    

 

	 	 	(xvi)	issue
    or sell Series A Preferred Shares other than pursuant to the Series A SPA;
	 	 	 	 
	 	 	(xvii)	create,
    or hold capital stock in, or make any loan or advance to any subsidiary that is not wholly owned (either directly or through
    one or more other subsidiaries) by the Company, or sell, transfer or otherwise dispose of any capital stock of any direct
    or indirect subsidiary of the Company, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license
    or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets
    of such subsidiary; or
	 	 	 	 
	 	 	(xviii)	enter
    into any contract, arrangement or transaction with an affiliate of the Company or any office holder of the Company or any
    of their family members, unless such contract, arrangement or transaction (A) is on terms that are no less favorable to the
    Company than those the Company would have been reasonably likely to obtain as a result of arms-length negotiations with an
    unrelated third party and (B) has been approved by a majority vote of the disinterested members of the Board of Directors
    of the Company (“Related Party Transaction”). For the avoidance of doubt any transfer of shares
    by a shareholder to a Permitted Transferee shall not be deemed to be a Related Party Transaction.

 

(b)
Subject to Article 75(d) below, the Company shall not: (i) make an Amendment to the Articles; (ii) make any Change of Business
Plan or Budget; or (iii) enter into a Related Party Transaction: without (A) the written consent, not to be unreasonably withheld
or delayed, of NGT, if the matter is brought before the Shareholders; or (B) the affirmative vote, not to be unreasonably withheld
or delayed, of the NGT Director, if the matter is brought before the Board.

 

(c)
Notwithstanding anything in these Articles to the contrary, with respect to any exclusive rights granted to a specific named shareholder
(not by virtue of such shareholders holdings) (the “Specific Rights”), the Company shall not and shall
ensure that no subsidiary of the Company shall amend, change, or modify such Specific Rights, without the prior specific written
consent of the holder(s) of the relevant Specific Rights proposed to be amended, changed or modified.

 

(d)
Notwithstanding the foregoing any veto rights granted to NGT in Article 75(b)(i) (Amendment to the Articles) and in Article 75(b)(iii)
(Related Party Transaction) shall terminate (and the affirmative vote of the NGT Director shall not be required to have been obtained)
(x) when the Second Milestone Closing has been fully consummated by ABV and Orchestra as contemplated in the Series A SPA, (y)
if or NGT shall have become a Defaulting Purchaser, or (z) if the Second Milestone is not met by the Second Milestone Closing
Date (as such terms are defined in the Series A SPA). Notwithstanding the foregoing any veto rights granted to NGT in Article
75(b)(ii) (Change of Business Plan or Budget) shall terminate (and the affirmative vote of the NGT Director shall not be required
to have been obtained) (x) when the Third Milestone Closing has been fully consummated by ABV and Orchestra as contemplated in
the Series A SPA, (y) if or NGT shall have become a Defaulting Purchaser, or (z) if the Third Milestone is not met by the Third
Milestone Closing Date (as such terms are defined in the Series A SPA).

 

76.
Bring Along.

 

(a)
Subject to the provisions of and without derogating from Article 75 above and the provisions of Section 341 of the Companies Law,
notwithstanding anything in these Articles to the contrary, until a Qualified IPO, if any person or entity offers to purchase
all of the issued and outstanding share capital of the Company (the “Bring Along Transaction”), and
shareholders holding more than (i) seventy percent (70%) of the voting power in the Company calculated on an as converted basis;
and (ii) 67% of the Preferred Shares, indicate their acceptance of such offer (the “Proposing Shareholders”),
and such offer is approved by a majority of the Board, then at the closing of such transaction, all holders of all classes of
shares in the Company will transfer their shares to such person or entity at the same price and on the same terms and conditions
as the Proposing Shareholders subject to any adjustments as may be necessary in order to give full effect to Article 74 hereof.
The distribution of the consideration of such Bring Along Transaction shall be distributed in accordance with the provisions of
Article 74 above, and in the order of preference and priority as set forth therein, and shall not derogate from the liquidation
preferences set forth in such Article 73 and Article 74 in relation to a Deemed Liquidation Event.

 

    	 	39 	 

    	 	 	 

    

 

Disclosure
Schedule

 

Capitalized
terms used but not defined herein shall have the meanings ascribed to them in the Agreement. Each disclosure is listed in a numbered
Exhibit in accordance with the numbered section of the Agreement for which it is most relevant. Any information disclosed under
a specific Exhibit shall be deemed to be disclosed and incorporated only under that Exhibit except to the extent that it is readily
apparent from a reading of the disclosure that such disclosure is applicable to other Exhibits, in which case such information
shall be deemed to be disclosed and incorporated under such other Exhibit.

 

Nothing
in these Exhibits is intended to expand the scope of any representation or warranty of the Company contained in the Agreement.

 

Inclusion
of any item in these Exhibits (i) does not necessarily represent a determination by the Company that such item is material nor
shall it necessarily be deemed to establish a standard of materiality, (ii) does not necessarily represent a determination by
the Company that such item did not arise in the ordinary course of business, and (iii) shall not constitute, or be deemed to be,
an admission to any third party, except the Purchasers, concerning such item by the Company. Without derogating from the representations
contained in Section 3 of the Agreement, these Exhibits include descriptions of instruments or brief summaries of certain aspects
of the Company and its business, which descriptions are not necessarily complete and the brief summaries and identification provided
in these Exhibits are meant to identify documents or other materials. Any reference to an agreement or document includes reference
to all exhibits and schedules attached thereto.

 

Unless
otherwise indicated, all information included is provided as of the date of the Agreement.

 

    	 	 	 

    	 

    

 

Exhibit
3.4

 

Cap
Table

 

    	 	 	 

    	 

    

 

Exhibit
3.6

 

Litigation

 

Zohar
will send a description of the claims and proceedings in connection with the lease agreement.

 

Mark
– are there any other actions, proceedings or governmental inquiry or investigation pending or, to the knowledge of
the Company, threatened against the Company or any of its officers, directors, or employees (in their capacity as such), or against
any of the Company’s properties, or with regard to the Company’s business or assets, before any court, arbitration
board or tribunal or administrative or other governmental agency, or, to the knowledge of the Company, is there any basis for
any of the foregoing, or any actions or proceedings that the Company intends to initiate?

 

    	 	 	 

    	 

    

 

Exhibit
3.7

 

Material Liabilities

 

    	 	 	 

    	 

    

 

AMENDMENT
AND JOINDER TO CONVERTIBLE NOTES AGREEMENT

 

This
Amendment and Joinder to Convertible Notes Agreement (this “Joinder”) is made as of December __, 2015 (the
“Effective Date”), by and among Motus GI Medical Technologies Ltd., a company organized under the laws of the
State of Israel, with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”), the Purchasers listed
on Exhibit A to the CNA (the “Initial Purchasers”) and the persons and entities listed on Schedule
I attached hereto (the “New Purchasers”) (each of the Initial Purchasers and each of the New Purchasers,
a “Purchaser” and together, the “Purchasers” and each Purchaser and the Company separately,
a “Party” and together, the “Parties”).

 

	WHEREAS,
    	the
    Company and the Initial Purchasers are parties to a Convertible Notes Agreement dated June 9, 2015, attached hereto as Exhibit
    A (the “CNA”) (capitalized not defined herein shall have the meaning ascribed to them in the CNA,
    unless it is specifically provided otherwise); and 
	 	 
	WHEREAS,	pursuant
    to the CNA, the Initial Purchasers have committed to extend to the Company a convertible loan in the aggregate principal amount
    of US$ 5,495,951 (the “Loan Amount”) in four installments, all under the terms and conditions set forth
    therein; and 
	 	 
	WHEREAS,	as
    of the date hereof, the First Installment and the Second Installment of the Loan Amount, in the aggregate principal amount
    of US$2,910,894, have been extended in full to the Company; and
	 	 
	WHEREAS,	the
    Company and the Initial Purchasers wish to amend certain terms of the CNA, including an increase of the Loan Amount to an
    aggregate principal amount of up to US$9 Million and to allow the New Purchasers to join the Third Installment and the Fourth
    Installment of the CNA, as amended herein, and the New Purchasers wish to so join the CNA, all under the terms and conditions
    set forth herein.

 

NOW
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

	1.	The
    Transaction

 

	 	1.1.	Joining
    to CNA. The Parties acknowledge and agree that by execution of this Joinder each of the New Purchasers shall automatically
    become, as of the Third Closing, a party to the CNA as a “Purchaser” for all intents and purposes and shall have
    all the rights and obligations of a “Purchaser” thereunder.

 

    	 	- 40 -	 

    	 	 	 

    

 

	 	1.2.	Additional
    Loan Amount extended by the New Purchaser and Amendment of Exhibit A. The New Purchasers shall extend to the Company a
    principal amount of US$ 937,500 at the Third Closing as part of the Third Installment and an aggregate principal amount of
    US$ 312,500 at the Fourth Closing as part of the Fourth Installment. Such additional amounts extended by the New Purchasers
    shall be deemed to be part of the “Loan Amount”. Accordingly, Exhibit A of the CNA shall be replaced in
    its entirety with the attached Exhibit B (the “Amended Exhibit A”). 
	 	 	 
	 	1.3.	Third
    Notes and Fourth Notes. The forms of the Third Note (Exhibit D1 of the CNA) and the Fourth Note (Exhibit E1
    of the CNA) shall be replaced in their entirety with the attached Exhibit C and Exhibit D,
    respectively. 
	 	 	 
	 	1.4.	Third
    Closing Date. The words “within one hundred and eighty (180) days after the First Closing” in Section 2.5
    of the CNA shall be deleted and replaced in their entirety with the following words: “on December 29, 2015”. 
	 	 	 
	 	1.5.	Deliveries
    and Transactions at the Third Closing. At the Third Closing, the following transactions shall occur, in addition to and
    simultaneously with the transactions specified in Section 2.6 of the CNA:

 

	 	(i)	The
    Company shall deliver to the Purchasers copies of duly executed resolutions of the Board, in the form attached hereto as Exhibit
    E, approving, inter alia, the execution, delivery and performance of this Joinder by the Company. 
	 	 	 
	 	(ii)	The
    Company shall deliver to the Purchasers copies of duly executed resolutions of the Company’s shareholders, in the form
    attached hereto as Exhibit F, approving, inter alia, the execution, delivery and performance of this
    Joinder by the Company. 
	 	 	 
	 	(iii)	The
    First Notes and the Second Notes shall be replaced by the Company with amended notes in the forms attached hereto as Exhibit
    G and Exhibit H, respectively.

 

	 	1.6.	Fourth
    Closing Date. The words “at such time and place as the Company and the Purchasers shall mutually agree in writing,
    but in any event not later than fourteen (14) days after the Board determines that the Company’s cash position requires
    the infusion of additional funds to continue to operate its business” in Section 2.7 of the CNA shall be deleted and
    replaced in their entirety with the following words: “on April 26, 2016, or at such other time and place as the Company
    and the Purchasers shall mutually agree in writing”.

 

    	 	- 41 -	 

    	 	 	 

    

 

	 	1.7.	Deferred
    Closing(s). The following Sections shall be added after Section 2.6 of the Agreement:

 

“2.6A.
Subject to the terms and conditions hereof, the Company may consummate an additional closing or series of closings (each, a “Deferred
Closing”) with an additional purchaser or purchasers approved by the Board (each, an “Additional Purchaser”
and collectively, the “Additional Purchasers”) on the same terms and conditions set forth in this Agreement
and the provisions of Section 2.6 shall apply to such Deferred Closing, mutatis mutandis; provided that (i) any such Deferred
Closing shall occur no later than one hundred and twenty (120) days from the Third Closing; and (ii) the aggregate amount to be
extended by the Additional Purchasers (the “Additional Loan Amount”), together with the aggregate Loan Amount,
shall not exceed US$9 Million. Simultaneously with the consummation of a Deferred Closing, the Additional Purchasers shall execute
and deliver to the Company a joinder agreement in the form attached as Exhibit 2.6A hereto, pursuant to which each
such Additional Purchaser shall become a party to this Agreement and for all purposes under this Agreement, the Additional Purchaser
shall be deemed to be a “Purchaser” and the Additional Loan Amount shall be deemed to be part of the “Loan Amount”.”

 

	 	1.8.	Amendment
    to the Company’s Representations and Warranties. Sections 3.4 and 3.7 of the CNA shall be deleted in their entirety
    and replaced with the following:

 

“3.4.
Capitalization. The authorized share capital of the Company immediately prior to the Third Closing shall consist of NIS
272,000 divided into (i) 34,000,000 Ordinary Shares, par value NIS 0.01 each, of which 4,271,092 are issued and outstanding, and
(ii) 23,200,000 Series A Preferred Shares, par value NIS 0.01 each, of which 13,500,000 are issued and outstanding. An accurate
capitalization table listing all of the Company’s shares, options, and warrants (or other rights or securities convertible
into or exchangeable for shares in the Company (collectively, the “Equity Securities”) and their respective
record holders and, to the knowledge of the Company, beneficial owners on a fully diluted basis is set forth in Exhibit
3.4 attached hereto (the “Cap Table”).”

 

    	 	- 42 -	 

    	 	 	 

    

 

“3.7.
Material Liabilities. Except as set forth on Exhibit 3.7 attached hereto, the Company does not have any liability,
debt or obligation, which exceeds US$200,000, whether accrued, absolute or contingent or otherwise, including to previous employees
or consultants for any reason. Except as set forth on Exhibit 3.7 attached hereto, the Company has not provided
any loans or advances to any person or given a guarantee or created any charge, lien or other encumbrance on any of its assets
and/or its un-issued share capital for any obligation of any person.”

 

	2.	Assignment
    and Transfer by the New Purchasers

 

Notwithstanding
Section 9.2 of the CNA and 11.2 of the Notes, each of the New Purchasers shall be entitled to assign or transfer any of its rights
and/or obligations under the CNA (as amended herein), including any Notes issued to it pursuant to the CNA, to any other New Purchaser
that is its Permitted Transferee (as such term is defined in the Company’s Articles of Association as may be amended from
time to time), without the consent of the other Parties.

 

	3.	Representations
    and Warranties

 

	 	2.1.	The
    Company hereby represents and warrants to the New Purchasers that all representations and warranties set forth in Section
    3 of the CNA (as qualified by the Disclosure Schedule) shall have been true and correct when made, and shall be true and correct
    in all material respects as of the Third Closing Date (subject to the amendments herein); provided that any reference in Section
    3 of the CNA to the CNA shall include also this Joinder. 
	 	 	 
	 	2.2.	Each
    of the New Purchasers hereby makes all representations and warranties specified in Section 4 of the CNA in respect of itself,
    and represents and warrants to the Company and acknowledges that the Company is entering into this Joinder in reliance thereon,
    that all the representations and warranties set forth in Section 4 of the CNA are true and correct in respect of such New
    Purchaser as of the date hereof and shall be true and correct in all material respects as of the Third Closing and the Fourth
    Closing, provided that any reference in Section 4 of the CNA to the CNA shall include also this Joinder.

 

    	 	- 43 -	 

    	 	 	 

    

 

	3.	Miscellaneous

 

	 	6.1.	The
    headings in this Joinder are for convenience only and shall not be used for purposes of construction.
	 	 	 
	 	6.2.	All
    terms and conditions of the CNA (including any of its exhibits) shall remain in full force and effect subject to the provisions
    of this Joinder, which shall be regarded as an integral part of the CNA. In case of a contradiction between this Joinder and
    the CNA, the provisions of this Joinder shall prevail.
	 	 	 
	 	6.3.	This
    Joinder may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together
    shall constitute a single instrument.

 

[Signature
Pages to Follow]

 

    	 	- 44 -	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Joinder as of the date first above written.

 

THE
COMPANY:

 

	 	 
	Motus
    GI Medical Technologies Ltd. 	 
	 	 	 
	By:	                                          	 
	 	 	 
	Title:	                                           	 

 

THE
PURCHASERS:

 

	 	 	 
	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
    MOTUS Co-Investment Partners, LLC 
	 	 	 
	By:	                                          	 	By:	                                          
	 	 	 	 	 
	Title:	                                          	 	Title:	                                          
	 	 	 
	 	 	 
	Ascent
    Biomedical Ventures II, L.P.(3)	 	Ascent
    Biomedical Ventures Synecor, L.P.
	 	 	 
	By:	                                          	 	By:	                                          
	 	 	 	 	 
	Title:	                                          	 	Title:	                                          
	 	 	 
	 	 	 
	Jacobs
    Investments Company LLC	 	 
	 	 	 
	By:	                                          	 	 
	 	 	 	 
	Title:	                                          	 	 

 

[Signature
Page 1 to amendment and Joinder to Convertible Notes Agreement]

 

    	 	- 45 -	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Joinder as of the date first above written.

 

	                                          	 	                                          
	E.
                                         Jeffrey Peierls
	 	Brian
    Eliot Peierls
			 
	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	UD
    E.F. Peierls for E. Jeffrey Peierls 
	 	 	 
	By:	                                          	 	By:	                                          
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	 	 	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	UD
    J.N. Peierls for E. Jeffrey Peierls
	 	 	 
	By:	                                          	 	By:	                                          
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	UD
    Ethel F. Peierls Charitable Lead Trust
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	 	 	 
	The
    Peierls Bypass Trust	 	UD
    E.S. Peierls for E.F. Peierls et al
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	 	 	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation 	 	UW
    E.S. Peierls for E. Jeffrey Peierls - Accumulation
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	The
    Peierls Foundation, Inc.
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Title:	 	 	Title:	 

 

[Signature
Page 2 to amendment and Joinder to Convertible Notes Agreement]

 

    	 	- 46 -	 

    	 	 	 

    

 

Schedule
I

 

The
New Purchasers

 

	E.
    Jeffrey Peierls
	 
	Brian
    Eliot Peierls
	 
	THROUGH
    ACCOUNT AT NORTHERN TRUST:
	 
	UD
    E.F. Peierls for Brian E. Peierls
	 
	UD
    E.F. Peierls for E. Jeffrey Peierls 
	 
	UD
    J.N. Peierls for Brian Eliot Peierls
	 
	UD
    J.N. Peierls for E. Jeffrey Peierls
	 
	UW
    J.N. Peierls for Brian E. Peierls
	 
	UW
    J.N. Peierls for E. Jeffrey Peierls
	 
	UD
    Ethel F. Peierls Charitable Lead Trust
	 
	The
    Peierls Bypass Trust
	 
	UD
    E.S. Peierls for E.F. Peierls et al
	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation 
	 
	UW
    E.S. Peierls for E. Jeffrey Peierls - Accumulation
	 
	The
    Peierls Foundation, Inc.

 

    	 	- 47 -	 

    	 	 	 

    

 

Exhibit
A

 

CNA

 

    	 	- 48 -	 

    	 	 	 

    

 

EXHIBIT
B TO FIRST AMENDMENT AND JOINDER TO CNA

 

Amended
Exhibit A

 

Loan
Amount and Notes

 

	Name	 	Loan
    Amount	 	 	First
    Installment	 	 	Second
    Installment	 	 	Third
    Installment	 	 	Fourth
    Installment	 	 	Address
	Orchestra
    Medical Ventures II, L.P.	 	US$	1,239,996	 	 	US$	309,999	 	 	US$	309,999	 	 	US$	309,999	 	 	US$	309,999	 	 	
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	US$	977,511	 	 	US$	325,837	 	 	US$	325,837	 	 	US$	325,837	 	 	US$	0	 	 	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	US$	1,665,108	 	 	US$	416,277
                                         	 	 	US$	416,277	 	 	US$	416,277	 	 	US$	416,277	 	 	 
	Ascent
    Biomedical Ventures Synecor, L.P.	 	US$	831,304	 	 	US$	207,826	 	 	US$	207,826	 	 	US$	207,826	 	 	US$	207,826	 	 	 
	Jacobs
    Investments Company LLC	 	US$	782,032	 	 	US$	195,508
                                         	 	 	US$	195,508	 	 	US$

US$	195,508	 	 	US$	195,508	 	 	 
	E.
    Jeffrey Peierls	 	US$	130,000	 	 	 	-	 	 		-	 	 	US$	97,500	 	 	US$	32,500	 	 	 
	Brian
    Eliot Peierls	 	US$	80,000	 	 		-	 	 	 	-	 	 	US$	60,000	 	 	US$	20,000	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	US$	54,000	 	 		-	 	 		-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UD
    E.F. Peierls for E. Jeffrey Peierls	 	US$	54,000	 	 		-	 	 		-	 	 	US$	40,500	 	 	US$	13,500	 	 	 

 

    	 		 

     

    

 

	Name	 	Loan
    Amount	 	 	 	First
                                         Installment	 	 	 	Second
                                         Installment	 	 	Third
    Installment	 	 	Fourth
    Installment	 	 	Address
	UD
    J.N. Peierls for Brian Eliot Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UD
    J.N. Peierls for E. Jeffrey Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	US$	56,000	 	 	 	-	 	 	 	-	 	 	US$	42,000	 	 	US$	14,000	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	US$	56,000	 	 	 	-	 	 	 	-	 	 	US$	42,000	 	 	US$	14,000	 	 	 
	UD
    Ethel F. Peierls Charitable Lead Trust	 	US$	50,000	 	 	 	-	 	 	 	-	 	 	US$	37,500	 	 	US$	12,500	 	 	 
	The
    Peierls Bypass Trust	 	US$	20,000	 	 	 	-	 	 	 	-	 	 	US$	15,000	 	 	US	5,000	 	 	 
	UD
    E.S. Peierls for E.F. Peierls et al	 	US$	38,000	 	 	 	-	 	 	 	-	 	 	US$	28,500	 	 	US$	9,500	 	 	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	US$	46,000	 	 	 	-	 	 	 	-	 	 	US$	34,500	 	 	US$	11,500	 	 	 
	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	US$	28,000	 	 	 	-	 	 	 	-	 	 	US$	21,000	 	 	US$	7,000	 	 	 
	The
    Peierls Foundation, Inc.	 	US$	530,000	 	 	 	-	 	 	 	-	 	 	US$	397,500	 	 	US$	132,500	 	 	 

 

    	 		 

     

    

 

	Name	 	 	Loan
                                         Amount	 	 	 	First
                                         Installment	 	 	 	Second
                                         Installment	 	 	 	Third
                                         Installment	 	 	 	Fourth
                                         Installment	 	 	Address
	Total	 	US$	6,745,951	 	 	US$	1,455,447	 	 	US$	1,455,447	 	 	US$	2,392,947	 	 	US$	1,442,110	 	 	

  

Warrants

 

	Name	 	First
    Warrants	 	 	Second
    Warrants	 	 	Third
    Warrants	 	 	Fourth
    Warrants	 	 	Total
    Warrants	 
	Orchestra
    Medical Ventures II, L.P.	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	409,200	 
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	107,526	 	 	 	107,526	 	 	 	107,526	 	 	 	0	 	 	 	322,578	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	137,371	 	 	 	137,371	 	 	 	137,371	 	 	 	137,371	 	 	 	549,484	 
	Ascent
    Biomedical Ventures Synecor, L.P.	 	 	68,583	 	 	 	68,583	 	 	 	68,583	 	 	 	68,583	 	 	 	274,332	 
	Jacobs
    Investments Company LLC	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	258,072	 
	E.
    Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	32,175	 	 	 	10,725	 	 	 	42,900	 
	Brian
    Eliot Peierls	 	 	-	 	 	 	-	 	 	 	19,800	 	 	 	6,600	 	 	 	26,400	 

 

    	 		 

     

    

 

	Name	 	First
    Warrants	 	 	Second
    Warrants	 	 	Third
    Warrants	 	 	Fourth
    Warrants	 	 	Total
    Warrants	 
	UD
    E.F. Peierls for Brian E. Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    E.F. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    J.N. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UW
    J.N. Peierls for Brian E. Peierls	 	 	-	 	 	 	-	 	 	 	13,860	 	 	 	4,620	 	 	 	18,480	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,860	 	 	 	4,620	 	 	 	18,480	 
	UD
    Ethel F. Peierls Charitable Lead Trust	 	 	-	 	 	 	-	 	 	 	12,375	 	 	 	4,125	 	 	 	16,500	 
	The
    Peierls Bypass Trust	 	 	-	 	 	 	-	 	 	 	4,950	 	 	 	1,650	 	 	 	6,600	 
	UD
    E.S. Peierls for E.F. Peierls et al	 	 	-	 	 	 	-	 	 	 	9,405	 	 	 	3,135	 	 	 	12,540	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	 	-	 	 	 	-	 	 	 	11,385	 	 	 	3,795	 	 	 	15,180	 
	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	 	-	 	 	 	-	 	 	 	6,930	 	 	 	2,310	 	 	 	9,240	 
	The
    Peierls Foundation, Inc.	 	 	-	 	 	 	-	 	 	 	131,175	 	 	 	43,725	 	 	 	174,900	 
	Total	 	 	480,298	 	 	 	480,298	 	 	 	789,673	 	 	 	475,897	 	 	 	2,226,166	 

 

    	 		 

     

    

 

EXHIBIT
C TO FIRST AMENDMENT AND JOINDER TO CNA

 

Date:____________

 

Purchaser:
___________

Principal
Amount: US$___________

 

CONVERTIBLE

 

PROMISSORY
NOTE

 

For
value received, Motus GI Medical Technologies Ltd., an Israeli company (“Company”) promises to pay to
the Purchaser named above (“Holder”), the principal sum stated above (the “Principal Amount”)
in accordance with the terms set forth herein, as follows:

 

	1.	Note
    Part of a Series. This Note is being sold by the Company as part of a series of notes issued pursuant to that certain
    Convertible Notes Agreement dated as of June 9, 2015, by and among the Company and purchasers of such Notes (the “CNA”).
    The term “Notes” shall mean herein all Notes issued under the CNA.
	 	 
	2.	Interest.
    Interest shall accrue on the unpaid Principal Amount of this Note from the date of this Note until the actual repayment of
    all amounts due hereunder, at an annual rate of 10% (ten percent), compounded annually. Interest shall be computed on the
    basis of a year of 360 days for the actual number of days occurring in the period for which such interest is payable. Upon
    conversion of the Principal Amount in accordance with the terms hereof, all interest accrued thereon shall be converted together
    with the Principal Amount or repaid to the Holder in cash, after deduction of all applicable taxes with respect thereto, as
    shall be determined by the Company, at its sole discretion. The actual amount to be converted in accordance with the Company’s
    election, as specified in the preceding sentence, shall be hereinafter referred to as the “Conversion Amount.”
	 	 
	3.	Automatic
    Conversion upon QFR. To the extent not previously converted or repaid according to the terms specified herein, the
    Conversion Amount shall be automatically converted, immediately prior and subject to the closing of a QFR (as defined below),
    on the same terms and conditions applicable to the QFR, such that the Holder shall receive the same type of securities issued,
    and any other rights granted to the investors in such QFR (the “QFR Securities”), under the same terms
    as if the Holder had participated in the QFR as an investor (including any warrants or any other securities granted to the
    investors therein), but at a conversion price per share equal to the QFR Conversion Price (as defined below).
	 	 
	 	It
    being agreed and acknowledged that (a) the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of QFR Securities issued to the Holder shall be set to be the QFR Conversion Price, and any
    rights that are attached to the QFR Securities issued to the Holder which are determined, derived, calculated, triggered,
    or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend preferences,
    anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual QFR Conversion
    Price; and (b) in the event that the QFR Securities also comprise of warrants to purchase, or other securities convertible
    into, shares of the Company (any such preceding convertible security a “Convertible Security”), then (i)
    upon such conversion, the Holder shall be entitled to receive such number of warrants and/or Convertible Securities of the
    same class or type that are issued to the investors in the framework of the QFR, in a number which shall be determined using
    the same warrant and/or Convertible Securities coverage ratio offered to the investors in such QFR, such that the ratio between
    the shares and the warrants and/or Convertible Securities issued to the Holder shall be equal to the ratio between the shares
    and the warrants and/or Convertible Securities issued to each investor in such QFR; and (ii) the discount rate reflected in
    the QFR Conversion Price shall not apply in respect of the exercise price or conversion price (as applicable) of such warrants
    and/or Convertible Securities.

 

    	 		 

     

    

 

For
example, if the terms of the QFR are as follows:

 

	 	●	The
    QFR unit price is US$10.
	 	 	 
	 	●	Each
    unit is comprised of two (2) Ordinary Shares and one (1) warrant to purchase one (1) Ordinary Share.
	 	 	 
	 	●	The
    discount rate reflected in the QFR Conversion Price of the Holder is 10%. 
	 	 	 
	 	●	The
    exercise price of the warrants issued in the QFR is US$12.
	 	 	 
	 	●	The
    Conversion Amount of the Holder is US$1,800.

 

then,
in the framework of such QFR, the Holder shall be issued, upon conversion of the Conversion Amount, 200 Ordinary Shares ((US$1,800))/((1-10%)*US$10))
and 100 warrants to purchase 100 Ordinary Shares (100/2), at an exercise price per share of US$12, while an investor, who is not
a holder of Notes, and invests in the QFR the same amount (i.e., US$1,800), shall be issued only 180 Ordinary Shares and 90 warrants
to purchase 90 Ordinary Shares, at an exercise price per share of US$12.

 

The
term “QFR” means the first financing round consummated by the Company after the date of the Note, through an
equity investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance of
shares upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate investment
amount of not less than US$12,000,000 (Twelve Million US Dollars), including the outstanding principal amount of the Notes and
all accrued and unpaid interest thereon.

 

The
term “QFR Conversion Price” means a conversion price reflecting the lower of (i) a 10% discount on the price
paid by the investor(s) for the shares issued in the QFR; or (ii) US$1.15 per share. Notwithstanding the foregoing, in the event
that the QFR in an initial public offering with gross proceeds to the Company of not less than US$25,000,000 (Twenty Five Million
US Dollars) (including the outstanding principal amount of the Notes and all accrued and unpaid interest thereon) (the “QIPO”),
the QFR Conversion Price shall mean a conversion price reflecting a 50% discount on the price paid for the shares issued in the
QIPO and if the price in such QIPO is fixed per each unit offered in the QIPO, the discount shall be applicable to such unit price.

 

    	-2- 

    	 		 

    

 

If
this Note is converted in accordance with this Section ‎3, written notice shall be delivered to the Holder of this Note, notifying
the Holder of the conversion, specifying the Conversion Amount, the date of such conversion, and the securities issued upon conversion.
For the avoidance of doubt, in such event this Note shall be null and void even if not surrendered to the Company.

 

	4.	Automatic
    Conversion upon M&A Event. In the event that, prior to the conversion of the Conversion Amount or its repayment
    according to the terms specified herein, an M&A Event (as defined below) shall occur, then immediately prior and subject
    to the closing of such M&A Event, the Conversion Amount shall be automatically converted into Series A Preferred Shares,
    par value NIS 0.01 per share, of the Company (the “Preferred A Shares”), at a conversion price equal to
    the price per share paid by the Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “M&A
    Conversion Price”). 
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the M&A Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    M&A Conversion Price.
	 	 
	 	The
    term “M&A Event” means (i) a merger or consolidation of the Company in which the Company’s shareholders
    immediately prior to such transaction do not own, directly or indirectly, more than 50% of the share capital of the surviving
    entity; (ii) the acquisition of more than 50% of the Company’s outstanding share capital by a single unaffiliated person,
    entity or group ,or by persons or entities acting in concert; (iii) the sale or transfer of all or substantially all of the
    assets of the Company; or (iv) a reverse triangular merger in which the Company is the surviving entity but the shares of
    the Company’s share capital outstanding immediately prior to the merger are converted by virtue of the merger into other
    property, whether in the form of securities, cash or otherwise.
	 	 
	5.	Voluntary
    Conversion upon NQFR. In the event that, prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company shall consummate a financial round through an equity investment, either in one
    transaction or in series of transactions (including an initial public offering but excluding the issuance of any convertible
    notes or the issuance of shares upon conversion of such notes), which is not a QFR (a “NQFR”), then the
    holders of Notes reflecting 70% (Seventy percent) of the aggregate outstanding principal amount of the Notes (the “Majority
    Holders”), shall be entitled, no later than fourteen (14) days prior to the closing of such NQFR, to notify the
    Company in writing of their choice to convert the entire Conversion Amount of the Notes (the “Aggregate Conversion
    Amount”). In such event the entire Aggregate Conversion Amount shall be converted immediately prior and subject
    to the closing of the NQFR, on the same terms and conditions specified in Section ‎3 above (“Automatic Conversion
    upon a QFR”), mutatis mutandis. The election of the Majority Holders to convert the entire Aggregate Conversion
    Amount shall be binding on all of the holders of the Notes and each such holder shall be deemed to have elected to convert
    its respective portion of the Aggregate Conversion Amount in accordance with the terms and conditions specified herein.

 

    	-3- 

    	 		 

    

 

	6.	Maturity
    Date. If not converted or repaid according to the terms set forth herein until thirty (30) months from the date of
    this Note (i.e., ____________) (the “Maturity Date”), then at the Maturity Date the Conversion Amount shall
    be automatically converted into Preferred A Shares, at a conversion price per share equal to the price per share paid by the
    Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “Maturity Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the applicable Articles of
    Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Maturity Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Maturity Conversion Price.
	 	 
	7.	Event
    of Default. In the event that, prior to the conversion of the Conversion Amount or its repayment according to the
    terms hereunder an Event of Default occurs, then the Conversion Amount shall be, at the election of the Holder, at its sole
    discretion, either: (i) become immediately due and payable to the Holder in cash; or (ii) converted into Preferred A Shares,
    at a conversion price per share equal to the price per share paid by the Company’s investors in consideration for the
    Preferred A Shares (i.e., US$1) (the “Default Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Default Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Default Conversion Price.
	 	 
		The
    term “Event of Default” means (a) dissolution, termination of existence, suspension or discontinuance of
    business or ceasing to operate as going concern for a period of more than thirty (30) days; (b) the appointment of a receiver,
    trustee, custodian or similar official, for the Company or any material portion of the property or assets of the Company and
    the continuation of such appointment without dismissal for a period of thirty (30) days or more; (c) the conveyance of any
    material portion of the assets of the Company to a trustee, mortgage or liquidating agent or an assignment for the benefit
    of creditors by the Company which is not dismissed within a period of thirty (30) days; (d) the commencement of any proceeding,
    whether federal or state, relating to bankruptcy, insolvency, dissolution, reorganization, composition, renegotiations of
    outstanding indebtedness, arrangement or otherwise to the relief or debtors or the readjustment of indebtedness, by or against
    the Company, which is not stayed, vacated or released within sixty (60) days of commencement; (e) any material breach by the
    Company of any covenant or obligation in the Note, CAN or any documents and agreements ancillary thereto (the “Transaction
    Documents”) which is not cured, if curable, within thirty (30) days following receipt by the Company of a written
    notice of such breach; (f) any material misrepresentation has occurred in the Transaction Documents, which is not cured, if
    curable, within thirty (30) days following receipt by the Company of a written notice of such breach; (g) the Company shall
    fail to make any required payment of interest, principal or otherwise under the Notes, which is not cured within thirty (30)
    days following receipt by the Company of a written notice of such failure. The Company undertakes to notify the Holder immediately
    following occurrence of any of the events detailed in clauses (a) to (g) above. 

 

    	-4- 

    	 		 

    

 

	8.	Conversion;
    Fractional Interests. Each conversion shall be deemed to have been effected as to this Note (or the specified portion
    thereof) on the date on which the requirements set forth above in this Note required to be satisfied by the Holder, or the
    circumstances that are required to exist, have been satisfied as to this Note (or portion thereof), and the person whose name
    any certificate or certificates for shares shall be issuable upon such conversion shall be deemed to have become on said date
    the holder of record of the shares represented thereby. No fractional shares or scrip representing fractional shares shall
    be issued upon conversion of this Note and the number of shares issued shall be rounded to the nearest whole number.
	 	 
	9.	Payments;
    Taxes

 

	 	9.1.	Payments.
    All payments of interest and of principal shall be in U.S. Dollar (“US$”) or in the New Israeli Shekels
    (“NIS”) equivalent. If any payment is paid in a NIS equivalent, it shall be paid in accordance with the
    representative rate of exchange of the U.S. Dollar against the NIS last published by the Bank of Israel immediately prior
    to the certain payment date.
	 	 	 
	 	9.2.	Taxes
    on Payments. To the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be
    made by the Company pursuant to this Note. The Company shall be entitled to deduct and withhold any withholding taxes which
    the Company determines it is legally required to deduct or withhold from any payment to be made by the Company pursuant to
    this Note.

 

	10.	Not
    a Shareholder. Prior to the conversion of this Note or any portion thereof according to the provisions specified herein,
    the Holder, in its capacity as an Holder, shall not be entitled to any rights of a shareholder of the Company, including,
    without limitation, the right to vote or to receive dividends or other distributions, with respect to the Note and the shares
    issuable upon conversion of the Note.
	 	 
	11.	Miscellaneous

 

	 	11.1.	Governing
    Law. This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall
    be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute arising
    under or in relation to this Agreement shall be resolved exclusively in the competent court in New York New York, and each
    of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	11.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Note may be assigned or transferred without the prior consent
    in writing of each party to this Note.

 

    	-5- 

    	 		 

    

 

	 	11.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Holder upon any breach or default by the other under this Note shall impair any such right or remedy, nor shall it be construed
    to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter occurring.
	 	 	 
	 	11.4.	Entire
    Agreement. This Note, when read together with the CNA, contains the entire understanding of the parties with respect
    to its subject matter and all prior negotiations, discussions, commitments, and understandings heretofore had between them
    with respect hereto are merged therein. In the case of any discrepancy between the provisions of this Note and the provisions
    of any other agreement previously entered into by the Company or the Holder, the provisions of this Note and the CNA shall
    prevail.
	 	 	 
	 	11.5.	Amendment.
    Any term of this Note – as well as of all other Notes - may be amended (either generally or in a particular instance
    and either retroactively or prospectively) only with the written consent of the Company and the Majority Holders. 
	 	 	 
	 	11.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Note.
	 	 	 
	 	11.7.	Notices.
    All notices and other communications made pursuant to this Note shall be in writing and shall be conclusively deemed to have
    been duly given if delivered in accordance with the notice provisions of the CNA. 
	 	 	 
	 	11.8.	Severability.
    If any provision of this Note is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Note and the remainder of this Note shall be interpreted as if such provision were
    so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Note shall be
    interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
    intention of the excluded provision as determined by such court of competent jurisdiction.

 

	 	Motus
    GI Medical Technologies Ltd.
	 	 
	 	By:	           
	 	Name:	 
	 	Title:	 

 

    	-6- 

    	 		 

    

 

Exhibit
D

 

Fourth
Notes

 

Exhibit
E

 

Board
Resolutions

 

Exhibit
F

 

Shareholders
Resolutions

 

Exhibit
G

 

First
Notes

 

Exhibit
H

 

Second
Notes

 

Schedule
3.4

 

Cap
Table

 

Schedule
3.7

 

Material
Liabilities

 

	●	The
    Company granted a guarantee pursuant to the lease agreement for its offices in Israel.
	 	 
	●	The
    Company’s incorporation was under the framework of the Office of the Chief Scientist at the Ministry of Industry Trade
    and Labor (the “OCS”) 8.3 Program for Technological Entrepreneurship Incubator Centers (the “8.3
    Program”). As part of the Company’s incorporation and funding under the framework of the OCS 8.3 Program,
    N.G.T. New Generation Technologies Ltd. (“NGT”) was required to pledge an amount of 45,000 Ordinary Shares
    of the Company (the “Pledged Shares”) to the State of Israel, in order to secure the repayment of the funds
    which were transferred to NGT by the OCS, and which were invested in the Company as an incubator company under the 8.3 Program.
    The terms and conditions of the pledge are in accordance with the debenture signed by and between the NGT and the State of
    Israel, dated August 16, 2009, and any applicable law. 
	 	 
	●	The
    Company is subject to the provisions, limitations and restrictions which apply to companies that receive funding from the
    OCS, including such restrictions and obligations set forth in The Encouragement of Research and Development in Industry Law
    5744-1984 (the “R&D Law”)
    and the regulations, rules and procedures promulgated thereunder, including without limitation, the limitations relating to
    the transfer or other disposition of know-how and/or production rights to third parties and the payment of fees and penalties
    to the OCS in the event of such disposition.

 

    	 

    	 

    

 

SECOND
AMENDMENT TO CONVERTIBLE NOTES AGREEMENT

 

This
Second Amendment to Convertible Notes Agreement (this “Amendment”) is made as of February __, 2016 (the “Effective
Date”), by and among Motus GI Medical Technologies Ltd., a company organized under the laws of the State of Israel,
with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”) and the Purchasers Schedule I
attached hereto (each, a “Purchaser” and together, the “Purchasers” and each Purchaser and
the Company separately, a “Party” and together, the “Parties”).

 

	WHEREAS,
    	the
    Company and the Purchasers are parties to a Convertible Notes Agreement dated June 9, 2015 (the “Original CNA”),
    as amended on December 29, 2015 (the “First Amendment” and together with the Original CNA, the “CNA”),
    attached hereto as Exhibit A (capitalized not defined herein shall have the meaning ascribed to them in the
    CNA, unless it is specifically provided otherwise); and 
	

                                                                             
	 
	WHEREAS,	the
    Company and the Purchasers wish to amend certain terms of the CNA, all under the terms and conditions set forth herein.

 

NOW
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

	1.	Notwithstanding
    the provisions of the CNA, the Parties hereby acknowledge and agree that:

 

	 	1.1.	Ascent
    Biomedical Ventures Synecor, L.P. shall assign and transfer all of its rights and obligations in connection with the Third
    Installment and the Fourth Installment pursuant to the CNA to Ascent Biomedical Ventures II, L.P. (3). Accordingly, Exhibit
    A of the CNA shall be replaced in its entirety with the attached Exhibit B. 
	 	 	 
	 	1.2.	The
    Third Installment of Ascent Biomedical Ventures Synecor, L.P. (assigned and transferred as aforementioned) shall be transferred
    by Ascent Biomedical Ventures II, L.P. (3) to the Company on _______, 2016. 

 

	2.	All
    terms and conditions of the CNA (including any of its exhibits) shall remain in full force and effect subject to the provisions
    of this Amendment, which shall be regarded as an integral part of the CNA. In case of a contradiction between this Amendment
    and the CNA, the provisions of this Amendment shall prevail.
	 	 
	3.	This
    Amendment may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together
    shall constitute a single instrument.

 

    	 	- 1 -	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

THE
COMPANY:

 

	Motus
    GI Medical Technologies Ltd.	 
	 	 	 
	By:	 	 
	 	 	 
	Title:
    	 	 

 

THE
PURCHASERS:

 

	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
                                         MOTUS Co-Investment Partners, LLC 

        

	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:
    	 	 	Title:	 

 

	Ascent
                                         Biomedical Ventures II, L.P.(3)

        
	 	Ascent
    Biomedical Ventures Synecor, L.P.
	 	 	 	 	 
	By:
    		 	By:	 
	Title:
    	 	 	Title:	 

 

	Jacobs
                                         Investments Company LLC
	 
	 	 	 
	By:
    	 	 
	Title:	 	 

 

[Signature
Page 1 to Second Amendment to Convertible Notes Agreement]

 

    	 	- 2 -	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Joinder as of the date first above written.

 

THE
PURCHASERS:

 

	E.
                                         Jeffrey Peierls
	 	Brian
    Eliot Peierls
	 	 	 
	UD
                                         E.F. Peierls for Brian E. Peierls
	 	UD
                                         E.F. Peierls for E. Jeffrey Peierls 

	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	UD
                                         J.N. Peierls for Brian Eliot Peierls

        
	 	UD
    J.N. Peierls for E. Jeffrey Peierls
	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:
    	 	 	Title:	 
	 	 	 	 	 
	UW
                                         J.N. Peierls for Brian E. Peierls

        
	 	UD
    Ethel F. Peierls Charitable Lead Trust
	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	The
                                         Peierls Bypass Trust

        
	 	UD
                                         E.S. Peierls for E.F. Peierls et al

        

	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:
    	 	 	Title:	 
	 	 	 	 	 
	UW
                                         E.S. Peierls for Brian E. Peierls - Accumulation 
	 	UW
                                         E.S. Peierls for E. Jeffrey Peierls - Accumulation

        

	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:
    	 	 	Title:	 
	 	 	 	 	 
	UW
                                         J.N. Peierls for E. Jeffrey Peierls
	 	The
                                         Peierls Foundation, Inc.

	 	 	 	 	 
	By:
    	 	 	By:	 
	Title:
    	 	 	Title:	 

 

[Signature
Page 2 to Second Amendment to Convertible Notes Agreement]

 

    	 	- 3 -	 

    	 

    

 

Schedule
I

 

The
Purchasers

 

	Orchestra
    Medical Ventures II, L.P. 
	Orchestra
    MOTUS Co-Investment Partners, LLC 
	Ascent
    Biomedical Ventures II, L.P.(3)
	Ascent
    Biomedical Ventures Synecor, L.P.
	Jacobs
    Investments Company LLC
	E.
    Jeffrey Peierls
	Brian
    Eliot Peierls
	THROUGH
    ACCOUNT AT NORTHERN TRUST:
	UD
    E.F. Peierls for Brian E. Peierls
	UD
    E.F. Peierls for E. Jeffrey Peierls 
	UD
    J.N. Peierls for Brian Eliot Peierls
	UD
    J.N. Peierls for E. Jeffrey Peierls
	UW
    J.N. Peierls for Brian E. Peierls
	UW
    J.N. Peierls for E. Jeffrey Peierls
	UD
    Ethel F. Peierls Charitable Lead Trust
	The
    Peierls Bypass Trust
	UD
    E.S. Peierls for E.F. Peierls et al
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation 
	UW
    E.S. Peierls for E. Jeffrey Peierls - Accumulation
	The
    Peierls Foundation, Inc.

 

    	 	- 4 -	 

    	 

    

 

Exhibit
A

 

CNA

 

Exhibit
B

 

Amended
Exhibit A

 

    	 	- 5 -	 

    	 

    

 

EXHIBIT
B TO SECOND AMENDMENT TO CNA

 

Amended
Exhibit A

 

Loan
Amount and Notes

 

	Name	 	Loan
    Amount	 	 	First
    Installment	 	 	Second
    Installment	 	 	Third
    Installment	 	 	Fourth
    Installment	 	 	Address
	Orchestra
    Medical Ventures II, L.P.	 	US$	1,239,996	 	 	US$	309,999	 	 	US$	309,999	 	 	US$	309,999	 	 	US$	309,999	 	 	
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	US$	977,511	 	 	US$	325,837	 	 	US$	325,837	 	 	US$	325,837	 	 	US$	0	 	 	
	Ascent
    Biomedical Ventures II, L.P. (3)	 	US$	1,665,108	 	 	US$	416,277	 	 	US$	416,277	 	 	US$	624,103	 	 	US$	624,103	 	 	
	Ascent
    Biomedical Ventures Synecor, L.P.	 	US$	831,304	 	 	US$	207,826	 	 	US$	207,826	 	 	US$	0	 	 	US$	0	 	 	 
	Jacobs
    Investments Company LLC	 	US$	782,032	 	 	US$	195,508	 	 	US$	195,508	 	 	US$	195,508	 	 	US$	195,508	 	 	 
	E.
    Jeffrey Peierls	 	US$	130,000	 	 	 	-	 	 	 	-	 	 	US$	97,500	 	 	US$	32,500	 	 	 
	Brian
    Eliot Peierls	 	US$	80,000	 	 	 	-	 	 	 	-	 	 	US$	60,000	 	 	US$	20,000	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UD
    E.F. Peierls for E. Jeffrey Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 

 

    	 

    	 		 

    

 

	Name	 	Loan
    Amount	 	 	First
    Installment	 	 	Second
    Installment	 	 	Third
    Installment	 	 	Fourth
    Installment	 	 	Address
	UD
    J.N. Peierls for Brian Eliot Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UD
    J.N. Peierls for E. Jeffrey Peierls	 	US$	54,000	 	 	 	-	 	 	 	-	 	 	US$	40,500	 	 	US$	13,500	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	US$	56,000	 	 	 	-	 	 	 	-	 	 	US$	42,000	 	 	US$	14,000	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	US$	56,000	 	 	 	-	 	 	 	-	 	 	US$	42,000	 	 	US$	14,000	 	 	 
	UD
    Ethel F. Peierls Charitable Lead Trust	 	US$	50,000	 	 	 	-	 	 	 	-	 	 	US$	37,500	 	 	US$	12,500	 	 	 
	The
    Peierls Bypass Trust	 	US$	20,000	 	 	 	-	 	 	 	-	 	 	US$	15,000	 	 	US$	5,000	 	 	 
	UD
    E.S. Peierls for E.F. Peierls et al	 	US$	38,000	 	 	 	-	 	 	 	-	 	 	US$	28,500	 	 	US$	9,500	 	 	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	US$	46,000	 	 	 	-	 	 	 	-	 	 	US$	34,500	 	 	US$	11,500	 	 	 
	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	US$	28,000	 	 	 	-	 	 	 	-	 	 	US$	21,000	 	 	US$	7,000	 	 	 
	The
    Peierls Foundation, Inc.	 	US$	530,000	 	 	 	-	 	 	 	-	 	 	US$	397,500	 	 	US$	132,500	 	 	 
	Total	 	US$	6,745,951	 	 	US$	1,455,447	 	 	US$	1,455,447	 	 	US$	2,392,947	 	 	US$	1,442,110	 	 	 

 

    	 

    	 		 

    

 

Warrants

 

	Name	 	First
    Warrants	 	 	Second
    Warrants	 	 	Third
    Warrants	 	 	Fourth
    Warrants	 	 	Total
    Warrants	 
	Orchestra
    Medical Ventures II, L.P.	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	102,300	 	 	 	409,200	 
	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	107,526	 	 	 	107,526	 	 	 	107,526	 	 	 	0	 	 	 	322,578	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	137,371	 	 	 	137,371	 	 	 	205,954	 	 	 	205,954	 	 	 	686,650	 
	Ascent
    Biomedical Ventures Synecor, L.P.	 	 	68,583	 	 	 	68,583	 	 	 	0	 	 	 	0	 	 	 	137,166	 
	Jacobs
    Investments Company LLC	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	64,518	 	 	 	258,072	 
	E.
    Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	32,175	 	 	 	10,725	 	 	 	42,900	 
	Brian
    Eliot Peierls	 	 	-	 	 	 	-	 	 	 	19,800	 	 	 	6,600	 	 	 	26,400	 

 

    	 

    	 		 

    

 

	Name	 	First
    Warrants	 	 	Second
    Warrants	 	 	Third
    Warrants	 	 	Fourth
    Warrants	 	 	Total
    Warrants	 
	Brian
    Eliot Peierls	 	 	-	 	 	 	-	 	 	 	19,800	 	 	 	6,600	 	 	 	26,400	 
	UD
    E.F. Peierls for Brian E. Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    E.F. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UD
    J.N. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,365	 	 	 	4,455	 	 	 	17,820	 
	UW
    J.N. Peierls for Brian E. Peierls	 	 	-	 	 	 	-	 	 	 	13,860	 	 	 	4,620	 	 	 	18,480	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	 	-	 	 	 	-	 	 	 	13,860	 	 	 	4,620	 	 	 	18,480	 
	UD
    Ethel F. Peierls Charitable Lead Trust	 	 	-	 	 	 	-	 	 	 	12,375	 	 	 	4,125	 	 	 	16,500	 
	The
    Peierls Bypass Trust	 	 	-	 	 	 	-	 	 	 	4,950	 	 	 	1,650	 	 	 	6,600	 
	UD
    E.S. Peierls for E.F. Peierls et al	 	 	-	 	 	 	-	 	 	 	9,405	 	 	 	3,135	 	 	 	12,540	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	 	-	 	 	 	-	 	 	 	11,385	 	 	 	3,795	 	 	 	15,180	 
	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	 	-	 	 	 	-	 	 	 	6,930	 	 	 	2,310	 	 	 	9,240	 
	The
    Peierls Foundation, Inc.	 	 	-	 	 	 	-	 	 	 	131,175	 	 	 	43,725	 	 	 	174,900	 
	Total	 	 	480,298	 	 	 	480,298	 	 	 	789,673	 	 	 	475,897	 	 	 	2,226,166	 

 

    	 

    	 		 

    

 

THIRD
AMENDMENT AND JOINDER TO CONVERTIBLE NOTES AGREEMENT

 

This
Third Amendment and Joinder to Convertible Notes Agreement (this “Joinder”) is made and entered into as of
the __ day of July, 2016 (the “Effective Date”), by and among Motus GI Medical Technologies Ltd., a company
organized under the laws of the State of Israel, with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”)
and the persons and entities listed on Exhibit A attached hereto (the “Purchasers”) (each Purchaser
and the Company separately, a “Party”, and together, the “Parties”).

 

	WHEREAS,
    	the
    Company and the Purchasers are parties to that certain Convertible Notes Agreement dated June 9, 2015, as amended on December
    29, 2015 and on February 15, 2016 (collectively, the “CNA”), attached hereto as Exhibit B (capitalized
    not defined herein shall have the meaning ascribed to them in the CNA, unless it is specifically provided otherwise); and
	 	 
	WHEREAS,
    	as
    of the date hereof, the First Installment, the Second Installment, the Third Installment and the Fourth Installment of the
    Loan Amount, in the aggregate principal amount of US$6,745,951, have been extended in full to the Company; and
	 	 
	WHEREAS,
    	the
    Company requires additional funds to continue to operate its business; and
	 	 
	WHEREAS,
    	the
    Board of Directors of the Company (the “Board”) has decided to raise additional funds by means of convertible
    loans in accordance with the terms and conditions of the CNA, as amended by this Joinder; and
	 	 
	WHEREAS,
    	the
    Parties wish to further amend certain terms of the CNA, including the increase of the aggregate Loan Amount to an aggregate
    principal amount of up to US$11 Million and the extension of additional Loan Amount by the Purchasers listed in Exhibit
    C attached hereto (each, a “Major Purchaser” and together, the “Major Purchasers”)
    and potentially additional purchasers approved by the Board, all under the terms and conditions set forth herein.

 

NOW
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

	1.	Extension
    of Additional Loan Amounts by the Major Purchasers
	 	 
	 	Subject
    to the terms and conditions of this Joinder, each of the Major Purchasers will extend to the Company the additional Loan Amount
    set forth opposite such Major Purchaser’s name in Exhibit C attached hereto (such additional Loan Amounts extended
    by the Major Purchasers shall be deemed to be part of the “Loan Amount”), to be transferred to the Company in
    three installments, as follows: 

 

    	 	 	 

     

    

 

	 	1.1.	At
    the Fifth Closing and subject thereto, each Major Purchaser shall transfer to the Company the amount set forth next to such
    Major Purchaser’s name in the column titled “Fifth Installment” in the table set forth in Exhibit C
    (the “Fifth Installment”) and the Company will issue, sell, transfer, assign and deliver to each
    of the Major Purchasers a convertible note in the form attached hereto as Exhibit D1 (the “Fifth Notes”).
    In addition, at the Fifth Closing and subject thereto, the Company will issue to each Major Purchaser a warrant to purchase
    such number of Preferred A Shares as set forth next to such Major Purchaser’s name in the column titled “Fifth
    Warrant” in the table set forth in Exhibit C, all subject to the terms and the conditions of the warrant certificate
    attached hereto as Exhibit D2 (the “Fifth Warrants”).
	 	 	 
	 	1.2.	At
    the Sixth Closing (as defined below) and subject thereto, each Major Purchaser shall transfer to the Company the amount set
    forth next to such Major Purchaser's name in the column titled "Sixth Installment" in the table set forth in Exhibit
    C (the "Sixth Installment") and the Company will issue, sell, transfer, assign and deliver to each of
    the Major Purchasers a convertible note in the form attached hereto as Exhibit E1 (the "Sixth Notes").
    In addition, at the Sixth Closing and subject thereto, the Company will issue to each Major Purchaser a warrant to purchase
    such number of Preferred A Shares as set forth next to such Major Purchaser's name in the column titled "Sixth Warrant"
    in the table set forth in Exhibit C, all subject to the terms and the conditions of the warrant certificate attached
    hereto as Exhibit E2 (the "Sixth Warrants").
	 	 	 
	 	1.3.	At
    the Seventh Closing (as defined below) and subject thereto, each Major Purchaser shall transfer to the Company the amount
    set forth next to such Major Purchaser's name in the column titled "Seventh Installment" in the table set forth
    in Exhibit C (the "Seventh Installment") and the Company will issue, sell, transfer, assign and deliver
    to each of the Major Purchasers a convertible note in the form attached hereto as Exhibit F1 (the "Seventh
    Notes"). In addition, at the Seventh Closing and subject thereto, the Company will issue to each Major Purchaser
    a warrant to purchase such number of Preferred A Shares as set forth next to such Major Purchaser's name in the column titled
    "Seventh Warrant" in the table set forth in Exhibit C, all subject to the terms and the conditions of the
    warrant certificate attached hereto as Exhibit F2 (the "Seventh Warrants").

 

    	 	- 2 - 	 

     

    

 

As
of the date hereof: (i) the First Notes, the Second Notes, the Third Notes, the Fourth Notes, the Fifth Notes, the Sixth Notes
and the Seventh Notes shall be collectively referred to as the "Notes"; (ii) The First Warrants, the Second Warrants,
the Third Warrants, the Fourth Warrants, the Fifth Warrants, the Sixth Warrants and the Seventh Warrants shall be collectively
referred to as the "Warrants".

 

	2.	Closings

 

	 	2.1.	Time
    and Place of the Fifth Closing. The sale of the Fifth Notes and the issuance of the Fifth Warrants shall take place
    at a fifth closing (the "Fifth Closing") at the offices of Company’s counsel, Fischer Behar Chen Well
    Orion & Co., at Ha-Migdal, 3 Dani'el Frisch St., Tel Aviv, Israel, on July 25, 2016, or at such later time and place as
    the Company and the Major Purchasers shall mutually agree in writing (the "Fifth Closing Date"). 
	 	 	 
	 	2.2.	Deliveries
    and Transactions at the Fifth Closing. At the Fifth Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.2.1.	Board
                                         Resolutions. Copies of duly executed resolutions of the Board, in the form attached
                                         hereto as Exhibit ‎2.2.1 shall be delivered to the Major Purchasers,
                                         approving, inter alia, the execution, delivery and performance by the Company
                                         of this Joinder.

	 	 	 	 
	 	 	2.2.2.	Shareholders
                                         Resolutions. Copies of duly executed resolutions of the Company’s shareholders,
                                         in the form attached hereto as Exhibit ‎2.2.2(a), shall be delivered
                                         to the Major Purchasers, approving, inter alia: (i) the execution, delivery and performance
                                         by the Company of this Joinder; and (ii) the replacement of the Company's current Articles
                                         of Association with the Fourth Amended and Restated Articles of Association, substantially
                                         in the form attached hereto as Exhibit ‎2.2.2(b) (the "Amended
                                         Articles").

 

    	 	- 3 - 	 

     

    

 

	 	 	2.2.3.	Delivery
    of Fifth Notes. The Company shall deliver to each Major Purchaser a validly executed Note, in the form of Exhibit D1,
    reflecting the Fifth Notes purchased by each Major Purchaser hereunder.
	 	 	 	 
	 	 	2.2.4.	Delivery
    of Fifth Warrants. The Company shall deliver to each Major Purchaser a validly executed Warrant, in the form of Exhibit
    D2, reflecting the Fifth Warrants of each Major Purchaser.
	 	 	 	 
	 	 	2.2.5.	Amendment
    and Replacement of Notes. The First Notes, the Second Notes, the Third Notes and the Fourth Notes shall be replaced in
    their entirety with amended notes in the form attached hereto as Exhibit G.
	 	 	 	 
	 	 	2.2.6.	Payment.
    The Purchasers shall pay to the Company the Fifth Installment, in accordance with Section 1.2 of the CNA.

 

	 	2.3.	Time
    and Place of the Sixth Closing. The sale of the Sixth Notes and the issuance of the Sixth Warrants shall take place
    at a sixth closing (the "Sixth Closing") at the offices of Company’s counsel, Fischer Behar Chen Well
    Orion & Co., at Ha-Migdal, 3 Dani'el Frisch St., Tel Aviv, Israel, on September 15, 2016, or at such other time and place
    as the Company and the Major Purchasers shall mutually agree in writing (the "Sixth Closing Date"). 
	 	 	 
	 	2.4.	Deliveries
    and Transactions at the Sixth Closing. At the Sixth Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.4.1.	Delivery
    of Sixth Notes. The Company shall deliver to each Major Purchaser a validly executed Note, in the forms of Exhibit
    E1, reflecting the Sixth Notes purchased by each Major Purchaser hereunder.
	 	 	 	 
	 	 	2.4.2.	Delivery
    of Sixth Warrants. The Company shall deliver to each Major Purchaser a validly executed Warrant, in the form of Exhibit
    E2, reflecting the Sixth Warrants of each Major Purchaser.
	 	 	 	 
	 	 	2.4.3.	Payment.
    The Purchasers shall pay to the Company the Sixth Installment, in accordance with Section 1.2 of the CNA.

 

    	 	- 4 - 	 

     

    

 

	 	2.5.	Time
    and Place of the Seventh Closing. The sale of the Seventh Notes and the issuance of the Third Warrants shall take
    place at a seventh closing (the "Seventh Closing") at the offices of Company’s counsel, Fischer Behar
    Chen Well Orion & Co., at Ha-Migdal, 3 Dani'el Frisch St., Tel Aviv, on November 11, 2016, or at such other time and place
    as the Company and the Major Purchasers shall mutually agree in writing (the "Seventh Closing Date").
	 	 	 
	 	2.6.	Deliveries
    and Transactions at the Seventh Closing. At the Seventh Closing, the following transactions shall occur simultaneously
    (no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed
    and all required documents delivered):

 

	 	 	2.6.1.	Delivery
    of Seventh Notes. The Company shall deliver to each Major Purchaser a validly executed Note, in the forms of Exhibit
    F1, reflecting the Seventh Notes purchased by each Major Purchaser hereunder.
	 	 	 	 
	 	 	2.6.2.	Delivery
    of Seventh Warrants. The Company shall deliver to each Major Purchaser a validly executed Warrant, in the form of Exhibit
    F2, reflecting the Seventh Warrants of each Major Purchaser.
	 	 	 	 
	 	 	2.6.3.	Payment.
    The Purchasers shall pay to the Company the Seventh Installment, in accordance with Section 1.2 of the CNA.

 

	3.	Deferred
    Closing(s) 

 

Subject
to the terms and conditions hereof, the Company may consummate an additional closing or series of closings (each, a "Deferred
Closing") with an additional purchaser or purchasers approved by the Board (each, an "Additional Purchaser"
and collectively, the "Additional Purchasers") on the same terms and conditions set forth in the CNA and this
Joinder and the provisions of Section 2.6 of this Joinder shall apply to such Deferred Closing, mutatis mutandis; provided
that (i) any such Deferred Closing shall occur no later than one hundred and twenty (120) days from the Fifth Closing; and (ii)
the aggregate amount to be extended by the Additional Purchasers (the "Additional Loan Amount"), together with
the aggregate Loan Amount (including, for greater certainty, the additional Loan Amounts to be extended by the Major Purchasers
pursuant to the Joinder), shall not exceed US$11 Million. Simultaneously with the consummation of a Deferred Closing, the Additional
Purchasers shall execute and deliver to the Company a joinder agreement, pursuant to which each such Additional Purchaser shall
become a party to the CNA and this Joinder and for all purposes under the CNA and this Joinder, the Additional Purchaser shall
be deemed to be a "Purchaser" and the Additional Loan Amount shall be deemed to be part of the "Loan Amount".

 

    	 	- 5 - 	 

     

    

 

	4.	Conditions
    to Closing by the Major Purchasers. The Major Purchasers obligation to consummate the transactions contemplated hereby
    at each Closing is subject to the satisfaction and fulfillment, prior to or at the applicable Closing, of each of the following
    conditions precedent (any or all of which may be waived, in whole or in part, by each of the Major Purchasers, which waiver
    shall be at the sole discretion of each Major Purchaser with respect to itself):

 

	 	4.1.	Accurate
    Representations and Warranties. The representations and warranties of the Company in Section 3 of the CNA, as qualified
    by the Disclosure Schedule and as amended in Section ‎7 of the Joinder, shall be true and correct when made and shall
    be true and correct in all material respects as of the Fifth Closing Date.
	 	 	 
	 	4.2.	Compliance
    with Covenants. The Company shall have performed and complied with all of its covenants, agreements and undertakings set
    forth herein.
	 	 	 
	 	4.3.	Actions
    Taken; Delivery of Documents. All the actions to be taken by the Company’s shareholders or by the Company as set
    forth in Section ‎2.2, ‎2.4 or ‎2.6 above, as applicable, above shall have been completed to the satisfaction
    of the Major Purchasers. 
	 	 	 
	 	4.4.	Proceedings
    and Documents. All corporate and other proceedings in connection with the transactions contemplated by the Joinder shall
    be satisfactory in substance and form to the Major Purchasers, and the Major Purchasers shall have received all such counterpart
    copies of such documents as the Major Purchasers may reasonably request.

 

	5.	Conditions
    to Closing by the Company. The Company’s obligation to consummate the transactions contemplated hereby at each
    Closing is subject to the satisfaction and fulfillment, prior to or at the applicable Closing, of each of the following conditions
    precedent (any or all of which may be waived, in whole or in part, by the Company, which waiver shall be at the sole discretion
    of the Company):

 

	 	5.1.	Accurate
    Representations and Warranties. The representations and warranties of the Major Purchasers in Section 4 of the CNA and
    in Section ‎8 of the Joinder shall be true and correct when made and shall be true and correct in all material respects
    as of the applicable Closing Date.

 

    	 	- 6 - 	 

     

    

 

	 	5.2.	Compliance
    with Covenants. The Major Purchasers shall have performed and complied with all of their covenants, agreements, and undertakings
    as set forth in the CNA and in the Joinder.
	 	 	 
	 	5.3.	Consents.
    The Company shall have secured all permits, consents and authorizations that shall be necessary or required lawfully to
    consummate the transactions contemplated by the Joinder, including without limitation, third party consents and approvals,
    corporate approvals and waivers from shareholders of the Company entitled to preemptive rights, participation rights, anti-dilution
    rights or any other similar rights in connection with the transactions contemplated by the Joinder, including without limitation,
    in connection with the issuance of any securities upon conversion of the Notes and the issuance of any securities upon exercise
    of the Warrants. 

 

	6.	Participation
    in QFR

 

Notwithstanding
anything to the contrary in the Joinder, in the event that at any time prior to the consummation of the Fifth, Sixth and/or Seventh
Closing, the Company consummates a QFR (as defined below), then each of the Major Purchasers shall be obligated to participate
in such QFR and invest its portion of the Loan Amount not yet extended to the Company in accordance with the CNA and the Joinder
(i.e., such Major Purchaser's portion of the Fifth Installment, Sixth Installment and/or Seventh Installment, as applicable) (the
"Major Purchaser's QFR Amount"), on the same terms and conditions of the QFR (including, for greater certainty,
at same price per share). In such event the provisions relating to the consummation of the Fifth Closing, the Sixth Closing and/or
Seventh Closing, as applicable, shall terminate and shall have no further force and effect. It is agreed and acknowledged that
the participation and investment of the Major Purchaser's QFR Amount in the QFR as described above, shall be deemed as exercise
of such Major Purchaser preemption rights (whether such rights exist under the Company's Articles of Association, as amended from
time to time, under applicable law or under any other agreement or document, if any), such that the Major Purchaser's QFR Amount
shall be deducted from such Major Purchaser pro-rata share (including overallotment pro-rata share) of the investment amount in
the QFR.

 

The
term "QFR" means the first financing round consummated by the Company after the date hereof, through an equity
investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance of shares
upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate investment
amount of not less than US$3,000,000 (Three Million US Dollars), excluding the outstanding principal amount of the Notes and all
accrued and unpaid interest thereon.

 

    	 	- 7 - 	 

     

    

 

	7.	Representations
    and Warranties of the Company 

 

	 	7.1.	The
    Company hereby represents and warrants to the Major Purchasers that all representations and warranties set forth in Section
    3 of the CNA, as qualified by the Disclosure Schedule and as amended in the Joinder, shall be true and correct in all material
    respects as of the Fifth Closing Date; provided that any reference in Section 3 of the CNA to the CNA shall also include the
    Joinder. 
	 	 	 
	 	7.2.	As
    of the date hereof, Section 3.4 of the CNA shall be deleted in its entirety and replaced with the following:

 

	 	 	“3.4
    	Capitalization.
    The authorized share capital of the Company immediately prior to the Fifth Closing shall consist of NIS 780,000 divided into
    (i) 45,000,000 Ordinary Shares, par value NIS 0.01 each, of which 4,271,094 are issued and outstanding, and (ii) 33,000,000
    Series A Preferred Shares, par value NIS 0.01 each, of which 13,500,000 are issued and outstanding. An accurate capitalization
    table listing all of the Company’s shares, options, and warrants (or other rights or securities convertible into or
    exchangeable for shares in the Company (collectively, the "Equity Securities") and their respective record
    holders and, to the knowledge of the Company, beneficial owners on a fully diluted basis is set forth in Exhibit 3.4
    attached hereto (the "Cap Table")."

 

	8.	Representations
    and Warranties of the Major Purchasers

 

Each
of the Major Purchasers hereby represents and warrants to the Company and acknowledges that the Company is entering into the Joinder
in reliance thereon, that all the representations and warranties set forth in Section 4 of the CNA are true and correct in respect
of such Major Purchaser as of the date hereof and shall be true and correct in all material respects as of the Fifth Closing,
Sixth Closing and Seventh Closing, provided that any reference in Section 4 of the CNA to the CNA shall also include the Joinder.

 

    	 	- 8 - 	 

     

    

 

	9.	Miscellaneous

 

	 	9.1.	The
    headings in this Joinder are for convenience only and shall not be used for purposes of construction.
	 	 	 
	 	9.2.	All
    terms and conditions of the CNA (including any of its exhibits) shall remain in full force and effect subject to the provisions
    of this Joinder, which shall be regarded as an integral part of the CNA. In case of a contradiction between this Joinder and
    the CNA, the provisions of this Joinder shall prevail.
	 	 	 
	 	9.3.	This
    Joinder may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together
    shall constitute a single instrument.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Third Amendment and Joinder to Convertible Notes Agreement on the date
first above written.

 

 

	Motus
    GI Medical Technologies Ltd.	 
	 	             	 
	By:	 	 
	Title:	 	 

 

[Purchasers’
Signature Pages to Follow]

 

    	 	- 9 - 	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Third Amended to Convertible Notes Agreement on the date first above
written.

 

 

	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
    MOTUS Co-Investment Partners, LLC 
	 	 	 	 	 
	By:	 
               	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	              
	 	 	 	 	 
	Ascent
    Biomedical Ventures II, L.P.(3) 	 	Ascent
    Biomedical Ventures Synecor, L.P. 
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	Jacobs
    Investments Company LLC	 	 	 
	 	 	 	 	 
	By:	 	 	 	 
	Title:	 	 	 	 

 

    	 	- 10 - 	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Third Amended to Convertible Notes Agreement on the date first above
written.

 

	E.
    Jeffrey Peierls	 	Brian
    Eliot Peierls
	 	 	 	 	 
	 	 	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	UD
    E.F. Peierls for E. Jeffrey Peierls
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	         	 	Title:	           
	 	 	 	 	 
	 	 	 	 	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	UD
    J.N. Peierls for E. Jeffrey Peierls
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	UD
    Ethel F. Peierls Charitable Lead Trust
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	The
    Peierls Bypass Trust	 	UD
    E.S. Peierls for E.F. Peierls et al
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	UW
    E.S. Peierls for E. Jeffrey Peierls - Accumulation
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	The
    Peierls Foundation, Inc.
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 

 

    	 	- 11 - 	 

     

    

 

Exhibit
A

 

Orchestra
Medical Ventures II, L.P.

 

Orchestra
MOTUS Co-Investment Partners, LLC

 

Ascent
Biomedical Ventures II, L.P.(3)

 

Ascent
Biomedical Ventures Synecor, L.P.

 

Jacobs
Investments Company LLC

 

E.
Jeffrey Peierls

 

Brian
Eliot Peierls

 

UD
E.F. Peierls for Brian E. Peierls

 

UD
E.F. Peierls for E. Jeffrey Peierls

 

UD
J.N. Peierls for Brian Eliot Peierls

 

UD
J.N. Peierls for E. Jeffrey Peierls

 

UW
J.N. Peierls for Brian E. Peierls

 

UD
Ethel F. Peierls Charitable Lead Trust

 

The
Peierls Bypass Trust

 

UD
E.S. Peierls for E.F. Peierls et al

 

UW
E.S. Peierls for Brian E. Peierls - Accumulation

 

UW
E.S. Peierls for E. Jeffrey Peierls - Accumulation

 

UW
J.N. Peierls for E. Jeffrey Peierls

 

The
Peierls Foundation, Inc.

 

    	 	- 12 - 	 

     

    

 

Exhibit
C

 

Additional
Loan Amount and Notes

 

	Name	 	 	 	Additional
    Loan Amount	 	 	 	Fifth
    Installment	 	 	 	Sixth
    Installment	 	 	 	Seventh
    Installment	 	Address	 
	Orchestra
    Medical Ventures II, L.P.	 	 	US$	898,000	 	 	US$	315,000	 	 	US$	315,000	 	 	US$	268,000	 	 		 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	US$	840,000	 	 	US$	294,000	 	 	US$	294,000	 	 	US$	252,000	 	 	 	 
	Jacobs
    Investments Company LLC	 	 	US$	262,000	 	 	US$	91,000	 	 	US$	91,000	 	 	US$	80,000	 	 	 	 
	Total	 	 	US$	2,000,000	 	 	US$	700,000	 	 	US$	700,000	 	 	US$	600,000	 	 	 	 

 

    	 	- 13 - 	 

     

    

 

Additional
Warrants

 

	Name	 	Fifth
    Warrants	 	 	Sixth
    Warrants	 	 	Seventh
    Warrants	 	 	Total
    Additional Warrants	 
	Orchestra
    Medical Ventures II, L.P.	 	 	103,950	 	 	 	103,950	 	 	 	88,440	 	 	 	296,340	 
	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	97,020	 	 	 	97,020	 	 	 	83,160	 	 	 	277,200	 
	Jacobs
    Investments Company LLC	 	 	30,030	 	 	 	30,030	 	 	 	26,400	 	 	 	86,460	 
	Total	 	 	231,000	 	 	 	231,000	 	 	 	198,000	 	 	 	660,000	 

 

    	 	- 14 - 	 

     

    

 

EXHIBIT
D1

 

_______________

Purchaser:
______________________

 

Principal
Amount: US$____________

 

CONVERTIBLE

 

PROMISSORY
NOTE

 

For
value received, Motus GI Medical Technologies Ltd., an Israeli company (“Company”) promises to pay to
the Purchaser named above (“Holder”), the principal sum stated above (the “Principal Amount”)
in accordance with the terms set forth herein, as follows:

 

	1.	Note
    Part of a Series. This Note is being sold by the Company as part of a series of notes issued pursuant to that certain
    Convertible Notes Agreement dated as of June 9, 2015, by and among the Company and purchasers of such Notes, as amended (the
    “CNA”). The term “Notes” shall mean herein all Notes issued under the CNA.
	 	 
	2.	Interest.
    Interest shall accrue on the unpaid Principal Amount of this Note from the date of this Note until the actual repayment of
    all amounts due hereunder, at an annual rate of 10% (ten percent), compounded annually. Interest shall be computed on the
    basis of a year of 360 days for the actual number of days occurring in the period for which such interest is payable. Upon
    conversion of the Principal Amount in accordance with the terms hereof, all interest accrued thereon shall be converted together
    with the Principal Amount or repaid to the Holder in cash, after deduction of all applicable taxes with respect thereto, as
    shall be determined by the Company, at its sole discretion. The actual amount to be converted in accordance with the Company’s
    election, as specified in the preceding sentence, shall be hereinafter referred to as the “Conversion Amount.”
	 	 
	3.	Automatic
    Conversion upon QFR. To the extent not previously converted or repaid according to the terms specified herein, the
    Conversion Amount shall be automatically converted, immediately prior and subject to the closing of a QFR (as defined below),
    on the same terms and conditions applicable to the QFR, such that the Holder shall receive the same type of securities issued,
    and any other rights granted to the investors in such QFR (the “QFR Securities”), under the same terms
    as if the Holder had participated in the QFR as an investor (including any warrants or any other securities granted to the
    investors therein), but at a conversion price per share equal to the QFR Conversion Price (as defined below).

 

    	 	 	 

     

    

 

		It
                                         being agreed and acknowledged that (a) the original issue price (or any equivalent term
                                         used under the then applicable Articles of Association of the Company) of QFR Securities
                                         issued to the Holder shall be set to be the QFR Conversion Price, and any rights that
                                         are attached to the QFR Securities issued to the Holder which are determined, derived,
                                         calculated, triggered, or otherwise based on the original price of such shares (including,
                                         without limitation, liquidation and dividend preferences, anti-dilution rights or the
                                         like) shall be determined, calculated, triggered or otherwise based on the actual QFR
                                         Conversion Price; and (b) in the event that the QFR Securities also comprise of warrants
                                         to purchase, or other securities convertible into, shares of the Company (any such preceding
                                         convertible security a “Convertible Security”), then (i) upon such
                                         conversion, the Holder shall be entitled to receive such number of warrants and/or Convertible
                                         Securities of the same class or type that are issued to the investors in the framework
                                         of the QFR, in a number which shall be determined using the same warrant and/or Convertible
                                         Securities coverage ratio offered to the investors in such QFR, such that the ratio between
                                         the shares and the warrants and/or Convertible Securities issued to the Holder shall
                                         be equal to the ratio between the shares and the warrants and/or Convertible Securities
                                         issued to each investor in such QFR; and (ii) the discount rate reflected in the QFR
                                         Conversion Price shall not apply in respect of the exercise price or conversion price
                                         (as applicable) of such warrants and/or Convertible Securities.
	 	 
	 	For
                                         example, if the terms of the QFR are as follows:

 

	 	●	The
    QFR unit price is US$10.
	 	 	 
	 	●	Each
    unit is comprised of two (2) Ordinary Shares and one (1) warrant to purchase one (1) Ordinary Share.
	 	 	 
	 	●	The
    discount rate reflected in the QFR Conversion Price of the Holder is 10%. 
	 	 	 
	 	●	The
    exercise price of the warrants issued in the QFR is US$12.
	 	 	 
	 	●	The
    Conversion Amount of the Holder is US$1,800.

 

	 	then,
    in the framework of such QFR, the Holder shall be issued, upon conversion of the Conversion Amount, 200 Ordinary Shares ((US$1,800))/((1-10%)*US$10))
    and 100 warrants to purchase 100 Ordinary Shares (100/2), at an exercise price per share of US$12, while an investor, who
    is not a holder of Notes, and invests in the QFR the same amount (i.e., US$1,800), shall be issued only 180 Ordinary Shares
    and 90 warrants to purchase 90 Ordinary Shares, at an exercise price per share of US$12. 
	 	 
	 	The
    term “QFR” means the first financing round consummated by the Company after the date of the Note, through
    an equity investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance
    of shares upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate
    investment amount of not less than US$3,000,000 (Three US Dollars), excluding the outstanding principal amount of the Notes
    and all accrued and unpaid interest thereon.
	 	 
	 	The
    term “QFR Conversion Price” means a conversion price reflecting the lower of (i) a 10% discount on the
    price paid by the investor(s) for the shares issued in the QFR; or (ii) US$1.15 per share. Notwithstanding the foregoing,
    in the event that the QFR in an initial public offering with gross proceeds to the Company of not less than US$25,000,000
    (Twenty Five Million US Dollars) (including the outstanding principal amount of the Notes and all accrued and unpaid interest
    thereon) (the “QIPO”), the QFR Conversion Price shall mean a conversion price reflecting a 50% discount
    on the price paid for the shares issued in the QIPO and if the price in such QIPO is fixed per each unit offered in the QIPO,
    the discount shall be applicable to such unit price.
	 	 
	 	If
    this Note is converted in accordance with this Section ‎3, written notice shall be delivered to the Holder of this Note,
    notifying the Holder of the conversion, specifying the Conversion Amount, the date of such conversion, and the securities
    issued upon conversion. For the avoidance of doubt, in such event this Note shall be null and void even if not surrendered
    to the Company.

 

    	-2- 

    	 		 

    

 

	4.	Automatic
    Conversion upon M&A Event. In the event that, prior to the conversion of the Conversion Amount or its repayment
    according to the terms specified herein, an M&A Event (as defined below) shall occur, then immediately prior and subject
    to the closing of such M&A Event, the Conversion Amount shall be automatically converted into Series A Preferred Shares,
    par value NIS 0.01 per share, of the Company (the “Preferred A Shares”), at a conversion price equal to
    the price per share paid by the Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “M&A
    Conversion Price”). 
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the M&A Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    M&A Conversion Price.
	 	 
	 	The
    term “M&A Event” means (i) a merger or consolidation of the Company in which the Company’s shareholders
    immediately prior to such transaction do not own, directly or indirectly, more than 50% of the share capital of the surviving
    entity; (ii) the acquisition of more than 50% of the Company’s outstanding share capital by a single unaffiliated person,
    entity or group ,or by persons or entities acting in concert; (iii) the sale or transfer of all or substantially all of the
    assets of the Company; or (iv) a reverse triangular merger in which the Company is the surviving entity but the shares of
    the Company’s share capital outstanding immediately prior to the merger are converted by virtue of the merger into other
    property, whether in the form of securities, cash or otherwise.
	 	 
	5.	Voluntary
    Conversion upon NQFR. In the event that, prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company shall consummate a financial round through an equity investment, either in one
    transaction or in series of transactions (including an initial public offering but excluding the issuance of any convertible
    notes or the issuance of shares upon conversion of such notes), which is not a QFR (a “NQFR”), then the
    holders of Notes reflecting 70% (Seventy percent) of the aggregate outstanding principal amount of the Notes (the “Majority
    Holders”), shall be entitled, no later than fourteen (14) days prior to the closing of such NQFR, to notify the
    Company in writing of their choice to convert the entire Conversion Amount of the Notes (the “Aggregate Conversion
    Amount”). In such event the entire Aggregate Conversion Amount shall be converted immediately prior and subject
    to the closing of the NQFR, on the same terms and conditions specified in Section ‎3 above (“Automatic Conversion
    upon a QFR”), mutatis mutandis. The election of the Majority Holders to convert the entire Aggregate Conversion
    Amount shall be binding on all of the holders of the Notes and each such holder shall be deemed to have elected to convert
    its respective portion of the Aggregate Conversion Amount in accordance with the terms and conditions specified herein.

 

    	-3- 

    	 		 

    

 

	6.	Maturity
    Date. If not converted or repaid according to the terms set forth herein until thirty (30) months from the date of
    this Note (i.e., ___________) (the “Maturity Date”), then at the Maturity Date the Conversion Amount shall
    be automatically converted into Preferred A Shares, at a conversion price per share equal to the price per share paid by the
    Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “Maturity Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the applicable Articles of
    Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Maturity Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Maturity Conversion Price.
	 	 
	7.	Event
    of Default. In the event that, prior to the conversion of the Conversion Amount or its repayment according to the
    terms hereunder an Event of Default occurs, then the Conversion Amount shall be, at the election of the Holder, at its sole
    discretion, either: (i) become immediately due and payable to the Holder in cash; or (ii) converted into Preferred A Shares,
    at a conversion price per share equal to the price per share paid by the Company’s investors in consideration for the
    Preferred A Shares (i.e., US$1) (the “Default Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Default Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Default Conversion Price.
	 	 
		The
    term “Event of Default” means (a) dissolution, termination of existence, suspension or discontinuance of
    business or ceasing to operate as going concern for a period of more than thirty (30) days; (b) the appointment of a receiver,
    trustee, custodian or similar official, for the Company or any material portion of the property or assets of the Company and
    the continuation of such appointment without dismissal for a period of thirty (30) days or more; (c) the conveyance of any
    material portion of the assets of the Company to a trustee, mortgage or liquidating agent or an assignment for the benefit
    of creditors by the Company which is not dismissed within a period of thirty (30) days; (d) the commencement of any proceeding,
    whether federal or state, relating to bankruptcy, insolvency, dissolution, reorganization, composition, renegotiations of
    outstanding indebtedness, arrangement or otherwise to the relief or debtors or the readjustment of indebtedness, by or against
    the Company, which is not stayed, vacated or released within sixty (60) days of commencement; (e) any material breach by the
    Company of any covenant or obligation in the Note, CAN or any documents and agreements ancillary thereto (the “Transaction
    Documents”) which is not cured, if curable, within thirty (30) days following receipt by the Company of a written
    notice of such breach; (f) any material misrepresentation has occurred in the Transaction Documents, which is not cured, if
    curable, within thirty (30) days following receipt by the Company of a written notice of such breach; (g) the Company shall
    fail to make any required payment of interest, principal or otherwise under the Notes, which is not cured within thirty (30)
    days following receipt by the Company of a written notice of such failure. The Company undertakes to notify the Holder immediately
    following occurrence of any of the events detailed in clauses (a) to (g) above.

 

    	-4- 

    	 		 

    

 

	8.	Conversion;
    Fractional Interests. Each conversion shall be deemed to have been effected as to this Note (or the specified portion
    thereof) on the date on which the requirements set forth above in this Note required to be satisfied by the Holder, or the
    circumstances that are required to exist, have been satisfied as to this Note (or portion thereof), and the person whose name
    any certificate or certificates for shares shall be issuable upon such conversion shall be deemed to have become on said date
    the holder of record of the shares represented thereby. No fractional shares or scrip representing fractional shares shall
    be issued upon conversion of this Note and the number of shares issued shall be rounded to the nearest whole number.
	 	 
	9.	Payments;
    Taxes

 

	 	9.1.	Payments.
    All payments of interest and of principal shall be in U.S. Dollar (“US$”) or in the New Israeli Shekels
    (“NIS”) equivalent. If any payment is paid in a NIS equivalent, it shall be paid in accordance with the
    representative rate of exchange of the U.S. Dollar against the NIS last published by the Bank of Israel immediately prior
    to the certain payment date.
	 	 	 
	 	9.2.	Taxes
    on Payments. To the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be
    made by the Company pursuant to this Note. The Company shall be entitled to deduct and withhold any withholding taxes which
    the Company determines it is legally required to deduct or withhold from any payment to be made by the Company pursuant to
    this Note.

 

	10.	Not
    a Shareholder. Prior to the conversion of this Note or any portion thereof according to the provisions specified herein,
    the Holder, in its capacity as an Holder, shall not be entitled to any rights of a shareholder of the Company, including,
    without limitation, the right to vote or to receive dividends or other distributions, with respect to the Note and the shares
    issuable upon conversion of the Note.

 

	11.	Miscellaneous

 

	 	11.1.	Governing
    Law. This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall
    be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute arising
    under or in relation to this Agreement shall be resolved exclusively in the competent court in New York New York, and each
    of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	11.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Note may be assigned or transferred without the prior consent
    in writing of each party to this Note.

 

    	-5- 

    	 		 

    

 

	 	11.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Holder upon any breach or default by the other under this Note shall impair any such right or remedy, nor shall it be construed
    to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter occurring.
	 	 	 
	 	11.4.	Entire
    Agreement. This Note, when read together with the CNA, contains the entire understanding of the parties with respect
    to its subject matter and all prior negotiations, discussions, commitments, and understandings heretofore had between them
    with respect hereto are merged therein. In the case of any discrepancy between the provisions of this Note and the provisions
    of any other agreement previously entered into by the Company or the Holder, the provisions of this Note and the CNA shall
    prevail.
	 	 	 
	 	11.5.	Amendment.
    Any term of this Note – as well as of all other Notes - may be amended (either generally or in a particular instance
    and either retroactively or prospectively) only with the written consent of the Company and the Majority Holders. 
	 	 	 
	 	11.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Note.
	 	 	 
	 	11.7.	Notices.
    All notices and other communications made pursuant to this Note shall be in writing and shall be conclusively deemed to have
    been duly given if delivered in accordance with the notice provisions of the CNA. 
	 	 	 
	 	11.8.	Severability.
    If any provision of this Note is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Note and the remainder of this Note shall be interpreted as if such provision were
    so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Note shall be
    interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
    intention of the excluded provision as determined by such court of competent jurisdiction.

 

	 	Motus
    GI Medical Technologies Ltd.
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	-6- 

    	 		 

    

 

NEITHER
THIS WARRANT CERTIFICATE NOR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER SECURITIES ACT, AND THIS WARRANT CERTIFICATE AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT CERTIFICATE MAY NOT BE SOLD, OFFERED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH APPLICABLE SECURITIES LAWS AND THE RESTRICTIONS, TERMS AND CONDITIONS SET FORTH HEREIN.

 

Motus
GI Medical Technologies Ltd.

 

Preferred
A SHARES warrant Certificate 

 

To
purchase 

_________
Preferred A Shares (subject to adjustment) of

Motus
GI Medical Technologies Ltd. (the “Company”)

at
a per share price and subject to the terms detailed below

VOID
AFTER 17:00 p.m. Israel Standard Time

on
the last day of the Warrant Period (as defined below)

 

THIS
IS TO CERTIFY THAT, _______________ (the “Holder”), is entitled to purchase from the Company, an aggregate
of up to _______ (as may be adjusted hereunder) Preferred A Shares of the Company, nominal value NIS 0.01 per share (the “Warrant
Shares”), at an aggregate purchase price of US$ _________, reflecting an exercise price per share of US$ 1.00 (the “Exercise
Price”), during the Warrant Period.

 

This
Warrant Certificate (this “Warrant”) is issued to the Holder in connection with that certain Convertible Notes
Agreement dated June 9, 2015 by and among the Company and the Purchasers listed on Exhibit A thereto, as amended (the “Convertible
Notes Agreement”).

 

	1.	EXERCISE
    OF WARRANT

 

	 	1.1.	Warrant
    Period. This Warrant may be exercised, subject to the terms and conditions hereof, in whole or in part, at one time or
    from time to time during the period commencing on __________ (the “Initial Date”) until the earlier of:
    (i) seven (7) years thereafter (i.e., __________); and (ii) the closing of an Exit Event (as defined in Section‎ 5 below);
    provided that such Exit Event is consummated within 180 days from the Exit Event Notice (each of (i) or (ii), the “Expiry
    Date”). The period between the Initial Date and the Expiry Date shall be referred to hereinafter as the “Warrant
    Period.”

 

    	 		 

     

    

 

	 	1.2.	Exercise
    for Cash. This Warrant may be exercised by presentation and surrender thereof to the Company at its principal office or
    at such other office or agency as it may designate from time to time, accompanied by:

 

	 	(a)	A
    duly executed notice of exercise, in the form attached hereto as Schedule ‎1.1 (the “Exercise Notice”);
    and
	 	 	 
	 	(b)	Payment
    to the Company, for the account of the Company, of the Exercise Price for the number of Warrant Shares purchased payable in
    immediately available funds by wire transfer to the Company’s bank account. The Exercise Price will be paid in United
    States Dollars or the equivalent sum in NIS according to the Bank of Israel exchange rate as published upon the date immediately
    prior to the exercise date.

 

	 	1.3.	Exercise
    on Net Issuance Basis. In lieu of payment to the Company as set forth in Section ‎1.1 above, the Holder may elect
    to exercise this Warrant into the number of Warrant Shares calculated pursuant to the formula below, by presentation and surrender
    thereof to the Company at its principal office or at such other office or agency it may designate from time to time, accompanied
    by a duly executed notice of exercise, in the form attached hereto as Schedule 1.3 (the “Net Issuance
    Notice”):

 

	 	 	Y*(A
    - B)
	X	=	——————
	 	 	A

 

Where:

 

		X
                                         =	the
                                         number of Warrant Shares to be issued to the Holder;
	 	 	 
		Y
                                         =	the
                                         number of Warrant Shares in respect of which the net issuance election is being made;
	 	 	 
		A
                                         =	the
                                         Fair Market Value (as defined below) of one Warrant Share; and
	 	 	 
		B
                                         =	the
                                         Exercise Price of one Warrant Share.

 

    	2 

    	 		 

    

 

For
purposes of this Section ‎1.3, the “Fair Market Value” of one Warrant Share as of a particular date (the
“Determination Date”) shall be: 

 

	 	(a)	If
    the net issuance right is exercised in connection with and contingent upon an initial public offering of the Company’s
    shares (an “IPO”), then the initial “price to public” (i.e., before deduction of discounts,
    commissions or expenses) specified in the final prospectus or registration statement with respect to such offering.
	 	 	 
	 	(b)	If
    the net issuance right is exercised in connection with and contingent upon an Exit Event that is not an IPO, the price per
    Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) in such Exit Event. 
	 	 	 
	 	(c)	If
    the net issuance right is not exercised in connection with and contingent upon an Exit Event, then as follows:

 

	 	(i)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are traded on a securities exchange, the Fair Market Value shall be deemed to
    be the average of the closing prices of such shares on such exchange over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date;
	 	 	 
	 	(ii)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are quoted for trading on an over-the-counter system, the Fair Market Value shall
    be deemed to be the average of the closing bid prices of such shares over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date; and
	 	 	 
	 	(iii)	If
    there is no public market for the Preferred A Shares (or any securities to which the Preferred A Shares have been converted
    to in accordance with the Company’s organizational documents and applicable law), the Fair Market Value of the shares
    shall be determined in good faith by the Board of Directors of the Company.

 

    	3 

    	 		 

    

 

	 	1.4.	Issuance
    of Warrant Shares. Upon presentation and surrender of this Warrant, accompanied by (a) the duly executed Exercise Notice
    and the payment of the applicable Exercise Price for the Warrant Shares being purchased pursuant to Section ‎1.1 above;
    or (b) the duly executed Net Issuance Notice pursuant to Section ‎1.3 above, as the case may be, the Company shall promptly
    (i) issue to the Holder the Warrant Shares to which the Holder is entitled; and (ii) deliver to the Holder the share certificate
    evidencing such Warrant Shares. 
	 	 	 
	 		Upon
    receipt by the Company of this Warrant and the applicable duly executed notice of exercise (and the Exercise Price for the
    Warrant Shares being purchased, if applicable), together with any other documents and/or approvals that may be required by
    law, the Holder shall be deemed to be the holder of record of the Warrant Shares issuable upon such exercise, notwithstanding
    that the share transfer books of the Company shall then be closed or that certificates representing such shares shall not
    then be actually delivered to the Holder.
	 	 	 
	 	1.5.	Fractional
    Shares. No fractions of shares shall be issued in connection with the exercise of this Warrant, and the number of shares
    issued shall be rounded to the nearest whole number.
	 	 	 
	 	1.6.	Partial
    Exercise. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant for cancellation,
    execute and deliver a new Warrant evidencing the rights of the Holder to purchase the balance of the Warrant Shares purchasable
    hereunder.
	 	 	 
	 	1.7.	Additional
    Documents. The Holder will sign and deliver any and all documents or approvals required by law, to facilitate the issuance
    of the Warrant Shares upon exercise of this Warrant. 
	 	 	 
	 	1.8.	Loss
    or Destruction of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
    or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonable reimbursement of expenses and
    satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute
    and deliver a new Warrant of like tenor and date.

 

    	4 

    	 		 

    

 

	2.	TAXES

 

	 	2.1.	The
    Holder acknowledges that the grant of the Warrant, the issuance of the Warrant Shares and the execution and/or performance
    of this Warrant may have tax consequences to the Holder and that the Company is not able to ensure or represent to the Holder
    the nature and extent of such tax consequences. 
	 	 	 
	 	2.2.	The
    Company shall pay all of the applicable taxes and other charges payable by the Company in connection with the issuance of
    the Warrant Shares and the preparation and delivery of share certificates in the name of the Holder (such as transfer taxes
    in respect of the issuance or delivery of Warrant Shares upon exercise of this Warrant), if any, but shall not pay any taxes
    payable by the Holder by virtue of the holding, issuance, exercise, sale of this Warrant or the Warrant Shares by the Holder.

 

	3.	RESERVATION
    OF SHARES; preservation of rights of holder

 

	 	3.1.	Reservation
    of Shares. The Company hereby agrees that, at all times prior to the expiration or exercise of this Warrant, it will maintain
    and reserve, free from pre-emptive or similar rights, such number of authorized but unissued shares so that this Warrant may
    be exercised without additional authorization of shares.
	 	 	 
	 	3.2.	Preservation
    of Rights. The Company will not, by amendment of its organizational documents or through reorganization, recapitalization,
    consolidation, merger, dissolution, transfer of assets, issue or sale of securities or any other voluntary act, avoid or seek
    to avoid the observance or performance of any of the covenants, stipulations, conditions or terms to be observed or performed
    hereunder, but will at all times in good faith assist in the carrying out of all the provisions hereof and in taking of all
    such actions and making all such adjustments as may be necessary or appropriate in order to fulfill the provisions hereof.

 

    	5 

    	 		 

    

 

	4.	ADJUSTMENT

 

	 	4.1.	The
    number of Warrant Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment
    from time to time or upon exercise, as follows:

 

	 	(a)	Bonus
    Shares. In the event that during the Warrant Period the Company shall distribute a non-cash dividend or shares pursuant
    to a reclassification of its share capital, to all of the holders of shares of the Company (i.e., bonus shares), then this
    Warrant shall represent the right to acquire, in addition to the number of Warrant Shares indicated in the caption of this
    Warrant, the amount of such bonus shares that are distributed to persons holding the class of share capital for which the
    Warrant is exercisable and/or to receive the stock dividends which are distributed to persons holding the class of share capital
    for which the Warrant is exercisable, without payment of any additional consideration therefor, to which the Holder would
    have been entitled had this Warrant been exercised prior to the distribution of the stock dividends or the bonus shares. 
	 	 	 
	 	(b)	Consolidation
    and Division. In the event that during the Warrant Period the Company consolidates its share capital into shares of greater
    par value, or subdivides them into shares of lesser par value, then the number of Warrant Shares to be allotted on exercise
    of this Warrant after such consolidation or subdivision shall be reduced or increased accordingly, as the case may be, and
    in each case the Exercise Price shall be adjusted appropriately such that the aggregate consideration hereunder to the Company
    shall not change.
	 	 	 
	 	(c)	Capital
    Reorganization. In the event that during the Warrant Period a reorganization of the share capital of the Company is effected
    (other than subdivision, combination or reclassification provided for elsewhere in this Section 4) and the Preferred A Shares
    are exchanged for other securities of the Company, then, as part of such reorganization, provision shall be made so that the
    Holder shall be entitled to purchase upon exercise of this Warrant such kind and number of shares or other securities of the
    Company to which the Holder would have been entitled had this Warrant been exercised without taking into effect such reorganization.
    

 

    	6 

    	 		 

    

 

	 	4.2.	Whenever
    an adjustment is effected hereunder, the Company shall promptly compute such adjustment and deliver to the Holder a certificate
    setting forth the number of Warrant Shares (or any other securities) for which this Warrant is exercisable and the Exercise
    Price as a result of such adjustment, a brief statement of the facts requiring such adjustment and the computation thereof
    and when such adjustment has or will become effective.
	 	 	 
	 	4.3.	Except
    as otherwise provided herein, Sections 4.1(a) to 4.1(c) hereof are intended to operate independently of one another. If an
    event occurs that requires the application of more than one subsection, all applicable subsections shall be given independent
    effect, but there shall be no duplicate adjustments if two separate subsections provide the same protection.
	 	 	 
	 	4.4.	Notices
    of Certain Transactions. In case:

 

	 	(a)	the
    Company shall take a record of the holders of its Preferred A Shares (or other stock or securities at the time deliverable
    upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution,
    or
	 	 	 
	 	(b)	of
    the voluntary or involuntary dissolution, liquidation or winding-up of the Company then, and in each such case, the Company
    will mail or cause to be mailed to the Holder a notice specifying, as the case may be, (i) the date on which a record is to
    be taken for the purpose of such dividend or distribution, and stating the amount and character of such dividend or distribution,
    or (ii) the effective date on which such voluntary dissolution, liquidation or winding-up is to take place, and the time,
    if any is to be fixed, as of which the holders of record of Shares (or such other shares or securities at the time deliverable
    upon such voluntary dissolution, liquidation or winding-up) are to be determined. Such notice shall be mailed at least seven
    (7) days prior to the record date or effective date for the event specified in such notice. 

 

	5.	EXERCISE
    OF THE WARRANT UPON AN EXIT EVENT
	 	 
	 	Notwithstanding
    anything to the contrary in this Warrant, if at any time during the Warrant Period, the Company consummates an Exit Event,
    or at the discretion of the Board of Directors of the Company, in the event that the Company believes that an Exit Event is
    likely to be consummated during such period, the Company shall provide written notice of such Exit Event (or, if applicable,
    an anticipated Exit Event) to the Holder (the “Exit Event Notice”). Within fourteen (14) days after Holder’s
    receipt of the Exit Event Notice, Holder must notify the Company if it intends to exercise this Warrant pursuant to Section
    ‎1.2
    or ‎1.3 of this Warrant, in which case such exercise shall be effective contingent
    upon and immediately prior to the consummation of the Exit Event. Thereafter, so long as the Company consummates such Exit
    Event within one hundred and eighty (180) days after Holder’s receipt of the Exit Event Notice (to the extent the Exit
    Event shall not have occurred prior to the Exit Event Notice), Holder shall have no further rights hereunder and this Warrant
    shall be automatically terminated if not so exercised. If the Company fails to consummate such Exit Event within such time,
    then this Warrant shall remain in effect subject to the provisions contained herein 

 

    	7 

    	 		 

    

 

	 	For
    the purposes hereof, an “Exit Event” shall mean the closing of (i) an initial public offering; (ii) a merger of
    the Company with or into another corporation, (iii) an acquisition of all or substantially all of the shares of the Company,
    (iv) the sale or license of all or substantially all of the assets of the Company, any with respect to (ii)-(iv), other than
    a merger or transaction in which the persons that beneficially owned, directly or indirectly, a majority of the share capital
    of the Company immediately prior to such merger or transaction, beneficially own, directly or indirectly, a majority of the
    total shares of capital stock of the surviving or transferee entity.

 

	6.	RIGHTS
    OF THE HOLDER

 

	 	6.1.	This
    Warrant shall not entitle the Holder, by virtue hereof, to any voting rights or other rights as a shareholder of the Company,
    except for the rights expressly set forth herein.
	 	 	 
	 	6.2.	The
    Holder acknowledges that the Warrant Shares shall be subject to such rights, privileges, restrictions and limitations as set
    forth in this Warrant and the organizational documents of the Company (or any other agreement with respect thereto), as may
    be amended from time to time, and that, as a result, inter alia, of such limitations, it may be difficult or impossible
    for the Holder to realize his investment and/or to sell or otherwise transfer the Warrant Shares. The Holder further acknowledges
    that the Company’s shares are not publicly traded.

 

	7.	TERMINATION
	 	 
	 	Notwithstanding
    anything to the contrary, this Warrant and all the rights conferred hereby shall terminate and expire at the aforementioned
    time on the Expiry Date.

 

    	8 

    	 		 

    

 

	8.	MISCELLANEOUS

 

	 	8.1.	Entire
    Agreement; Amendment. This Warrant sets forth the entire understanding of the parties with respect to the subject matter
    hereof and supersedes all existing agreements among them concerning such subject matter. All article and section headings
    herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provision
    of this Warrant. Subject to Section ‎8.8 below, no modification or amendment of this Warrant will be valid unless executed
    in writing by the Company and the Holder. 
	 	 	 
	 	8.2.	Waiver.
    No failure or delay on the part of any of the parties in exercising any right, power or privilege hereunder and/or under any
    applicable law or the exercise of such right or power in a manner inconsistent with the provisions of this Warrant or applicable
    law shall operate as a waiver thereof. Any waiver must be evidenced in writing signed by the party against whom the waiver
    is sought to be enforced.
	 	 	 
	 	8.3.	Successors
    and Assigns; Assignment. Except as otherwise expressly limited herein, this Warrant shall inure to the benefit of, be
    binding upon, and be enforceable by the Holder and its respective successors, and administrators and is otherwise non-transferable
    without the prior consent of the Company. The Holder represents and warrants to the Company that this Warrant and the Warrant
    Shares, if and when purchased by the Holder, are for the Holder’s own account and for investment purposes only and not
    with a view for resale or transfer and that all the rights pertaining to the Warrant or the Warrant Shares, by law or equity,
    shall be purchased and possessed by the Holder for the Holder exclusively. 
	 	 	 
	 	8.4.	Governing
    Law. This Warrant shall be exclusively governed and construed in accordance with the laws of the State of New York, without
    regard to conflicts of laws provisions thereof.
	 	 	 
	 	8.5.	Notices.
    All notices and other communications made pursuant to this Warrant shall be in writing and shall be conclusively deemed to
    have been duly given if delivered in accordance with the notice provisions of the Convertible Notes Agreement. 

 

    	9 

    	 		 

    

 

	 	8.6.	Severability.
    If any provision of this Warrant is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Warrant and the remainder of this Warrant shall be interpreted as if such provision
    were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Warrant
    shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the
    meaning and intention of the excluded provision as determined by such court of competent jurisdiction.
	 	 	 
	 	8.7.	Counterparts.
    This Warrant may be executed in any number of counterparts, each of which shall be an original, but all of which together
    shall constitute one instrument. Facsimile or electronic signatures of a party shall be binding as evidence of such party’s
    agreement hereto and acceptance hereof.
	 	 	 
	 	8.8.	Amendments.
    To the extent that any amendment(s) to the Convertible Notes Agreement or the transactions contemplated thereby result in
    a required amendment to the terms of this Warrant, this Warrant shall be deemed amended to the extent that the amendment(s)
    to the Convertible Notes Agreement are completed in accordance with the terms thereof.

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.

 

	Dated:	 	 	Motus
    GI Medical Technologies Ltd. 
	 	 	 	 
	 	 	 	Signature:	 
	 	 	 	Name:	 
	 	 	 	Title:	 

 

    	10 

    	 		 

    

 

Schedule
1.2

 

Exercise
Notice

 

	Date:			 
	 		 	 
	To:		Motus
                                         GI Medical Technologies Ltd.	 

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to purchase _________ Warrant Shares (as such term is defined in the Warrant) pursuant to Section ‎1.1 of the
Warrant, and herewith makes payment of _____________, representing the full Exercise Price for such shares as provided for in
such Warrant. 

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	11 

    	 		 

    

 

Schedule
1.3

 

Net
Issuance Notice

 

	Date:			 
	 	 	 	 
	To:		Motus
                                         GI Medical Technologies Ltd.	 

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to exercise the Warrant for the purchase of Warrant Shares (as such term is defined in the Warrant), pursuant to
the provisions of Section 1.3 of the Warrant.

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 
	 	 	 	 	 

 

	Signature:			 
	 		 	 
	Address:			 

 

    	12 

    	 		 

    

 

EXHIBIT
2.2.2(b)

 

FOURTH
AMENDED AND RESTATED ARTICLES OF ASSOCIATION

 

OF

 

MOTUS
GI MEDICAL TECHNOLIGIES, LTD.

 

A
PRIVATE COMPANY LIMITED BY SHARES

 

UNDER
THE COMPANIES LAW, 5759-1999

 

*
* * *

 

1.
Definitions; Interpretation.

 

1.1
Definitions

 

In
these Articles of Association, the following terms shall have the meaning appearing opposite them, unless another interpretation
is expressly stated herein:

 

	 	“ABV”-	 	means
    Ascent Biomedical Ventures II L.P., Ascent Biomedical Ventures Synecor, L.P., and all of their respective limited and general
    partners, members and any Permitted Transferee and any Permitted Transferee thereof of any of the foregoing;
	 	 	 	 
	 	“ABV
    Director”- 	 	means
    the Director appointed by ABV except as otherwise provided for herein in Article 40; 
	 	 	 	 
	 	“Affiliates”
    - 	 	means,
    with respect to any Person, any other Person, directly or indirectly, through one or more intermediary Persons, controlling,
    controlled by or under common control with such Person;
	 	 	 	 
	 	“Annual
    General Meeting”-	 	means
    the annual general meeting of the Company’s shareholders (if convened);
	 	 	 	 
	 	“Articles”
    -	 	means
    these Articles of Association, as amended from time to time;
	 	 	 	 
	 	“ATI”
    -	 	means
    Accelerated Technologies, Inc.;
	 	 	 	 
	 	“Board”
    or - 	 	 
	 	 	 	 
	 	“Board
    of Directors” -	 	means
    the Board of Directors of the Company;

 

    	 	 	 

    	 	 	 

    

 

	 	“Chairman”-	 	means
    the Chairman of the Board of Directors as set forth in Article 50 herein;
	 	 	 	 
	 	“Company”
    -	 	means
    Motus GI Medical Technologies, Ltd.;
	 	 	 	 
	 	“Companies
    Law” -	 	means
    the Israeli Companies Law, 5759-1999, as the same shall be amended from time to time;
	 	 	 	 
	 	“Conversion
    Notice”	 	has
    the meaning set forth in Article 5(c).
	 	 	 	 
	 	 “Conversion
    Price”	 	has
    the meaning set forth in Article 5(d).
	 	 	 	 
	 	“Deemed
    Issuance” 	 	Deemed
    Issuance shall mean the issuance of options to purchase or rights to subscribe to any Additional Shares, or securities by
    their terms convertible of exchangeable for Additional Shares, or options to purchase or rights to subscribe to such convertible
    or exchangeable securities, which may be exercised of converted into Additional Shares; 
	 	 	 	 
	 	 “Director”
    - 	 	means
    a member of the Board of Directors;
	 	 	 	 
	 	“Excluded
    Securities”	 	has
    the meaning set forth in Article 5(d)(ii)(G);
	 	 	 	 
	 	“Extraordinary
    General Meeting(s)” -	 	has
    the meaning set forth in Article 25;
	 	 	 	 
	 	“Founder”
    - 	 	means
    Boris Shtul Identity number 307247049 and NGT to the extent pertaining to the Ordinary Shares held by NGT;
	 	 	 	 
	 	“General
    Meeting(s)” - 	 	means
    either an Annual General Meeting or an Extraordinary General Meeting;
	 	 	 	 
	 	 “IPO”
    - 	 	means
    the closing of a bona fide initial underwritten offering of the Company’s securities to the public on a recognized exchange
    (e.g. NASDAQ, AIM), pursuant to a registration statement under the U.S. Securities Act of 1933, as amended, the Israeli Securities
    Law - 1968, or similar securities laws of another jurisdiction; 
	 	 	 	 
	 	“Jacobs”
    -	 	means
    Jacobs Investments LLC and any Permitted Transferee thereof;
	 	 	 	 
	 	“NGT”-	 	means
    N.G.T. New Generation Technologies Ltd. and any Permitted Transferee thereof;
	 	 	 	 
	 	“NGT
    Director(s)”- 	 	means
    the Director appointed by NGT;

 

    	 	2	 

    	 	 	 

    

 

	 	 “Office
    Holder” - 	 	means
    every Director and every officer of the Company, including without limitation, each of the persons defined as “Nosei
    Misra” in the Companies Law; 
	 	 	 	 
	 	“Orchestra”
    -	 	means
    Orchestra Medical Ventures II, Orchestra Medical Ventures II Annex, Orchestra Medical Ventures GP, LLC, Orchestra Motus Co-Investment
    Partners LLC and all of their respective limited and general partners, members and any Permitted Transferee of any of the
    foregoing;
	 	 	 	 
	 	 “Orchestra
    Director(s)”- 	 	means
    the Director(s) appointed by Orchestra except as otherwise provided for herein in Article 40;
	 	 	 	 
	 	“Ordinary
    Director”- 	 	means
    the Director appointed by the holders of the majority of the issued and outstanding Ordinary Shares;
	 	 	 	 
	 	 “Ordinary
    Shares” -	 	means
    the Company’s Ordinary Shares, nominal value NIS 0.01 each; 
	 	 	 	 
	 	“Original
    Issue Price” -	 	means,
    with respect to a Preferred Share, the Price Per Share (subject to adjustment in the event of share splits, share dividends,
    reclassifications and other like events); 
	 	 	 	 
	 	“Permitted
    Transferee” - 	 	means,
    with respect to: (A) any shareholder: (i) any member of such shareholder’s immediate family (including, with respect
    to Boris Shtul, Ms. Alexandra Pevzner I.D 307285841); (ii) any Person Affiliated with such shareholder subject to the approval
    of the Board which approval shall not be unreasonably withheld; (iii) any fund, or any beneficiary of any trust or any account
    or arrangement managed by such shareholder or by the general partner or managing entity of such shareholder, or by an affiliate
    thereof; (iv) any shareholder, member or other equity holder of such shareholder; or (B) with respect to Orchestra or ABV:
    any member, general partner or any limited partner of Orchestra or ABV, respectively; or (C) with respect to NGT: (i) any
    affiliate entity of NGT that shall be established pursuant to restructuring and/or reorganization of NGT or any transfer/sale
    of NGT’s holdings to other entity controlled by NGT’s shareholders pursuant to an assets purchase agreement or
    a merger; or (ii) NGT’s, employees and consultants (each in this subsection (ii), an “NGT Transferee”),
    provided that a transfer(s) to such NGT’s Transferee shall be limited to the aggregate amount of 300,000 Ordinary Shares
    of the Company and that such NGT’s Transferee assumes NGT’s rights and obligations towards the Company and/or
    its shareholders and is subject to the provisions of these Articles, as applicable; 

 

    	 	3	 

    	 	 	 

    

 

	 	“Person”
    - 	 	means
    an individual, corporation, partnership, joint venture, trust, and any other body corporate or unincorporated organization;
	 	 	 	 
	 	“Preferred
    Shareholder(s)” - 	 	means
    the holders of the Preferred Shares; 
	 	 	 	 
	 	“Preferred
    Share(s)” -	 	means
    the Company’s Series A Preferred Shares, nominal value NIS 0.01 each;
	 	 	 	 
	 	“Price
    Per Share” -	 	means,
    with respect to a Preferred Share, the price actually paid for such Preferred Share upon the issuance thereof;
	 	 	 	 
	 	“Qualified
    IPO”-	 	means
    the Company’s IPO at a price per share which is at least 5 (five) times the Original Issue Price (adjusted for share
    combinations or splits or other recapitalizations of the Company’s Shares), yielding gross proceeds to the Company of
    at least US$30,000,000 (Thirty Million US Dollars); 
	 	 	 	 
	 	“Register
    of Shareholders” - 	 	means
    the register of shareholders that must be maintained pursuant to Section 127 of the Companies Law;
	 	 	 	 
	 	“Series
    A Director(s)” - 	 	means
    any of the Orchestra Director(s), the ABV Director and or the NGT director;
	 	 	 	 
	 	“Series
    A Investors” -	 	means
    the purchasers of Series A Preferred Shares under the Series A Share Purchase Agreement;
	 	 	 	 
	 	“Series
    A SPA” – 	 	means
    the Series A Share Purchase Agreement dated September 15, 2011 entered into between the Company and each of the purchasers
    of Series A Preferred Shares thereunder; and
	 	 	 	 
	 	 “Year”
    and “Month” -	 	a
    Gregorian month or year.

 

  1.2 Interpretation

 

(a)
Any capitalized term used but not otherwise defined in these Articles shall have the meaning ascribed to it in the Companies Law.

 

(b)
Words and expressions importing the singular shall include the plural and vice versa; words and expressions importing the masculine
gender shall include the feminine gender; and words and expressions importing persons shall include bodies corporate.

 

(c)
The captions used in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction
of any portion hereof.

 

(d)
Any use, reference or application of the terms “conversion”, “convert”, “convertible”
or “converting” of Preferred Shares as detailed in these Articles shall be deemed to include conversion by
way of reclassification to the extent reasonably applicable in the context.

 

    	 	4	 

    	 	 	 

    

 

(e)
For the purposes of these Articles the phrase “on an as-converted basis” means that with respect to any given
right in question, and for any calculation of shareholding in the Company, Preferred Shares shall be calculated as, and shall
have the effect of, such number of Ordinary Shares into which such Preferred Shares are convertible at that time.

 

(f)
All shares held (beneficially or of record), at the time of applicable calculation, by shareholders who are Permitted Transferees
(including Affiliates) of each other, shall be aggregated together for the purpose of determining the availability to such holders
of any rights under these Articles, and such rights – to the extent they are determined to be available at such time - may
be exercised (up to the maximum extent so determined to be available in the aggregate to all such shareholders) by any, some or
all of such shareholders who are Permitted Transferees (including Affiliates) of each other.

 

(g)
In the event of a conflict between by English version of these Articles and the Hebrew version thereof, the English version shall
govern.

 

 2. Private Company; Objects of the Company

 

2.1
The Company is a private company, and accordingly:

 

(a)
The Company may not offer its securities to the public.

 

(b)
The right to transfer shares of the Company is restricted as provided in these Articles.

 

2.2
The number of shareholders of the Company at any time (other than employees or former employees of the Company who continue to
be shareholders of the Company) shall not exceed 50; provided, however, that if two or more individuals hold a share or shares
of the Company jointly, they shall be deemed to be one shareholder for purposes of this Article.

 

2.3
The objects of the Company shall be to engage in any lawful activity.

 

2.4
The Company may contribute reasonable amounts for any suitable purpose or categories of purposes even if such contributions do
not fall within business considerations of the Company. The Board of Directors may determine the amounts of the contributions,
the purpose or categories of purposes for which the contribution is to be made, and the identity of the recipient of any contribution.

 

3.
Limitation of Liability. The liability of the shareholders is limited to the payment of the nominal value of the shares
in the Company held thereby, and which remains unpaid, and only to that amount. If the Company’s share capital shall at
any time include shares without a nominal value, the liability of the holders of such shares shall be limited to the payment of
up to NIS 0.01 for each such share held thereby, and which remains unpaid, and only to that amount.

 

    	 	5	 

    	 	 	 

    

 

SHARE
CAPITAL

 

	 	4.	Share
    Capital 

 

4.1
The authorized share capital of the Company is seven hundred eighty thousand New Israeli Shekels (NIS 780,000) divided into forty
five million (45,000,000) Ordinary Shares, of nominal value NIS 0.01 each, and thirty three million (33,000,000) Series A Preferred
Shares, of nominal value NIS 0.01 each.

 

4.2
The Preferred Shareholders shall have the rights, preference, privileges and restrictions granted to and imposed on the Preferred
Shares as may be specifically indicated in these Articles and/or as the context may reasonably require. The Ordinary Shares shall
have the rights and restrictions granted to and imposed on the same as set forth in these Articles.

 

4.3
The holders of Ordinary Shares are each entitled to receive notices of, and to attend, General Meetings of the shareholders of
the Company, and for each share held, to one vote at such meetings for all purposes, and, subject to Article 54 hereof, to share
in such dividends as may be declared in accordance with these Articles out of funds legally available therefore, and, subject
to Articles 73 and 74 hereof, upon liquidation or dissolution, to share in the assets of the Company legally available for distribution
to the shareholders after payment of all debts and other liabilities of the Company.

 

	 	5.	The
    Preferred Shares

 

The
Preferred Shares confer on the holders thereof all rights accruing to holders of Ordinary Shares in the Company, and in addition,
bear the following rights:

 

(a)
Subject to any provisions hereof conferring special rights as to voting, or restricting the right to vote, every holder of Preferred
Shares shall have one vote for each Ordinary Share into which the Preferred Shares held by him of record could be converted (as
provided in this Article), on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by
written ballot or by any other means. The Preferred Shareholder shall be entitled to vote, together with the holders of Ordinary
Shares. Except as provided otherwise in these Articles or as otherwise provided by law, the Preferred Shareholders shall vote
together with the holders of the Ordinary Shares as a single class (on an as-converted basis).

 

(b)
Each Preferred Share shall be initially convertible at the option of the holder thereof, at any time after the date of issuance
of such share, at the registered office of the Company (“Office”), into such number of fully
paid and non-assessable Ordinary Shares as is determined by dividing the applicable Original Issue Price by the applicable Conversion
Price and subject to adjustment under Article 5(d)) at the time in effect for such share. Furthermore, each Preferred Share shall
be converted into such number of fully paid and non-assessable Ordinary Shares as is determined by dividing the applicable Original
Issue Price by the applicable Conversion Price and subject to adjustment under Article 5(d)) at the time in effect for such share
immediately prior to the closing of a Qualified IPO.

 

    	 	6	 

    	 	 	 

    

 

(c)
Before any holder of Preferred Shares shall be entitled (in the case of a conversion at such holder’s option) to convert
the same into Ordinary Shares, he/she/it shall surrender the certificate or certificates therefor, duly endorsed, at the Office,
and shall give written notice by mail, postage prepaid, to the Company at its principal corporate office, of the election to convert
the same and shall state therein the name or names of any nominee for such holder in which the certificate or certificates for
Ordinary Shares are to be issued. In the event that any Preferred Shareholder holding conversion rights pursuant to Article 5
elects to convert any of its Preferred Shares into Ordinary Shares such shareholder shall surrender the certificate or certificates
representing such shares, to the Office, and shall give written notice to the Company at its Office, accompanied with a detailed
written explanation as to how many Preferred Shares the Preferred Shareholder wishes to reclassify (“Conversion Notice”).
Within a reasonable time after the receipt of the Conversion Notice by the Company, the Company shall seek any shareholders’
resolutions necessary to effectuate any such conversion by reclassification (if any). If no shareholders resolutions are required
to give effect to such reclassification, such reclassification shall be deemed to have been effected immediately prior to the
close of business on the date on which the Company received the Conversion Notice, or such later date as may be detailed in the
Conversion Notice. However, if such reclassification requires an additional shareholders resolution(s), then in such event, such
reclassification shall be deemed to have been effected immediately upon the adoption of the said resolution(s) or such later date
as may be detailed in the Conversion Notice. The Company shall, as soon as practicable after the conversion by reclassification
and tender of the certificate for the shares converted by reclassification, against the receipt of the original share certificate,
issue and deliver a certificate or certificates for the number of Ordinary Shares to which such shareholder shall be entitled
as a result of the aforesaid and shall indicate the same in the Register of Shareholders. If the conversion is in connection with
a an IPO, then the conversion shall be deemed to have taken place automatically upon the reclassification of Preferred Shares
into Ordinary Shares regardless of whether the certificates representing such shares have been tendered to the Company, but from
and after such conversion any such certificates not tendered to the Company shall be deemed to evidence solely the Ordinary Shares
received upon such conversion and the right to receive a certificate for such Ordinary Shares. If the conversion is in connection
with a an IPO, the conversion may, at the option of any holder tendering Preferred Shares for conversion, be conditioned upon
the closing with the underwriter of the sale of securities pursuant to such offering, in which event the person(s) entitled to
receive the Ordinary Shares issuable upon such conversion of the Preferred Shares shall not be deemed to have converted such Preferred
Shares until immediately prior to the closing of such offer of securities. The Company shall, as soon as practicable after the
conversion and tender of the certificate for the Preferred Shares converted, issue and deliver at such office to such holder of
Preferred Shares or to the nominee or nominees of such holder of Preferred Shares, a certificate or certificates for the number
of Ordinary Shares to which such holder shall be entitled as aforesaid. In the event that at any time the Company receives a Conversion
Notice or in the event of a Qualified IPO or any other conversion by reclassification contemplated in Article 5, each shareholder
shall execute any document and/or resolution requested by the Company reasonably necessary in order to give effect to the reclassification
privileges as set forth in Article 5.

 

(d)
The initial conversion price for the Preferred Shares shall be the Original Issue Price (subject to any adjustments under this
Article 5(d)) (the “Conversion Price”). The Conversion Price shall be adjusted from time to time as
follows:

 

(i)
(A) Upon each issuance (or Deemed Issuance, as defined above) by the Company of any Additional Shares (as defined below) at a
price per share less than the applicable Conversion Price then in effect, except for an issuance described in Article 5(d)(iv)
below, such Conversion Price will be reduced, for no additional consideration, in accordance with a weighted average anti-dilution
formula, to a price (calculated to the nearest cent) determined by the following formula :

 

CP2
= CP1 * (A+B) / (A+C)

 

	 	CP2	=	New
    Series A Conversion Price following the issuance of Additional Shares

 

    	 	7	 

    	 	 	 

    

 

	 	CP1	=	Series
    A Conversion Price in effect immediately prior to the new issuance of Additional Shares
	 	 	 	 
	 	A	=	Number
    of Ordinary Shares deemed to be outstanding immediately prior to new issue of Additional Shares on an as converted basis,
    treating for this purpose as outstanding all Ordinary Shares issuable upon conversion of all issued Preferred Shares and all
    Ordinary Shares issuable upon conversion or exercise of any other then currently outstanding convertible securities, warrants
    or options, but such number of Ordinary Shares shall not include any convertible securities converting into the then applicable
    Additional Shares.
	 	 	 	 
	 	B	=	Aggregate
    consideration received by the Company with respect to the new issue of Additional Shares divided by CP1. (i.e.
    Aggregate consideration / CP1)
	 	 	 	 
	 	C	=	Number
    of Additional Shares issued 

 

(B)
No adjustments to the Conversion Price shall be made in an amount less than one agura (NIS 0.01) per share. No adjustment to the
Conversion Price shall be made if it has the effect of increasing the Conversion Price beyond the applicable Conversion Price
immediately prior to such adjustment.

 

(C)
The consideration for the issuance of Additional Shares in the case of the issuance of Additional Shares for cash shall be deemed
to be the amount of cash received therefor. In the case of the issuance of the Additional Shares for consideration in whole or
in part other than cash, the consideration other than cash shall be deemed to be the fair value thereof as determined by the Board
of Directors in good-faith. In the case of a Deemed Issuance of Additional Shares, the consideration for the Additional Shares
shall be deemed to be the aggregate consideration received by the Company on the issuance of the securities themselves, taken
together with any additional consideration (if any) to be paid to the Company on the exercise or conversion of the securities.

 

(D)
In the case of the issuance of options to purchase or rights to subscribe for Ordinary Shares, or securities by their terms convertible
into or exchangeable for Ordinary Shares or options to purchase or rights to subscribe for such convertible or exchangeable securities,
the aggregate maximum number of Ordinary Shares deliverable upon exercise (assuming the satisfaction of any conditions to exercise,
including without limitation, the passage of time, but without taking into account potential anti-dilution adjustments) of such
options to purchase or rights to subscribe for Ordinary Shares, or upon the exchange or conversion of such security, shall be
deemed to be Additional Shares issued at the time of the issuance of such options, rights or securities, at a consideration equal
to the consideration (determined in the manner provided in Sub-article (d)(i)(C)), received by the Company upon the issuance of
such options, rights or securities plus any additional consideration payable to the Company pursuant to the term of such options,
rights or securities (without taking into account potential anti-dilution adjustments) for the Ordinary Shares covered thereby;
provided, however, that if any options as to which an adjustment to the Conversion Price has been made pursuant to this Article
4(d)(i)(D) expire without having been exercised, then the Conversion Price shall be readjusted as if such options had not been
issued (without any effect, however, on adjustments to the Conversion Price as a result of other events described in this Article).

 

(E)
For purpose of Sub-article (d)(i) hereof, the consideration for any Additional Shares shall be taken into account at the U.S.
Dollar equivalent thereof, on the day such Additional Shares are issued or deemed to be issued pursuant to Sub-article (d)(i)(D).

 

    	 	8	 

    	 	 	 

    

 

(ii)
“Additional Shares” shall mean any Ordinary Shares issued, or deemed to have been issued pursuant to
Subarticle (d)(i)(D), by the Company other than:

 

(A)
Ordinary Shares or Preferred Shares issued or issuable upon a pro-rata share split, share dividend, or any subdivision
of Ordinary Shares pursuant to a transaction described in Subarticles (d)(iii) or (d)(iv) hereof.

 

(B)
Ordinary Shares (or options to purchase such Ordinary Shares) issued or issuable to employees, directors, consultants of the Company
or other persons (including without limitation, corporate entities) pursuant to any option plan approved by the Board of Directors
including an Orchestra Director and an ABV Director.

 

(C)
Securities issuable upon conversion of any of the Preferred Shares, or as a dividend or distribution on the Preferred Shares.

 

(D)
Securities issued upon the conversion of any debenture, warrant, option, or other convertible security (the issuance of which
did not cause an adjustment hereunder).

 

(E)
Any Ordinary Shares issuable to ATI pursuant to the Consulting Services Agreement between the Company and ATI dated September
15, 2011. 

 

(F)
Preferred Shares issuable in the Second Milestone Closing, Third Milestone Closing or Final Milestone Closing of the Series A
SPA (as such terms are defined therein), including any shares issuable pursuant to any acceleration of any of the aforementioned
closings, or pursuant to Section 2.2.6 of the Series A SPA, or Ordinary Share issued to or reclassified into Ordinary Shares for
a Defaulting Purchaser under the Series A SPA. 

 

(G)
Securities issued by the Company in connection with an IPO or a Qualified IPO.

 

(I)
Securities constituting not more than 5% of Ordinary Shares, calculated on a fully diluted as converted basis, to a strategic
investor (as determined as such by the Board including an Orchestra Director and an ABV Director).

 

sub-Articles
5 (d)(ii) (A)-(G) inclusive, collectively referred to as “Excluded Securities”. 

 

(iii)
If the Company subdivides or combines its Ordinary Shares, the Conversion Price shall be proportionately reduced, in case of subdivision
of shares, as at the effective date of such subdivision, or if the Company fixes a record date for the purpose of so subdividing,
as at such record date, whichever is earlier, or shall be proportionately increased, in the case of combination of shares, as
at the effective date of such combination, or, if the Company fixes a record date for the purpose of so combining, as at such
record date, whichever is earlier.

 

(iv)
If the Company at any time pays a dividend, with respect to its Ordinary Shares only, payable in additional shares of Ordinary
Shares or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional
shares of Ordinary Shares, without any comparable payment or distribution to the holders of Preferred Shares (hereinafter referred
to as “Ordinary Shares Equivalents”), then the Conversion Price shall be adjusted as at the date the
Company fixes as a record date for the purpose of receiving such dividend (or if no such record date is fixed, as at the date
of such payment) to that price determined by multiplying the applicable Conversion Price in effect immediately prior to such record
date (or if no record date is fixed then immediately prior to such payment) by a fraction (a) the numerator of which shall be
the total number of Ordinary Shares outstanding and those issuable with respect to Ordinary Shares Equivalents prior to the payment
of such dividend, and (b) the denominator of which shall be the total number of shares of Ordinary Shares outstanding and those
issuable with respect to such Ordinary Shares Equivalents immediately after the payment of such dividend (plus, in the event that
the Company paid cash for fractional shares, the number of additional shares which would have been outstanding had the Company
issued fractional shares in connection with such dividend).

 

    	 	9	 

    	 	 	 

    

 

(e)
In the event the Company declares a distribution payable in securities of other persons, evidences of indebtedness issued by the
Company or other persons, assets (excluding cash dividends) or options or rights not referred to in Subarticle (d)(iv) other than
as part of a Deemed Liquidation, then, in each such case, the holders of the Preferred Shares shall be entitled to receive a proportionate
share of any such distribution, in respect of their holdings on an as-converted basis as of the record date for such distribution.

 

(f)
If at any time or from time to time there shall be a recapitalization of the Ordinary Shares (other than a subdivision, combination
or merger or sale of assets transaction provided for elsewhere in this Article 5), provision shall be made so that the holders
of the Preferred Shares shall thereafter be entitled to receive upon conversion of the Preferred Shares the number of Ordinary
Shares or other securities or property of the Company or otherwise, to which a holder of Ordinary Shares deliverable upon conversion
of the Preferred Shares would have been entitled immediately prior to such recapitalization. In any such case, appropriate adjustments
shall be made in the application of the provisions of this Article 5 with respect to the rights of the holders of the Preferred
Shares after the recapitalization to the end that the provisions of this Article 5 (including adjustments of the Conversion Price
then in effect and the number of shares issuable upon conversion of the Preferred Shares) shall be applicable after that event
as nearly equivalent as may be practicable.

 

(g)
The Company will not, by amendment of these Articles or through any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder in this Article 5 by the Company, but will at all times in good faith
assist in the carrying out of all the provisions of this Article 5 and in taking of all such action as may be necessary or appropriate
in order to protect the conversion rights of the holders of the Preferred Shares against impairment.

 

(h)
No fractional shares shall be issued upon conversion of the Preferred Shares, and the number of shares of Ordinary Shares to be
issued shall be rounded to the nearest whole share.

 

(i)
Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Article 5, the Company, at its
expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to
each holder of Preferred Shares a certificate setting forth each adjustment or readjustment and showing in detail the facts upon
which such adjustment or readjustment is based. The Company shall furnish or cause to be furnished to such holder a like certificate
setting forth (A) such adjustment or readjustment, (B) the Conversion Price at the time in effect, and (C) the number of shares
of Ordinary Shares and the amount, if any, of other property which at the time would be received upon the conversion of a Preferred
Share.

 

(j)
[RESERVED]

 

    	 	10	 

    	 	 	 

    

 

(k)
The Company shall at all times reserve and keep available out of its authorized but unissued Ordinary Shares, solely for the purpose
of effecting the conversion of the Preferred Shares, such number of its Ordinary Shares as shall from time to time be sufficient
to effect the conversion of all issued and outstanding Preferred Shares; and if at any time the number of authorized but unissued
Ordinary Shares shall not be sufficient to effect the conversion of all then outstanding Preferred Shares, in addition to such
other remedies as shall be available to the holders of such Preferred Shares, the Company will take such corporate action as may,
in the opinion of its counsel, be necessary to increase its authorized but unissued Ordinary Share capital to such number of shares
as shall be sufficient for such purposes.

 

(l)
Notwithstanding any of the aforesaid, in the event that a Purchaser (as defined in the Series A SPA) is a Defaulting Purchaser
(as defined in the Series A SPA), any Preferred Shares which have already been issued to such Defaulting Purchaser hereunder,
shall be immediately and automatically converted and/or reclassified into an equal number of Ordinary Shares on a non-preferential
basis, and each of the shareholders irrevocably undertakes to pass any resolution required to give effect to such conversion and/or
reclassification and to take any such actions as may be required to effect such conversion and/or reclassification. 

 

	 	6.	Increase
    of Share Capital

 

(a)
Subject to and in accordance with Article 75, the Company may, from time to time, by resolution of its shareholders, whether or
not all the shares then authorized have been issued, and whether or not all the shares issued have been called up for payment,
increase its authorized share capital. Any such increase shall be in such amount and shall be divided into shares of such nominal
amounts, with such rights and preferences and subject to such restrictions, as such resolution shall provide.

 

(b)
Except to the extent otherwise provided in such resolution, any new shares included in the authorized share capital increased
as aforesaid shall be subject to all the provisions of these Articles which are applicable to shares included in the existing
share capital, without regard to class (and, if such new shares are of the same class as a class of shares included in the existing
share capital, to all of the provisions that are applicable to shares of such class included in the existing share capital).

 

	 	7.	Special
    Rights; Modification of Rights

 

(a)
Subject to and in accordance with Article 75, and without prejudice to any special rights previously conferred upon the holders
of existing shares in the Company the Company may, from time to time, by resolution of the holders of a majority of its shares
provide for shares with such preferred or deferred rights or rights of redemption or other special rights or restrictions, whether
in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such resolution.

 

(b)
If at any time the share capital is divided into different classes of shares, the rights, preferences, privileges or powers of,
or the restrictions attached to any class, subject to Article 75 and unless otherwise provided by these Articles, may be modified
or abrogated by the Company by resolution of its shareholders, subject to the consent in writing, or vote at a separate meeting,
of the holders of at least 50% of the issued shares of such class.

 

(c)
The provisions of these Articles relating to General Meetings shall, mutatis mutandis, apply to any separate General Meeting
of the holders of the shares of a particular class; provided, however, that the requisite quorum at any such separate General
Meeting shall be one or more shareholders present in person or by proxy and holding at least 50% of the issued shares of such
class.

 

    	 	11	 

    	 	 	 

    

 

(d)
Unless otherwise provided for in these Articles, the enlargement of an authorized class of shares, or the issuance of additional
shares of such a class out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 7 to
modify or abrogate the rights, preferences, privileges or powers of, or the restrictions attached to previously issued shares
of such class or of any other class;

 

(e)
Any right or limitation provided for the express benefit of a specifically named shareholder may not be amended or waived without
the prior written consent of such shareholder.

 

	 	8.	Consolidation,
    Subdivision, Cancellation and Reduction of Share Capital

 

(a)
The Company may, from time to time, by a resolution by the holders of at least 50% of the voting power of the Company calculated
on as converted basis (subject, however, to the provisions of Article 7(b) and 75 of these Articles and to applicable law):

 

(i)
consolidate and divide all or any part of its issued or unissued authorized share capital into shares of a per share nominal value
that is greater than the per share nominal value of its existing shares;

 

(ii)
subdivide its shares (issued or unissued) or any of them into shares of lesser nominal value than is fixed by these Articles;

 

(iii)
cancel any shares that, at the date of the adoption of such resolution, have not been purchased or subscribed for; or

 

(iv)
reduce its share capital in any manner, and with and subject to any incident authorized, and consent required, by law.

 

(b)
With respect to any consolidation of issued shares into shares of a greater nominal value per share, and with respect to any other
action that may result in fractional shares, the Board of Directors may, subject to these Articles, settle any dispute that may
arise with regard thereto as it deems fit, and in connection with any such consolidation or other action that may result in fractional
shares may, subject to Article 75, without limitation:

 

(i)
determine, as to any holder of shares so consolidated, which issued shares shall be consolidated into a share of a greater nominal
value per share;

 

(ii)
allot, in contemplation of or subsequent to such consolidation or other action, shares or fractional shares sufficient to preclude
or remove fractional share holdings; or

 

(iii)
redeem, in the case of redeemable preference shares and subject to applicable law, such shares or fractional shares sufficient
to preclude or remove fractional share holdings.

 

    	 	12	 

    	 	 	 

    

 

SHARES

 

	 	9.	Issuance
    of Share Certificates: Replacement Certificates 

 

(a)
Share certificates shall bear the signature (or facsimile thereof) of one Director or of any other person or persons authorized
by the Board of Directors.

 

(b)
Each shareholder shall be entitled to one numbered certificate for all the shares of any class registered in his name, and if
the Board of Directors so approves, to several certificates, each for one or more of such shares.

 

(c)
A share certificate registered in the names of two or more persons shall be delivered to the person first named in the Register
of Shareholders in respect of such co-ownership.

 

(d)
A share certificate that has been defaced, lost or destroyed may be replaced, and the Company shall issue a new certificate to
replace such defaced, lost or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership
and such indemnity, as the Board of Directors in its discretion deems fit.

 

	 	10.	Registered
    Holder

 

Except
as otherwise provided in these Articles, the Company shall be entitled to treat the registered holder of each share as the absolute
owner thereof, and accordingly shall not, except as ordered by a court of competent jurisdiction or as required by law, be obligated
to recognize any equitable or other claim to, or interest in, such share on the part of any other person.

 

	 	11.	Allotment
    of Shares; Preemptive Rights. 

 

(a)
Subject to the provisions of Articles 11(b) and 75, the shares shall be under the control of the Board of Directors, who shall
have the power to allot, issue or otherwise dispose of shares to such persons, at such times, on such terms and conditions (including,
inter alia, terms relating to calls as set forth in Article 13 hereof), and either at par value, at a premium or,
subject to the provisions of the Companies Law, at a discount or with payment of commission, all as the Board of Directors deems
fit; and, the Board of Directors shall also have the power to give any person the option to acquire from the Company any shares,
either at nominal value, at a premium or, subject to the provisions of the Companies Law, at a discount or with payment of commission,
for such period and for such consideration as the Board of Directors deems fit.

 

(b)
Until an IPO or a Deemed Liquidation, each Shareholder holding not less than 2% of the Ordinary Shares of the Company (on an as-converted
basis) (the “Preemptive Purchaser(s)” and the “Minimum Holdings”, respectively)
shall have pre-emptive rights to purchase, pro-rata, all (or any part) of New Securities (as defined below) that the Company may,
from time to time, propose to sell and issue. Each Preemptive Purchaser’s pro rata share shall be the ratio of the number
of shares of the Ordinary Shares of the Company (on an as-converted basis) then held by such Preemptive Purchaser as of the date
of the Rights Notice (as defined in Article 11(b)(ii)), to the sum of the total number of Ordinary Shares (on an as-converted
basis) issued and outstanding as of such date.

 

(i)
“New Securities” shall mean any Ordinary Shares or preferred shares of any kind of the Company, whether
now or hereafter authorized, and rights, options, or warrants to purchase said Ordinary Shares or preferred shares, and securities
of any type whatsoever that are, or may become, convertible into or exchangeable for said Ordinary Shares or preferred shares;
provided, however, that “New Securities” shall not include (i) Excluded Securities; or (ii) securities issued in an
IPO or in connection with the acquisition of another corporation, business entity or line of business of another business entity
by the Company by merger, consolidation, purchase of all or substantially all of the assets, or other reorganization as a result
of which the Company owns not less than fifty percent (50%) of the voting power of such corporation; or (iii) Preferred Shares
reclassified into Ordinary Shares pursuant to Section 8 of the Series A SPA;

 

    	 	13	 

    	 	 	 

    

 

(ii)
If the Company proposes to issue New Securities, it shall give each Preemptive Purchaser written notice to its registered address
(the “Rights Notice”) of its intention, describing the New Securities, the price, the general terms
upon which the Company proposes to issue them, and the number of shares that each Preemptive Purchaser has the right to purchase
under this Article 11(b). Each Preemptive Purchaser shall have seven (7) days from delivery of the Rights Notice to agree to purchase
all or any part of its pro-rata share of such New Securities. Additionally, only the Preferred Shareholders shall have seven (7)
days from delivery of the Rights Notice to agree to purchase all or any part of the pro-rata share of any other Preemptive Purchaser
entitled to such rights to the extent that such Preemptive Purchaser does not elect to purchase its pro-rata share, in each case
for the price and upon the general terms specified in the Rights Notice, by giving written notice to the Company setting forth
the quantity of New Securities to be purchased. If a Preemptive Purchaser does not respond to a Rights Notice within the aforesaid
seven (7) day period, it shall be deemed to have waived its preemptive rights in full in connection with the issuance of the New
Securities that are covered by such Rights Notice. If a Preferred Shareholder elects to purchase its full pro-rata shares and
also elects to purchase additional shares such that the Preemptive Purchasers in the aggregate have elected to purchase more than
100% of the New Securities, such New Securities shall be issued to such Preferred Shareholder in accordance with its pro-rata
share amongst the shares then held by all Preferred Shareholders.

 

(iii)
To the extent that the Preemptive Purchasers fail to exercise in full their preemptive rights within the period or periods specified
in Article 11(b)(ii), the Company shall have one hundred and twenty (120) days after delivery of the Rights Notice to sell the
unsold portion of the New Securities at a price and upon general terms no more favorable to the purchasers thereof than specified
in the Company’s notice. If the Company has not sold the New Securities within said one hundred and twenty (120) day period
the Company shall not thereafter issue or sell any New Securities without first offering such securities to the Preemptive Purchasers
in the manner provided above.

 

(iv)
Notwithstanding any of the aforesaid, in the event that the implementation of the provisions of this Article ‎11 may require,
in the opinion of the Board of Directors, the publication of a prospectus under the Israeli Securities Law, as a result of the
number of Shareholders who are entitled to receive a Rights Notice, then the pre-emptive right pursuant to this Article 11 shall
be in effect only in respect of such number of Shareholders which shall not require the preparation of a prospectus (in accordance
with the Israeli Securities Law), and the Preemptive Purchasers who are entitled to purchase the largest pro rata portion of the
New Securities (as determined pursuant to Article 11(b) above) among all those Shareholders that are entitled to the pre-emptive
right hereunder.

 

	 	12.	Payment
    in Installments

 

If,
pursuant to the terms of allotment or issuance of any share, all or any portion of the price thereof shall be payable in installments,
every such installment shall be paid to the Company on the due date thereof by the then registered holder(s) of the share or the
person(s) then entitled thereto.

 

    	 	14	 

    	 	 	 

    

 

	 	13.	Calls
    on Shares

 

(a)
The Board of Directors may, from time to time, as it in its discretion deems fit, make calls for payment upon shareholders in
respect of any sum that has not been paid up in respect of shares held by such shareholders and which is not, pursuant to the
terms of allotment or issuance of such shares or otherwise, payable at a fixed time. Each shareholder shall pay the amount of
every call so made upon him (and of each installment thereof if the same is payable in installments), to the Company at the time(s)
and place(s) designated by the Board of Directors, as any such time(s) may subsequently be extended or place(s) changed. Unless
otherwise stipulated in the resolution of the Board of Directors (and in the notice referred to below), each payment in response
to a call shall be deemed to constitute a pro rata payment on account of all the shares of the shareholder making payment in respect
of which such call was made.

 

(b)
Notice of any call for payment by a shareholder shall be given in writing to such shareholder not less than fourteen (14) days
prior to the time of payment fixed in such notice, and shall specify the time and place of payment, and the person to whom such
payment is to be made. Prior to the time for any such payment fixed in a notice of a call given to a shareholder, the Board of
Directors may in its absolute discretion, by notice in writing to such shareholder, revoke such call in whole or in part, extend
the time fixed for payment of such call or designate a different place of payment or person to whom payment is to be made. In
the event of a call payable in installments, only one notice thereof need be given.

 

(c)
If pursuant to the terms of allotment or issuance of a share, or otherwise, an amount is made payable at a fixed time (whether
on account of such share or by way of premium), such amount shall be payable at such time as if it were payable by virtue of a
call made by the Board of Directors and for which notice was given in accordance with sub-articles (a) and (b) of this Article
13, and the provisions of these Articles with regard to calls (and the nonpayment thereof) shall be applicable to such amount
(and the non-payment thereof).

 

(d)
Joint holders of a share shall be jointly and severally liable to pay all calls for payment in respect of such share and all interest
payable thereon.

 

(e)
Any amount called for payment that is not paid when due shall bear interest from the date fixed for payment until actual payment,
at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel) and shall be payable
at such time(s) as the Board of Directors may prescribe.

 

(f)
Upon the allotment of shares, the Board of Directors may provide for differences among the allottees of such shares as to the
amounts and times for payment and of calls for payment in respect of such shares.

 

	 	14.	Prepayment

 

With
the consent of the Board of Directors any shareholder may pay to the Company any amount not yet payable in respect of his shares,
and the Board of Directors may approve the payment by the Company of interest on any such amount until the same would be payable
if it had not been paid in advance, at such rate and time(s) as may be approved by the Board of Directors. The Board of Directors
may at any time cause the Company to repay all or any part of the money so advanced, without premium or penalty. Nothing in this
Article 14 shall derogate from the right of the Board of Directors to make any call for payment before or after receipt by the
Company of any such advance.

 

    	 	15	 

    	 	 	 

    

 

	 	15.	Forfeiture
    and Surrender

 

(a)
If any shareholder fails to pay an amount payable by virtue of a call, or interest thereon as provided for in accordance with
these Articles, on or before the day fixed for payment of the same, the Board of Directors may at any time after the day fixed
for such payment, so long as such amount or any portion thereof remains unpaid, forfeit all or any of the shares in respect of
which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon,
including, without limitation, attorneys’ fees and costs of legal proceedings, shall be added to, and shall for all purposes
(including the accrual of interest thereon) constitute a part of the amount payable to the Company in respect of such call.

 

(b)
Upon the adoption of a resolution as to the forfeiture of a shareholder’s share, the Board of Directors shall cause notice
thereof to be given to such shareholder, which notice shall state that, in the event of the failure to pay the entire amount so
payable by a date specified in the notice (which date shall be not less than fourteen (14) days after the date such notice is
given and which may be extended by the Board of Directors), such shares shall ipso facto be forfeited; provided, however,
that prior to such date the Board of Directors may nullify such resolution of forfeiture, but no such nullification shall stop
the Board of Directors from adopting a further resolution of forfeiture in respect of the non-payment of the same amount.

 

(c)
Without derogating from Articles 56 and 61 of these Articles, whenever shares are forfeited as herein provided, all dividends,
if any, theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time.

 

(d)
The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.

 

(e)
Any share forfeited or surrendered as provided herein shall become the property of the Company, and the same, subject to the provisions
of these Articles, may be sold, re-allotted or otherwise disposed of as the Board of Directors deems fit.

 

(f)
Any shareholder whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or
surrendered shares, but shall nonetheless be liable to pay and shall promptly pay, to the Company all calls, interest and expenses
owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of
forfeiture or surrender until actual payment at the rate prescribed in Article 13(e) above, and the Board of Directors, in its
discretion, may enforce the payment of such moneys or any part thereof. In the event of such forfeiture or surrender, the Company,
by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owed to the Company
by the shareholder in question (but not yet due) in respect of all shares owned by such shareholder, solely or jointly with another.

 

(g)
The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold, re-allotted or otherwise
disposed of, nullify the forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the
Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 15.

 

    	 	16	 

    	 	 	 

    

 

	 	16.	Lien

 

(a)
Except to the extent that the same may be waived or subordinated in writing, the Company shall have a first and paramount lien
upon all the shares registered in the name of each shareholder (without regard to any equitable or other claim or interest in
such shares on the part of any other person), and upon the proceeds of the sale thereof, for his debts, liabilities and obligations
to the Company arising from any amount payable by such shareholder in respect of any unpaid or partly paid share, whether or not
such debt, liability or obligation has matured. Such lien shall extend to all dividends from time to time declared or paid in
respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be
a waiver on the part of the Company of any lien existing on such shares immediately prior to such transfer.

 

(b)
The Board of Directors may cause the Company to sell a share subject to such a lien when the debt, liability or obligation giving
rise to such lien has matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such
debt, liability or obligation has not been satisfied within fourteen (14) days after written notice of the intention to sell shall
have been served on such shareholder, his executors or administrators.

 

(c)
The net proceeds of any such sale, after payment of the costs thereof, shall be applied in or toward satisfaction of the debts,
liabilities or obligations of such shareholder in respect of such share, and any residue shall be paid to the shareholder, his
executors, administrators or assigns.

 

	 	17.	Sale
    After Forfeiture or Surrender or in Enforcement of Lien

 

Upon
any sale of a share after forfeiture or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute
an instrument of transfer of the share so sold and cause the purchaser’s name to be entered in the Register of Shareholders
in respect of such share. The purchaser shall be registered as the shareholder and shall not be bound to see to the regularity
of the sale proceedings or to the application of the proceeds of such sale, and after his name has been entered in the Register
of Shareholders in respect of such share, the validity of the sale shall not be impeached by any person, and the remedy of any
person aggrieved by the sale shall be in damages only and against the Company exclusively.

 

	 	18.	Redeemable
    Shares.

 

The
Company may, subject to applicable law and Article 74, issue redeemable shares and redeem the same.

 

TRANSFER
OF SHARES

 

	 	19.	Prohibited
    Transfers; Rights of First Refusal; and Permitted Transfers.

 

(a)
Prohibited Transfers

 

(i)
The Ordinary Shares of employees of the Company shall not be transferable for so long as they are employed by the Company.

 

(ii)
Until the earlier of an (a) an IPO (b) a Deemed Liquidation, (c) 36 months from the date of the Initial Closing (as defined in
the Series A SPA) and (d) the Third Milestone Closing Date (as such term is defined in the Series A SPA), the Ordinary Shares
held by NGT and/or Boris Shtul (only after he is no longer employed by the Company) shall be transferable (subject to the rights
of first refusal set out herein) only with the prior written consent of Orchestra and ABV, provided however, that Orchestra and/or
ABV shall only have the right to reject such transferee(s) on reasonable grounds. After the Third Milestone Closing Date such
shares shall be transferable subject to the rights of first refusal set out below.

 

    	 	17	 

    	 	 	 

    

 

(iii)
Legend. Each certificate representing shares of the Holders shall be endorsed with the following legend:

 

THE
SALE OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THE ARTICLES
OF ASSOCIATION OF THE COMPANY. COPIES OF SUCH ARTICLES MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.

 

(b)
Rights of First Refusal.

 

Until
an IPO or a Deemed Liquidation Event (as defined in Article 74), except for: (i) transfers and/or dispositions to Permitted Transferees,
or (ii) disposition as of the result of a realization of a pledge of ordinary shares held by NGT in favor of the State of Israel
or the Office of the Chief Scientist (up to an aggregate amount of 1,350,000 ordinary shares), any transfer of shares by any shareholder
shall be subject to the following:

 

(i)
Each holder of Ordinary Share and/or Preferred Shares proposing to transfer all or any of its shares, pursuant to the terms of
a bona fide offer received from any person or entity, except to a Permitted Transferee (the “Offeror”)
shall first request the Company, by written notice (which shall contain all the information necessary to enable the Company to
do so), to offer such shares (for purposes of this Article 19(b), the “Offered Shares”), on the terms
of the proposed transfer, to the Preferred Shareholders (the “Primary Offeree(s)” and “Primary
Right”, respectively). The Company shall comply with such request by sending the Primary Offerees a written notice
(the “Offer”), stating therein the identity of the Offeror and of the proposed transferee(s) and the
proposed terms of sale of the Offered Shares. Any Primary Offeree may accept such Offer in respect of all or any of the Offered
Shares by giving the Company notice to that effect within twenty-one (21) days after being served with the Offer. Any Primary
Offeree that fails to respond to an Offer within the aforesaid twenty-one (21) day period shall be deemed to have waived its rights
in connection with the sale of the Offered Shares pursuant to such Offer.

 

(ii)
If the acceptances with respect to the Primary Right, in the aggregate, are in respect of all of, or more than, the Offered Shares,
then the accepting Primary Offerees shall acquire the Offered Shares, on the terms aforementioned, in proportion to their respective
holdings, provided, that no Primary Offeree shall be entitled to acquire under the provisions of this Article 19(b) more than
the number of Offered Shares initially accepted by such Primary Offeree, and upon the allocation to it of the full number of shares
so accepted, it shall be disregarded in any subsequent computations and allocations hereunder. Any shares remaining after the
computation of such respective entitlements shall be re-allocated among the accepting Primary Offerees (other than those to be
disregarded as aforesaid), in the same manner, until one hundred percent (100%) of the Offered Shares have been allocated as aforesaid.

 

    	 	18	 

    	 	 	 

    

 

(iii)
In the event that none of the Primary Offerees have elected to exercise the Primary Right in accordance with Article 19(b) above,
or if the amount of the Offered Shares the Primary Offerees elect to purchase does not equal or exceed the total amount of the
Offered Shares, the Company shall give notice of the Offer terms in writing to the Ordinary Shareholders holding at least 1% of
the outstanding Ordinary Shares who do not hold Preferred Shares (the “Secondary Offeree(s)”). Each
Secondary Offeree shall have the right (the “Secondary Right”) to purchase from the Offeror at the same
price and on the same terms (x) that portion of the Offered Shares as the aggregate number of shares of Ordinary Shares held by
such Secondary Offeree bears to the total number of shares of Ordinary Shares held by all the Secondary Offerees (the “Secondary
Basic Amount(s)”) and (y) such additional portion of the remaining Offered Shares as any Secondary Offeree indicates
it will purchase, for a period of seven (7) business days after delivery of such notice (the “Secondary Right Period”).
Any shares remaining after the computation of such respective entitlements shall be re-allocated among the accepting Secondary
Offerees, in the same manner, until one hundred percent (100%) of the Offered Shares have been allocated as aforesaid.

 

(iv)
If the acceptances set forth above, in the aggregate, are in respect of less than the number of Offered Shares, then the accepting
Primary Offerees and Secondary Offerees shall not be entitled to acquire the Offered Shares, and the Offeror, at the expiration
of the aforementioned twenty-one (21) day period or seven (7) day period (as applicable), shall be entitled to transfer all (but
not less than all) of the Offered Shares to the proposed transferee(s) identified in the Offer, provided, however, that in no
event shall the Offeror transfer any of the Offered Shares to any transferee other than such proposed transferee(s) or transfer
the same on terms more favorable to the proposed transferee than those stated in the Offer, and, provided, further, that any of
the Offered Shares not transferred within ninety (90) days after the expiration of such twenty-one (21) day period shall again
be subject to the provisions of this Article 19(b).

 

(v)
For the purposes of any Offer under this Article 19(b), the respective holdings of any number of accepting Primary Offerees and
Secondary Offerees shall mean the respective proportions of the aggregate number of Ordinary and/or Preferred Shares held by such
accepting Primary Offerees and Secondary Offerees as determined prior to such Offer.

 

(vi)
The provisions of Article 19 shall apply, mutatis mutandis, to the transfer of any other Company securities that are convertible
or exercisable, into Preferred Shares and/or Ordinary Shares of the Company.

 

(c)
Permitted Transfers.

 

Notwithstanding
Articles 19(a) and (b), any Shareholder of the Company may transfer (whether or not for consideration) shares to a Permitted Transferee
without being subject to the provision of Articles 19(a) and (b). No transfer under this Article 19 shall be made to any transferee,
unless such transferee agrees in writing to be bound by all agreements binding upon the transferor immediately prior to such transfer.
No subsequent transfer of any of such shares may be made except in conformity with the provisions of this Article 19. Should any
shareholder wish to transfer shares to more than 2 Permitted Transferees, in a single transfer or a series of transfers, in accordance
with these Articles, such Permitted Transferees shall enter into a proxy or similar arrangement reasonably acceptable to the Board,
which proxy shall apply to all such Permitted Transferees as a group.

 

    	 	19	 

    	 	 	 

    

 

	 	20.	Approval
    and Registration of Transfers.

 

(a)
No transfer, other than transfers to Permitted Transferees, shall be effective until approved by the Board, which approval shall
not be unreasonably withheld. The Board may reasonably and in good faith, subject to these Articles and subject to any of the
Company’s written agreements with or undertakings in writing towards any shareholder of the Company, refuse to approve such
transfer of shares to: (i) a direct competitor of the Company; (ii) any third party, until such time as the Board is satisfied
in its reasonable discretion that all applicable provisions of these Articles have been complied with in full and in good faith
in connection with such proposed transfer. The determination of whether a proposed transferee is a direct competitor shall be
in the sole discretion of the Board, provided that such determination is done reasonably and in good faith. Prior to the registration
of a transfer of shares, the Board may require proof of compliance with the provisions of these Articles in respect of such transfer.
If the Board makes use of its powers in accordance with this Article and refuses to register a transfer of shares, it must provide
written notice of its refusal to the transferee within fourteen (14) days from the date the deed of transfer was furnished to
the Company.

 

(b)
No transfer of shares shall be registered unless there has been compliance with the procedure set forth in Article 19, and made
in writing in the form appearing below, or any other form satisfactory to the Board of Directors from time to time. Such form
of transfer shall be delivered to the offices of the Company, together with share certificate(s) and such other evidence of title
as the Board of Directors may reasonably require. Until the transferee has been registered in the Register of Shareholders in
respect of the shares so transferred, the Company may continue to regard the transferor as the owner thereof.

 

Deed
of Transfer of Shares

 

__________
(the “Transferor”) hereby transfers to ____________, of ________________ (the “Transferee”)
_______ share(s) having nominal value of NIS ________ each in Motus GI Medical Technologies, Ltd., to the Transferee, its executors,
administrators, and assigns, subject to the several conditions on which the Transferor held the same at the time of the execution
hereof; and the Transferee, does hereby agree to take said share(s) subject to the conditions aforesaid. As witness we have hereunto
set our hands the ____ day of _____ 20__.

 

	[Name
    of Transferee]	 	[Name
    of Transferor]
	 	 	 
	By:
    	                                    	 	By:	                                    
	 	 	 
	Name:	 	 	Name:	 
	 	 	 
	Address:	 	 	Address:	 
	 	 	 
	[Name
    of Witness to Transferee]	 	[Name
    of Witness to Transferor]
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Name:	 	 	Name:	 
	 	 	 
	Address:	 	 	Address:	 

 

    	 	20	 

    	 	 	 

    

 

(c)
The deed of share transfer shall be executed both by the transferor and transferee, and the transferor shall be deemed to remain
a holder of the share until the name of the transferee is entered into the Register of Shareholders in respect thereof.

 

(d)
The Board of Directors may, to the extent it deems necessary in its discretion, close the Register of Shareholders for registrations
of transfers of shares during any year for one period, not to exceed two weeks, determined by the Board of Directors, and no registrations
of transfers of shares shall be made by the Company during any such period during which the Register of Shareholders is so closed.

 

21.
Record Date for Notices of General Meetings. Despite any contrary provision of these Articles, the Board of Directors may
fix a date, not exceeding forty-five (45) days prior to the date of any General Meeting, as the date as of which shareholders
entitled to notice of and to vote at such meeting shall be determined, and only those persons who were holders of record of voting
shares on such date shall be entitled to notice of and to vote at such meeting.

 

TRANSMISSION
OF SHARES

 

	 	22.	Decedent’s
    Shares.

 

(a)
In case of a share registered in the names of two or more holders, the Company may recognize the survivor(s) as the sole owner(s)
thereof unless and until the provisions of Article 22(b) of these Articles have been effectively invoked.

 

(b)
Any person becoming entitled to a share in consequence of the death of any person, upon producing evidence of the grant of probate
or letters of administration or declaration of succession (or such other evidence as the Board of Directors may reasonably deem
sufficient), shall be registered as a shareholder in respect of such share and such transfer shall not be subject to articles
19(a) and 19(b) hereof, or may, subject to the articles as to transfer herein contained, transfer such share.

 

	 	23.	Receivers
    and Liquidators.

 

(a)
Notwithstanding Articles 19(a) and (b) hereof, the Company may recognize any receiver, liquidator or similar official appointed
to wind up, dissolve or otherwise liquidate a corporate shareholder, and a trustee, manager, receiver, liquidator or similar official
appointed in bankruptcy or in connection with the reorganization of, or similar proceeding with respect to a shareholder or its
properties, as being entitled to the shares registered in the name of such shareholder.

 

(b)
Such receiver, liquidator or similar official appointed to wind up, dissolve or otherwise liquidate a corporate shareholder, and
such trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization
of, or similar proceeding with respect to a shareholder or its properties, upon producing such evidence as the Board of Directors
may deem sufficient as to his authority to act in such capacity or under this Article, shall with the consent of the Board of
Directors (which the Board of Directors may grant or refuse in its absolute discretion), be registered as a shareholder in respect
of such shares, or may, subject to the regulations as to transfer contained in these Articles, transfer such shares.

 

    	 	21	 

     

     

GENERAL
MEETINGS

 

	 	24.	Annual
    General Meeting.

 

The
Company shall not be required to hold an Annual General Meeting unless required for the purposes of appointing an auditor or unless
one of the shareholders or Directors requests the Company to hold such a meeting, provided, however, that the Directors’
report and the Company’s financial statements for that year are sent to all shareholders no later than fifteen (15) months
after the holding of the last preceding General Meeting (or the mailing of the last preceding Directors’ report and financial
statements as per this Article).

 

	 	25.	Extraordinary
    General Meetting. 

 

All
General Meetings other than Annual General Meetings (if convened) shall be called “Extraordinary General Meetings”.
The Board of Directors may, whenever it deems fit, convene an Extraordinary General Meeting, at such time and place, within
the State of Israel, as may be determined by the Board of Directors, and shall be obligated to do so upon a request in writing
in accordance with Sections 63 or 64 of the Companies Law.

 

	 	26.	Notice
    of General Meetings; Omission to Give Notice.

 

(a)
Notice of a General Meeting shall be delivered at least seven (7) days prior to the date for convening of the meeting (but not
more than forty-five (45) days before such date) to each of the shareholders listed in the Register of Shareholders to its registered
address in the manner specified in these Articles. Each such notice shall specify the place and the date and hour of the meeting,
the agenda, reasonable detail of the matters to be discussed at the meeting, and arrangements for voting by proxy if the matters
on the agenda for the meeting include matters in respect of which shareholders may vote by proxy under any law or in accordance
with these Articles. If the agenda of the meeting includes a proposal to amend these Articles, the text of the proposed amendment
shall be specified.

 

(b)
A resolution may be proposed and adopted at a meeting even though the notice prescribed in this Article has not been given, subject
to the consent of all of the shareholders entitled to vote thereon.

 

(c)
The non-receipt of notice sent to a shareholder to his/her/its registered address, shall not invalidate the proceedings at such
meeting.

 

PROCEEDINGS
AT GENERAL MEETINGS

 

	 	27.	Quorum.

 

(a)
No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles
for such General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business.

 

(b)
In the absence of contrary provisions in these Articles, two or more shareholders (not in default in payment of any sum referred
to in Article 33(a) of these Articles), present in person or by proxy within half an hour after the time set for the General Meeting
and holding in the aggregate at least 50% of the outstanding voting power of the Company calculated on an as-converted basis shall
constitute a quorum of General Meetings.

 

    	 	22	 

     

    

 

(c)
If within half an hour from the time appointed for the meeting a quorum is not present, the meeting, if convened upon request
under Sections 63 or 64 of the Companies Law, shall be dissolved, but in any other case it shall be adjourned to the same day
in the next week, at the same time and place, or to such day and at such time and place as the Chairman of the meeting may determine
with the consent of the holders of at least 50% of the voting power represented at the meeting in person or by proxy and voting
on the question of adjournment. No business shall be transacted at any adjourned meeting except business that might lawfully have
been transacted at the meeting as originally called. At such adjourned meeting (other than an adjourned separate meeting of a
particular class of shares as referred to in Article 7 of these Articles), any two shareholders (not in default as aforesaid)
present in person or by proxy holding in the aggregate at least 50% of the outstanding voting power of the Company calculated
above on an as-converted basis shall constitute a quorum.

 

	 	28.	Chairman.
    

 

The
Chairman of the Board of Directors shall preside at every General Meeting of the Company. If at any meeting the Chairman is not
present within 15 minutes after the time fixed for holding the meeting or is unwilling to take the chair, the shareholders present
shall choose someone of their number to be the chairman of such meeting. The office of Chairman shall not entitle the holder thereof
to a casting vote.

 

	 	29.	Adoption
    of Resolutions at General Meetings.

 

(a)
Subject to the provisions of Article 75, a resolution shall be deemed adopted if approved by the holders of at least 67% of the
voting power represented at the meeting in person or by proxy and voting thereon.

 

(b)
Every question submitted to a General Meeting shall be decided by a count of votes.

 

(c)
A declaration by the Chairman of the meeting that a resolution has been carried unanimously, or carried by a particular majority,
or defeated, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without
proof of the number or proportion of the votes recorded in favor of or against such resolution.

 

(d)
Shareholders may participate in a general meeting by means of a conference telephone call or similar communications equipment
by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this
Article shall constitute presence in person at such meeting.

 

	 	30.	Resolutions
    in Writing. 

 

A
resolution in writing signed by all shareholders of the Company then entitled to attend and vote at General Meetings or to which
all such shareholders have given their written consent (by letter, telegram, telex, facsimile or otherwise) shall be deemed to
have been unanimously adopted by a General Meeting duly convened and held.

 

    	 	23	 

     

     

	 	31.	Power
    to Adjourn. 

 

The
Chairman of a General Meeting at which a quorum is present may, with the consent of the holders of a majority of the voting power
represented in person or by proxy and voting on the question of adjournment, and shall if so directed by the meeting, adjourn
the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting except business
that might lawfully have been transacted at the meeting as originally called.

 

	 	32.	Voting
    Power. 

 

Subject
to the provisions of Articles 5 and 33(a) and subject to any provisions of these Articles conferring special rights as to voting,
or restricting the right to vote, every shareholder shall have one vote for each share held by him of record, on every resolution,
without regard to whether the vote thereon is conducted by a show of hands, by written ballot or by any other means.

 

	 	33.	Voting
    Rights.

 

(a)
No shareholder shall be entitled to vote at any General Meeting (or be counted as part of the quorum) unless all calls then payable
by him in respect of his shares in the Company have been paid.

 

(b)
A company or other corporate body being a shareholder of the Company may duly authorize any person to be its representative at
any meeting of the Company or to authorize or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise
on behalf of such shareholder all the power that the latter could have exercised if it were a natural person. Upon the request
of the Chairman of the meeting, written evidence of such authorization (in form acceptable to the Chairman) shall be delivered
to him.

 

(c)
Any shareholder entitled to vote may vote either in person or by proxy (who need not be a shareholder of the Company), or if the
shareholder is a company or other corporate body by a representative authorized pursuant to Article 33(b).

 

(d)
If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person or by
proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purposes of this Article 33(d),
seniority shall be determined by the order of registration of the joint holders in the Register of Shareholders.

 

PROXIES

 

	 	34.	Instrument
    of Appointment.

 

(a)
An instrument appointing a proxy shall be in writing and shall be substantially in the following form:

 

“I
[Name of Shareholder] of [Address of Shareholder] being a shareholder of Motus GI Medical Technologies, Ltd. hereby appoint [Name
of Proxy] of [Address of Proxy] as my proxy to vote for me and on my behalf at the General Meeting of the Company to be held on
the _____ day of _____________ and at any adjournment(s) thereof.

 

Signed
this ____ day of ______________, [signature of appointer].”

 

    	 	24	 

     

     

or
in any usual or common form or in such other form as may be approved by the Board of Directors. Such proxy shall be duly signed
by the appointor or such person’s duly authorized attorney or, if such appointor is a company or other corporate body, under
its common seal or stamp or the hand of its duly authorized agent(s) or attorney(s).

 

(b)
The instrument appointing a proxy (and the power of attorney or other authority, if any, under which such instrument has been
signed) shall either be delivered to the Company (at its principal place of business or at the offices of its registrar or transfer
agent, or at such place as the Board of Directors may specify) not less than 24 hours before the time fixed for the meeting at
which the person named in the instrument proposes to vote, or presented to the Chairman at such meeting.

 

	 	35.	Effect
    of Death of Appointor or Transfer of Share or Revocation of Appointment.

 

(a)
A vote cast in accordance with an instrument appointing a proxy shall be valid despite the prior death or bankruptcy of the appointing
shareholder (or of his attorney-in-fact, if any, who signed such instrument), or the transfer of the share in respect of which
the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairman of such meeting
prior to such vote being cast.

 

(b)
An instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairman, subsequent to receipt
by the Company of such instrument, of written notice signed by the person who signed such instrument or by the shareholder appointing
such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument
appointing a different proxy (and such other documents, if any, required under Article 34(b) for such new appointment), provided
such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery
of the instrument revoked thereby as referred to in Article 34(b) of these Articles, or (ii) if the appointing shareholder is
present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairman of such meeting
of written notice from such shareholder of the revocation of such appointment, or if and when such shareholder votes at such meeting.
A vote cast in accordance with an instrument appointing a proxy shall be valid despite the revocation or purported cancellation
of the appointment, or the presence in person or vote of the appointing shareholder at a meeting for which it was rendered, unless
such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 35(b) at or prior
to the time such vote was cast.

 

BOARD
OF DIRECTORS

 

	 	36.	Powers
    of Board of Directors.

 

	 	(a)	General.
    

 

The
management of the business of the Company shall be vested in the Board of Directors, which may exercise all such powers and do
all such acts and things as the Company is authorized to exercise and do, and are not required by law or these Articles to be
done by the Company by action of its shareholders at a General Meeting. The authority conferred on the Board of Directors by this
Article 36 shall be subject to the provisions of the Companies Law, these Articles and any regulation or resolution consistent
with these Articles adopted from time to time by the Company by action of its shareholders at a General Meeting; provided, however,
that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors
that would have been valid if such regulation or resolution had not been adopted.

 

    	 	25	 

     

     

	 	(b)	Borrowing
    Power. 

 

Subject
to Article 75, the Board of Directors may from time to time, at its discretion, cause the Company to borrow or guaranty the payment
of any sum or sums of money for the purposes of the Company, and may secure or provide for the repayment of such sum or sums in
such manner, at such times and upon such terms and conditions as it deems fit, and in particular by the issuance of bonds, perpetual
or redeemable debentures, debenture stock, or any mortgages, charges or other security interest on the whole or any part of the
property of the Company, both present and future, including its uncalled or called but unpaid capital for the time being.

 

	 	(c)	Reserves.
    

 

The
Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves
for any purpose(s) that the Board of Directors, in its absolute discretion, shall deem fit, and may invest any sum so set aside
in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any
such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets
of the Company, and may subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose,
all as the Board of Directors may from time to time think fit.

 

	 	37.	Exercise
    of Powers of Board of Directors.

 

(a)
A meeting of the Board of Directors at which a quorum is present shall be competent to exercise all the authorities, powers and
discretion vested in or exercisable by the Board of Directors.

 

(b)
Subject to Article 75 below, a resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved
by a majority of the Directors lawfully entitled to vote thereon and present when such resolution is put to a vote and voted thereon.

 

(c)
A resolution may be adopted by the Board of Directors without convening a meeting as a resolution in writing signed (by letter,
telegram, telex, facsimile or otherwise) by all of the Directors then in office and lawfully entitled to vote thereon.

    	 	26	 

     

     

	 	38.	Delegation
    of Powers.

 

(a)
Subject to Section 112 of the Companies Law, the Board of Directors may delegate any or all of its powers to committees, each
comprising of at least: (i) one Orchestra Director, (ii) one ABV Director and (iii) up until the Second Milestone Closing Date,
one NGT Director or Ordinary Director) in each case if appointed, and it may from time to time revoke such delegation or alter
the composition of any such committee. Any committee so formed (in these Articles referred to as a “Committee of the
Board of Directors”), shall, in the exercise of the powers so delegated, conform to any regulations imposed on it
by the Board of Directors. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis,
be governed by the provisions herein contained for regulating the meetings of the Board of Directors, so far as not superseded
by any regulations adopted by the Board of Directors under this Article. Unless otherwise expressly provided by the Board of Directors
in delegating powers to a Committee of the Board of Directors, such Committee shall not be empowered to further delegate such
powers.

 

(b)
Without derogating from the provisions of Article 52, the Board of Directors may, subject to the provisions of the Companies Law,
from time to time appoint a secretary to the Company, as well as officers, agents, employees and independent contractors, as the
Board of Directors may think appropriate, and may terminate the service of any such person. The Board of Directors may, subject
to the provisions of the Companies Law, determine the powers and duties, as well as the terms and conditions of employment, of
all such persons, and may require security in such cases and in such amounts as it thinks appropriate.

 

(c)
The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of
persons to be the attorney or attorneys of the Company at law or in fact for such purpose(s) and with such powers, authorities
and discretions, and for such period and subject to such conditions, as it thinks fit, and any such power of attorney or other
appointment may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board
of Directors may think fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions
vested in him.

 

	 	39.	Number
    of Directors. 

 

	 	 	The
    Board of Directors shall consist of up to seven (7) Directors, to be appointed as follows: 
	 	 	 
	 	(a)	the
    Ordinary Shareholders, (by a majority class vote) shall be entitled to appoint one (1) Director; 
	 	 	 
	 	(b)	Orchestra
    shall be entitled to appoint two (2) Directors; 
	 	 	 
	 	(c)	ABV
    shall be entitled to appoint one (1) Director; 
	 	 	 
	 	(d)	NGT
    shall be entitled to appoint one (1) Director; 
	 	 	 
	 	(e)	Mr.
    Mark Pomeranz shall be appointed by the Directors appointed in accordance with the provisions of sub-Sections 39(a)-(d), as
    a Director of the Company, and shall serve as a Director of the Company for as long as he continues to serve as the Chief
    Executive Officer of the Company; and 
	 	 	 
	 	(f)
    	the
    members of the Board of Directors (by a majority vote), shall be entitled to elect (1) Director, who shall be an independent
    industry expert. 

 

    	 	27	 

     

     

	 	40.
    	Defaulting
    Purchasers

 

(a)
In the event that Orchestra funds all of ABV’s obligations under the Series A SPA, or visa versa, then in such case, Orchestra
or ABV, as the case may be, shall have the right to appoint the ABV Director or the Orchestra Directors, as the case may be.

 

(b)
In the event that Orchestra funds only a portion of ABV’s obligations under the Series A SPA, or visa versa, and the remaining
deficiency is met by the other shareholders, then in such case, the Orchestra Directors or ABV Director, shall be appointed by
the holders of the majority of the Preferred Shares taken up from the Defaulting Purchaser.

 

(c)
In the event that any of (i) ABV; (ii) Orchestra; (iii) NGT shall have become a Defaulting Purchaser (as such term is defined
in the Series A SPA) in connection with any Milestone Closing (as defined is the Series A SPA), then such Defaulting Purchaser
shall ipso facto cease to have any right to nominate its Director(s), and, subject to Article 40(a) and 40(b) above, any Director(s)
theretofore appointed thereby shall automatically cease to serve as Directors. The aforesaid shall not affect any rights hereunder
to elect the Ordinary Director.

 

	 	41.	Appointment
    and Removal of Directors.

 

(a)
Except as otherwise provided in these Articles, Directors shall not be elected but shall be appointed as provided for herein.

 

(b)
The appointment or removal of a Director shall be effected by the delivery of a notice to the Company at its principal office,
signed by the holders of the shares entitled to effect such appointment or removal. Any appointment or removal shall become effective
on the date fixed in the notice or upon delivery of the notice to the Company, whichever is later.

 

	 	42.	Qualification
    of Directors. 

 

No
person shall be disqualified to serve as a Director by reason of his not holding shares in the Company or by reason of his having
served as a Director in the past.

 

	 	43.	Continuing
    Directors in the Event of Vacancies. 

 

Subject
to Article 39, in the event of one or more vacancies in the Board of Directors, the remaining Directors may continue to act in
every matter and, pending the filling of any vacancy pursuant to the provisions of Articles 39 and 41, may appoint Directors to
fill any such vacancy temporarily (such temporarily appointed Director being automatically deemed to be removed from the Board
upon the appointment of a Director to fill the previous vacancy in accordance with Articles 39 and 41); provided, however, that
if they number less than a majority of the number provided for pursuant to Article 39 of these Articles, they may act only in
an emergency or to fill the office of Director that has become vacant up to the minimum number or in order to call a General Meeting
of the Company for the purpose of electing Directors to fill any or all vacancies, so that at least a majority of the number of
Directors provided for pursuant to Article 39 are in office as a result of such meeting.

 

    	 	28	 

     

     

	 	44.	Vacation
    of Office.

 

(a)
The office of a Director shall be vacated, ipso facto, upon his death, or if he be found lunatic or become of unsound mind,
or if he becomes bankrupt (or if the Director is a company, upon its winding-up).

 

(b)
The office of a Director shall be vacated by his written resignation. Such resignation shall become effective on the date fixed
therein or upon the delivery to the Company, whichever is later.

 

	 	45.	Remuneration
    of Directors; Reimbursement of Expenses

 

A
Director may be paid remuneration by the Company for his services as a Director, to the extent such remuneration shall have been
approved by a General Meeting of the Company. The Company shall reimburse Directors for reasonable expenses incurred in connection
with their service on the Board of Directors.

 

	 	46.	Conflict
    of Interests. 

 

Subject
to the provisions of the Companies Law, no Director shall be disqualified by virtue of his office from holding any office or relationship
of profit with the Company or with any company in which the Company shall be a shareholder or have another interest, or from contracting
with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into by
or on behalf of the Company in which any Director shall in any way be interested, be avoided, nor, other than as required under
the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office or relationship
of profit or realized from such contract or arrangement by reason only of such Director’s holding that office or of the
fiduciary relations thereby established, but the nature of his interest, as well as any material fact or document, must be disclosed
by him at the meeting of the Board of Directors at which the contract or arrangement is first considered, if his interest then
exists, or in any other case no later than the first meeting of the Board of Directors after the acquisition of his interest.

 

	 	47.	Alternate
    Directors. 

 

(a)
A Director may, by written notice to the Company, appoint an alternate for himself (in these Articles referred to as an “Alternate
Director”), remove such Alternate Director and appoint another Alternate Director in place of any Alternate Director
appointed by him whose office has been vacated for any reason whatsoever. Unless the appointing Director, by the instrument appointing
an Alternate Director or by written notice to the Company, limits such appointment to a specified period of time or restricts
it to a specified meeting or action of the Board of Directors, or otherwise restricts its scope, the appointment shall be for
an indefinite period, and for all purposes.

 

(b)
Any notice given to the Company pursuant to Article 47(a) shall become effective on the date fixed therein, or upon the delivery
thereof to the Company, whichever is later.

 

(c)
An Alternate Director shall have all the rights and obligations of the Director who appointed him, provided, however, that he
may not in turn appoint an alternate for himself, and provided further, that an Alternate Director shall have no standing at any
meeting of the Board of Directors or any committee thereof while the Director who appointed him is present.

 

    	 	29	 

     

     

(d)
Any person that meets the qualifications of a director under the Companies Law may act as an Alternate Director. One person may
act as an Alternate Director for more than one Director, and a person serving as a director of the Company may act as an Alternate
Director.

 

(e)
An Alternate Director shall have the duties and responsibility of a Director. The appointment of an Alternate Director shall not
negate the responsibility of the Director who appointed him.

 

(f)
The office of an Alternate Director shall be vacated under the circumstances, mutatis mutandis, set forth in Article 44,
and such office shall ipso facto be vacated if the Director who appointed such Alternate Director ceases to be a Director.

 

PROCEEDINGS
OF THE BOARD OF DIRECTORS

 

	 	48.	Meetings.

 

(a)
The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Directors
deem fit, provided, however, that the Board of Directors shall meet at least quarterly, unless otherwise agreed by a vote of the
majority of the Directors.

 

(b)
Any one (1) Director may at any time, and the Chairman of the Board of Directors upon the request of any Director shall, convene
a meeting of the Board of Directors, but not less than five (5) days notice shall be given of any meeting so convened, provided,
that the Board of Directors may convene a meeting without such prior notice with the consent of all of the Directors. Notice of
any such meeting may be given in writing or by mail, telex, email, telegram or facsimile. Despite anything to the contrary in
these Articles, failure to deliver notice to a Director of any such meeting in the manner required hereby may be waived by such
Director, and a meeting shall be deemed to have been duly convened despite such defective notice if such failure or defect is
waived prior to action being taken at such meeting by all Directors entitled to participate in such meeting to whom notice was
not duly given.

 

(c)
Directors may attend any meeting via telephone so long as all may hear and be heard.

 

	 	49.	Quorum.
    

 

Until
otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted
by the presence in person or by telephone conference of a majority of the number of Directors appointed pursuant to Article 39
and lawfully entitled to vote on the subject matter of the relevant meeting, including at least one (1) Orchestra Director and
the ABV Director (in each case if appointed) and until the Second Milestone Closing Date, the NGT Director, provided, that, all
members of the Board of Directors received due notice of such meeting or telephone conference. No business shall be transacted
at a meeting of the Board of Directors unless the requisite quorum is present (in person or by telephone conference) when the
meeting proceeds to business. If within half an hour from the time appointed for the meeting a quorum is not present it shall
be adjourned to the next business day, at the same time and place, unless a majority of the Board of Directors decides otherwise.
No business shall be transacted at any adjourned meeting except business that might lawfully have been transacted at the meeting
as originally called. At such adjourned meeting the Directors (appointed pursuant to Article 39) present, and lawfully entitled
to vote on the subject matter of the relevant meeting shall constitute a quorum. A Director who waives his/her right to be present
at a meeting of the Board of Directors shall not be taken into account for the purpose of establishing the quorum requirements
provided in this Article 49.

 

    	 	30	 

     

     

	 	50.	Chairman
    of the Board of Directors. 

 

The
Board may from time to time (by a majority vote) elect a Chairman from the acting Directors, and decide the period of time he
shall hold such an office, and he shall preside at the meetings of the Board of Directors. The Chairman shall preside at every
meeting of the Board of Directors, but if there is no such Chairman, or if at any meeting he is not present within fifteen (15)
minutes of the time fixed for the meeting, or if he is unwilling to take the chairmanship, the Directors present shall choose
one of their number to be the chairman of such meeting. The Chairman shall not have a casting or deciding vote.

 

	 	51.	Validity
    of Acts Despite Defects. 

 

All
acts done bona fide at any meeting of the Board of Directors, or of a committee of the Board of Directors, or by any person(s)
acting as Director(s), shall, even if it is subsequently discovered that there was some defect in the appointment of the participants
in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid
as if there were no such defect or disqualification.

 

GENERAL
MANAGER

 

	 	52.	General
    Manager. 

 

The
Board of Directors may from time to time appoint one or more persons, whether or not Directors, as General Manager, and may confer
upon such person(s), and from time to time modify or revoke, such title(s) and such duties and authorities as the Board of Directors
may deem fit, subject to such limitations and restrictions as the Board of Directors may from time to time prescribe. Unless otherwise
determined by the Board of Directors, the General Manager shall have authority with respect to management of the Company in the
ordinary course of business.

 

MINUTES

 

	 	53.	Minutes.

 

(a)
Minutes of each General Meeting, of each meeting of the Board of Directors and of each meeting of a Committee of the Board of
Directors shall be recorded and duly entered in books provided for that purpose, and shall be held by the Company at its principal
office or such other place as shall be determined by the Board of Directors. Such minutes shall, in all events, set forth the
name of the persons present at the meeting and all resolutions adopted at the meeting.

 

(b)
Any such minutes, if purporting to be signed by the Chairman of the Board of Directors, shall constitute prima facie evidence
of the matters recorded therein.

 

    	 	31	 

     

     

DIVIDENDS

 

	 	54.
    	Declaration
    of Dividends; Dividend Preference. 

 

Subject
to Article 75, the holders of Preferred Shares shall be entitled to non-cumulative dividends (whether paid in cash or otherwise),
at a rate of eight percent (8%) per year, payable out of funds legally available therefore, prior and in preference to the payment
of dividends on any other class of shares of the Company (the “Dividend Preference”). Such dividends
shall be payable only when, as and if approved by the Board of Directors.

 

Following
the full payment of the Dividend Preference, the holders of Preferred Shares shall be entitled to participate, pro rata,
in any dividends paid on the Ordinary Shares, on an as-converted basis.

 

	 	55.	Funds
    Available for Payment of Dividends. 

 

No
dividend shall be paid otherwise than in accordance with the provisions of the Companies Law.

 

	 	56.	Amount
    Payable by Way of Dividends. 

 

Subject
to the rights of the holders of Preferred Shares as to dividends pursuant to Article 54 above, any dividend paid by the Company
shall be allocated among the shareholders entitled thereto in proportion to the sums paid up or credited as paid up on account
of the nominal value of their respective holdings of the shares in respect of which such dividend is being paid without taking
into account the premium paid up for the shares. The amount paid up on account of a share that has not yet been called for payment
or fallen due for payment and upon which the Company pays interest to the shareholder shall not be deemed, for the purposes of
this Article, to be a sum paid on account of the share.

 

	 	57.	Interest.
    

 

No
dividend shall carry interest as against the Company.

 

	 	58.	Payment
    in Specie. 

 

Upon
the resolution of the Board of Directors, the Company (i) may cause any moneys, investments or other assets forming part of the
undivided profits of the Company, standing to the credit of a reserve fund or to the credit of a reserve fund for the redemption
of capital, or in the control of the Company and available for dividends, or representing premiums received on the issuance of
shares and standing to the credit of the share premium account, to be capitalized and distributed among such of the shareholders
as would be entitled to receive the same if distributed by way of dividend and in the same proportion, on the basis that they
become entitled thereto as capital, or may cause any part of such capitalized fund to be applied on behalf of such shareholders
in paying up in full, either at par or at such premium as the resolution may provide, any unissued shares or debentures or debenture
stock of the Company that shall be distributed accordingly, in payment, in whole or in part, of the uncalled liability on any
issued shares or debentures or debenture stock; and (ii) may cause such distribution or payment to be accepted by such shareholders
in full satisfaction of their interest in the said capitalized sum.

 

	 	59.	Implementation
    of Powers under Article 58. 

 

For
the purpose of giving full effect to any resolution under Article 58, and without derogating from the provisions of Article 7
hereof, the Board of Directors may settle any difficulty that may arise in regard to the distribution as it deems expedient, and
in particular may issue fractional certificates, and may fix the value for distribution of any specific assets, and may determine
that cash payments shall be made to any shareholders upon the basis of the value so fixed, or that fractions of less value than
the nominal value of one share may be disregarded in order to adjust the rights of all parties, and may vest any such cash, shares,
debentures, debentures stock or specific assets in trustees upon such trusts for the persons entitled to the dividend or capitalized
fund as may seem expedient to the Board of Directors.

 

    	 	32	 

     

     

	 	60.	Dividends
    on Unpaid Shares. 

 

Without
derogating from Article 56, the Board of Directors may give an instruction that shall prevent the distribution of a dividend to
the holders of shares on which the full nominal amount has not been paid up.

 

	 	61.	Retention
    of Dividends.

 

(a)
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share on which
the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities or obligations in respect of
which the lien exists.

 

(b)
The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share in respect
of which any person is, under Articles 22 and 23, entitled to become a shareholder, or which any person is, under such Articles,
entitled to transfer, until such person shall become a shareholder in respect of such share or shall transfer the same.

 

	 	62.	Unclaimed
    Dividends.

 

 

All
unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board of Directors
for the benefit of the Company until claimed. The payment by the Board of Directors of any unclaimed dividend or such other moneys
into a separate account shall not constitute the Company a trustee in respect thereof. The principal (and only the principal)
of an unclaimed dividend or such other moneys shall be, if claimed, paid to a person entitled thereto.

 

	 	63.	Mechanics
    of Payment. 

 

Any
dividend or other moneys payable in cash in respect of a share may be paid by check or draft sent through the post to, or left
at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two
or more persons are registered as joint holders of such share or are entitled jointly thereto in consequence of the death or bankruptcy
of the holder or otherwise, to the joint holder whose name is registered first in the Register of Shareholders or his bank account
or the person whom the Company may then recognize as the owner thereof or entitled thereto under Article 22 or 23 hereof, as applicable,
or such person’s bank account), or to such person and at such other address as the person entitled thereto may by writing
direct. Every such check or draft shall be made payable to the order of the person to whom it is sent, or to such person as the
person entitled thereto as aforesaid may direct, and payment of the check or draft by the bank upon which it is drawn shall be
a good discharge to the Company.

 

    	 	33	 

     

     

	 	64.	Receipt
    from a Joint Holder. 

 

If
two or more persons are registered as joint holders of any share, or are entitled jointly thereto in consequence of the death
or bankruptcy of the holder or otherwise, any one of them may give effectual receipts for any dividend or other moneys payable
or property distributable in respect of such share.

 

ACCOUNTS;
AUDITS

 

	 	65.	Books
    of Account. 

 

The
Board of Directors shall cause accurate books of account to be kept in accordance with the provisions of the Companies Law and
of any other applicable law. Such books of account shall be kept at the principal office of the Company, or at such other place
or places as the Board of Directors may deem fit, and they shall always be open to inspection by all Directors. Such books of
account and other corporate documents and records shall also be open to inspection by the shareholders and by auditors appointed
by the members, provided that such shareholders and auditors shall enter into confidentiality undertakings reasonably satisfactory
to the Board of Directors.

 

	 	66.	Audit.
    

 

At
least once in every fiscal year the accounts of the Company shall be audited and the correctness of the profit and loss account
and balance sheet certified by one or more duly qualified auditors.

 

	 	67.	Auditors.
    

 

The
appointment, authorities, rights and duties of the auditor(s) of the Company shall be regulated by Companies Law; provided, however,
that the Board of Directors shall have the authority to fix the remuneration of the auditor(s).

 

RIGHTS
OF SIGNATURE, STAMP AND SEAL

 

	 	68.	Rights
    of Signature, Stamp and Seal.

 

(a)
The Board shall be entitled to authorize any person or persons (who need not be Directors) to act and sign on behalf of the Company,
and the acts and signature(s) of such person(s) on behalf of the Company shall bind the Company to the extent such person acted
and signed within the scope of his or their authority.

 

(b)
The Board may provide for a seal. If the Board so provides, it shall also provide for the safe custody thereof. Such seal shall
not be used except by the authority of the Board of Directors and in the presence of the person(s) authorized to sign on behalf
of the Company, who shall sign every instrument to which such seal is affixed.

 

    	 	34	 

     

     

NOTICES

	 	69.	Notices.

 

(a)
For purposes of this Section, the term “Business Day” means a day on which the banks are open for business
in the country of receipt of any notice.

 

(b)
All notices and other communications made pursuant to these Articles shall be in writing and shall be conclusively deemed to have
been duly given:

 

(i)
in the case of hand delivery to the address of the respective Person, on the next Business Day after delivery;

 

(ii)
in the case of delivery by an internationally recognized overnight courier to the address of the respective Person, freight prepaid,
on the next Business Day after delivery;

 

(iii)
in the case of a notice sent by facsimile transmission to the fax number of the respective Person, on the next Business Day after
delivery, if facsimile transmission is confirmed;

 

(iv)
in the case of a notice sent by email to the email address of the respective Person (if any), on the date of written acknowledgment
of receipt of such e-mail by the recipient.

 

(c)
In the event that notices are given pursuant to one of the methods listed in sub-clauses (b)(i) to (iii) above, a copy of the
notice should also be sent by email (if one is provided).

 

(d)
A Person may change or supplement the contact details for service of any notice pursuant to these Articles, or designate additional
addresses, facsimile numbers and email addresses for the purposes of this Section, by giving the other Persons written notice
of the new contact details in the manner set forth above.

 

EXEMPTION,
INDEMNITY AND INSURANCE

 

	 	70.	Exemption
    From Liability

 

Subject
to the provisions of the Companies Law, the Company may exempt an Office Holder in advance from all or part of such Officer Holder’s
responsibility or liability for damages caused to the Company due to any breach of such Office Holder’s duty of care towards
the Company.

 

	 	71.	Indemnification

 

(a)
Subject to the provisions of the Companies Law, the Company may indemnify any Office Holder to the fullest extent permitted by
the Companies Law, with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed
on or incurred by such Office Holder in such Office Holder’s capacity as an Office Holder of the Company:

(i)
A financial obligation imposed on an Office Holder in favor of another person by a court judgment, including a compromise judgment
or an arbitrator’s award approved by a court of law;

 

    	 	35	 

     

     

(ii)
Reasonable legal expenses, including attorney’s fees, expended by the Office Holder as a result of an investigation or proceeding
instituted against the Office Holder by a competent authority, provided that such investigation or proceeding concluded without
the filing of an indictment against him and either (A) concluded without the imposition of any financial liability in lieu of
criminal proceedings, or (B) concluded with the imposition of a financial liability in lieu of criminal proceedings but relates
to a criminal offense that does not require proof of criminal intent; and

 

(iii)
Reasonable legal expenses, including attorney’s fees, which the Office Holder incurred or with which the Office Holder was
charged by a court of law, in a proceeding brought against the Office Holder, by the Company or by another on behalf of the Company,
or in a criminal prosecution in which the Office Holder was acquitted, or in a criminal prosecution in which the Office Holder
was convicted of an offense that does not require proof of criminal intent.

 

(b)
Subject to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder as aforesaid (i) prospectively,
provided, that, in respect of Article 71(a)(i), the undertaking is limited to events which, in the opinion of the Board of Directors
are foreseeable in light of the Company’s actual operations when the undertaking to indemnify is given, and to an amount
or criteria set by the Board of Directors as reasonable under the circumstances, and further provided that such events and amount
or criteria are set forth in the undertaking to indemnify, and (ii) retroactively.

 

	 	72.	Insurance

 

(a)
Subject to the provisions of the Companies Law, the Company may enter into a contract to insure an Office Holder for all or part
of the liability that may be imposed on such Office Holder in connection with an act performed by such Office Holder in such Office
Holder’s capacity as an Office Holder of the Company, with respect to each of the following:

 

(i)
breach of his duty of care to the Company or to another person;

 

(ii)
breach of his duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to
assume that the action in question would not prejudice the interests of the Company; and

(iii)
a financial obligation imposed on him in favor of another person.

 

(b)
Articles 70, 71 and 72(a) shall not apply under any of the following circumstances:

 

(i)
a breach of an Office Holder’s fiduciary duty, in which the Office Holder did not act in good faith and with reasonable
grounds to assume that the action in question would not prejudice the interests of the Company;

 

(ii)
a grossly negligent or intentional violation of an Office Holder’s duty of care;

 

(iii)
an intentional action by an Office Holder in which such Office Holder intended to reap a personal gain illegally; and

 

(iv)
a fine or ransom levied on an Office Holder.

 

    	 	36	 

     

     

(c)
The Company may procure insurance for or indemnify any person who is not an Office Holder, including without limitation, any employee,
agent, consultant or contractor, provided, however, that any such insurance or indemnification is in accordance with the provisions
of these Articles and the Companies Law.

 

(d)
The Company may procure insurance for or indemnify any person who is not an Office Holder, including without limitation, any employee,
agent, consultant, the Observer or contractor (and in case of an Officer holders - to the extent that the insurance, release or
indemnity is not prohibited by law), provided, however, that any such insurance or indemnification is in accordance with the provisions
of these Articles and the Companies Law, and was duly approved by the Board of Directors.

 

WINDING
UP

 

	 	73.	Winding
    Up.

 

In
the event of a liquidation, bankruptcy, winding-up, dissolution, or reorganization of the Company (other than a solvent reorganization),
the following shall apply:

 

(a)
First, each Preferred Share shall entitle its holder to a per share distribution in the amount of the applicable Original Issue
Price (adjusted for share combinations or subdivisions or other recapitalizations of the Company’s shares) multiplied by
1.5, less the amount of the Dividend Preference and other distributions actually paid, plus an amount equal to declared but unpaid
dividends, if any, on each Preferred Share prior to payments to the other shareholders of the Company (the “Preference”).
In the event that the assets of the Company available for distribution shall be insufficient to pay the Preference in full to
the Preferred Shareholders, all of such assets shall be distributed among the holders of the Preferred Shares in proportion to
the full Preference such holders would otherwise be entitled to receive, subject to applicable law.

 

(b)
In the event of a Deemed Liquidation Event, and to the extent that the assets of the Company available for distribution and are
being distributed shall exceed the amount necessary to pay the Preference, any remaining assets, up to an aggregate amount of
US$350,000, shall be distributed to NGT or its assignee in preference to all holders of Ordinary Shares to cover the obligations
of NGT and/or the Company to the Office of the Chief Scientist in Israel (“NGT Payment”).

 

(c)
In the event that the assets of the Company that available for distribution shall exceed the amount necessary to pay the Preference
and the NGT Payment, the remaining assets shall be distributed among the holders of the Preferred Shares and the Ordinary Shares
in proportion to the respective percentage holdings of all of the Ordinary Shares (assuming conversion of the Preferred Shares).

 

	 	74.	Deemed
    Liquidation Event

 

For
purposes of Article 73, in addition to any liquidation, dissolution, reorganization or winding up of the Company under applicable
law, the Company shall be deemed to be liquidated (a “Deemed Liquidation Event”): (a) in the event of
a consolidation, merger, acquisition, or reorganization of the Company with or into, or a sale of all or substantially all of
the Company’s assets, or substantially all of the Company’s issued and outstanding share capital, to, any other company,
or any other entity or person, other than a wholly-owned subsidiary of the Company, excluding a transaction in which shareholders
of the Company prior to the transaction will maintain voting control of the surviving or acquiring entity after the transaction
(provided, however, that shares of the surviving or acquiring entity held by shareholders of the Company acquired by means other
than the exchange or conversion of the shares of the Company shall not be used in determining if the shareholders of the Company
own more than fifty percent (50%) of the voting power of the surviving or acquiring entity (or its parent)), but shall be used
for determining the total outstanding voting power of the surviving or acquiring entity); (b) in the event that pursuant to a
transaction or series of transactions a person or entity acquires, fifty percent (50%) or more of the issued and outstanding shares
of the Company; or (c) in the event of any lease, transfer or exclusive license of all or substantially all of the assets of the
Company (other than to a wholly owned subsidiary of the Company). Upon any deemed liquidation event of the Company as described
in this Article 74, at the closing of the transaction at which the Company is deemed for purposes of this Article 74 to be liquidated,
the shareholders shall be paid in cash, securities or a combination thereof, an amount equal to the amount per share which would
be payable to the shareholders of the Company, respectively, pursuant to Article 73 as if all consideration being received by
the Company and its shareholders in connection with such transaction were being distributed in a liquidation of the Company.

 

    	 	37	 

     

    

 

MAJOR
DECISIONS

 

	 	75.	Major
    Decisions. 

 

(a)
Subject to Article 75(d) below, the Company shall not and shall ensure that no subsidiary of the Company shall, without first
obtaining: (A) the written consent of the holders of 67% of the Preferred Shares if the matter is brought before the Shareholders;
or (B) the affirmative vote of the majority of the ABV Director or the Orchestra Director(s) (if appointed) if the matter is brought
before the Board, either directly or by amendment, merger, consolidation or otherwise, do any of the following or cause any subsidiary
to carry out any of such actions:

 

	 	(i)	Any
    amendment or replacement of the articles of association of the Company (“Amendment to Articles”);
	 	 	 
	 	(ii)	any
    amendment or change of the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of,
    the Preferred Shares;
	 	 	 
	 	(iii)	Any
    issuance of any class of shares having rights, preferences or privileges equal to or more favorable than the rights, preferences
    or privileges of the Preferred Shares;
	 	 	 
	 	(iv)	Any
    increase in the authorized share capital of the Company, or any increase in the number of issued Preferred Shares, except
    as contemplated by the Series A SPA;
	 	 	 
	 	(v)	Any
    purchase, redemption, subdivision, consolidation, re-designation or other variation of or in the share capital of the Company
    (including any action that reclassifies any outstanding shares) or the rights attaching to shares in the share capital of
    the Company;
	 	 	 
	 	(vi)	Any
    reduction in the amount standing to the Company’s capital redemption or share premium reserve;
	 	 	 
	 	(vii)	Any
    merger, consolidation, acquisition or similar transaction of the Company with one or more other companies in which the shareholders
    of the Company prior to such transaction, or series of transactions, would hold shares representing less than a majority of
    the voting power of the outstanding shares of the surviving corporation immediately after such transaction, or series of transactions;

 

    	 	38	 

     

    

 

	 	(viii)	The
    sale of all or substantially all of the Company’s assets;
	 	 	 
	 	(ix)	Any
    transaction or series of transactions whereby the Company acquires another company, including the acquisition of shares representing
    a majority of the voting power of the outstanding shares of another company, or an acquisition of all or substantially all
    of another company’s assets;
	 	 	 
	 	(x)	Any
    resolution for the winding up or liquidation of the Company;
	 	 	 
	 	(xi)	Any
    declaration or payment of a dividend or resolution to declare a dividend;
	 	 	 
	 	(xii)	[Reserved]
	 	 	 
	 	(xiii)	Material
    change in the nature of the business of the Company or in the Company’s business plan or budget (“Change
    of Business Plan or Budget”);
	 	 	 
	 	(xiv)	Any
    increase or decrease in the authorized number of directors of the Company;
	 	 	 
	 	(xv)	Instruct
    or enter into any engagement, agreement or understanding whatsoever with any broker, advisor (including, without limitation,
    financial, accounting, auditing or legal advisors), investment bank or similar party (each a “Service Provider”),
    to provide any services in connection with the listing of any of the Company’s shares or the merger or consolidation
    of the Company with or into, or the sale of all or substantially all of the assets or shares of the Company to, any person
    or entity;
	 	 	 
	 	(xvi)	issue
    or sell Series A Preferred Shares other than pursuant to the Series A SPA;
	 	 	 
	 	(xvii)	create,
    or hold capital stock in, or make any loan or advance to any subsidiary that is not wholly owned (either directly or through
    one or more other subsidiaries) by the Company, or sell, transfer or otherwise dispose of any capital stock of any direct
    or indirect subsidiary of the Company, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license
    or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets
    of such subsidiary; or
	 	 	 
	 	(xviii)	enter
    into any contract, arrangement or transaction with an affiliate of the Company or any office holder of the Company or any
    of their family members, unless such contract, arrangement or transaction (A) is on terms that are no less favorable to the
    Company than those the Company would have been reasonably likely to obtain as a result of arms-length negotiations with an
    unrelated third party and (B) has been approved by a majority vote of the disinterested members of the Board of Directors
    of the Company (“Related Party Transaction”). For the avoidance of doubt any transfer of shares
    by a shareholder to a Permitted Transferee shall not be deemed to be a Related Party Transaction.

 

    	 	39	 

     

     

(b)
Subject to Article 75(d) below, the Company shall not: (i) make an Amendment to the Articles; (ii) make any Change of Business
Plan or Budget; or (iii) enter into a Related Party Transaction: without (A) the written consent, not to be unreasonably withheld
or delayed, of NGT, if the matter is brought before the Shareholders; or (B) the affirmative vote, not to be unreasonably withheld
or delayed, of the NGT Director, if the matter is brought before the Board.

 

(c)
Notwithstanding anything in these Articles to the contrary, with respect to any exclusive rights granted to a specific named shareholder
(not by virtue of such shareholders holdings) (the “Specific Rights”), the Company shall not and shall
ensure that no subsidiary of the Company shall amend, change, or modify such Specific Rights, without the prior specific written
consent of the holder(s) of the relevant Specific Rights proposed to be amended, changed or modified.

 

(d)
Notwithstanding the foregoing any veto rights granted to NGT in Article 75(b)(i) (Amendment to the Articles) and in Article 75(b)(iii)
(Related Party Transaction) shall terminate (and the affirmative vote of the NGT Director shall not be required to have been obtained)
(x) when the Second Milestone Closing has been fully consummated by ABV and Orchestra as contemplated in the Series A SPA, (y)
if or NGT shall have become a Defaulting Purchaser, or (z) if the Second Milestone is not met by the Second Milestone Closing
Date (as such terms are defined in the Series A SPA). Notwithstanding the foregoing any veto rights granted to NGT in Article
75(b)(ii) (Change of Business Plan or Budget) shall terminate (and the affirmative vote of the NGT Director shall not be required
to have been obtained) (x) when the Third Milestone Closing has been fully consummated by ABV and Orchestra as contemplated in
the Series A SPA, (y) if or NGT shall have become a Defaulting Purchaser, or (z) if the Third Milestone is not met by the Third
Milestone Closing Date (as such terms are defined in the Series A SPA).

 

	 	76.	Bring
    Along. 

 

(a)
Subject to the provisions of and without derogating from Article 75 above and the provisions of Section 341 of the Companies Law,
notwithstanding anything in these Articles to the contrary, until a Qualified IPO, if any person or entity offers to purchase
all of the issued and outstanding share capital of the Company (the “Bring Along Transaction”), and
shareholders holding more than (i) seventy percent (70%) of the voting power in the Company calculated on an as converted basis;
and (ii) 67% of the Preferred Shares, indicate their acceptance of such offer (the “Proposing Shareholders”),
and such offer is approved by a majority of the Board, then at the closing of such transaction, all holders of all classes of
shares in the Company will transfer their shares to such person or entity at the same price and on the same terms and conditions
as the Proposing Shareholders subject to any adjustments as may be necessary in order to give full effect to Article 74 hereof.
The distribution of the consideration of such Bring Along Transaction shall be distributed in accordance with the provisions of
Article 74 above, and in the order of preference and priority as set forth therein, and shall not derogate from the liquidation
preferences set forth in such Article 73 and Article 74 in relation to a Deemed Liquidation Event.

 

    	 	40	 

     

     

FOURTH
AMENDMENT TO CONVERTIBLE NOTES AGREEMENT

 

This
Fourth Amendment to Convertible Notes Agreement (this “Amendment”) is made and entered into as of the 18 day
of October, 2016 (the “Effective Date”), by and among Motus GI Medical Technologies Ltd., a company organized
under the laws of the State of Israel, with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”)
and the persons and entities listed on Exhibit A attached hereto (the “Purchasers”) (each Purchaser
and the Company separately, a “Party”, and together, the “Parties”).

 

	WHEREAS,
    	 	the
    Company and the Purchasers are parties to that certain Convertible Notes Agreement dated June 9, 2015, as amended on December
    29, 2015, on February 15, 2016 and on July 25, 2016 (the “Third Amendment” and collectively with all amendments,
    the “CNA”), attached hereto as Exhibit B (capitalized not defined herein shall have the meaning
    ascribed to them in the CNA, unless it is specifically provided otherwise); 
	 	 	 
	WHEREAS,	 	the
    Board of Directors of the Company has decided that it is in the best interest of the Company to increase the aggregate amount
    the Company may raise under the CNA to US$12.5 Million; and
	 	 	 
	WHEREAS,
    	 	the
    Parties wish to amend certain terms of the CNA, including the increase of the aggregate Loan Amount to an aggregate principal
    amount of up to US$12.5 Million, and amend certain terms of the Notes and the Warrants issued to the Purchasers under the
    CNA (including any Deferred Closing Notes and Deferred Closing Warrants issued or to be issued in the future under the CNA.)
    

 

NOW
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

	1.	Amendments
    

 

	 	1.1.	Section
    3 of the Third Amendment is hereby amended such that the aggregate amount that may be extended by Additional Purchasers (the
    “Additional Loan Amount”), together with the aggregate Loan Amount previously extended or committed to
    be extended by the Purchasers and/or previous Additional Purchasers (including, for greater certainty, the additional Loan
    Amounts to be extended by the Major Purchasers pursuant to the Third Amendment) shall not exceed US$12.5 Million. 
	 	 	 
	 	1.2.	The
    Notes issued to the Purchasers and /or Additional Purchasers under the CNA (including any Deferred Closing Notes issued or
    to be issued in the future under the CNA) are hereby amended and restated in their entirety to be on the form of the Amended
    Notes attached hereto as Exhibit C (the “Amended Notes”). 

 

    	 	 	 

    	 		 

    

 

	 	1.3.	The
    Warrants issued to the Purchasers and/or Additional Purchasers under the CNA (including any Deferred Closing Warrants issued
    or to be issued in the future under the CNA) are hereby amended and restated in their entirety to be in the form of the Amended
    Warrants attached hereto as Exhibit D (the “Amended Warrants”).
	 	 	 
	 	1.4.	Within
    [__] days following the execution of this Agreement, the Company shall issue to the Purchasers, Amended Notes and Amended
    Warrants in accordance with the allocation set forth in Exhibit A attached hereto, against surrender to the
    Company by each Purchaser of the original copy of the Note and Warrant previously issued to it under the CNA or an affidavit
    of loss of such Note and Warrant, in a form and substance reasonably acceptable to the Company. 
	 	 	 
	 	1.5.	Notwithstanding
    anything herein to the contrary, upon issuance by the Company of such Amended Notes and Amended Warrants to the Purchasers,
    the Notes and Warrants previously issued to such Purchasers under the CNA shall immediately and automatically terminate and
    shall have no further force and effect whether or not physically surrendered to the Company.
	 	 	 
	 	1.6.	Any
    reference in the CNA to Notes and Warrants shall be deemed to refer to the Amended Notes and the Amended Warrants. 

 

	2.	Miscellaneous

 

	 	2.1.	The
    headings in this Amendment are for convenience only and shall not be used for purposes of construction.
	 	 	 
	 	2.2.	All
    terms and conditions of the CNA (including any of its exhibits) shall remain in full force and effect subject to the provisions
    of this Amendment, which shall be regarded as an integral part of the CNA. In case of a contradiction between this Amendment
    and the CNA, the provisions of this Amendment shall prevail.
	 	 	 
	 	2.3.	This
    Amendment may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together
    shall constitute a single instrument.

 

    	- 2 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fourth Amendment to Convertible Notes Agreement on the date first above written.

 

 

	Motus
    GI Medical Technologies Ltd.	 
	 	 	 
	By:	           	 
	Title:	 	 

 

[Purchasers’
Signature Pages to Follow]

 

    	- 3 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fourth Amendment to Convertible Notes Agreement on the date first above written.

 

 

	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
    MOTUS Co-Investment Partners, LLC 
	 	 	 	 	 
	By:	         	 	By:	         
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	Ascent
    Biomedical Ventures II, L.P.(3)	 	Ascent
    Biomedical Ventures Synecor, L.P.
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	Jacobs
    Investments Company LLC	 	 	 
	 	 	 	 	 
	By:	 	 	 	 
	Title:	 	 	 	 

 

    	- 4 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fourth Amendment to Convertible Notes Agreement on the date first above written.

 

 

	E.
    Jeffrey Peierls	 	Brian
    Eliot Peierls
	 	 	 	 	 
	 	 	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	UD
    E.F. Peierls for E. Jeffrey Peierls
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	UD
    J.N. Peierls for E. Jeffrey Peierls
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	UD
    Ethel F. Peierls Charitable Lead Trust
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	The
    Peierls Bypass Trust	 	UD
    E.S. Peierls for E.F. Peierls et al
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	UW
    E.S. Peierls for E. Jeffrey Peierls - Accumulation
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Peierls	 	The
    Peierls Foundation, Inc.
	By:	 	 	By:	               
	Title:	 	 	Title:	 
	 	 	 	 	 
	James
    T. Lenehan	 	 	 

 

    	- 5 -

    	 

    

 

Exhibit
A

 

	Installment	 	Shareholder	 	Date	 	 	Note	 	 	Warrant	 
	First	 	Orchestra
    Medical Ventures II, L.P.	 	 	07/08/2015	 	 	$	309,999	 	 	 	102,300	 
	 	 	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	07/08/2015	 	 	$	325,837	 	 	 	107,526	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	23/06/2015	 	 	$	416,277	 	 	 	137,371	 
	 	 	Ascent
    Biomedical Ventures Synecor, L.P.	 	 	10/07/2015	 	 	$	207,826	 	 	 	68,583	 
	 	 	Jacobs
    Investments Company LLC	 	 	09/06/2015	 	 	$	195,508	 	 	 	64,518	 
	Second
    Installment	 	Orchestra
    Medical Ventures II, L.P.	 	 	21/09/2015	 	 	$	309,999	 	 	 	102,300	 
	 	 	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	21/09/2015	 	 	$	325,837	 	 	 	107,526	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	24/09/2015	 	 	$	416,277	 	 	 	137,371	 
	 	 	Ascent
    Biomedical Ventures Synecor, L.P.	 	 	15/10/2015	 	 	$	207,826	 	 	 	68,583	 
	 	 	Jacobs
    Investments Company LLC	 	 	15/10/2015	 	 	$	195,508	 	 	 	64,518	 
	Third
    Installment	 	Orchestra
    Medical Ventures II, L.P.	 	 	14/12/2015	 	 	$	309,999	 	 	 	102,300	 
	 	 	Orchestra
    MOTUS Co-Investment Partners, LLC	 	 	14/12/2015	 	 	$	325,837	 	 	 	107,526	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	24/12/2015	 	 	$	416,277	 	 	 	137,371	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	16/02/2016	 	 	$	207,826	 	 	 	68,583	 
	 	 	Jacobs
    Investments Company LLC	 	 	14/12/2015	 	 	$	195,508	 	 	 	64,518	 
	 	 	E.
    Jeffrey Peierls	 	 	14/01/2016	 	 	$	97,500	 	 	 	32,175	 
	 	 	Brian
    Eliot Peierls	 	 	14/01/2016	 	 	$	60,000	 	 	 	19,800	 
	 	 	UD
    E.F. Peierls for Brian E. Peierls	 	 	14/01/2016	 	 	$	40,500	 	 	 	13,365	 
	 	 	UD
    E.F. Peierls for E. Jeffrey Peierls	 	 	14/01/2016	 	 	$	40,500	 	 	 	13,365	 
	 	 	UD
    J.N. Peierls for Brian Eliot Peierls	 	 	14/01/2016	 	 	$	40,500	 	 	 	13,365	 

 

    	- 6 -

    	 

    

 

	 	 	UD
    J.N. Peierls for E. Jeffrey Peierls	 	 	14/01/2016	 	 	$	40,500	 	 	 	13,365	 
	 	 	UW
    J.N. Peierls for Brian E. Peierls	 	 	14/01/2016	 	 	$	42,000	 	 	 	13,860	 
	 	 	UW
    J.N. Peierls for E. Jeffrey Peierls	 	 	14/01/2016	 	 	$	42,000	 	 	 	13,860	 
	 	 	UD
    Ethel F. Peierls Charitable Lead Trust	 	 	14/01/2016	 	 	$	37,500	 	 	 	12,375	 
	 	 	The
    Peierls Bypass Trust	 	 	14/01/2016	 	 	$	15,000	 	 	 	4,950	 
	 	 	UD
    E.S. Peierls for E.F. Peierls et al	 	 	14/01/2016	 	 	$	28,500	 	 	 	9,405	 
	 	 	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	 	14/01/2016	 	 	$	34,500	 	 	 	11,385	 
	 	 	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	 	14/01/2016	 	 	$	21,000	 	 	 	6,930	 
	 	 	The
    Peierls Foundation, Inc.	 	 	14/01/2016	 	 	$	397,500	 	 	 	131,175	 
	Fourth
    Installments	 	Orchestra
    Medical Ventures II, L.P.	 	 	04/05/2016	 	 	$	309,999	 	 	 	102,300	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	03/06/2016	 	 	$	624,103	 	 	 	205,954	 
	 	 	Jacobs
    Investments Company LLC	 	 	25/04/2016	 	 	$	195,508	 	 	 	64,518	 
	 	 	E.
    Jeffrey Peierls	 	 	28/04/2016	 	 	$	32,500	 	 	 	10,725	 
	 	 	Brian
    Eliot Peierls	 	 	28/04/2016	 	 	$	20,000	 	 	 	6,600	 
	 	 	UD
    E.F. Peierls for Brian E. Peierls	 	 	28/04/2016	 	 	$	13,500	 	 	 	4,455	 
	 	 	UD
    E.F. Peierls for E. Jeffrey Peierls	 	 	28/04/2016	 	 	$	13,500	 	 	 	4,455	 
	 	 	UD
    J.N. Peierls for Brian Eliot Peierls	 	 	28/04/2016	 	 	$	13,500	 	 	 	4,455	 
	 	 	UD
    J.N. Peierls for E. Jeffrey Peierls	 	 	28/04/2016	 	 	$	13,500	 	 	 	4,455	 
	 	 	UW
    J.N. Peierls for Brian E. Peierls	 	 	28/04/2016	 	 	$	14,000	 	 	 	4,620	 
	 	 	UW
    J.N. Peierls for E. Jeffrey Peierls	 	 	28/04/2016	 	 	$	14,000	 	 	 	4,620	 
	 	 	UD
    Ethel F. Peierls Charitable Lead Trust	 	 	28/04/2016	 	 	$	12,500	 	 	 	4,125	 
	 	 	The
    Peierls Bypass Trust	 	 	28/04/2016	 	 	$	5,000	 	 	 	1,650	 
	 	 	UD
    E.S. Peierls for E.F. Peierls et al	 	 	28/04/2016	 	 	$	9,500	 	 	 	3,135	 
	 	 	UW
    E.S. Peierls for Brian E. Peierls - Accumulation	 	 	28/04/2016	 	 	$	11,500	 	 	 	3,795	 
	 	 	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation	 	 	28/04/2016	 	 	$	7,000	 	 	 	2,310	 
	 	 	The
    Peierls Foundation, Inc.	 	 	28/04/2016	 	 	$	132,500	 	 	 	43,725	 

 

    	- 7 -

    	 

    

 

	Fifth
    Installments	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Orchestra
    Medical Ventures II, L.P.	 	 	10/08/2016	 	 	$	143,479
                                         (according to CNA shall be $315,000)	 	 	 	47,348
                                         (according to CNA shall be 103,950)	 
	 	 	Ascent
    Biomedical Ventures II, L.P. (3)	 	 	04/08/2016	 	 	$	294,000	 	 	 	97,020	 
	 	 	Jacobs
    Investments Company LLC	 	 	01/08/2016	 	 	$	91,000	 	 	 	30,030	 
	Deferred
    Closing	 	James
    T. Lenehan	 	 	31/08/2016	 	 	$	100,000	 	 	 	33,000	 
	Sixth
    Installment	 	Orchestra
    Medical Ventures II, L.P.	 	 	16/09/2016	 	 	 	$
                                         143,479 (according to CNA shall be $315,000)	 	 	 	47,348(according
                                         to CNA shall be 103,950)	 
	 	 	Jacobs
    Investments Company LLC	 	 	16/09/2016	 	 	$	91,000	 	 	 	30,030	 

 

    	- 8 -

    	 

    

 

Exhibit
B

 

CNA

 

    	- 9 -

    	 

    

 

EXHIBIT
C TO FOURTH AMENDMENT TO CONVERTIBLE NOTE AGREEMENT

 

Date:
______________

Purchaser:
________________________

 

Principal
Amount: US$________________

 

CONVERTIBLE

 

PROMISSORY
NOTE

 

For
value received, Motus GI Medical Technologies Ltd., an Israeli company (“Company”) promises to pay to
the Purchaser named above (“Holder”), the principal sum stated above (the “Principal Amount”)
in accordance with the terms set forth herein, as follows:

 

	1.	Note
    Part of a Series. This Note is being sold by the Company as part of a series of notes issued pursuant to that certain
    Convertible Notes Agreement dated as of June 9, 2015, by and among the Company and purchasers of such Notes, as amended (the
    “CNA”). The term “Notes” shall mean herein all Notes issued under the CNA.
	 	 
	2.	Interest.
    Interest shall accrue on the unpaid Principal Amount of this Note from the date of this Note until the actual repayment of
    all amounts due hereunder, at an annual rate of 10% (ten percent), compounded annually. Interest shall be computed on the
    basis of a year of 360 days for the actual number of days occurring in the period for which such interest is payable. Upon
    conversion of the Principal Amount in accordance with the terms hereof, all interest accrued thereon shall be converted together
    with the Principal Amount or repaid to the Holder in cash, after deduction of all applicable taxes with respect thereto, as
    shall be determined by the Company, at its sole discretion. The actual amount to be converted in accordance with the Company’s
    election, as specified in the preceding sentence, shall be hereinafter referred to as the “Conversion Amount.”
	 	 
	3.	Automatic
    Conversion upon QFR. To the extent not previously converted or repaid according to the terms specified herein, the
    Conversion Amount shall be automatically converted, immediately prior and subject to the closing of a QFR (as defined below),
    on the same terms and conditions applicable to the QFR, such that the Holder shall receive the same type of securities issued,
    and any other rights granted to the investors in such QFR (the “QFR Securities”), under the same terms
    as if the Holder had participated in the QFR as an investor (including any warrants or any other securities granted to the
    investors therein), but at a conversion price per share equal to the QFR Conversion Price (as defined below).

 

    	 	 	 

     

    

 

	 	It
    being agreed and acknowledged that (a) the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of QFR Securities issued to the Holder shall be set to be the QFR Conversion Price, and any
    rights that are attached to the QFR Securities issued to the Holder which are determined, derived, calculated, triggered,
    or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend preferences,
    anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual QFR Conversion
    Price; and (b) in the event that the QFR Securities also comprise of warrants to purchase, or other securities convertible
    into, shares of the Company (any such preceding convertible security a “Convertible Security”), then (i)
    upon such conversion, the Holder shall be entitled to receive such number of warrants and/or Convertible Securities of the
    same class or type that are issued to the investors in the framework of the QFR, in a number which shall be determined using
    the same warrant and/or Convertible Securities coverage ratio offered to the investors in such QFR, such that the ratio between
    the shares and the warrants and/or Convertible Securities issued to the Holder shall be equal to the ratio between the shares
    and the warrants and/or Convertible Securities issued to each investor in such QFR; and (ii) the discount rate reflected in
    the QFR Conversion Price shall not apply in respect of the exercise price or conversion price (as applicable) of such warrants
    and/or Convertible Securities.

 

	 	For
    example, if the terms of the QFR are as follows:
	 	 	 
	 	●	The
    QFR unit price is US$10.
	 	 	 
	 	●	Each
    unit is comprised of two (2) Ordinary Shares and one (1) warrant to purchase one (1) Ordinary Share.
	 	 	 
	 	●	The
    discount rate reflected in the QFR Conversion Price of the Holder is 10%.
	 	 	 
	 	●	The
    exercise price of the warrants issued in the QFR is US$12.
	 	 	 
	 	●	The
    Conversion Amount of the Holder is US$1,800.

 

	 	then,
    in the framework of such QFR, the Holder shall be issued, upon conversion of the Conversion Amount, 200 Ordinary Shares ((US$1,800))/((1-10%)*US$10))
    and 100 warrants to purchase 100 Ordinary Shares (100/2), at an exercise price per share of US$12, while an investor, who
    is not a holder of Notes, and invests in the QFR the same amount (i.e., US$1,800), shall be issued only 180 Ordinary Shares
    and 90 warrants to purchase 90 Ordinary Shares, at an exercise price per share of US$12.
	 	 
	 	The
    term “QFR” means the first financing round consummated by the Company after the date of the Note, through
    an equity investment (including an initial public offering but excluding the issuance of any convertible notes, or the issuance
    of shares upon conversion of such notes), either in one transaction or in a series of related transactions, with an aggregate
    investment amount of not less than US$3,000,000 (Three US Dollars), excluding the outstanding principal amount of the Notes
    and all accrued and unpaid interest thereon.
	 	 
	 	The
    term “QFR Conversion Price” means a conversion price reflecting the lower of (i) a 10% discount on the
    price paid by the investor(s) for the shares issued in the QFR; or (ii) US$1.15 per share. Notwithstanding the foregoing,
    in the event that the QFR in an initial public offering with gross proceeds to the Company of not less than US$25,000,000
    (Twenty Five Million US Dollars) (including the outstanding principal amount of the Notes and all accrued and unpaid interest
    thereon) (the “QIPO”), the QFR Conversion Price shall mean a conversion price reflecting a 50% discount
    on the price paid for the shares issued in the QIPO and if the price in such QIPO is fixed per each unit offered in the QIPO,
    the discount shall be applicable to such unit price.

 

    	- 2 -

    	 

    

 

	 	If
    this Note is converted in accordance with this Section ‎3, written notice shall be delivered to the Holder of this Note,
    notifying the Holder of the conversion, specifying the Conversion Amount, the date of such conversion, and the securities
    issued upon conversion. For the avoidance of doubt, in such event this Note shall be null and void even if not surrendered
    to the Company.

 

	4	Automatic
    Conversion upon M&A Event. 

 

	 	4.1.	In
    the event that, prior to the conversion of the Conversion Amount or its repayment according to the terms specified herein,
    an M&A Event (as defined below) shall occur, then immediately prior and subject to the closing of such M&A Event,
    the Conversion Amount shall be automatically converted into Series A Preferred Shares, par value NIS 0.01 per share, of the
    Company (the “Preferred A Shares”), at a conversion price equal to the price per share paid by the Company’s
    investors in consideration for the Preferred A Shares (i.e., US$1) (the “M&A Conversion Price”).
	 	 	 
	 	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the M&A Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    M&A Conversion Price.
	 	 	 
	 	 	The
    term “M&A Event” means (i) a merger or consolidation of the Company in which the Company’s shareholders
    immediately prior to such transaction do not own, directly or indirectly, more than 50% of the share capital of the surviving
    entity; (ii) the acquisition of more than 50% of the Company’s outstanding share capital by a single unaffiliated person,
    entity or group ,or by persons or entities acting in concert; (iii) the sale or transfer of all or substantially all of the
    assets of the Company; or (iv) a reverse triangular merger in which the Company is the surviving entity but the shares of
    the Company’s share capital outstanding immediately prior to the merger are converted by virtue of the merger into other
    property, whether in the form of securities, cash or otherwise.
	 	 	 
	 	4.2.	Irrespective
    of any other provision of this Note, in the event that prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company becomes a subsidiary of a newly-formed entity formed under the laws of one of the
    states of the United States (“Newco”) either by way of a reverse triangular merger or by way of share swap
    or by way of any other similar transaction or series of related transactions, the result of which will be the capital stock
    of the Company being wholly owned by Newco (or any other entity into which or with which Newco merges), and simultaneously
    with or in connection with such transaction(s) or shortly thereafter, Newco (or any other entity into which or with which
    Newco merges), consummates an equity financing of at least US$ 10,000,000 (the “New Financing”), the Conversion
    Amount will be automatically exchanged for a number of securities (including any “units” or basket of securities
    that consist of stock together with warrants and/or securities or rights convertible or exchangeable for stock) sold in the
    New Financing calculated on the basis of an exchange price of 90% of the sale price of the units issued in such New Financing.

 

    	- 3 -

    	 

    

 

	5.	Voluntary
    Conversion upon NQFR. In the event that, prior to the conversion of the Conversion Amount or its repayment according
    to the terms specified herein, the Company shall consummate a financial round through an equity investment, either in one
    transaction or in series of transactions (including an initial public offering but excluding the issuance of any convertible
    notes or the issuance of shares upon conversion of such notes), which is not a QFR (a “NQFR”), then the
    holders of Notes reflecting 70% (Seventy percent) of the aggregate outstanding principal amount of the Notes (the “Majority
    Holders”), shall be entitled, no later than fourteen (14) days prior to the closing of such NQFR, to notify the
    Company in writing of their choice to convert the entire Conversion Amount of the Notes (the “Aggregate Conversion
    Amount”). In such event the entire Aggregate Conversion Amount shall be converted immediately prior and subject
    to the closing of the NQFR, on the same terms and conditions specified in Section ‎3 above (“Automatic Conversion
    upon a QFR”), mutatis mutandis. The election of the Majority Holders to convert the entire Aggregate Conversion
    Amount shall be binding on all of the holders of the Notes and each such holder shall be deemed to have elected to convert
    its respective portion of the Aggregate Conversion Amount in accordance with the terms and conditions specified herein.
	 	 
	6.	Maturity
    Date. If not converted or repaid according to the terms set forth herein until thirty (30) months from the date of
    this Note (i.e., ___________) (the “Maturity Date”), then at the Maturity Date the Conversion Amount shall
    be automatically converted into Preferred A Shares, at a conversion price per share equal to the price per share paid by the
    Company’s investors in consideration for the Preferred A Shares (i.e., US$1) (the “Maturity Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the applicable Articles of
    Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Maturity Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Maturity Conversion Price.
	 	 
	7.	Event
    of Default. In the event that, prior to the conversion of the Conversion Amount or its repayment according to the
    terms hereunder an Event of Default occurs, then the Conversion Amount shall be, at the election of the Holder, at its sole
    discretion, either: (i) become immediately due and payable to the Holder in cash; or (ii) converted into Preferred A Shares,
    at a conversion price per share equal to the price per share paid by the Company’s investors in consideration for the
    Preferred A Shares (i.e., US$1) (the “Default Conversion Price”).
	 	 
	 	It
    being agreed and acknowledged that the original issue price (or any equivalent term used under the then applicable Articles
    of Association of the Company) of the Preferred A Shares issued to the Holder shall be set to be the Default Conversion Price,
    and any rights that are attached to such Preferred A Shares issued to the Holder which are determined, derived, calculated,
    triggered, or otherwise based on the original price of such shares (including, without limitation, liquidation and dividend
    preferences, anti-dilution rights or the like) shall be determined, calculated, triggered or otherwise based on the actual
    Default Conversion Price.

 

    	- 4 -

    	 

    

 

	 	The
    term “Event of Default” means (a) dissolution, termination of existence, suspension or discontinuance of
    business or ceasing to operate as going concern for a period of more than thirty (30) days; (b) the appointment of a receiver,
    trustee, custodian or similar official, for the Company or any material portion of the property or assets of the Company and
    the continuation of such appointment without dismissal for a period of thirty (30) days or more; (c) the conveyance of any
    material portion of the assets of the Company to a trustee, mortgage or liquidating agent or an assignment for the benefit
    of creditors by the Company which is not dismissed within a period of thirty (30) days; (d) the commencement of any proceeding,
    whether federal or state, relating to bankruptcy, insolvency, dissolution, reorganization, composition, renegotiations of
    outstanding indebtedness, arrangement or otherwise to the relief or debtors or the readjustment of indebtedness, by or against
    the Company, which is not stayed, vacated or released within sixty (60) days of commencement; (e) any material breach by the
    Company of any covenant or obligation in the Note, CAN or any documents and agreements ancillary thereto (the “Transaction
    Documents”) which is not cured, if curable, within thirty (30) days following receipt by the Company of a written
    notice of such breach; (f) any material misrepresentation has occurred in the Transaction Documents, which is not cured, if
    curable, within thirty (30) days following receipt by the Company of a written notice of such breach; (g) the Company shall
    fail to make any required payment of interest, principal or otherwise under the Notes, which is not cured within thirty (30)
    days following receipt by the Company of a written notice of such failure. The Company undertakes to notify the Holder
    immediately following occurrence of any of the events detailed in clauses (a) to (g) above.
	 	 
	8.	Conversion;
    Fractional Interests. Each conversion shall be deemed to have been effected as to this Note (or the specified portion
    thereof) on the date on which the requirements set forth above in this Note required to be satisfied by the Holder, or the
    circumstances that are required to exist, have been satisfied as to this Note (or portion thereof), and the person whose name
    any certificate or certificates for shares shall be issuable upon such conversion shall be deemed to have become on said date
    the holder of record of the shares represented thereby. No fractional shares or scrip representing fractional shares shall
    be issued upon conversion of this Note and the number of shares issued shall be rounded to the nearest whole number.
	 	 
	9.	Payments;
    Taxes
	 	 

 

	 	9.1.	Payments.
    All payments of interest and of principal shall be in U.S. Dollar (“US$”) or in the New Israeli Shekels
    (“NIS”) equivalent. If any payment is paid in a NIS equivalent, it shall be paid in accordance with the
    representative rate of exchange of the U.S. Dollar against the NIS last published by the Bank of Israel immediately prior
    to the certain payment date.
	 	 	 
	 	9.2.	Taxes
    on Payments. To the extent required pursuant to applicable law, VAT shall be added by the Company to any payment to be
    made by the Company pursuant to this Note. The Company shall be entitled to deduct and withhold any withholding taxes which
    the Company determines it is legally required to deduct or withhold from any payment to be made by the Company pursuant to
    this Note.

 

    	- 5 -

    	 

    

 

	10.	Not
    a Shareholder. Prior to the conversion of this Note or any portion thereof according to the provisions specified herein,
    the Holder, in its capacity as an Holder, shall not be entitled to any rights of a shareholder of the Company, including,
    without limitation, the right to vote or to receive dividends or other distributions, with respect to the Note and the shares
    issuable upon conversion of the Note.
	 	 
	11.	Miscellaneous

	 	 	 
	 	11.1.	Governing
    Law. This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall
    be construed in accordance with the laws of said state, without regard to principles of conflict of laws. Any dispute arising
    under or in relation to this Agreement shall be resolved exclusively in the competent court in New York New York, and each
    of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.
	 	 	 
	 	11.2.	Successors
    and Assigns. Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be
    binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. None of the rights, privileges,
    or obligations set forth in, arising under, or created by this Note may be assigned or transferred without the prior consent
    in writing of each party to this Note.
	 	 	 
	 	11.3.	Delays
    or Omissions; Waiver. No delay or omission to exercise any right, power, or remedy accruing to either the Company or the
    Holder upon any breach or default by the other under this Note shall impair any such right or remedy, nor shall it be construed
    to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter occurring.
	 	 	 
	 	11.4.	Entire
    Agreement. This Note, when read together with the CNA, contains the entire understanding of the parties with respect
    to its subject matter and all prior negotiations, discussions, commitments, and understandings heretofore had between them
    with respect hereto are merged therein. In the case of any discrepancy between the provisions of this Note and the provisions
    of any other agreement previously entered into by the Company or the Holder, the provisions of this Note and the CNA shall
    prevail.
	 	 	 
	 	11.5.	Amendment.
    Any term of this Note – as well as of all other Notes - may be amended (either generally or in a particular instance
    and either retroactively or prospectively) only with the written consent of the Company and the Majority Holders.
	 	 	 
	 	11.6.	Headings.
    All article and section headings herein are inserted for convenience only and shall not modify or affect the construction
    or interpretation of any provision of this Note.
	 	 	 
	 	11.7.	Notices.
    All notices and other communications made pursuant to this Note shall be in writing and shall be conclusively deemed to have
    been duly given if delivered in accordance with the notice provisions of the CNA.
	 	 	 
	 	11.8.	Severability.
    If any provision of this Note is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Note and the remainder of this Note shall be interpreted as if such provision were
    so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Note shall be
    interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
    intention of the excluded provision as determined by such court of competent jurisdiction.

 

	 	Motus
    GI Medical Technologies Ltd.
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	- 6 -

    	 

    

 

EXHIBIT
D TO FOURTH AMENDMENT TO CONVERTIBLE NOTES AGREEMENT

 

NEITHER
THIS WARRANT CERTIFICATE NOR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER SECURITIES ACT, AND THIS WARRANT CERTIFICATE AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT CERTIFICATE MAY NOT BE SOLD, OFFERED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH APPLICABLE SECURITIES LAWS AND THE RESTRICTIONS, TERMS AND CONDITIONS SET FORTH HEREIN.

 

Motus
GI Medical Technologies Ltd.

 

Preferred
A SHARES warrant Certificate 

 

To
purchase

[_____]
Preferred A Shares (subject to adjustment) of

Motus
GI Medical Technologies Ltd. (the “Company”)

at
a per share price and subject to the terms detailed below

VOID
AFTER 17:00 p.m. Israel Standard Time

on
the last day of the Warrant Period (as defined below)

 

THIS
IS TO CERTIFY THAT, [_____________] (the “Holder”), is entitled to purchase from the Company, an aggregate
of up to [___________] (as may be adjusted hereunder) Preferred A Shares of the Company, nominal value NIS 0.01 per share (the
“Warrant Shares”), at an aggregate purchase price of US$ [__________], reflecting an exercise price per share
of US$ 1.00 (the “Exercise Price”), during the Warrant Period.

 

This
Warrant Certificate (this “Warrant”) is issued to the Holder in connection with that certain Convertible Notes
Agreement dated June 9, 2015 by and among the Company and the Purchasers listed on Exhibit A thereto, as amended (the “Convertible
Notes Agreement”).

 

	1.	EXERCISE
    OF WARRANT

 

	 	1.1.	Warrant
    Period. This Warrant may be exercised, subject to the terms and conditions hereof, in whole or in part, at one time or
    from time to time during the period commencing on __________ (the “Initial Date”) until the earlier of:
    (i) seven (7) years thereafter (i.e., __________); and (ii) the closing of an Exit Event (as defined in Section‎ 5 below);
    provided that such Exit Event is consummated within 180 days from the Exit Event Notice (each of (i) or (ii), the “Expiry
    Date”). The period between the Initial Date and the Expiry Date shall be referred to hereinafter as the “Warrant
    Period.”

 

    	 	 	 

    	 	 	 

    

 

	 	1.2.	Exercise
    for Cash. This Warrant may be exercised by presentation and surrender thereof to the Company at its principal office or
    at such other office or agency as it may designate from time to time, accompanied by:

 

	 	(a)	A
    duly executed notice of exercise, in the form attached hereto as Schedule ‎1.1 (the “Exercise Notice”);
    and
	 	 	 
	 	(b)	Payment
    to the Company, for the account of the Company, of the Exercise Price for the number of Warrant Shares purchased payable in
    immediately available funds by wire transfer to the Company’s bank account. The Exercise Price will be paid in United
    States Dollars or the equivalent sum in NIS according to the Bank of Israel exchange rate as published upon the date immediately
    prior to the exercise date.

 

	 	1.3.	Exercise
    on Net Issuance Basis. In lieu of payment to the Company as set forth in Section ‎1.1 above, the Holder may elect
    to exercise this Warrant into the number of Warrant Shares calculated pursuant to the formula below, by presentation and surrender
    thereof to the Company at its principal office or at such other office or agency it may designate from time to time, accompanied
    by a duly executed notice of exercise, in the form attached hereto as Schedule 1.3 (the “Net Issuance
    Notice”): 

 

	 	X
        =	Y*(A
                                         - B)

        ——————

        A
	 

 

Where:

 

	 	X
    =	the
    number of Warrant Shares to be issued to the Holder;
	 	 	 
	 	Y
    =	the
    number of Warrant Shares in respect of which the net issuance election is being made;
	 	 	 
	 	A
    =	the
    Fair Market Value (as defined below) of one Warrant Share; and
	 	 	 
	 	B
    =	the
    Exercise Price of one Warrant Share.

 

    	 	2	 

    	 	 	 

    

 

For
purposes of this Section ‎1.3, the “Fair Market Value” of one Warrant Share as of a particular date (the
“Determination Date”) shall be: 

 

	 	(a)	If
    the net issuance right is exercised in connection with and contingent upon an initial public offering of the Company’s
    shares (an “IPO”), then the initial “price to public” (i.e., before deduction of discounts,
    commissions or expenses) specified in the final prospectus or registration statement with respect to such offering.
	 	 	 
	 	(b)	If
    the net issuance right is exercised in connection with and contingent upon an Exit Event that is not an IPO, the price per
    Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) in such Exit Event. 
	 	 	 
	 	(c)	If
    the net issuance right is not exercised in connection with and contingent upon an Exit Event, then as follows:

 

	 	(i)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are traded on a securities exchange, the Fair Market Value shall be deemed to
    be the average of the closing prices of such shares on such exchange over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date;
	 	 	 
	 	(ii)	If
    the Preferred A Share (or any securities to which the Preferred A Shares have been converted to in accordance with the Company’s
    organizational documents and applicable law) are quoted for trading on an over-the-counter system, the Fair Market Value shall
    be deemed to be the average of the closing bid prices of such shares over the fifteen (15) trading days immediately prior
    to (but not including) the Determination Date; and
	 	 	 
	 	(iii)	If
    there is no public market for the Preferred A Shares (or any securities to which the Preferred A Shares have been converted
    to in accordance with the Company’s organizational documents and applicable law), the Fair Market Value of the shares
    shall be determined in good faith by the Board of Directors of the Company.

 

    	 	3	 

    	 	 	 

    

 

	 	1.4.	Issuance
    of Warrant Shares. Upon presentation and surrender of this Warrant, accompanied by (a) the duly executed Exercise Notice
    and the payment of the applicable Exercise Price for the Warrant Shares being purchased pursuant to Section ‎1.1 above;
    or (b) the duly executed Net Issuance Notice pursuant to Section ‎1.3 above, as the case may be, the Company shall promptly
    (i) issue to the Holder the Warrant Shares to which the Holder is entitled; and (ii) deliver to the Holder the share certificate
    evidencing such Warrant Shares. 
	 	 	 
	 	 	Upon
    receipt by the Company of this Warrant and the applicable duly executed notice of exercise (and the Exercise Price for the
    Warrant Shares being purchased, if applicable), together with any other documents and/or approvals that may be required by
    law, the Holder shall be deemed to be the holder of record of the Warrant Shares issuable upon such exercise, notwithstanding
    that the share transfer books of the Company shall then be closed or that certificates representing such shares shall not
    then be actually delivered to the Holder.

 

	 	1.5.	Fractional
    Shares. No fractions of shares shall be issued in connection with the exercise of this Warrant, and the number of shares
    issued shall be rounded to the nearest whole number.
	 	 	 
	 	1.6.	Partial
    Exercise. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant for cancellation,
    execute and deliver a new Warrant evidencing the rights of the Holder to purchase the balance of the Warrant Shares purchasable
    hereunder.
	 	 	 
	 	1.7.	Additional
    Documents. The Holder will sign and deliver any and all documents or approvals required by law, to facilitate the issuance
    of the Warrant Shares upon exercise of this Warrant. 
	 	 	 
	 	1.8.	Loss
    or Destruction of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
    or mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonable reimbursement of expenses and
    satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute
    and deliver a new Warrant of like tenor and date.

 

    	 	4	 

    	 	 	 

    

 

	2.	TAXES

 

	 	2.1.	The
    Holder acknowledges that the grant of the Warrant, the issuance of the Warrant Shares and the execution and/or performance
    of this Warrant may have tax consequences to the Holder and that the Company is not able to ensure or represent to the Holder
    the nature and extent of such tax consequences. 
	 	 	 
	 	2.2.	The
    Company shall pay all of the applicable taxes and other charges payable by the Company in connection with the issuance of
    the Warrant Shares and the preparation and delivery of share certificates in the name of the Holder (such as transfer taxes
    in respect of the issuance or delivery of Warrant Shares upon exercise of this Warrant), if any, but shall not pay any taxes
    payable by the Holder by virtue of the holding, issuance, exercise, sale of this Warrant or the Warrant Shares by the Holder.

 

	3.	RESERVATION
    OF SHARES; preservation of rights of holder

 

	 	3.1.	Reservation
    of Shares. The Company hereby agrees that, at all times prior to the expiration or exercise of this Warrant, it will maintain
    and reserve, free from pre-emptive or similar rights, such number of authorized but unissued shares so that this Warrant may
    be exercised without additional authorization of shares.
	 	 	 
	 	3.2.	Preservation
    of Rights. The Company will not, by amendment of its organizational documents or through reorganization, recapitalization,
    consolidation, merger, dissolution, transfer of assets, issue or sale of securities or any other voluntary act, avoid or seek
    to avoid the observance or performance of any of the covenants, stipulations, conditions or terms to be observed or performed
    hereunder, but will at all times in good faith assist in the carrying out of all the provisions hereof and in taking of all
    such actions and making all such adjustments as may be necessary or appropriate in order to fulfill the provisions hereof.

 

    	 	5	 

    	 	 	 

    

 

	4.	ADJUSTMENT

 

	 	4.1.	The
    number of Warrant Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment
    from time to time or upon exercise, as follows:

 

	 	(a)	Bonus
    Shares. In the event that during the Warrant Period the Company shall distribute a non-cash dividend or shares pursuant
    to a reclassification of its share capital, to all of the holders of shares of the Company (i.e., bonus shares), then this
    Warrant shall represent the right to acquire, in addition to the number of Warrant Shares indicated in the caption of this
    Warrant, the amount of such bonus shares that are distributed to persons holding the class of share capital for which the
    Warrant is exercisable and/or to receive the stock dividends which are distributed to persons holding the class of share capital
    for which the Warrant is exercisable, without payment of any additional consideration therefor, to which the Holder would
    have been entitled had this Warrant been exercised prior to the distribution of the stock dividends or the bonus shares. 
	 	 	 
	 	(b)	Consolidation
    and Division. In the event that during the Warrant Period the Company consolidates its share capital into shares of greater
    par value, or subdivides them into shares of lesser par value, then the number of Warrant Shares to be allotted on exercise
    of this Warrant after such consolidation or subdivision shall be reduced or increased accordingly, as the case may be, and
    in each case the Exercise Price shall be adjusted appropriately such that the aggregate consideration hereunder to the Company
    shall not change.
	 	 	 
	 	(c)	Capital
    Reorganization. In the event that during the Warrant Period a reorganization of the share capital of the Company is effected
    (other than subdivision, combination or reclassification provided for elsewhere in this Section 4) and the Preferred A Shares
    are exchanged for other securities of the Company, then, as part of such reorganization, provision shall be made so that the
    Holder shall be entitled to purchase upon exercise of this Warrant such kind and number of shares or other securities of the
    Company to which the Holder would have been entitled had this Warrant been exercised without taking into effect such reorganization.
    

 

    	 	6	 

    	 	 	 

    

 

	 	(d)	Irrespective
    of any other provision of this Warrant, in the event that during the Warrant Period the Company becomes a subsidiary of a
    newly-formed entity formed under the laws of one of the states of the United States (“Newco”) either by
    way of a reverse triangular merger or by way of share swap or by way of any other similar transaction or series of related
    transactions, the result of which will be the capital stock of the Company being wholly owned by Newco (or any other entity
    into which or with which Newco merges), and simultaneously with or in connection with such transaction(s) or shortly thereafter,
    Newco (or any other entity into which or with which Newco merges) consummates an equity financing of at least US$ 10,000,000(the
    “New Financing” and the “Qualified Transaction”, respectively), this Warrant shall be
    automatically exchanged for five-year Newco (or any other entity into which or with which Newco merges) warrants exercisable
    for Newco (or any other entity into which or with which Newco merges) Common Stock at an exercise price per share of 100%
    of the original issue price of the securities (including any “units” or basket of securities that consist of stock
    together with warrants and/or securities or rights convertible or exchangeable for stock) issued in the New Financing (the
    “Original Issue Price”). The number of Common Stock underlying such new warrant shall be equal to one-third
    (1/3) of the principal amount of that certain Note dated [________] issued by the Company to the Holder, divided by the Original
    Issue Price. For greater certainty, the Qualified Transaction described in this sub-section (d) shall not be deemed an Exit
    Event. 

 

	 	4.2.	Whenever
    an adjustment is effected hereunder, the Company shall promptly compute such adjustment and deliver to the Holder a certificate
    setting forth the number of Warrant Shares (or any other securities) for which this Warrant is exercisable and the Exercise
    Price as a result of such adjustment, a brief statement of the facts requiring such adjustment and the computation thereof
    and when such adjustment has or will become effective.
	 	 	 
	 	4.3.	Except
    as otherwise provided herein, Sections 4.1(a) to 4.1(d) hereof are intended to operate independently of one another. If an
    event occurs that requires the application of more than one subsection, all applicable subsections shall be given independent
    effect, but there shall be no duplicate adjustments if two separate subsections provide the same protection.

 

    	 	7	 

    	 	 	 

    

 

	 	4.4.	Notices
    of Certain Transactions. In case:

 

	 	(a)	the
    Company shall take a record of the holders of its Preferred A Shares (or other stock or securities at the time deliverable
    upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution,
    or
	 	 	 
	 	(b)	of
    the voluntary or involuntary dissolution, liquidation or winding-up of the Company
	 	 	 
	 	 	then,
    and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be,
    (i) the date on which a record is to be taken for the purpose of such dividend or distribution, and stating the amount and
    character of such dividend or distribution, or (ii) the effective date on which such voluntary dissolution, liquidation or
    winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Shares (or such other
    shares or securities at the time deliverable upon such voluntary dissolution, liquidation or winding-up) are to be determined.
    Such notice shall be mailed at least seven (7) days prior to the record date or effective date for the event specified in
    such notice.

 

	5.	EXERCISE
    OF THE WARRANT UPON AN EXIT EVENT

 

Notwithstanding
anything to the contrary in this Warrant, if at any time during the Warrant Period, the Company consummates an Exit Event, or
at the discretion of the Board of Directors of the Company, in the event that the Company believes that an Exit Event is likely
to be consummated during such period, the Company shall provide written notice of such Exit Event (or, if applicable, an anticipated
Exit Event) to the Holder (the “Exit Event Notice”). Within fourteen (14) days after Holder’s receipt
of the Exit Event Notice, Holder must notify the Company if it intends to exercise this Warrant pursuant to Section ‎1.2 or
‎1.3 of this Warrant, in which case such exercise shall be effective contingent upon and immediately prior to the consummation
of the Exit Event. Thereafter, so long as the Company consummates such Exit Event within one hundred and eighty (180) days after
Holder’s receipt of the Exit Event Notice (to the extent the Exit Event shall not have occurred prior to the Exit Event
Notice), Holder shall have no further rights hereunder and this Warrant shall be automatically terminated if not so exercised.
If the Company fails to consummate such Exit Event within such time, then this Warrant shall remain in effect subject to the provisions
contained herein.

 

    	 	8	 

    	 	 	 

    

 

For
the purposes hereof, an “Exit Event” shall mean the closing of (i) an initial public offering; (ii) a merger
of the Company with or into another corporation, (iii) an acquisition of all or substantially all of the shares of the Company,
(iv) the sale or license of all or substantially all of the assets of the Company, any with respect to (ii)-(iv), other than a
merger or transaction in which the persons that beneficially owned, directly or indirectly, a majority of the share capital of
the Company immediately prior to such merger or transaction, beneficially own, directly or indirectly, a majority of the total
shares of capital stock of the surviving or transferee entity. For greater certainty, the Qualified Transaction described in Section
4.1(d) shall not be deemed an Exit Event and the provisions of this Section 5 shall not apply solely in connection with such Qualified
Transaction.

 

	6.	RIGHTS
    OF THE HOLDER

 

	 	6.1.	This
    Warrant shall not entitle the Holder, by virtue hereof, to any voting rights or other rights as a shareholder of the Company,
    except for the rights expressly set forth herein.
	 	 	 
	 	6.2.	The
    Holder acknowledges that the Warrant Shares shall be subject to such rights, privileges, restrictions and limitations as set
    forth in this Warrant and the organizational documents of the Company (or any other agreement with respect thereto), as may
    be amended from time to time, and that, as a result, inter alia, of such limitations, it may be difficult or impossible
    for the Holder to realize his investment and/or to sell or otherwise transfer the Warrant Shares. The Holder further acknowledges
    that the Company’s shares are not publicly traded.

 

	7.	TERMINATION

 

Notwithstanding
anything to the contrary, this Warrant and all the rights conferred hereby shall terminate and expire at the aforementioned time
on the Expiry Date.

 

    	 	9	 

    	 	 	 

    

 

	8.	MISCELLANEOUS

 

	 	8.1.	Entire
    Agreement; Amendment. This Warrant sets forth the entire understanding of the parties with respect to the subject matter
    hereof and supersedes all existing agreements among them concerning such subject matter. All article and section headings
    herein are inserted for convenience only and shall not modify or affect the construction or interpretation of any provision
    of this Warrant. Subject to Section ‎8.8 below, no modification or amendment of this Warrant will be valid unless executed
    in writing by the Company and the Holder. 
	 	 	 
	 	8.2.	Waiver.
    No failure or delay on the part of any of the parties in exercising any right, power or privilege hereunder and/or under any
    applicable law or the exercise of such right or power in a manner inconsistent with the provisions of this Warrant or applicable
    law shall operate as a waiver thereof. Any waiver must be evidenced in writing signed by the party against whom the waiver
    is sought to be enforced.
	 	 	 
	 	8.3.	Successors
    and Assigns; Assignment. Except as otherwise expressly limited herein, this Warrant shall inure to the benefit of, be
    binding upon, and be enforceable by the Holder and its respective successors, and administrators and is otherwise non-transferable
    without the prior consent of the Company. The Holder represents and warrants to the Company that this Warrant and the Warrant
    Shares, if and when purchased by the Holder, are for the Holder’s own account and for investment purposes only and not
    with a view for resale or transfer and that all the rights pertaining to the Warrant or the Warrant Shares, by law or equity,
    shall be purchased and possessed by the Holder for the Holder exclusively. 
	 	 	 
	 	8.4.	Governing
    Law. This Warrant shall be exclusively governed and construed in accordance with the laws of the State of New York, without
    regard to conflicts of laws provisions thereof.
	 	 	 
	 	8.5.	Notices.
    All notices and other communications made pursuant to this Warrant shall be in writing and shall be conclusively deemed to
    have been duly given if delivered in accordance with the notice provisions of the Convertible Notes Agreement. 

 

    	 	10	 

    	 	 	 

    

 

	 	8.6.	Severability.
    If any provision of this Warrant is held by a court of competent jurisdiction to be unenforceable under applicable law, then
    such provision shall be excluded from this Warrant and the remainder of this Warrant shall be interpreted as if such provision
    were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Warrant
    shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the
    meaning and intention of the excluded provision as determined by such court of competent jurisdiction.
	 	 	 
	 	8.7.	Counterparts.
    This Warrant may be executed in any number of counterparts, each of which shall be an original, but all of which together
    shall constitute one instrument. Facsimile or electronic signatures of a party shall be binding as evidence of such party’s
    agreement hereto and acceptance hereof.
	 	 	 
	 	8.8.	Amendments.
    To the extent that any amendment(s) to the Convertible Notes Agreement or the transactions contemplated thereby result in
    a required amendment to the terms of this Warrant, this Warrant shall be deemed amended to the extent that the amendment(s)
    to the Convertible Notes Agreement are completed in accordance with the terms thereof.

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.

 

	Dated:	                                     	 	Motus
    GI Medical Technologies Ltd. 
	 	 	 	 	 
	 	 	 	Signature:	                                             
	 	 	 	 	 
	 	 	 	Name:	 
	 	 	 	 	 
	 	 	 	Title:	 

 

    	 	11	 

    	 	 	 

    

 

Schedule
1.2

 

Exercise
Notice

 

Date:
____________

 

To:
Motus GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to purchase _________ Warrant Shares (as such term is defined in the Warrant) pursuant to Section ‎1.1 of the
Warrant, and herewith makes payment of _____________, representing the full Exercise Price for such shares as provided for in
such Warrant. 

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 
	 	 	 	 	 

 

	Signature:	                              	 
	 	 	 
	Address:	 	 

 

    	 	12	 

    	 	 	 

    

 

Schedule
1.3

 

Net
Issuance Notice

 

Date:
____________

 

To:
Motus GI Medical Technologies Ltd.

 

The
undersigned, pursuant to the provisions set forth in the Warrant to which this Exercise Notice is attached (the “Warrant”),
hereby elects to exercise the Warrant for the purchase of Warrant Shares (as such term is defined in the Warrant), pursuant to
the provisions of Section 1.3 of the Warrant.

 

The
undersigned hereby irrevocably directs that the said shares (or such other securities into which the Warrant is exercisable) be
issued and registered in the name of the undersigned, as set forth below.

 

	Names
    	 	Address	 	No.
    of Shares
	 	 	 	 	 
	 	 	 	 	 

 

	Signature:	                              	 
	 	 	 
	Address:	 	 

 

    	 	13	 

    	 	 	 

    

 

FIFTH
AMENDMENT TO CONVERTIBLE NOTES AGREEMENT

 

This
Fifth Amendment to Convertible Notes Agreement (this “Amendment”) is made and entered into as of the __ day
of November, 2016 (the “Effective Date”), by and among Motus GI Medical Technologies Ltd., a company organized
under the laws of the State of Israel, with offices at Keren Hayesod 22 Tirat Carmel, Israel (the “Company”)
and the persons and entities listed on Exhibit A attached hereto (the “Purchasers”) (each Purchaser
and the Company separately, a “Party”, and together, the “Parties”).

 

	WHEREAS,
    	the
    Company and the Purchasers are parties to that certain Convertible Notes Agreement dated June 9, 2015, as amended on December
    29, 2015, on February 15, 2016, on July 25, 2016 (the “Third Amendment”) and on October 18, 2016 (the “Fourth
    Amendment” and collectively with all amendments, the “CNA”), attached hereto as Exhibit
    B (capitalized not defined herein shall have the meaning ascribed to them in the CNA, unless it is specifically provided
    otherwise); 
	 	 
	WHEREAS,	the
    Board of Directors of the Company has decided that it is in the best interest of the Company to increase the aggregate amount
    the Company may raise under the CNA to US$14 Million; and
	 	 
	WHEREAS,
    	the
    Parties wish to increase the aggregate Loan Amount to an aggregate principal amount of up to US$14.

 

NOW
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.
Amendments 

 

Section
3 of the Third Amendment (as amended in the Fourth Amendment) is hereby amended such that the aggregate amount that may be extended
by Additional Purchasers (the “Additional Loan Amount”), together with the aggregate Loan Amount previously
extended or committed to be extended by the Purchasers and/or previous Additional Purchasers (including, for greater certainty,
the additional Loan Amounts to be extended by the Major Purchasers pursuant to the Third Amendment) shall not exceed US$14 Million.

 

2.
Miscellaneous

 

	 	2.1.	The
    headings in this Amendment are for convenience only and shall not be used for purposes of construction.

 

    	 

    	 

    

 

	 	2.2.	All
    terms and conditions of the CNA (including any of its exhibits) shall remain in full force and effect subject to the provisions
    of this Amendment, which shall be regarded as an integral part of the CNA. In case of a contradiction between this Amendment
    and the CNA, the provisions of this Amendment shall prevail.
	 	 	 
	 	2.3.	This
    Amendment may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together
    shall constitute a single instrument.

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fifth Amendment to Convertible Notes Agreement on the date first above written.

 

	 	 
	Motus
    GI Medical Technologies Ltd.	 
	 	 	 
	By:	_______________                          	 
	 	 	 
	Title:	 ________________	 

 

[Purchasers’
Signature Pages to Follow]

 

    	- 2 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fifth Amendment to Convertible Notes Agreement on the date first above written.

 

	 	 	 
	Orchestra
    Medical Ventures II, L.P. 	 	Orchestra
                                         MOTUS Co-Investment

                                                                              Partners,
                                         LLC 

	By:________________	 	 
		 	By:__________________
	Title:_______________	 	 
		 	Title:_________________

 

	 	 	 
	Ascent
    Biomedical Ventures II, L.P.(3)	 	Ascent
    Biomedical Ventures Synecor, L.P.
	 	 	 
	By:______________	 	By:_____________
	 	 	 
	Title:________________	 	Title:______________

 

	 	 
	Jacobs
    Investments Company LLC	 
	 	 	 
	By:	 _______________	 
	 	          	 
	Title:	 ________________	 

 

    	- 3 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fifth Amendment to Convertible Notes Agreement on the date first above written.

 

	 	 	 
	E.
    Jeffrey Peierls	 	Brian
    Eliot Peierls

 

	 	 	 
	UD
    E.F. Peierls for Brian E. Peierls	 	UD
    E.F. Peierls for E. Jeffrey Peierls
	By:_______________	 	By:________________
	Title:______________	 	Title:_______________

 

	 	 	 
	UD
    J.N. Peierls for Brian Eliot Peierls	 	UD
    J.N. Peierls for E. Jeffrey Peierls
	By:___________________	 	By:_______________
	Title:___________________	 	Title:______________

 

	 	 	 
	UW
    J.N. Peierls for Brian E. Peierls	 	UD
    Ethe l F. Pe ierls Charitable Lead Trust
	By:__________________	 	By:_______________
	Title:_________________	 	Title:______________

 

	 	 	 
	The
    Peierls Bypass Trust	 	UD
    E.S. Peierls for E.F. Peierls et al
	By:_______________	 	By:________________
	Title:______________	 	Title:_______________

 

	 	 	 
	UW
    E.S. Peierls for Brian E. Pe ie rls -Accumulation	 	UW
    E.S. Peierls for E. Jeffrey Peierls  -Accumulation
	By:______________	 	By:__________________
	Title:_____________	 	Title:_________________

 

	 	 	 
	UW
    J.N. Peierls for E. Jeffrey Pe ie rls	 	The
    Pe ierls Foundation, Inc.
	By:_____________	 	By:______________
	Title:____________	 	Title:_____________

 

 

James
T. Lenehan

 

    	- 4 -

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto constituting at least 70% of the aggregate outstanding principal amount of the Notes have
executed this Fifth Amendment to Convertible Notes Agreement on the date first above written.

 

	 	 	 
	Isagen
    LLC.	 	Sunny
    Wong

 

	 	 	 
	Perceptive
    Life Sciences Master Fund	 	Titan
    Perc Ltd
	By:_____________	 	By:______________
	Title:____________	 	Title:_____________

 

	 	 	 
	A.K.S.
    Fa mily Partners, LP	 	Rexford
    Capital, LLC
	By:_____________________	 	By:________________
	Title:___________________	 	Title:______________

 

	 	 	 
	Jason
    Batansky	 	Douglas
    Jay Cohen

 

	 	 	 
	Lester
    Petracca	 	Arthur
    Fo le y

 

	 	 	 
	Narinde
    r S. Arora	 	DB
    Investor Group LLC
	 	 	By:________________
	 	 	Title:________________

 

	 	 	 
	Patrick
    Casey Lorenz	 	Dominion
    Capital LLC
	 	 	By:________________
	 	 	Title:_______________

 

	 	 	 
	Derek
    Sroufe	 	First
    Riverside Investors, LP
	 	 	By:_________________
	 	 	Title:_______________

 

	Keith
    Murphy	 	RGM
    Group, LLC.
	 	 	By:_________________
	 	 	Title:________________

 

	John
    P. Brancacc io	 	Natalie
    E. Cohen
	 	 	 
	John
    E. Dell	 	Harry
    Shufflebarger

 

    	- 5 -

    	 

    

 

	 	 	 
	Anemarie
    Edmundowic z	 	Anne
    S Hand

 

	 	 	 
	Ramnarain
    Jaigobing	 	GJG
    LifeSc iences LLC.
	 	 	By:__________________
	 	 	Title:_________________

 

	 	 	 
	LPD
    Invesments Ltd.	 	LGA
    Family Partners
	 	 	By:_________________
	 	 	Title:________________

 

	 	 	 
	Altbach
    Co LLC Roth 401-K Plan.	 	RBC
                                         Capital Markets LLC Csdn fbo Laurence Allen IRA

	By:_________________	 	By:________________
	Title:_________________	 	Title:________________

 

	 	 	 
	Harry
    Ioannou	 	A.I
    International

 

    	- 6 -

    	 

    

 

Exhibit
A

 

	1.	Orchestra
    Medical Ventures II, L.P.
	2.	Orchestra
    MOTUS Co-Investment Partners, LLC
	3.	Ascent
    Biomedical Ventures II, L.P. (3)
	4.	Ascent
    Biomedical Ventures Synecor, L.P.
	5.	Jacobs
    Investments Company LLC
	6.	E.
    Jeffrey Peierls
	7.	Brian
    Eliot Peierls
	8.	UD
    E.F. Peierls for Brian E. Peierls
	9.	UD
    E.F. Peierls for E. Jeffrey Peierls 
	10.	UD
    J.N. Peierls for Brian Eliot Peierls
	11.	UD
    J.N. Peierls for E. Jeffrey Peierls
	12.	UW
    J.N. Peierls for Brian E. Peierls
	13.	UW
    J.N. Peierls for E. Jeffrey Peierls
	14.	UD
    Ethel F. Peierls Charitable Lead Trust
	15.	The
    Peierls Bypass Trust
	16.	UD
    E.S. Peierls for E.F. Peierls et al
	17.	UW
    E.S. Peierls for Brian E. Peierls - Accumulation
	18.	UW
    E.S. Peierls for E. Jeffrey Peierls -Accumulation
	19.	The
    Peierls Foundation, Inc.
	20.	James
    T. Lenehan
	21.	Perceptive
    Life Sciences Master Fund 
	22.	Titan
    Perc Ltd
	23.	Isagen
    LLC.
	24.	A.K.S.
    Family Partners, LP
	25.	Sunny
    Wong
	26.	Rexford
    Capital, LLC
	27.	Jason
    Batansky
	28.	Douglas
    Jay Cohen
	29.	Lester
    Petracca
	30.	Arthur
    Foley

 

    	- 7 -

    	 

    

 

	31.	Narinder
    S. Arora
	32.	DB
    Investor Group LLC
	33.	Patrick
    Casey Lorenz
	34.	Dominion
    Capital LLC
	35.	Derek
    Sroufe
	36.	First
    Riverside Investors, LP
	37.	Keith
    Murphy
	38.	John
    P. Brancaccio
	39.	Natalie
    E. Cohen
	40.	John
    E. Dell
	41.	Harry
    Shufflebarger
	42.	RGM
    Group, LLC.
	43.	GJG
    LifeSciences LLC
	44.	LGA
    Family Partners
	45.	RBC
    Capital Markets LLC Csdn fbo Laurence Allen IRA
	46.	Anemarie
    Edmundowicz
	47.	Ramnarain
    Jaigobing
	48.	Anne
    S Hand
	49.	LPD
    Invesments Ltd.
	50.	Altbach
    Co LLC Roth 401-K Plan
	51.	A.I
    International
	52.	Harry
    Ioannou

 

    	- 8 -

    	 

    

 

Exhibit
B

 

CNA

 

Attached

 

    	- 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]